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Abstract 
The synapse is the functional unit for neuronal communication. Mutations in 
genes that encode relevant proteins for synaptic functions are being 
increasingly identified in neuropediatric disorders. The present work is 
focused on synaptic dysfunction in Rett Syndrome, which is caused by 
mutation in the MECP2 gene. This encodes for methyl-CpG-binding protein 2 
(MeCP2), an essential epigenetic regulator in mammalian brain development. 
Rett syndrome is characterized by a period of cognitive decline, hand 
stereotypies, autistic traits and seizures, following an apparently normal early 
infancy.  This disease can be classified as a synaptopathy, since it comprises 
simultaneously impairments in synaptogenesis, synaptic maturation and 
synaptic plasticity. There is evidence for the possibility of phenotypical rescue 
in Mecp2 deficient mice models, but current treatments for Rett Syndrome are 
primarily symptomatic therapies for epilepsy or behavioral disturbances, and 
not for correction of the underlying brain abnormalities.   
The molecule γ-amino butyric acid (GABA) is the main inhibitory 
(hyperpolarizing) neurotransmitter in the adult brain, but has excitatory 
(depolarizing) action in the developing brain, when it binds to GABA A 
receptors. This functional shift is dependent of neuronal maturational changes 
that include differences in the expression of cation chloride cotransporters, 
which regulate intracellular chloride concentration. One of the key molecular 
changes for this process is a perinatal neuronal membrane upregulation of 
potassium chloride cotransporter 2 (KCC2), an ion cotransporter that extrudes 
chloride form the cell, together with sodium potassium chloride cotransporter 
1 (NKCC1), which transports choride into the cell. Deregulation of cation 
chloride cotransporters’ expression or function has been associated with 
neurodevelopmental disorders like neonatal seizures, fragile X, tuberous 
sclerosis, Down syndrome, underpinning the relevance of this balance for an 
adequate central nervous system postnatal development.  
In the present thesis, I describe a disturbed GABAergic maturational process 
in Rett Syndrome, regarding intracellular chloride regulation. Starting from the 
clinic, we searched for a method to detect synaptic proteins in the 
cerebrospinal fluid of pediatric patients. The earlier postnatal period is 
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characterized by intense synaptogenesis and synaptic pruning, allowing the 
detection of these proteins in the cerebrospinal fluid, using immunoblot 
analysis. Since we were interested in GABAergic function maturation, and this 
process was dependent on the expression of NKCC1 and KCC2, 
abnormalities in the cerebrospinal fluid levels of these proteins were searched 
in Rett Syndrome patients and a decrease in KCC2 was observed.  
In order to obtain a model to understand the impact of this reduction of KCC2 
in neuronal function, human iPSCs were reprogramed from Rett patients’ 
fibroblasts. Human skin biopsies were collected in accordance with European 
and National ethical regulation and induced pluripotent stem cells were 
generated from fibroblasts upon infection with a retroviral vector expressing 
the four canonical transcription factors (Oct4, Sox2, Klf4, and Myc). Neural 
commitment of patient specific induced pluripotent stem cells was induced 
under defined conditions. Neuronal cortical populations were then derived in a 
monolayer culture system using a protocol that mimicks human cortical 
development in vitro. Perforated patch recordings were performed in these 
neurons, and GABA-evoked postsynaptic currents were measured to evaluate 
GABA A receptor equilibrium potencial.  Our preliminary data indicates that 
recordings from MECP2 mutant cells exhibit a GABA A receptor equilibrium 
potential that is more positive than in recordings from control cells, suggesting 
pathologic changes in chloride gradient, characteristic of an immature state.  
These results were complemented with experiments in the extensively 
characterized Mecp2 knock out mouse model (Mecp2tm1.1Bird/J). The level 
of KCC2 protein expression is lower in Mecp2-KO mice, when compared to 
control littermates, as addressed by western blot analysis of 6 week old 
hippocampi. Moreover, hippocampal electrophysiological recordings show 
reduction of membrane resting potential and threshold potential in the Mecp2 
knock-out model, where synaptic transmission evaluated by Input/Output 
curves reveals an increased excitatory synaptic transmission. 
Brain derived neurotrophic factor (BDNF) is a neurotrophin relevant for 
synaptic function, neuronal maturation and neuronal survival. Several groups 
have reproduced experiments that consistently support a regulatory role of 
MeCP2 upon BDNF expression. There is also evidence supporting the 
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interference of BDNF upon KCC2 expression. Since BDNF is highly relevant 
in Rett Syndrome pathology, several pre-clinical and clinical strategies are 
being designed and tested to improve Rett Syndrome, restoring BDNF levels 
and physiological actions. Based on the knowledge about a facilitatory effect 
of adenosine on BDNF actions, we hypothesized that the modulation of BDNF 
with adenosine receptor agonists would have a positive effect in synaptic 
function in the Rett Syndrome mouse model. Long-term potentiation (LTP) is 
accepted as a neurophysiological paradigm to test synaptic plasticity, the 
basic process underlying learning and memory. Adenosine is a 
neuromodulator that acts mainly through A1 and A2A receptors. The 
activation of A2A receptors (A2ARs) potentiates BDNF synaptic actions in 
healthy animals. Therefore, we explored whether the activation of A2ARs in 
the Rett Syndrome animal model facilitates BDNF action upon LTP. We found 
that BDNF facilitatory actions upon LTP are absent in the Rett Syndrome 
animal model, suggesting that, in addition to BDNF reduction, there is also 
impairment in its actions, even when it is administered exogenously. This 
dysfunction could be explained by a reduction in the levels of the main BDNF 
receptor (the full length tropomyosin-related kinase B), which we describe for 
the first time in the present study. When BDNF was combined with the 
selective A2AR agonist, CGS2168, the BDNF effect upon LTP was restored, 
similar to what was observed in hippocampal slices from wild type animals 
with BDNF alone. Together these data highlight A2ARs as new possible 
therapeutic targets to increase BDNF actions in Rett Syndrome. 
In conclusion, this work contributes to elucidate two significant downstream 
effects of MeCP2 impairment. The first is the abnormality of GABA 
postsynaptic actions upon GABAA receptors, suggested by a cerebrospinal 
fluid proteomic change and corroborated by findings in the Mecp2 knock out 
animal model and in human neurons, derived from induced pluripotent stem 
cells of Rett Syndrome patients. This system is now available for 
pharmacological screening of compounds that target the detected 
disturbances with direct evaluation of phenotypical rescue, at a cellular level. 
KCC2 reduction or impaired function appears to have also impact on synaptic 
structure and plasticity, and is a pathophysiological mechanism that 
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contributes to several neurodevelopmental disorders. The second is the 
reduction of the main BDNF receptors in the hippocampi of the Rett 
Syndrome animal model. We have also shown that, using an adenosine 
A2ARs agonist, it is possible to restore BDNF actions upon LTP, a paradigm 
for synaptic plasticity. Adenosine, through A2ARs, positively modulates the 
intracellular signaling cascades activated by BDNF, bypassing the BDNF-
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RESUMO 
 
A sinapse é a unidade funcional da comunicação neuronal. Mutações em 
genes que codificam proteínas relevantes para a função sináptica são 
descritas frequentemente como causa de doenças neuropediátricas. 
Esta  tese tem o seu foco na disfunção sináptica na Síndrome de Rett, 
predominantemente causada por mutações ou deleções no gene 
MECP2.  Este gene codifica a proteína “methyl-CpG-binding protein 2” 
(MeCP2), um regulador epigenético essencial para o desenvolvimento e 
função do cérebro dos mamíferos. A Síndrome de Rett é caracterizada por 
um período de desenvolvimento pós natal normal, seguido de perda das 
aquisições prévias, estereotipias manuais, traços autistas e convulsões. Já 
foram descritas alterações na sinaptogenese, na maturação sináptica e na 
plasticidade sináptica na Síndrome de Rett, que pode ser considerada uma 
sinaptopatia.   
Existem estudos que demonstram a possibilidade de reversão do fenótipo em 
modelos animais com alteração no gene Mecp2, mas as terapêuticas 
atualmente utilizadas na clínica são apenas sintomáticas, dirigidas à epilepsia 
ou a perturbações do comportamento e não à correção da disfunção cerebral 
subjacente.  
O ácido γ-amino butirico (GABA, γ-amino butyric acid) é o principal 
neurotransmissor inibitório (hiperpolarizante) no cérebro adulto, mas tem 
ação excitatória (despolarizante) no cérebro em desenvolvimento, quando se 
liga aos receptores GABA A. Esta modificação funcional depende de 
alterações moleculares nos neurónios em maturação que incluem diferenças 
na expressão dos cotransportadores de iões cloreto por catiões (Cation 
Chloride Cotransporters), reguladores da concentração intracelular de iões 
cloreto. Uma das alterações moleculares evolutivas relevantes para este 
processo é o aumento da expressão do cotransportador de cloreto e potássio 
do tipo 2 (KCC2), um cotransportador iónico transmembranar, especifico dos 
neurónios, que transporta cloreto para fora da célula. Por outro lado, o 
cotransportador de cloreto, potássio e sódio do tipo 1 (NKCC1) leva os iões 
cloreto para dentro da célula e verifica-se uma redução da sua expressão ao 
longo deste processo. A desregulação da expressão ou da função dos 
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cotransportadores de iões cloreto (sobretudo o KCC2 e o NKCC1), tem sido 
associada a doenças do desenvolvimento cerebral, tais como convulsões 
neonatais, Síndrome do X frágil, esclerose tuberosa, Síndrome de Down, 
sustentando a relevância deste equilíbrio para um desenvolvimento 
adequado do sistema nervoso central pós natal.  
Nesta tese, eu descrevo uma perturbação no processo de maturação 
GABAérgico na Síndrome de Rett, nomeadamente na regulação intracelular 
de iões cloreto que por sua vez determina a resposta à estimulação 
GABAérgica, ao nível dos receptores GABA A.  
Partindo da clínica, foi desenvolvido um método para detetar proteínas 
sinápticas no líquido cefalorraquidiano dos pacientes pediátricos. Nesta 
população verificam-se períodos de desenvolvimento caracterizados por 
sinaptogenese marcada e intensa remodelação sináptica o que permite a 
deteção destas proteínas no liquido cefalorraquidiano (LCR) através de 
análise por western blot. 
Uma vez que a  maturação da resposta GABAérgica depende de alterações 
evolutivas na expressão das proteínas NKCC1 e KCC2, foram determinados 
os níveis destas proteínas no LCR de doentes com Síndrome de Rett  e de 
controlos saudáveis. Neste estudo foi detetada uma redução de KCC2 no 
LCR destas doentes.  
Com o objetivo de obter um modelo celular humano para compreender o 
impacto desta redução de KCC2 na função dos neurónios, foram 
reprogramadas células humanas pluripotentes induzidas a partir de 
fibroblastos de doentes com Síndrome de Rett.  Foram recolhidas biópsias de 
pele humana de doentes e controlos saudáveis, respeitando as 
recomendações éticas Europeias e Nacionais. A partir dos fibroblastos 
humanos em cultura,  foram geradas células pluripotentes induzidas, através 
da infeção por retrovírus com um vetor que induz a expressão simultânea dos 
quatro fatores de transcrição  (Oct4, Sox2, Klf4 e Myc) que permitem a 
reprogramação.  
A partir das células pluripotentes induzidas humanas, foram então derivados 
neurónios corticais num sistema de cultura em monocamada, utilizando um 
protocolo que mimetiza, in vitro, o desenvolvimento cortical humano. Este 
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protocolo foi optimizado para a obtenção de progenitores neuronais em 
condições definidas. 
Para estudar a resposta neuronal à estimulação com GABA nos neurónios 
humanos dos doentes e controlos, foram realizados registros 
neurofisiológicos de perforated patch-clamp nestes neurónios e foi medida a 
corrente pós sináptica evocada de GABA para avaliar o potencial de 
equilíbrio do receptor GABAA.  
Os nossos resultados preliminares indicam que os registros de células com 
mutações no gene MECP2 exibem um potencial de equilíbrio do receptor 
GABAA que é mais positivo do que o potencial obtido nos registros de células 
controlo, sugerindo uma alteração patológica da resposta GABAérgica, 
característica de um estado imaturo.  
	   
Estes resultados foram complementados com experiências num modelo 
animal da Síndrome de Rett com ablação do gene Mecp2 (Mecp2 KO, 
Mecp2-knock out) (Mecp2tm1.1Bird/J), extensamente caracterizado na 
literatura. O nível de expressão da proteína KCC2 está significativamente 
reduzido nos ratos Mecp2-KO, quando comparado com animais controlo, tal 
como demonstramos através da análise de hipocampos dissecados do 
cérebro destes animais. Por outro lado, os registros eletrofisiológicos no 
hipocampo do mesmo modelo revelam um aumento da excitabilidade 
intrínseca destas células.  
 
O factor neurotrófico derivado do cérebro (BNDF, Brain Derived Neurotrophic 
Factor) é uma neurotrofina determinante para a função sináptica, maturação 
neuronal e sobrevivência neuronal. Vários grupos têm reproduzido 
experiências que suportam de uma forma consistente um papel de regulação 
do MeCP2 na expressão do BDNF. Existe também evidência que suporta a 
interferência de BDNF na expressão do gene que codifica o KCC2, SLC12A5. 
Considera-se que a desregulação das ações desta neurotrofina está na base 
das muitas das alterações encontradas nos modelos de Síndrome de Rett, 
pelo que várias estratégias pré clinicas e clinicas estão a ser desenhadas e 
testadas repor os níveis de BDNF e as suas acções fisiológicas nestes 
doentes. Baseados no conhecimento do efeito facilitador da adenosina nas 
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acções do BDNF, colocámos a hipótese  de que a modulação do BDNF com 
agonistas dos receptores de adenosina terá um efeito positivo na função 
sináptica dos animais sem expressão de Mecp2. Utilizámos um paradigma 
neurofisiológico, a Potenciação de Longa Duração (LTP, Long Term 
Potentiation), desenhado para testar a plasticidade sináptica, o processo 
básico subjacente à aprendizagem e à memória.  
A adenosina é um neuromodulador que atua sobretudo através dos 
receptores A1 e A2A. A activação dos receptores A2A potencia as acções do 
BDNF sobre a plasticidade sináptica em animais saudáveis. Foi testada esta 
reconhecida ação potenciadora da adenosina no efeito do BDNF sobre a 
plasticidade sináptica. 
Os nossos resultados indicam que a ação facilitadora do BDNF na LTP está 
ausente no modelo animal de RTT, sugerindo que, para além da redução do 
BDNF, existe também perda das suas acções, mesmo quando administrado 
exogenamente. Esta disfunção pode ser explicada por uma redução dos 
níveis do principal receptor de BDNF (TrkB, tropomyosin-related kinase B), 
que é descrita pela primeira vez neste estudo. Quando o BDNF foi associado 
ao agonista selectivo do receptor A2A, CGS2168, o efeito BDNF na LTP foi 
recuperado, de forma semelhante ao que foi observado em fatias de 
hipocampo de animais controlo, apenas com o BDNF. Estes dados apontam 
para os receptores A2A como um novo alvo terapêutico para recuperar a 
acção do BDNF na Síndrome de Rett.  
 
Em conclusão, este trabalho contribui para elucidar dois efeitos significativos 
do défice de MeCP2: 
O primeiro é a alteração das ações pós sinápticas do GABA nos receptores 
GABAA, sugerida por uma alteração na proteómica no LCR destas doentes e 
corroborada pelas descobertas no modelo animal de Mecp2-KO e em 
neurónios humanos, derivados de células pluripotentes induzidas de 
pacientes com Síndrome de Rett. Este sistema, baseado no modelo celular 
humano, está agora disponível para screening farmacológico de compostos 
que podem atenuar esta alteração. Com este modelo podemos avaliar 
directamente o efeito de um potencial fármaco no fenótipo celular. A redução 
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e/ou disfunção do KCC2 parece ser um mecanismo comum a várias doenças 
do desenvolvimento cerebral, com consequências na função GABAérgica, 
mas também na estrutura e plasticidade de sinapses glutamatérgicas, uma 
vez que este cotransportador exerce funções diretas nesses mecanismos.	   
O segundo é a redução dos recetores TrkB do BDNF no hipocampo do 
modelo animal da Síndrome de Rett. Demonstramos também que, utilizando 
um agonista do receptor A2A, é possível recuperar as acções do BDNF na 
LTP, um paradigma neurofisiológico para a plasticidade sináptica. Esta 
modulação da acção do BDNF pela adenosina é possível pela ativação 
intracelular de vias de sinalização do BDNF pelo receptor A2A, reduzindo as 
consequências do défice do recetor TrkB. 
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Abbreviations list 
 
[cl-]- Intracellular Chloride Concentration 
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EEG- electroencephalogram 
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ESCs- Embryonic stem cells  
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EU- European Union 
FDA- US Food and Drug Administration 
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FGF4- Fibroblast growth factor 4 
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FRET- Fluorescence resonance energy transfer 
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GABAAR- GABA A receptor 
GABA-PSCs- GABA-evoked postsynaptic currents 
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GATA2- GATA binding protein 2 
GDF3- Growth differentiation factor 3 
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HSJD- Hospital San Joan de Deu 
I/O- Input/Output 
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iPSCs- Induced Pluripotent Stem Cells 
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IST- Instituto Superior Técnico 
KCC2- K+– Cl− cotransporter 2 
KLF4- Kruppel-like factor 4 
KO- Knock Out 
KOSR- Knockout Serum Replacement 
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LTD- Long Term Depression 
LTP- Long Term Potentiation 
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MAP2- Microtubule associated protein 2 
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MeCP2- Methyl-CpG binding protein 2 
mRNA- Messenger RNA 
mTOR- mammalian target of rapamycin 
MRS- Magnetic Ressonance Spectroscopy 
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NLGN- Neurologin  
NMDA- N-Methyl-D-aspartic acid or N-Methyl-D-aspartate 
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NRXN- Neurexin  
NTs- Neurotransmitters 
OCT4- POU class 5 homeobox 1 
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OS- Ohtahara Syndrome 
PAX 6- Paired box 6 
PB- Phenobarbital 
PFA- Paraformaldehyde 
PI3K- phosphatidylinositol 3- kinase 
PSCs- Pluripotent Stem Cells 
PSD- Postsynaptic Density 
PVDF- polyvinylidene difluoride 
REX1- Reduced expression protein 1 
RMP- Resting Membrane Potential 
RNA- Ribonucleic acid 
RTT- Rett Syndrome 
SB- SB-431542  
SDS- Sodium dodecyl sulfate 
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SFFV- Spleen Focus Forming Virus 
SHANK3- SH3 And Multiple Ankyrin Repeat Domains 3 
Shc (Src homology 2/α-collagen-related protein) 
SM- “Sec1/Munc18-like” 
SMA- Smooth Muscle Actin 
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SOX2- SRY (Sex Determining Region Y)-Box 2 
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STXBP1- Syntaxin Binding Protein 1 
SV2- Synaptic vesicle proteins 2 
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TGFβ- transforming growth factor beta 
Trk- tropomyosin-related kinase 
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VAMP2- Vesicle associated membrane protein 2 
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VMAT2- Vesicular Monoamine Transporter 2 
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XIST- X inactive specific transcript 
YFP- Yellow Fluorescent Protein 
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1.1  Child neurology through synaptic communication 
	  
We are facing a fascinating era of exponential growth of knowledge in 
neuroscience and in biomedical technology. The application of this knowledge 
and the translation to clinical practice raises serious challenges for both 
clinicians and scientists. Projects focused in bringing these two fields together 
are certainly needed and relevant for the progress of our understanding about 
normal brain physiology and disease, leading to an improvement in treatment 
strategies and in disease prevention. In accordance, previous experience in 
the medical field suggests that therapeutic strategies and prognostic decision-
making are usually greatly facilitated as classifications move closer to the 
underlying pathophysiology (Craddock and Owen, 2010).  
The gap between clinical doctors and scientists results in an increased time 
lag between basic research discoveries and their application to patients, and 
also in the loss of precious information about normal physiology that arises 
from patients and their disorders. In particular, brain pathology has always 
been an excellent school to understand brain function, as long as studies 
focused on both aims, clinical and basic research ones, are done in 
coordination. Moreover, the study of the brain and brain diseases is amongst 
the most complex in human biology. Most current research addresses 
neurological disease in adults and the elderly, whereas the study of the child’s 
brain is proportionately underreported in the literature. Childhood represents a 
specific phase in the development of the synaptic network in the brain, 
characterized by overall remarkable plasticity. Although plasticity is present in 
the adult brain, it does not appear to involve the same set of mechanisms that 
are present in the developing brain (Ehninger et al., 2008).	   Studies on 
mechanisms that underlie activation and regulation of developmental synaptic 
plasticity in the central nervous system (CNS) are seminal in neuroscience, 
since reactivation of such mechanisms may potentially facilitate neural circuit 
plasticity during times when the adult brain is less plastic, like periods of 
rewiring after a stroke or other CNS insult. Additionally, research in this field 
may help to develop rational pharmacological approaches in order to correct 
alterations in the brain of children and adults with neurodevelopmental 
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disorders involving altered synapse formation and/or plasticity 
(Chattopadhyaya, 2011; Ehninger et al., 2008). 
The synapse is the basic unit for neuronal communication. Neuronal 
networking and neuron-to-neuron communication occurs at these specialized 
junctions, and one of the relevant fields expanding in neuroscience is the 
unraveling of the mechanisms of synaptic communication.  Neuronal 
connection complexity, specifically dendrite branching and morphology, 
facilitates and allows individual neurons to carry out specialized brain 
functions, such as social networking, learning, and memory (Kulkarni and 
Firestein, 2012). The establishment and maintenance of synaptic contacts, as 
well as synaptic plasticity, are crucial factors for normal brain function and the 
functional properties of a synapse are largely dependent on the molecular 
setup of synaptic proteins (Grabrucker, 2014). The mechanism of action of 
these pre and postsynaptic proteins is currently being unraveled but 
information about the impact of their dysfunction is also arising from several 
useful models, with mutations or deletions of genes that code synaptic 
proteins or their regulatory factors.  These models exhibit impaired neuronal 
circuitry by disrupted formation, plasticity and/or maturation of synapses. If we 
bridge this complex field of scientific knowledge with the clinical practice in 
child neurology, we can find that an extensive number of diseases, with 
different origins and heterogeneous symptoms, have a common 
pathophysiological element of disrupted synaptic function. Accordingly, the 
vast majority of child neurology disorders that exhibit manifestations like 
epilepsy, neuropsychiatric features, intellectual disability or movement 
disturbances, display primary or secondary synaptic dysfunctions (Garcia-
Cazorla et al., 2015). Actually, the concept of synaptopathy is increasingly 
being used to describe disorders in which synaptic dysfunction underlies the 
pathogenesis process.  
This work aims to contribute to the understanding of neurodevelopment 
disorders, particularly Rett syndrome (RTT) and other early encephalopathies 
with epilepsy and autistic traits. Using different approaches and different 
disease models, we have searched for molecular dysfunctions at the synaptic 
level that might underlie the signs and symptoms of these disorders. 
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1.2 The Synapse 
	  
The synapse is the functional unit of neuronal communication, corresponding 
to a specialized intracellular area, characterized at the pre synaptic level by a 
secretory machinery that allows fast, sub millisecond neurotransmitter 
release, through synaptic vesicle exocytosis when an action potential invades 
the nerve terminal (Katz, 1969) (Sudhof, 2004). At the postsynaptic level, the 
synaptic junction is enriched with clusters of neurotransmitter receptors, 
connected with intracellular signaling transduction proteins. Pre and 
postsynaptic compartments are linked by transsynaptic cell-adhesion 
molecules, which in turn are coupled to the presynaptic release machinery or 
to postsynaptic receptors, like neurexins and neuroligins, enriched at pre and 
postsynaptic membranes, respectively. Specific interactions between 
neurexins and neuroligins regulate various aspects of synaptogenesis and 
synaptic development and function, regulating the excitatory or inhibitory 
currents and their balance.  
1.2.1  Pre synaptic release machinery 
Presynaptic nerve terminals release neurotransmitters by synaptic vesicle 
(SV) exocytosis. SVs are the repositories of neurotransmitters (NTs). They 
are locally recycled at nerve terminals following exocytosis (Poudel and Bai, 
2014). These vesicles undergo Ca2+-dependent fusion with plasma 
membrane and, consequently, NTs are released to propagate chemical 
signaling between neurons. SVs exhibit an extremely high protein/lipid ratio 
(Takamori et al., 2006). Proteins account for more than 60% of the total mass 
of vesicles, suggesting that the vesicle surface is fully covered by proteins 
(Figure	   1.1	   ). SVs fuse with active zones, where they contact (“dock”) with 
plasma membrane and fusion leads to NT release. NT-filled vesicles can be 
observed in clusters in the vicinity of the active zone. These vesicles are 
subsequently primed for release. The rise in cytosolic Ca2+ that occurs during 
an action potential triggers the opening of a fusion pore between some of the 
primed, docked vesicles and the plasma membrane. A complex machinery 
that includes the SNARE (for “soluble NSF-attachment protein receptor”) 
complex and SM (for “Sec1/Munc18-like”) proteins brings the vesicle and 
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plasma membranes into close proximity before vesicle fusion and exocytosis 
(Sudhof and Rizo, 2011). Synaptobrevin, syntaxin and SNAP-25 are core 
proteins of the SNARE complex. Several of the genes that code synaptic 
vesicle proteins and presynaptic membrane proteins have been implicated in 
epilepsy and other neurological disorders (Waites and Garner, 2011). 
 
 
Figure 1.1 The glutamatergic synaptic vesicle 
a. Outside view of a SV. The model is based on space-filling models of all 
macromolecules at near atomic resolution. b. Electron Microscopy view. 
Adapted from Takamori S et al, Molecular anatomy of a trafficking organelle. Cell. 
2006;127(4):831-46 (Takamori et al., 2006). 
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1.2.2  Postsynaptic density 
The cardinal functional components of the postsynaptic specialization of 
excitatory and inhibitory synapses are the neurotransmitter receptors for 
glutamate and γ-aminobutyric acid (GABA), respectively. The postsynaptic 
side of excitatory synapses differs from inhibitory synapses not only in their 
content of NT receptors but also in their location, morphology, molecular 
composition and organization. The functional specialization at the 
postsynaptic membrane of the synapse is called the postsynaptic density 
(PSD). Receptor channels are concentrated at the postsynaptic membrane 
and interact with a dense and rich protein network comprised of anchoring 
and scaffolding molecules, signaling enzymes, cytoskeletal components, as 
well as other membrane proteins. During the development of nervous 
systems, immature neurons usually form synapses with a large number of 
target cells; many of these early connections are eliminated as the CNS 
matures, while the remaining ones are strengthened. The selective elimination 
(pruning) and strengthening of immature synapses, termed synaptic 
refinement, is essential for the development of neural circuits and behaviors.	   
These events are based in changes in conformation or concentration of PSD 
proteins, which can lead to long-term changes in synapses and neuronal 
circuits. Not only composition but also structure of PSDs change during the 
maturation of synapses (Sheng and Kim, 2011). Very relevant proteins like 
PSD-95, calcium calmodulin-dependent kinase II  (CaMKII) and α-amino-3-
hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor subunits 
increase during early postnatal development, when synaptogenesis and 
functional maturation of the synapses is taking place (Petralia et al., 2005). N-
Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors can also 
be found on neurons in early stages prior to synaptogenesis, where they may 
be involved in migration and differentiation (Petralia, 2012). Given the 
functional relationship of PSD proteins to synapse development, structure, 
and function, it is not surprising that mutations in many PSD proteins are 
associated with human neurologic and psychiatric disease (Bayes et al., 
2011) and particularly with neurodevelopmental disorders.  
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Figure 1.2 GABAergic synapse 
Schematic representation of the role of collybistin and gephyrin at the post synaptic 
site of the GABAergic synapse. Gephyrin recessive mutations result in molybdenium 
cofactor deficiency, a severe encephalopathy with intractable seizures. Collybistin 
(AHRGEF9 gene) result in severe epileptic encephalopathy. 
 
The postsynaptic region of GABAergic and glycinergic synapses is organized 
around a core scaffolding protein, gephyrin (GPHN), which forms multimeric 
complexes by auto-aggregation, and by interacting with other postsynaptic 
proteins, including GABAA receptors (GABAAR), glycine receptors (GlyR), 
neuroligins, and collybistin (Fritschy et al., 2008). Gephyrin was named from 
the Greek term for “bridge”, in line with its proposed function of connecting NT 
receptors with the postsynaptic microtubule cytoskeleton (Lionel et al., 2013), 
while collybistin is a brain-specific guanine nucleotide exchange factor, crucial 
for inhibitory synapse development. Gephyrin is also essential for 
postsynaptic stabilization of inhibitory synapses, and abnormal GPHN 
expression has been described in temporal lobe epilepsy, both in patients and 
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in animal models (Fang et al., 2011). As at excitatory synapses, synaptic 
adhesion molecules may guide the differentiation and maturation of inhibitory 
synapses by coupling axodendritic adhesion events with the recruitment of 
specific membrane and signaling proteins.  
1.3 Excitation and inhibition in the CNS 
Excitation and inhibition in the mature CNS are mediated mainly by the NTs 
glutamate and GABA, respectively. Processing of neural information is 
thought to occur by integration of excitatory and inhibitory synaptic inputs. As 
such, precise control mechanisms are needed to maintain an appropriate 
balance between each synapse type. Remarkably, neurons outfit each 
synapse type with characteristic structural and neurochemical features (Kim 
and Sheng, 2004; Luscher and Keller, 2004). For example, most excitatory 
synapses are formed through contact between glutamate-releasing axonal 
terminals and postsynaptic dendritic spines containing glutamate receptors 
(Levinson and El-Husseini, 2005). One of the basic hypotheses of the present 
thesis is based on this concept of unbalance between excitation and inhibition 
in neurodevelopmental disorders, particularly those that include epilepsy and 
autistic traits in the symptoms’ repertoire. Excitatory/inhibitory unbalance 
should be addressed from a neurodevelopmental perspective to study these 
disorders, considering the evolving changes of the CNS. In this work, focus 
was directed to the maturation of the GABAergic system, that can have 
opposite effects, depending on the developmental stage, and evolves from a 
relevant excitatory role to become the principal inhibitory system in the adult 
brain. 	  
1.3.1 Epilepsy and the Synapse 
Epilepsy, a disorder that affects 1% of the population worldwide 
(www.who.int/mental_health/neurology/epilepsy/euro_report.pdf) is classically 
thought to arise from an unbalance between excitation and inhibition either in 
a localized region, multiple brain areas or the whole brain. However, this is 
clearly a simplistic view, since several mechanisms related with synaptic 
release, ionic channels physiology, energetic metabolism and others, have 
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been arising from molecular and neurophysiological studies in epilepsy 
models.  
 
Figure 1.3 The Glutamatergic Synapse and Synaptic Proteins implicated 
in Epilepsy 
Synaptic vesicle proteins 2 (SV2) are a small family of integral transmembrane 
glycoproteins that are localized to synaptic vesicles and appear to function as 
modulators of Ca2+-dependent exocytosis. Both clinical and experimental data 
suggest that SV2, and particularly SV2A, are involved in epilepsy (Crevecoeur et al., 
2014). The anticonvulsant activity of levetiracetam (LEV), a powerful antiepileptic 
drug (AED), has been linked to its ability to bind to SV2A (Klitgaard and Verdru, 
2007). More recently developed LEV analogues, such as brivaracetam and 
seletracetam, also bind to SV2A (Matagne et al., 2008). 
The gene encoding syntaxin binding protein 1 (STXBP1, also known as MUNC18-1), 
an essential protein for synaptic vesicle release, has been associated with different 
epileptic syndromes: Ohtahara Syndrome (Saitsu et al., 2008; Saitsu et al., 2010), 
Infantile Spasms (Otsuka et al., 2010), Dravet Syndrome (Carvill et al., 2014) and 
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also other forms of epilepsy (Hamdan et al., 2011) or intellectual disability without 
epilepsy (Hamdan et al., 2011). Moreover, genetic variants of vesicle-associated 
membrane protein 2 (VAMP 2) and Synaptogamin XI have been associated with 
idiopathic generalized epilepsy (Yilmaz et al., 2014). At the post synaptic level, 
several neurotransmitter receptors, ionic channels and cotransporters, scaffolding 
molecules and signaling pathways have been implicated in epilepsy and 
epileptogenesis, and also as targets for anti epileptic drugs. Mutations in GRIN2A 
and GRIN2B encoding regulatory subunits of NMDA receptors cause mental 
retardation and early onset epileptic encephalopathy (Endele et al., 2010). 
Membrane-associated guanylate kinase inverted-2 (MAGI2) maps to 7q11.23-q21.1, 
and encodes for a scaffolding enzyme interacting with different presynaptic and 
postsynaptic receptors. A deletion including MAGI2 has been associated with 
Infantile Spasms (Marshall et al., 2008), although Röthlisberger and colaborators 
found the same deletion without including MAGI2 in patients with infantile spasms 
(Rothlisberger et al., 2010). SHANK proteins are elements of the postsynaptic 
density, linking synaptic transmission with the cytoskeleton. Deletions in SHANK2 
and SHANK3 are known genetic risk factors for a broad range of 
neurodevelopmental disorders. SHANK3 is located on the terminal end of 
chromosome 22 and is the main responsible gene for the phenotype of the 22q 
terminal deletion syndrome, also called Phelan-McDermid Syndrome. This 
neurodevelopmental syndrome presents with intellectual disability, autism, and a 
prominent severe speech delay. Seizures are common in patients with SHANK 3 
genetic defects (Soorya et al., 2013). Adapted from [Neuronal communication and 
synaptic metabolism in childhood epilepsy]. García-Cazorla À, Cortès-Saladelafont 
E, Duarte S. Rev Neurol. 2015 Mar 1;60(5):219-28. (Garcia-Cazorla et al., 2015) 
 
Long-term changes in presynaptic morphology and synaptic vesicle recycling 
have been described in animal models (Zhou and Roper, 2010). These 
changes include alterations in the structure of mossy fiber synaptic buttons, 
including increased size, number of release sites, and number of vesicles in 
the reserve pool and in the readily releasable pool (Casillas-Espinosa et al., 
2012). Moreover, mutations in genes that code for elements of the NT release 
machinery, and the efficacy of anti-epileptic drugs that act at the synaptic 
vesicle level bring the attention for the relevance of the presynaptic 
compartment for epilepsy. At the postsynaptic level, NT receptors, scaffolding 
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molecules and ion channels have also been implicated, as depicted in Figure 
1.3. 
From a child neurology perspective, it is particularly relevant to consider the 
normal patterns of brain maturation, regarding the GABAergic and 
glutamatergic systems. The immature brain is skewed towards excitation and 
different molecular mechanisms contribute for this status: the depolarizing 
effect of GABA and the high expression of AMPA and NMDA receptors with a 
composition that enhances excitability of neuronal networks. 
1.4 Synaptic Plasticity 
Chemical synapses are remarkable for their evolutionary specialization, 
serving as highly specialized cell junctions in the body, and retain 
considerable plasticity throughout their lifetime. Synaptic plasticity can be 
defined as enduring activity-driven changes in the efficacy of synaptic 
transmission (Chapleau et al., 2009). The strength of synaptic transmission 
can be modulated by either presynaptic or postsynaptic mechanisms and 
changes in this strength can last from a few hundred milliseconds to weeks or 
even longer. Short-term plasticity mechanisms are predominantly mediated 
through local modifications of proteins, while long-term plasticity leads to 
structural changes in synaptic contacts and is dependent on de novo protein 
synthesis (Lynch, 2004). Synaptic plasticity is considered as the basis for all 
key functions of the brain, including the processes of learning and memory 
(Grabrucker, 2014). The “hot spot” of this structural plasticity is the dendritic 
spine. Dendritic spines are small protrusions extending from dendrites that are 
the main postsynaptic site of excitatory glutamatergic synapses in the brain. 
The dynamic and plastic nature of spines observed in vitro (Fischer et al., 
1998) and in vivo (Mizrahi et al., 2004) supports the hypothesis that changes 
in the shape and number of spines contribute to the mechanisms of memory 
formation and storage (Chapleau et al., 2009; Ethell and Pasquale, 2005; 
Nimchinsky et al., 2002; Yuste and Bonhoeffer, 2001) 
The most well established models for activity-dependent synaptic 
strengthening and weakening are long-term potentiation (LTP) and long-term 
depression (LTD), respectively. Structural changes linked to synaptic strength 
can be addressed experimentally with stimulation patterns that induce long-
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term potentiation (LTP). LTP induces changes in spine number and 
morphology in regions important in learning and memory, such as the 
hippocampus and cortex. Induction of LTP followed by electron microscopy 
analysis revealed increases in spine size and number in the hippocampus and 
spine number in the neocortex (Harms and Dunaevsky, 2007). Unraveling the 
molecular mechanisms governing long-term synaptic plasticity is a key to 
understanding how the brain stores information in neural circuits and adapts 
to a changing environment. Mutations in genes that code proteins which are 
key players in synaptic plasticity, are considered the cause of several genetic 
neurodevelopmental disorders like RTT, Angelman Syndrome, Tuberous 
Sclerosis, Neurofibromatosis type 1 and Fragile X. 
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1.5  GABA 
GABA is the major inhibitory neurotransmitter in the adult brain. Glutamatergic 
neurons correspond to 80 to 90% of the neuronal population in the cortical 
Box 1. Glutamatergic Synapse Plasticity and Genetic Neurodevelopmental disorders  
 
Evidence indicates that many of the genes that are mutated in neurodevelopmental disorders 
with epilepsy, autistic traits and cognitive impairment are crucial components of the activity-
dependent signaling networks that regulate synapse development and plasticity. Deregulation of 
activity-dependent signaling pathways in neurons may therefore have a key role in these 
disorders. The Ras/ERK and PI3K/mTOR signaling pathways couple synaptic activity to the 
translational machinery and play essential roles in protein synthesis-dependent LTP and LTD. 
The PI3K/mTOR signaling cascade is a central regulator of cell growth, proliferation, survival, and 
cap-dependent protein translation. In brain, components of the mTOR pathway are present at 
synapses, where they regulate dendritic spine morphology, and are essential to synaptogenesis. 
Inactivating mutations in several negative regulators of the ERK and mTOR pathways, including 
NF1, PTEN, and TSC1/2, are responsible for genetic disorders with a high prevalence of 
cognitive impairment and autism. FMRP represses translation of specific target mRNAs, and loss 
of FMRP expression in fragile X syndrome also leads to cognitive impairment and autism. These 
signaling pathways are recruited downstream of the activation of NMDA receptors, metabotropic 
glutamate receptors, and neurotrophin Trk receptors.  
Interestingly, the Akt-mTOR (but not the 
ERK) signaling pathway is also affected in 
this RTT mouse model, although in this case 
the Akt-mTOR proteins (Akt, mTOR, 
p70S6K and S6) are hypophosphorylated, 
resulting in reduced protein synthesis. 
Addit ionally, BDNF levels reduction 
described in RTT can contribute to the 
pathway downregulation, since BDNF/TrKB 
signaling is a relevant upstream trigger . It 
has been postulated that the performance of 
neuronal networks mediating cognition is a 
function of the level of synaptic protein 
synthesis.  
Increases or decreases in the levels of plasticity-related proteins available to active synapses in 
autistic neurons may cause corresponding changes in synaptic connectivity, compromising 
network performance and producing cognitive impairment. In several single-gene disorders 
associated with autism, such as Fragile X syndrome, levels of synaptic protein availability and 
connectivity are increased, but in Rett’s syndrome these levels are decreased. In spite of an 
upregulation or a downregulation of protein synthesis synaptic pathways, with an increase (A) or 
decrease (B) in synaptic density,  these disorders have in common clinical features like epilepsy, 
autistic traits and cognitive impairment and also aberrant spine morphology an impaired LTP in 





Adapted from Kelleher 
and Bear, 2008, Irwin et 
al, 2000, Landi et al, 2011 
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circuits whereas GABAergic neurons constitute the remaining 20 to 10%. 
However, in spite of this underrepresentation, GABA plays a crucial role in 
controlling the activity of neurons in the entire brain (Hu et al., 2014). GABA-
producing inhibitory interneurons are essential for regulating cortical 
excitability and coordinating appropriate behaviors. GABAergic interneurons 
control several aspects of neuronal circuit function from neuronal excitability 
(Swadlow, 2003) and integration (Pouille and Scanziani, 2001), to the 
generation of temporal synchrony and oscillation among networks of 
excitatory neurons (Somogyi and Klausberger, 2005) thought to support 
distinct brain states and high cognitive functions (Klausberger and Somogyi, 
2008). Interneuron dysfunction has been implicated in many disorders like 
epilepsy (Freund and Katona, 2007), autism (Yip et al., 2008), schizophrenia 
(Nakazawa et al., 2012), several neurodevelopmental disorders like fragile X 
(Cea-Del Rio and Huntsman, 2014) and RTT (Tomassy et al., 2014) and can 
contribute to impairments in learning and memory or social behaviors.  
GABA receptors are the major inhibitory receptors in human synapses. They 
are of two types. GABA A receptors (GABAAR) are fast-acting ligand gated 
chloride ion channels that mediate membrane depolarization and thus inhibit 
NT release (Michels and Moss, 2007). GABA B receptors are slow acting 
metabotropic G protein coupled receptors that act via the inhibitory action of 
their G alpha/Go subunits on adenylate cyclase to reduce cAMP levels and 
decrease Protein Kinase A activity.	   In addition, their G beta/gamma subunits 
interact directly with N and P/Q Ca2+ channels to decrease the release of 
Ca2+. GABA B receptors also interact with Kir3 K+ channels and increase the 
influx of K+, leading to cell membrane hyperpolarization and inhibition of 
channels such as NMDA receptors (Pinard et al., 2010). Antagonists of GABA 
were recognized as epileptic agents leading to the classical concept of the 
excitatory/inhibitory balance needed to avoid seizures and hyperactivity. This 
was further reinforced by the discovery of the antiepileptic actions of pro-
GABA drugs like the benzodiazepines and phenobarbital (de Los Heros et 
al.). However, GABAergic systems fulfill a plethora of roles (Ben-Ari, 2014) 
that evolve during neural development and, as a consequence, 
pharmacological actions of GABA receptors targeted drugs translate these 
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developmental changes. Finding viable therapeutic treatments to modulate 
GABAergic transmission in neurodevelopmental disorders is thus both of 
great relevance and a big challenge. Addressing this issue implies the study 
of the fine modulation of GABAergic transmission during physiological 
conditions as a starting point to tackle dysfunctional transmission in 
neurodevelopmental disorders. The overall goal of such a challenging 
approach is to find a way to safely modulate GABAergic signaling without 
questioning the delicate equilibrium of the neuronal-network activity in a 
developing brain (Deidda et al., 2014). 
1.5.1 GABA during development 
The immature brain is highly susceptible to seizures. This heightened 
susceptibility is related, at least in part, to developmental changes that skew 
the balance between excitatory and inhibitory neurotransmitter systems in the 
brain, in favor of the former (Brooks-Kayal, 2005). During early development, 
GABA is depolarizing and mostly excitatory due to high intracellular chloride 
concentration (see section 1.5.1.1) and GABAergic interneurons regulate key 
developmental steps, from cell migration and differentiation to experience- 
dependent refinement of neuronal connections (Ben-Ari, 2002). In recent 
years, many studies have started to elucidate the development and function of 
cortical GABAergic circuits (Chattopadhyaya, 2011). BDNF also plays a 
critical role in migration and maturation of GABAergic interneurons. Once 
neurons have finished their migration and differentiation, they start shifting 
from a largely genetically oriented sequence of development to one in which 
the environment plays a progressively determinant role via synaptic currents. 
One of the first problems that the developing neuron must solve is how to 
establish and preserve equilibrium between excitation and inhibition. In adult 
neurons, inhibition is principally mediated by GABAergic synapses that 
generate a hyperpolarization via chloride permeable channels (Gozlan and 
Ben-Ari, 2003). However, during the first stages of development GABA 
actions can skew the excitatory/inhibitory actions towards excitation. 
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1.5.1.1	  Cation	  Chloride	  Cotransporters	  
GABA exerts its fast hyperpolarizing effect through activation of anion- 
permeable GABAA receptors, predominantly Cl− (Kaila, 1994). The inhibitory 
postsynaptic potentials (IPSPs) generated in mature neurons by GABAA and 
glycine receptors activation are dependent of a low intracellular chloride 
concentration (Kaila et al., 2014a). Intracellular chloride concentration is 
reduced in mature neurons due to a developmental upregulation and 
functional activation of the neuron-specific K+– Cl− cotransporter 2 (KCC2) 
that extrudes chloride from the cell (Rivera et al., 1999; Stein et al., 2004) 
(Zhu et al., 2005). However, during early development, GABAA-receptor-
mediated responses are often depolarizing and this property might be relevant 
for several developmental phenomena like neuronal proliferation, migration 
and consolidation of synaptic connections. The magnitude and direction of the 
ionic current through GABAARs depends on its driving force, defined as the 
difference between the electrochemical equilibrium potential of Cl- anions 
(reversal potential, Ecl) and the resting membrane potential of the neuron. If 
this difference is positive or negative, there will be a net flux of Cl- anions 
through the plasma membrane following GABAAR opening, and this will result 
in a change in the membrane potential of the neuron. In particular, the net flux 
of Cl- anions through GABAAR (i.e., toward inside or outside the cell) is 
defined by its intracellular concentration ([Cl-]i). (Deidda et al., 2014). The 
higher intracellular chloride concentration in young neurons depends on high 
expression of NKCC1 (Dzhala et al., 2005), and results in depolarizing 
GABAAR transmission. As development proceeds, KCC2 becomes 
expressed at higher levels than NKCC1 (Dzhala et al., 2005; Rivera et al., 
1999), and hyperpolarizing GABAergic transmission takes over (Ben-Ari, 
2002) (Cancedda et al., 2007) (Sernagor et al., 2010). Balanced activity of 
NKCC1 and KCC2 is therefore determinant for neuronal response to GABA 
(Deidda et al., 2014). 
The mammalian KCC2 gene generates two N-terminal splice isoforms, 
KCC2a and KCC2b, but only the of expression of KCC2b is strongly up- 
regulated during development, and accounts for most (> 90%) of the total 
KCC2 protein in the adult murine cortex (Uvarov et al., 2009). GABAergic 
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responses remain depolarizing in KCC2b knockout cortical cultures (Zhu et 
al., 2005), indicating that this isoform is responsible for the establishment of 
hyperpolarizing GABAAR-mediated transmission (Blaesse et al., 2009). 
Homozygous KCC2b knockout mice exhibit generalized seizures and die 
during the second postnatal week, whereas KCC2b heterozygotes, which 
express ~50% of the wild-type mouse KCC2 (mKCC2) protein level (Huber et 
al.), show increased susceptibility to induced seizures (Woo et al., 2002). 
Aditionally, genetic ablation of KCC2 prevents spinogenesis and excitatory 
synapse formation in immature neurons, through a mechanism independent 
of KCC2 transporter function that requires instead its interaction with actin 
binding (Chamma et al., 2013). Indeed, KCC2 could act as a synchronizing 
factor in the functional development of glutamatergic and GABAergic 
synapses in cortical neurons and networks(Li et al., 2007). 
In immature neurons, BDNF–TrkB signalling promotes KCC2 expression  
(Aguado et al., 2003; Carmona et al., 2006; Ludwig et al., 2011). In contrast, 
in mature neurons the BDNF/TrkB signaling mediates activity-dependent 
decrease in KCC2 expression, and this decrease can contribute to the 
pathogenesis of epilepsy after an insult like ischemia or trauma, bringing the 
cells to a hyperexcitable state (Overman and Carmichael, 2014) (Kaila et al., 
2014b). BDNF is secreted after an insult and the KCC2 decrease seems to be 
an adaptative mechanism that has the secondary effect of increased 
excitability and epilepsy. For instance, the frequently reported downregulation 
of KCC2 following neuronal trauma may be part of a general adaptive cellular 
response that facilitates neuronal survival by reducing the energetic costs, 
needed to preserve low intracellular chloride concentration and also by 
facilitating functional recovery through the removal of GABAergic inhibitory 
constraints on neuroplasticity (Kaila et al., 2014a).  
The process of development of hyperpolarization after GABAAR activation 
seems to include an upregulation of KCC2 expression, but also post 
transcriptional mechanisms like phosphorylation and fast membrane 
trafficking of the cotransporter. Bumetanide sensitive NKCC1 (Na+-K+-2Cl- 
cotransporter, which allows chloride to accumulate inside the cell) is also 
involved, since higher intracellular chloride concentration in young neurons 
	   	  Chapter 1 
 
	   37	  




Figure 1.4 Schematic representation of the developmental switch in 
chloride cotransporters expression  
KCC2 transports Cl− out of the cell; NKCC1, transports Cl− into the cell. The 
developmental increase in KCC2 and the decrease in NKCC1 triggers the switch 
from depolarizing to hyperpolarizing GABAAergic signaling (Brooks-Kayal, 2005; 
Galanopoulou, 2008a). Adapted from [Neuronal communication and synaptic 
metabolism in childhood epilepsy]. García-Cazorla À, Cortès-Saladelafont E, Duarte 
S. Rev Neurol. 2015 Mar 1;60(5):219-28. (Garcia-Cazorla et al., 2015) 
 
Since the limitations of experimentation in humans have been an obstacle in 
obtaining direct evidence for the age-related changes in GABAAR physiology 
(Galanopoulou, 2008a), we need to find strategies to understand GABAAR 
physiology in vivo, in humans. This understanding will allow the delineation of 
improved treatments for early epilepsies, where this process might be in 
course and not completely developed (Puskarjov et al., 2014).   
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1.5.2  Rett Syndrome and the Synapse 
Rett syndrome (RTT; MIM 312750) was first identified by Andreas Rett in 
1966, after the observation of 22 patients with similar unique symptoms (Rett, 
1966).  The constellation of features that represent RTT became more widely 
recognized as a specific neurodevelopmental disorder after subsequent larger 
studies by Hagberg et al (Hagberg et al., 1983). This rare 
neurodevelopmental disorder is caused primarily by mutations in the X-linked 
gene MECP2 (Methyl-CpG binding Protein 2). RTT is considered the leading 
cause of severe intellectual disability in females with a prevalence estimated 
at 1/9,000 in girls under the age of 12, whereas prevalence in the general 
population is estimated at approximately 1/30,000 (source: Orphanet).  
1.5.3 Clinical features 
Patients with RTT appear to develop normally up to 6–18 months of age. 
They typically achieve normal neurodevelopmental milestones, from gross 
and fine motor functions to social communication skills. The head 
circumference of RTT patients is normal at birth but head growth begins to 
decelerate and leads to microcephaly by the second or third year of life. 
Distinctive aspects contributing to the diagnosis include developmental 
regression, with accompanying loss of hand skills, mobility skills, and speech 
and stereotypic hand movements. As the syndrome progresses, social 
withdrawal and loss of language become apparent with features reminiscent 
of autistic traits. The onset of cognitive deterioration is accompanied by loss of 
motor coordination and the development of ataxia and gait apraxia. 
Associated features such as respiratory/autonomic abnormalities (Julu et al., 
2001), seizures, scoliosis, growth deficits and early hypotonia are very 
prevalent. Neurophysiologic evaluations show cortical hyperexcitability on the 
electroencephalogram (Willemsen et al.) and the occurrence of rhythmic slow 
activity, primarily in the frontal-central regions. Epilepsy is frequent in RTT, 
has an age-related pattern of occurrence and is associated with greater 
clinical severity. Other associated abnormalities during the postregression 
phase include teeth grinding, night laughing or crying, screaming fits and 
anxiety episodes elicited by distressing external events (Mount et al., 2001). 
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Most girls with RTT lose mobility and are often wheelchair-bound with severe 
scoliosis and dystonia during the teenage years. Impairment of the autonomic 
nervous system in RTT is suggested by vasomotor disturbances like 
hypotrophic cold blue feet, life threatening cardiac abnormalities (tachycardia, 
prolonged corrected QT interval, and sinus bradycardia) that can contribute to 
the higher incidence rate of sudden unexpected death in RTT patients, severe 
constipation, oropharyngeal dysfunction and abnormal breathing patterns.  
Even with high risk of sudden death because of respiratory and cardiac 
dysfunctions, several patients survive till the 6th or 7th decade of life with 
limited mobility (Chahrour and Zoghbi, 2007; Glaze et al., 2010; Hagberg, 
2005; Neul et al., 2010; Zoghbi and Bear, 2012).  
1.5.4 MeCP2 
During development, the expression pattern of different groups of genes are 
precisely regulated in a spatiotemporal manner, with intervention of multiple 
gene regulatory mechanisms (Ding, 2015). Time and space are the key 
metrics to all cortical operations, and developmental events such as regional 
patterning, neurogenesis, differentiation, migration, axogenesis, and 
synaptogenesis have different developmental timings that may vary 
throughout the CNS, increasing the complexity of this process. As in other cell 
types, precise control of neuronal gene expression is accomplished in part 
through the regulation of chromatin. Early studies found that MeCP2 interacts 
specifically with methylated cytosine with guanine (mCG) (Jones et al., 1998; 
Lewis et al., 1992; Nan et al., 1996). Recent in vivo studies in the adult mouse 
brain confirm the preference of MeCP2 for mCG over nonmethylated CG, 
although MeCP2 clearly binds widely across the entire genome (Skene et al., 
2010). Using mice in which the MeCP2 protein is tagged with a fluorescent 
green protein, Chen and coworkers (Chen et al., 2015) determined genome-
wide MeCP2 binding profiles in the adult animal brain. In addition to the 
expected finding of MeCP2 binding to methylated cytosine with guanine 
(mCG) with high affinity, they also found that MeCP2 binds to cytosine when it 
is followed by either adenine, cytosine or thymine instead of guanine (non-CG 
methylation or mCH). Whole-genome analysis using base-pair DNA 
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methylation and MeCP2 binding profiles indicate that MeCP2 shows the 
highest binding affinity for mCG, followed by mCH, and then significantly 
lower affinity for nonmethylated DNA elements. Chen and coworkers propose 
a model to explain why RTT patients have an initial period of postnatal life 
without symptoms: (i) During postnatal brain development the levels of 
MeCP2 and mCH increase as neurons mature, whereas mCG remains 
relatively stable. (ii) When DNA methylation patterns are fully developed 
together with higher levels of MeCP2 in the adult brain, differential binding 
affinity of MeCP2 for mCG, mCH and nonmethylated DNA becomes apparent. 
(iii) In this context, MeCP2 can now bind available mCH sites to influence 
transcription. Thus, changes to MeCP2 levels or function, which lead to 
disease related phenotypes, only become apparent after a long period of 
brain maturation. 
MeCP2 functions at multiple levels, from transcriptional control to post-
transcriptional regulation, and it is recognized as a key regulator in various 
cell types including excitatory neurons, inhibitory neurons, and glia. 
Furthermore, MeCP2 protein undergoes multiple posttranslational 
modifications such as phosphorylation, SUMOylation and acetylation, which 
impact its functions. 
Neuronal activity induces the phosphorylation of MeCP2 at Ser421 (Zhou et 
al., 2006) raising the possibility that activity-dependent phosphorylation of 
MECP2 mediates a genome-wide chromatin response to neuronal activity 
(Cohen et al., 2011). This fact can also contribute for the first manifestations 
of RTT in the first year of life — a time when experience is shaping synapse 
development. MeCP2 is a chromatin regulator that is modified in response to 
neuronal activity, which suggests that RTT may be due to a defect in the 
process of activity-dependent MecP2 mediated chromatin regulation or gene 
transcription that controls synaptic development, plasticity and behavior. The 
formation and adaptation of functional circuits within the brain is modulated by 
experience, like what happens with the acquisition of language during a 
child's development: the sounds of words spoken and heard lead to signaling 
between neurons within the brain and trigger changes in gene expression that 
promote connectivity. This type of experience-dependent gene activation 
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appears to rely on MeCP2 phosphorylation (Cohen et al., 2011; Tao et al., 
2009; Zhou et al., 2006). MeCP2's role in translating extracellular cues into 
the changes in gene expression is determinant for brain development and 
function (Cohen and Greenberg, 2010) and provides some insights to 
understand synaptic impairment in RTT. Accordingly, MECP2 has recently 
been shown to be required for experience-dependent synaptic remodelling of 
the retinogeniculate synapse. In Mecp2 knockout mice, the initial development 
and refinement of the retinogeniculate circuit proceeds without impairment, 
during a phase of development that does not depend on visual experience. 
However, during a late stage of development when visual experience is 
required for modulation and maintenance of the retinogeniculate circuit, the 
synapses that form on the neurons within this circuit are abnormal in Mecp2 
knockout mice, resulting in impaired synaptic plasticity on visual deprivation. 
This supports the possibility that during the late phase of development of the 
retinogeniculate circuit, MECP2 may regulate an experience-dependent gene 
expression program that controls synaptic remodelling, a program that could 
potentially be controlled by activity-dependent phosphorylation of MECP2 
(Noutel et al., 2011). 
RTT is mainly caused by MeCP2 deficiency, but duplications of MECP2-
containing loci are also detrimental to neural development and proper brain 
functions. Patients carrying MECP2 duplications usually manifest autistic 
features, mild RTT phenotypes, and mental retardation (Ramocki et al., 2009). 
All these results underscore the importance of the homeostatic modulation of 
MeCP2  expression, indicating that the dosage of MeCP2 protein is critical for 
the development of the CNS (Cheng and Qiu, 2014). 
There is also evidence that loss of MeCP2 impacts on the balance between 
inhibition and excitation in the brain, altering the neuronal response to sensory 
experience, with interference in glutamatergic system (Dani et al., 2005) and 
also in GABAergic system (Chao et al., 2010). Regional quantifications of 
GABA and glutamate suggest that this unbalance varies through different 
brain areas, and seems to impact mainly GABAergic system and, to a less 
extent, the glutamatergic one (El-Khoury et al., 2014). 
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Together, these studies suggest that MeCP2 is a key regulator of chromatin 
architecture and gene expression that modulates synaptic development, 
function and plasticity, and that RTT can be considered a synaptopathy 
(Boggio et al., 2010) (Weng et al., 2011). 
1.5.4.1	  Rett	  Syndrome,	  BDNF	  and	  adenosine	  
Since its discovery almost three decades ago, the secreted neurotrophin 
BDNF has been firmly implicated in the differentiation and survival of neurons 
in the CNS. More recently, BDNF has also emerged as an important regulator 
of synaptogenesis and synaptic plasticity mechanisms, during development 
and adult life. BDNF actions are exerted through p75 neurotrophin receptors 
and also Trk receptors (Figure 1.5).	   Among neurotrophins, BDNF, and its 
major receptor TrkB, has the most abundant and widespread expression in 
the developing and adult mammalian brain (Murer et al., 2001). BDNF is a 
critical player in activity-dependent neuronal development, not only for its role 
in normal physiology but also for the multiple links to neurodevelopmental 
disorders associated with mental retardation and autism spectrum disorders. 
Indeed, deregulation of any step in BDNF synthesis and release (i.e. 
transcription, translation, vesicular packaging, processing and trafficking, 
Ca2+-dependent regulated release, and signaling) may result in improper 
axonal, dendritic and synaptic development, as well as impaired activity-
dependent refinement of synaptic connections during brain development. 
BDNF binding to the TrkB receptor has been shown to promote the induction 
and maintenance of LTP, and BDNF or TrkB deficient mice exhibit a marked 
reduction in LTP (Cao et al., 2013). Through TrkB signaling, BDNF exerts a 
determinant action in synaptic plasticity orquestrating a process that involves 
de novo synthesis of synaptic proteins, along with protein trafficking and 
degradation. In response to synaptic inputs, the time, place, and amount of 
cellular protein synthesis needs to be fine-tuned. Disruptions in this process 
are at the basis of several neurodevelopmental disorders and BDNF interacts 
with several protein products of genes already implicated in these disorders 
like TSC 1 and 2, PTEN or FMRP (Panja and Bramham, 2014). 
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Figure 1.5 BDNF-TrkB signaling Regulates Multiple Events through 
PLCγ, PI3K and MAPK pathways.  
PI3K pathway regulates trafficking and PSD-95 to a synapse and cAMP regulates 
formation of synaptic PSD-95-TrkB complex. BDNF-TrkB signaling activates 
MAPK/Erk, increasese cAMP and activate CREB-regulated gene transcription. 
BDNF-TrkB signaling regulates protein translation through both MAPK/Erk and PI3K-
Akt-mTOR pathways. Adapted from Yoshii A, Constantine-Paton M. Postsynaptic 
BDNF-TrkB signaling in synapse maturation, plasticity, and disease. (Yoshii and 
Constantine-Paton, 2010) 
 
While a physiological amount of BDNF in the normal brain has been 
demonstrated to have positive effects on learning and memory, both 
increased and decreased levels of BDNF may disrupt the equilibrium between 
inhibitory and excitatory neurotransmission in the brain (Singh et al., 2006), 
leading to a loss of synaptic refinement and consequently impairing LTP, 
learning and memory (Johnson et al., 2007). 
An increasing body of evidence points to a deregulation of BDNF signaling in 
RTT. MeCP2 transcriptionally regulates BDNF. Lower Bdnf mRNA and BDNF 
protein levels, as well as impaired BDNF trafficking and activity-dependent 
release, have been highlighted as pathophysiological mechanisms of RTT 
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disease progression (Xu et al., 2014). Indeed, conditional Bdnf mutant mice 
show a similar phenotype to that observed in Mecp2 deficient mice. The 
similar phenotypic traits are: hindlimb clasping that mimics the stereotypic 
hand-wringing behavior characteristic of RTT patients, small brain weight and 
small neuronal size (Chang et al., 2006). On the other hand, several 
strategies to treat RTT through the manipulation of BDNF signaling have been 
tried with promising results (Chapleau et al., 2009). In spite of these results, 
the clinical use of BDNF has been hampered by critical limitations like the 
inability of BDNF to penetrate the blood brain barrier (BBB) and its short in 
vivo bioavailability (Zuccato and Cattaneo, 2009). Recently, a new line of 
investigation was initiated to identify small molecules that could potentiate the 
actions of endogenous neurotrophic factors present in the nervous system. 
One of the drugs attracting much attention is adenosine, due to its ability to 
modulate the actions of several molecules, including BDNF, in the nervous 
system mostly through the activation of adenosine receptors of the A2A 
(A2AR) and A1 (A1R) subtypes. Modulation of adenosine receptors has long 
thought to be a useful strategy in the treatment of multiple pathological states 
in the nervous system, such as sleep disorders, epilepsy and 
neurodegenerative diseases (Sebastiao and Ribeiro, 2009a). Actually, clinical 
trials using drugs that modulate adenosine receptors were already developed 
(Chen et al., 2007). Moreover, adenosine kinase (ADK) manipulation could 
also be other way to modulate adenosine levels. ADK, by phosphorylating 
intracellular adenosine to AMP, maintains an inward adenosine gradient, 
driving adenosine influx into the cell (Boison, 2009). When ADK levels are 
decreased, the resulting increase in adenosine levels leads to resistance to 
epileptic seizures and neuronal cell loss (Li et al., 2008). Interestingly, it was 
recently demonstrated that in transgenic mice that underexpress ADK in the 
forebrain, and therefore where adenosine levels are increased, BDNF effects 
upon synaptic transmission are strongly favoured due to the activation of 
A2ARs by endogenous adenosine (Diogenes et al., 2012).  
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In summary, A1R are typically inhibitory receptors and its activation has been 
suggested to be important in the control of epilepsy (Boison, 2009). A2ARs 
are excitatory receptors which activation is known to potentiate synaptic 
actions of BDNF (Sebastiao et al., 2011). Therefore, controlling epilepsy 
through the activation of A1Rs, and potentiating BDNF effects by the 
Box 2. Adenosine, Adenosine receptors and modulation of BDNF signaling by A2AR 
 
ATP and adenosine (ado) are essential components of all living cells, where they mediate 
energy conversion and nucleic acid synthesis. In addition to these functions, both molecules 
play a pivotal role in extracellular signaling. Whereas ATP may function as a neurotransmitter, 
co-transmitter, gliotransmitter, or even a neuromodulator at specific synapses, adenosine 
always assumes neuromodulatory actions. Adenosine clearance is mostly mediated by 
astrocytic adenosine kinase, which phosphorylates intracellular adenosine to AMP and critically 
controls homeostatic adenosine actions. Adenosine activates P1 receptors, composed of high-
affinity (A1 and A2A) and low-affinity (A2B) receptor subtypes; A3 receptor affinity for adenosine 
is species-dependent, and is high in humans and low in rodents. 
Basal extracellular adenosine levels are likely to only activate high-affinity A1R and A2ARs, the 
main receptors activated with basal adenosinergic brain tonus.  
A2A A2B A1 A3 
ADO 
The adenosine A2AR is a  G-
protein-coupled receptor  that 
has been extensively studied 
during the past few decades 
because it offers numerous 
possibilities for therapeutic 
applications. 
Signaling cascades activated by adenosine A 
2A and TrkB receptors: Adenosine A2AR are 
mainly implicated in the activation of G 
proteins and the cAMP/PKA signaling 
pathway. TrkB receptors predominantly signal 
through the activation of PLC!, Akt and 
MAPK pathways. As depicted in the figure, 
the presence o f common s igna l ing 
intermediates downstream A2A and TrkB 
receptors might account for the facilitatory 
action of adenosine A2ARs activation upon 
TrkB-mediated effects. Activation of A2ARs 
also induces translocation of TrkB receptors 
to lipid rafts. TrkB localization in these 
membrane microdomains is important for 
BDNF actions and may be involved in the 
modulation of TrkB-mediated signaling 
cascades by A2ARs. 
Adapted from De Lera Ruiz et al, 2014;  Dias et al, 2013; Sebastião et al, 2011 
A2AR 
	   	  Chapter 1 
 
	   46	  
activation of A2ARs, adenosine-based strategies emerges as a great 
possibility for RTT pharmacological treatment. Although systemic application 
of adenosine is precluded by peripheral side effects, several delivery 
approaches have been designed to overcome this problem (Boison, 2009). 
Focal adenosine achieved by devices such as synthetic slow-release 
polymers, pump systems, cellular implants or cell therapy or gene therapy 
approaches to locally augment the adenosine system are options already 
explored for epilepsy treatment and therefore reasonable to be considered for 
RTT patients. Another possibility is the use of specific receptor agonists, in 
order to modulate adenosinergic system. 
1.6 Epileptic encephalopathies and the Synapse 
Early seizures impact the neural development of thousands of human 
newborns, annually. Understanding the deleterious effects of seizures in early 
brain development and the molecular mechanisms underlying their origin is 
fundamental for age and mechanism specific treatment. Epileptic 
Encephalopathies (EEs; MIM 308350) are conditions in which epileptic activity 
dominates the clinical picture (Dulac, 2001), associated with cognitive 
impairment and autism. 
Classically, the term epileptic encephalopathy presupposes that epilepsy itself 
contributes to encephalopathy. However it is often difficult to weigh the role of 
epilepsy in newborns or infants against pre-existing severe neurological 
dysfunction, given that neither seizures nor electroencephalographic 
abnormalities substantially modify a poor outcome that is mainly explained by 
the underlying etiology, and its interference with normal brain development 
(Basel-Vanagaite et al., 2013). EEs are age-dependent, and the 
corresponding unique developmental window of onset seems to confer 
disease susceptibility. Ohtahara Syndrome (OS), Early Mioclonic Epilepsy 
(EME), and West Syndrome (WS) are associated with severe developmental 
outcomes. The etiology in many patients remains undetermined.  
Early infantile epileptic encephalopathy with suppression-burst (EIEE) is the 
earliest form of infantile epileptic syndrome and includes OS and EME. The 
transition from EIEE to WS occurs in 75% of individuals with EIEE, suggesting 
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a common pathological mechanism between these two syndromes (Saitsu et 
al., 2010).  
 
 
Figure 1.6 Genes implicated in early epileptic encephalopathies and the 
synapse 
A significant group of proteins coded by genes mutated in EIEEs have relevant roles 
at the synaptic level, mainly at the pre and postsynaptic densities, but also in 
astrocytes, that reduce the excess of glutamate in the synaptic cleft. Adapted from 
Allen NJ, Barres BA. Neuroscience: Glia - more than just brain glue. Nature. 2009; 
457(7230):675-7 (Allen and Barres, 2009) 
Recent genetic studies have identified a variety of genes implicated in EE 
(Backx et al., 2009; Kato et al., 2010; Kurian et al., 2010; Otsuka et al., 2010; 
Paciorkowski et al., 2011a; Paciorkowski et al., 2011b; Saitsu et al., 2012). 
These genes fall broadly into two categories: either linked to the development 
of the GABA forebrain system, or to synaptic function. GABA is considered to 
have a role not only in ictogenesis but also in the pathogenesis of the 
associated cognitive and behaviour impairments. In particular, genetic 
predisposition to EE may create an unbalance between excitation and 
inhibition through a preferential impair of GABAergic inhibition. Identifying new 
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genetic players in patients with both cognitive dysfunction and epilepsy may 
define key cellular pathways involved. The molecular diagnosis workup is 
challenging since similar phenotypes are associated with mutations in 
different genes and since mutations in one given gene can be associated with 
very different phenotypes (Milh et al., 2013). The immaturity of GABA 
inhibitory system and its dysregulation induced by seizures has been 
postulated as a pathophysiology mechanism.  
1.7 Autism Spectrum Disorders and the Synapse 
Autism spectrum disorders (ASD) affect about 0.7-1% of children and are 
characterized by deficits in social communication, absence or delay in 
language, and stereotyped and repetitive behaviors. In Portugal, the 
prevalence estimation of ASD for mainland Portugal and the Azores is  close 
to 10 per 10 000 children (Oliveira et al., 2007). ASD are defined by 1) deficits 
in social communication and social interaction and 2) restricted repetitive 
behaviors, interests, and activities. 
Several studies have identified genes implicated in synaptic dysfunction in 
patients with ASD. Moreover, mutations in genes associated with abnormal 
cellular or synaptic growth rate like TSC1/TSC2, NF1 or PTEN are identified 
in patients with syndromic ASD with tuberous sclerosis, neurofibromatosis or 
macrocephaly.  
Mutations in NLGN3/4, SHANK3, or NRXN1 alter synaptic function and lead 
to mental retardation, typical autism, or Asperger syndrome. The mTOR/ PI3K 
pathway is associated with abnormal cellular/synaptic growth rate, whereas 
the NRXN–NLGN–SHANK pathway is associated with synaptogenesis and 
imbalance between excitatory and inhibitory currents. 
The unbalance between excitation and inhibition can also be related with an 
abnormal maturation of GABAergic function in autism (Zimmerman and 
Connors, 2014).  
In summary, several synaptic role players have been reported as relevant for 
ASD and the study of these mechanisms is opening new therapeutic 
perspectives. 
	   	  Chapter 1 
 
	   49	  
1.8 From rare to common disorders 
Rare disorders, also called orphan disorders are individually rare but 
collectively have a significant prevalence. In the European Union (EU), rare 
disorders, defined as prevalence of less of 5 in 10 000, affect 6-8% of EU 
citizens, since there are 5000-8000 disorders in this category. 
Their burden is amplified by the fact that clinical trials are difficult to perform in 
small numbers of patients, and commercial and political interest is reduced 
since the potential use for a particular drug is limited to a small group of 
patients. 
However, mendelian monogenic disorders provide an opportunity for research 
in disease and eventually normal physiology. When a mutation is identified in 
a particular gene, one can then understand how that genetic defect impairs 
the function of a particular protein, and can establish a relationshiop between 
signs or symptoms and a molecular underlying disturbance. This approach is 
not that simple since, from genotype to phenotype, there is a serious 
variability imposed by the genetic background of the patient, epigenetic 
modifications and also environmental influence. In the brain, the plasticity and 
continuous adaptation to external stimulus increase the complexity of this 
interpretation, particularly during periods of higher synaptogenesis and circuit 
remodeling like infancy and childhood. That being said, when evidence 
converges, one can establish a link between a molecular defect and a certain 
sign or symptom, or a constellation of both. Like experience has been 
teaching us, in a group of patients with similar clinical features, mutations 
have been identified in different genes but that are related with each other at 
the protein functional level: they are part of the same pathway, they interfere 
with each other’s regulation or are similar or redundant in their functions. One 
paradigmatic example is the one of “RASopathies”, a class of developmental 
disorders that is caused by germline mutations in genes that encode protein 
components of the Ras/MAPK pathway. The vast majority of these mutations 
result in increased signal transduction down the Ras/MAPK pathway, but 
usually to a lesser extent than somatic mutations associated with 
oncogenesis. Each syndrome exhibits unique phenotypic features, however, 
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since they all cause dysregulation of the Ras/MAPK pathway, there are 
numerous overlapping phenotypic features between the syndromes, including 
characteristic facial features, cardiac defects, cutaneous abnormalities, 
neurocognitive delay and a predisposition to malignancies (Rauen, 2013). 
The same has happened with inborn errors of metabolism. They cause 
genetically determined alterations in biochemical pathways and generate a 
repertoire of neurological signs that can be associated with biological 
markers. They can produce symptoms such as severe epilepsy due to 
cerebral glucose deficiency, acute psychosis/encephalopathy due to cerebral 
ammonia intoxication, cognitive impairment and autistic traits due to cerebral 
creatine transport deficiency or parkinsonism due to neurotransmitter primary 
metabolic disorders (Garcia-Cazorla and Duarte, 2014). The study of 
neuropaediatric rare mendelian or syndromic disorders can also bring 
interesting inputs to common complex neurological disorders that afflict the 
pediatric and adult population. 
1.9 Animal Models for neurodevelopmental disorders: 
Strengths and Limitations 
In spite of the enormous contribution to our understanding of pathophysiology, 
research based exclusively on animal models of neurodevelopmental 
disorders is severely hampered by several problems: 
i) The complexity of the phenotype, with physiological developmental events 
taking place simultaneously with the disease manifestations, leading to a 
specific time dependent progression, and ii) the fact that neocortical 
development is highly divergent in mouse and mammalian species (Florio and 
Huttner, 2014) (Rakic, 2009), making the recapitulation of human disease 
phenotypes in rodents improbable, in particular for higher cortical functions. iii) 
The fact that most animal models are produced through knockout approaches 
in which gene function is totally abolished can be misleading in the sense that 
human mutations are far less disruptive and can originate completely different 
phenotypes, even at the molecular level.  
Questions have also arisen concerning the value even of genetic mouse 
models constructed with highly penetrant alleles that cause human disease, 
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because some effective therapeutic approaches in mouse models have failed 
in human trials (Hyman, 2014; Seok et al., 2013).  
Although some research is performed purely for the sake of studying the 
physiology and pathophysiology of animals, the goal of the majority of animal 
studies is to gain knowledge and insights that are useful for understanding 
human biology, the response of humans to treatments or other interventions, 
or both. However, care should be taken to consider the effects of the genetic 
backgrounds of the mouse lines being studied and introduction of bias in the 
analysis of phenotypes, particularly for more complex behavior paradigms 
(Ioannidis, 2012). Successful cross species translation requires the synthesis 
of data from different models and the acknowledgement that there are many 
biological steps between genes and behavioral outputs; moreover, the social 
and environmental contexts that shaped human behavior compared with that 
of rodents have been highly divergent over the course of evolutionary time. 
The primate cortex, and particularly the human cerebral cortex, differs in 
several respects from that of the rodent (Abuhatzira et al., 2007; Finlay and 
Darlington, 1995). In addition to a marked increase in the size of the cerebral 
cortex relative to the rest of the nervous system, these include the size, 
complexity and the nature of its developing stem cell populations, quantitative 
and qualitative differences in the gene composition and expression between 
the neocortex of rodents and primates (Rakic, 2009; Shi et al., 2012b), an 
increase in the diversity of upper layers, late-born neuronal cell types, and the 
presence of primate-specific neuron types in deep layers (Hill and Walsh, 
2005; Shi et al., 2012b). Additionally, the plasticity and the dynamic nature of 
the brain, specially in early developmental stages, further complicates the 
interpretation of data, because most of the observed molecular changes can 
be the result of an adaptation to the imposed genetic defect and contribute to 
an attempt of reducing their impact and not originally part of the pathological 
process.  
In summary, when interpreting the data arising from rodent animal models 
regarding human disorders, we have to consider the complex relationship 
of genotypes and phenotypes, considering the influence of environment 
and epigenetic factors, and also the differences arising from species specific 
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brain evolution with impact in the development of neocortex and also in 
mechanisms of adaptation to genetic defects. For studies of the nervous 
system in animal models, it is therefore required that these focus on neural 
phenotypes that involve cells, synapses, and circuits that are plausibly 
conserved in evolution, and that are thus potentially relevant to the human 
condition. 
1.10 Induced Pluripotent Stem Cells to model 
neurodevelopmental disorders: Strengths and Limitations 
Pluripotent stem cells (PSCs) are cells capable to differentiate and give rise to 
every tissue/cell in the human body (Mitalipov and Wolf, 2009). Until recently, 
these cells could only be isolated from the inner cell mass of the blastocyst, 
being designated embryonic stem cells (ESCs) (Keller and Snodgrass, 1999; 
Thomson et al., 1998). However, in 2007, Shinya Yamanaka and co-workers 
were able to reprogram human somatic cells into the pluripotent stem cell 
state using transfection of four transcription factors (Oct4, Sox2, Klf4, c-myc). 
These human induced pluripotent stem cells (iPSCs) brought many 
expectations into the biomedical field due to their potential applications in 
disease modeling, drug and toxicity screening, patient-tailored therapies and 
engineered tissues (Takahashi et al., 2007), potentially preventing 
immunosuppression and graft rejection, and opening new perspectives for the 
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Figure 1.7 Potential applications of iPSCs to the study of genetic 
neurological disorders 
The reprograming of human iPSCs from neurological somatic cells opens several 
possibilities for disease understanding and treatment. These cells can be 
differentiated into mature CNS cells for disease modeling and drug screening. They 
can also be genetically corrected through different genome editing approaches and 
be used for therapeutic trials using undifferentiated cells or neural precursors (NPs) 
or even fully differentiated cells. Adapted from http://science.psu.edu/news-and-
events/2010-news/Chen11-2010. 
 
In recent years, patient-derived iPSCs have been used to recapitulate the 
phenotypes of neurological diseases and broaden our understanding of the 
pathogenesis of many neurological diseases (Ito et al., 2012). The ultimate 
goal would be to develop cell based therapeutics using cells derived from the 
recipient, without the risks of immune rejection, but we still have some serious 
challenges to overcome: 
First, the generation, characterization and differentiation of human 
iPSCs is a time consuming and costly procedure. In rapidly progressive 
diseases this process configures a serious limitation. The methods are still not 
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optimized for this kind of application but published strategies like direct trans 
differentiation from fibroblasts to neurons can reduce the time issue (Xue et 
al., 2013).  
Second, another serious obstacle for iPSC based therapies is teratoma 
formation. Even a small number of undifferentiated cells can result in the 
formation of teratomas (germ cell tumors comprising several cell types, which 
confirm the pluripotency of stem cells). A key goal is to induce differentiation 
of human ESCs (hESCs) or iPSC into the required cell type while leaving few 
undifferentiated cells behind. Aberrant reprogramming may result in an 
impaired ability to differentiate and may increase the risk of immature 
teratoma formation after directed differentiation into the required cell type.  
Third, most iPSCs are generated by transduction of somatic cells with 
retroviruses or lentiviruses carrying transgenes, which are integrated into the 
host cell genome. Transgenes are largely silenced in iPSCs, but the 
reactivation of such transgenes (especially the transgene encoding c-Myc) 
could lead to tumorigenesis (Okita et al., 2007). When patients with X-linked 
severe combined immunodeficiency were treated with gene therapy using 
retroviruses, activation of the proto-oncogene LMO2 resulted in leukemia 
(Hacein-Bey-Abina et al., 2003). Leaky expression of these transgenes may 
also inhibit complete iPSC  differentiation and maturation, leading to a greater 
risk of immature teratoma formation. 
The high risk of tumorigenesis and mutagenesis (Han et al., 2011) led to the 
development of strategies to eliminate or reduce genome integration that 
include: development of excision systems, such as the cre-lox (Chang et al., 
2009) and PiggyBac transposon systems (Kaji et al., 2009), use of non-
integrating delivery approaches, such as episomal vectors (Yu et al., 2009), 
Sendai virus (Nakanishi and Otsu, 2012), plasmid DNA (Okita et al., 2008), 
mRNA (Schott et al., 2011) or direct protein delivery (Zhou et al., 2009). 
Further research has focused on improving the method of reprogramming with 
the goal of efficiently, rapidly and inexpensively generating non-tumorigenic 
iPSCs without use of oncogenes, such as c-Myc, or animal-derived products 
(Kramer et al., 2013; Lee-Kubli and Lu, 2015). Another way to avoid viral 
integration is to generate iPSCs using chemicals or small molecules. 
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Transplantation of iPSC-derived cells into animal models of sickle cell anemia, 
hemophilia, Parkinson’s disease, spinal cord injury, and diabetes has shown 
therapeutic potential (Alipio et al., 2010; Hanna et al., 2007; Tsuji et al., 2010; 
Wernig et al., 2008; Xu et al., 2009). More recently, transplantation of Pax7-
induced iPSC-derived myogenic progenitors into dystrophic mice resulted in 
extensive engraftment and an improvement in the contractile properties of 
treated muscles (Darabi et al., 2011). Thus, these types of approaches hold 
out much hope for future trial. In January 2009, the US Food and Drug 
Administration (FDA) approved the first clinical trial for using human ES cells 
to treat patients with spinal cord injury (Yamanaka, 2009). From that moment, 
several therapeutic strategies have been developed and some results have 
been published (Thomsen et al., 2014), focusing mainly in safety issues, 
which are very relevant as first steps in such a long journey.  
Neuronal transplants have serious connectivity and functional issues (Emsley 
et al., 2004), since transplanted neurons would have to anatomically integrate 
into the host brain, become localized to the diseased portion of the brain, 
receive afferent inputs, express appropriate neurotransmitters and receptors, 
and form precise axonal projections. However, the successful wiring of the 
cortical populations is normally achieved with isolated genetic programs 
(without environmental interference) initially and posteriorly results from the 
combination of genetic and environmental cues that newly integrating neurons 
missed during previous development and /or mature brain function. These 
limitations can be reduced if neuronal progenitors are used, as these could 
mature in place or simply provide neurotrophic factors or other relevant cues 
that potentially facilitate the recovery or improve the function of the original 
neuronal population. Accordingly, several stem cell transplantation studies 
involving animal models of CNS disease have attributed observed beneficial 
effects to grafted cells that were not part of the established circuits, but were 
genetically engineered to produce trophic factors, immunomodulatory 
molecules or other neuroprotective factors (Gowing and Svendsen, 2011). 
Knowing the important functions carried out by astrocytes in the CNS, 
astrocyte precursors or stem cell-derived astrocytes could promote axonal 
growth, support mechanisms and cells involved in myelination, modulate the 
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host immune response, deliver neurotrophic factors and provide protective 
molecules against oxidative or excitotoxic insults (Nicaise et al., 2015), 
amongst many possible benefits, including direct strategies to treat white 
matter disorders.  
Although many proof-of-principle reports support the potential of using tissues 
produced from iPSC for therapeutic purposes, the actual feasibility and safety 
of these modalities for human clinical applications remains controversial, 
given very limited relevant preclinical data (Hong et al., 2014). 
Notwithstanding, the use of iPSCs as models of neurological disease is an 
approach already validated in the literature. There are also several  limitations 
that should be considered: first, in many neurodegenerative diseases such as 
Amyotrophic Lateral Sclerosis (ALS) or Parkinson’s Disease, it takes several 
decades for symptoms to develop. We need to find ways to facilitate disease 
pathogenesis in patient-specific iPSCs and to mimic epigenetic changes 
caused by aging and the environment. Stimulation like oxidative stress or UV 
irradiation may be required to attain this aim.  When studying monogenic 
neurodevelopmental disorders, an advantage is that molecular and functional 
defects are expected at earlier stages, and protocols that reproduce 
embryonic neuronal development are promising for the recapitulation of the 
first consequences of a mutation in neuronal and synaptic function. 
Secondly, another important issue is that many diseases may be cell non-
autonomous. For example, motor neurons derived from ALS patient-specific 
iPSCs may not be able to reconstitute alone full disease pathogenesis, as 
they may need the interaction with mutated glial cells (Di Giorgio et al., 2007). 
Thus, multiple cell types may need to be generated from patient-specific 
iPSCs. In fact, regarding RTT, astrocytes have been implicated in disease 
pathology and effects of mutated astrocytes in wild type neurons have been 
identified (Ballas et al., 2009; Lioy et al., 2011). Protocols that start from 
iPSCs to derive cortical populations of neurons and astrocytes, may be a 
useful strategy to overcome this difficulty.  
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1.11 Aims 
Clinical practice in child neurology has allowed me to be in contact with very 
severe disorders that affect the child brain, and this perspective was the 
starting point for the questions that motivated this work. 
Two main aims were always present:  
• To search for a synaptic phenotype in early encephalopathies: improve 
diagnosis and classification of child neurology disorders, searching for 
biomarkers that pointed to the molecular pathophysiologic signature, 
particularly focusing on the synapse. 
• Direct research to molecular mechanisms that could be targeted 
pharmacologically, improving the treatment strategies in these 
disorders with a rational approach.  
The specificities of the developing brain are frequently forgotten when we 
treat early encephalopathies, since there is usually a dose adjustment but not 
clearly an adjustment to the developing state of the central nervous system, 
which is different in neonates, infants, toddlers, pre-school, school age, 
adolescents and adults. Another usually forgotten aspect when therapeutic 
strategies are delineated is the individual variability, which should be 
increasingly tackled when we move towards a “personalized medicine” 
approach. 
An increasing body of evidence points to the disrupted maturation of 
GABAergic system as implicated in several neurodevelopmental disorders, 
including RTT, Fragile X, epileptic encephalopathies and ASDs. The 
GABAergic system physiology was shown to exhibit several dramatic changes 
during postnatal development in rodents, but these changes are not yet 
sufficiently characterized in humans. Moreover, in the clinics, treatment of 
neonatal seizures has been crystalized during decades, with drugs that target 
the GABAergic system as if the maturation process was complete. The 
difficulties of performing clinical trials in neonates and the lack of translational 
research in the field have hampered the expected improvement of treatments. 
I focused on the control of intracellular chloride concentration, one of the 
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mechanisms with documented changes during CNS development, with a 
determinant impact in GABAergic actions (see 1.5.1.1) section in the 
introduction). 
First, I searched for a strategy to understand the individual status of the 
GABAergic system in a particular patient. A first possibility would be to try to 
obtain some information from individual biological samples. Cerebrospinal 
fluid (CSF) analysis is used to diagnose several child neurology conditions 
and CSF accumulates products from different CNS cellular populations, 
reflecting cellular physiology in a “global perspective”. The first experiments 
described in this thesis were performed with the objective of detecting 
synaptic proteins in the CSF, searching for differences in these proteins 
between patients and controls, in order to guide treatment and/or further 
research. 
The results from CSF analysis contributed to the delineation of new 
experiments, particularly in RTT, a disorder caused by mutations in the gene 
encoding MeCP2, a fascinating protein with multiple roles in development and 
neuronal function. The multiplicity of signs and symptoms in RTT patients 
document the relevance and extension of MecP2 actions in the CNS. 
I aimed to study a disease model that reflected the individual patient 
specificities and also allowed functional studies. These objectives led me to 
the resolution of generating iPSCs from patients with different MECP2 
mutations, and also different phenotypical severity. With iPSCs, I could obtain 
patient-specific neurons to study and possibly optimize treatment strategies.  
 
Reprogramming of human iPSCs is mainly applied for disease modeling, but 
there are also many studies oriented for cell-based treatment. Transplantation 
of iPSCs or their progeny into an immunocompetent recipient in a clinical 
setting requires feeder-free, and ideally, completely xenogeneic-free defined 
cell culture conditions. We aimed to develop an approach that reproduces 
neural commitment from human iPSCs using dual-SMAD inhibition under 
defined conditions in a vitronectin-based monolayer system, in order to obtain 
neuronal precursors in xeno-free conditions. 
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One of the limitations of disease modeling with human iPSCs is that it reflects 
individual cell pathological changes, but neuronal circuit formation is highly 
artificial in a culture plate. This limitation was the reason to perform additional 
experiments in a rodent model of RTT, in order to combine results from 
different disease models and increase the relevance of the results. 
 
BDNF is also a crucial role player in the CNS, during development, as well as 
for normal brain physiology in health and in response to insults. The BDNF 
gene has been consistently reported to be under the jurisdiction of MeCP2, 
regarding transcriptional control. Adenosine is a crucial modulator of BDNF 
and GABAergic actions, but the adenosinergic system was not previously 
studied in RTT, particularly as a modulator of BDNF actions. Importantly, 
adenosine A2AR activation gates the synaptic actions of BDNF. Accordingly, 
A2AR activation is required for the facilitatory action of BDNF on hippocampal 
synaptic transmission on LTP.  
One of the aims of the present work was to characterize BDNF-TrkB receptor 
signaling in RTT disease models. If we confirmed the expected impairment in 
this system, a second step would be to try to modulate BDNF-TrkB signaling, 
through A2AR activation.  
 
In summary, the main objectives of this work were: 
1. To search for biomarkers of early encephalopathies with epilepsy and 
autistic traits, particularly synaptic proteins in the cerebrospinal fluid. These 
biomarkers could contribute to the delineation of a synaptic phenotype as an 
additional molecular signature of disease. 
2. To obtain patient specific neuronal populations for functional studies. 
3. To obtain neuronal progenitors in defined conditions. 
4. To study GABAergic developmental changes in early encephalopathies. 
5. To contribute for treatment strategies of RTT, including the pharmacological 
modulation of two significant synaptic dysfunctions in RTT: GABAergic and 
BDNF-TrkB signaling impairments. 
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In this work Sofia Duarte performed part of the western blot experiments, 
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Abstract 
In a few rare diseases, specialised studies in the CSF are required to identify 
the underlying metabolic disorder. We aimed to explore the possibility of 
detecting key synaptic proteins in the CSF, in particular dopaminergic and 
GABAergic, as new procedures that could be useful for both 
pathophysiological and diagnostic purposes in investigation of inherited 
disorders of neurotransmission. 
Dopamine receptor type 2 (D2R), dopamine transporter (DAT) and vesicular 
monoamine transporter type 2 (VMAT2), were analysed in CSF samples from 
30 healthy controls (11 days to 17 years) by western blot analysis. Because 
VMAT2 was the only protein with intracellular localization, and in order to 
compare results, GABA vesicular transporter, which is another intracellular 
protein, was also studied. Spearman’s correlation and Student-t tests were 
applied to compare optical density signals between different proteins. 
All these synaptic proteins could be easily detected and quantified in the CSF. 
DAT, D2R and GABA VT expression decrease with age, particularly in the 
first months of life, reflecting the expected intense synaptic activity and 
neuronal circuitry formation. A statistically significant relation was found 
between D2R and DAT expression, reinforcing the previous evidence of DAT 
regulation by D2R. To our knowledge, there are no previous studies in human 
CSF reporting a reliable analysis of these proteins. These kinds of studies 
could help elucidate new causes of disturbed dopaminergic and gabaergic 
transmission as well as understanding of different responses to L-dopa in 
inherited disorders affecting dopamine metabolism. Moreover, this approach 
to synaptic activity in vivo can be extended to different groups of proteins and 
diseases.  
Synopsis: The detection and quantification of key synaptic proteins in the 
cerebrospinal fluid, in particular dopaminergic and gabaergic, is reported as a 
new procedure that could be useful for both pathophysiological and diagnostic 
purposes in the investigation of inherited disorders of neurotransmission. 
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2.1  Introduction 
Specialised investigations in cerebrospinal fluid can be crucial to identify 
some inborn errors of metabolism. Defects of biogenic amines (dopamine and 
serotonine), GABA and glycine make up the group of diseases that are 
currently considered to be inborn errors of neurotransmitters. In these 
disorders, quantification of some particular CSF metabolites (biogenic amines, 
GABA or glycine) is necessary in the diagnostic process. However, although 
growing evidence suggests that genetic or pathologic alterations of proteins 
involved in synaptic transmission may underlie a number of neurological and 
psychiatric disorders (Sudhof, 2008; Sudhof and Malenka, 2008) (Corradini et 
al., 2009; Kauer and Malenka, 2007; Witzmann et al., 2005), the study of 
these proteins is not normally included in the array of investigations carried 
out in disorders of this kind. In vivo measurement of synaptic activity is difficult 
to carry out in humans. CSF samples are easily accessible by standard 
lumbar puncture techniques. Additionally, biochemical changes in CSF may 
reflect pathological alteration of CNS physiology, as previously demonstrated 
(Ormazabal et al., 2005). Accordingly, CSF receives a wide variety of 
molecules released by different CNS cell populations (Thouvenot et al., 2008). 
Several authors, including some from our group, have shown that there is a 
strong variability of CSF biogenic amines with age in children not suffering 
neurologic disease (Ormazabal et al., 2005), which suggests that the same 
variability may be expected when analysing synaptic proteins related with 
classical neurotransmitter function.  
Synaptic transmission depends on neurotransmitter pools stored within 
vesicles that undergo regulated exocytosis. In the case of dopaminergic 
transmission, VMAT2 is responsible for the loading of dopamine and other 
monoamines into synaptic vesicles (Cartier et al.). DAT carries dopamine 
across the plasmalemmal membrane from the synaptic cleft into the 
cytoplasm (Volz et al., 2009). The central actions of dopamine are mediated 
by five distinct receptors that belong to the G-protein receptor family. They are 
classified as D1-like (D1 and D5) and D2-like (D2, D3 and D4), and their 
interaction with dopamine translates into activation/inhibition of specific 
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neurons and circuitries (De Mei et al., 2009). Those suffering DRD2 (D2 R 
gene) mutations exhibit postural abnormalities, bradykinesia with delayed 
initiation of movements, impaired coordination and prolonged periods of 
immobility (Glickstein and Schmauss, 2001). These symptoms are also 
characteristic of patients suffering dopaminergic neurotransmission disorders. 
In spite of the critical role of these proteins in dopaminergic transmission 
(Figure 2.1), information about procedures for studying them in CSF is very 
scarce, to our knowledge. However, such knowledge would be useful to 
increase understanding of the mechanisms of disturbed dopaminergic 
transmission in primary (inherited disorders of dopamine) and secondary 
deficiencies.   
 
 
Figure 2.1 Schematic representation of the dopaminergic synapse. 
The figure illustrates the link between VMAT2 (vesicular monoamine transporter 2), 
DAT (dopamine transporter ) and D2 R (D2 receptor).	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We aimed to analyse, in the CSF of a control population, the synaptic proteins 
VMAT2, DAT and D2 R. Because VMAT2 was the only protein with 
intracellular localization, GABA VT, which is another intracellular protein, was 
also included in the study. We evaluated the correlation of these proteins with 
each other and with the age of controls. Additionally, because total CSF 
protein concentration is known to decrease with age, we introduced this 
variable in the age correlation studies. 
2.2 Methods 
2.2.1 CSF Samples 
The study was performed in 30 subjects (age range: 11 days - 17 years; 
average: 1.8 years) whose CSF samples were submitted to Hospital San 
Joan de Déu laboratory for analysis under suspicion of viral or bacterial 
meningitis or encephalitis. Lumbar puncture was performed in the emergency 
room, and the first ten drops were used for routine 
cytochemical/microbiological studies. Inflammatory markers (C-reactive 
protein and procalcitonin) were also analysed. Exclusion criteria were 
diagnosis of viral or bacterial meningitis, a chronic neurological condition, and 
hematic or xanthochromic CSF (blood contamination).  Samples from patients 
were obtained in accordance with the Helsinki Declaration of 1964, as revised 
in 2000. The ethical committee of the Hospital Sant Joan de Déu (HSJD) 
approved the study. After collection, samples were stored at -80ºC up to the 
moment of the analysis.  
2.2.2 Western blot 
Western blot analysis was performed for each protein (DAT, D2 R, VMAT2, 
GABA VT). Twenty µL of CSF sample was loaded into the gel and proteins 
were separated on 10% sodium dodecyl sulphate-polyacrylamide gels and 
transferred to polyvinylidene difluoride (PVDF) membranes (AmershamTM 
HybondTM –ECL, GE Healthcare). The membranes were incubated in TBST 
buffer (0.02M Tris-base, pH7.6, 0.8% NaCl, 0.1% Tween 20) supplemented 
with 5% dried skimmed milk for 60 min to block non-specific binding. Anti-DAT 
extracellular loop (1:1000; Sigma®), anti-D2 R (1:1000; Millipore®), anti-VMAT 
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2 (1:1000; Santa Cruz Biotechnology®), and anti-GABA VT (1/500; Millipore®) 
antibodies were added, and the preparations were incubated at 4 ºC 
overnight. The membranes were washed three times with TBST buffer and 
then incubated with appropriate anti-rabbit (1:3000, Promega®) or anti-mouse 
(1:5000, Promega®)  IgG secondary antibodies at room temperature for 1 h. 
The blot was then washed six times with TBST and prepared with ECL 
(Pierce® ECL Western Blotting Substract, Thermo Scientific) for developing. 
Relative levels of each protein were quantified by measuring optical densities 
(OD) of the corresponding bands with Quantity One ® V 4.3.1. software. 
2.2.3 CSF total protein concentration, procalcitonin and C-reactive 
protein determination 
CSF total protein and C-Reactive Protein concentrations were measured by 
standard automated procedures in an Architect ci8200 analyzer (Abbott, 
USA). Procalcitonin was measured by fluorimetric detection, with Brahams-
Kryptor-Atom® analyser.  
2.2.4 Statistical analysis 
Statistical analysis was performed with the SPSS 17.0 program. Spearman’s 
correlation test was applied to search for associations among the OD signals 
of the different proteins and with the age of controls. Multivariate linear 
regression analysis was used to adjust the results by total CSF protein 
concentration. Student-t test was applied to compare OD signals of the 
different proteins according to gender. Statistical significance was considered 
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2.3  Results  
DAT, D2R, VMAT2 and GABA VT were clearly detectable at different ages 
using conventional western blot analysis in all the CSF samples studied 
(Figure 2.2).   
 
 
Figure 2.2 D2, DAT, VMAT and GABAVT detection in the CSF by western blot 
in different control samples. 
VMAT2 expression measured as OD showed a statistically significant 
negative correlation with age (Table 2.1). Correlation between DAT 
expression and age showed a strong tendency to significance (p value=0.05). 
D2R expression and GABA vesicular transporter expression did not show 
statistical association with age when all the CSF samples were included in the 
statistical study. However, since our sample population was predominantly 
younger than 200 days (for age distribution see Figure 2.3.A), we searched 
for a correlation between D2R and GABA VT expression with age in this 
group. A significant negative correlation was found for D2R and GABA VT. In 
order to rule out interference of the expected decrease in total CSF protein 
concentration with age, we adjusted these results by total CSF protein 
concentration (range, 7–77 g/l; mean, 34.7; median, 31; standard deviation, 
17.2. All values were within normal limits according to different age ranges) 
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(Biou et al., 2000). Except for VMAT2, the relation between age and 
expression of these synaptic proteins remained statistically significant (Table 
2.1). 
Table 2.1 
 D2 R DAT  VMAT2  
 








302541.9 598210.0 385135.9 356870.5 
Upper limit 
(OD measure) 
1126336 2115196 50255 1582609 
Lower limit 
(OD measure) 









(if age under 
200 days) 






































(if age under 
200 days) 
 
Table 1. Statistical data of the results for the synaptic proteins studied. Optic 
densities are expressed in arbitrary units. D2R: D2 receptor, DAT: dopamine 
transporter, VMAT2: vesicular monoamine transporter; GABA VT: GABA vesicular 
transporter. OD: Optic density.  
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Figure 2.3 Upper left: Population age distribution. Upper right, middle 
right, middle left, lower right: Correlation between age and synaptic 
proteins. Lower left: Correlation between DAT and D2. 
No differences were observed when we compared DAT, D2, VMAT2 and 
GABA VT protein expression according to gender. 
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Concerning association studies among the different proteins, OD signal of 
D2R, and DAT showed a statistically significant positive correlation 
(Spearman’s rho correlation test r=0.016; p=0.443), while no correlation was 
found between D2 R and VMAT, or between DAT and VMAT. 
Because VMAT2 is also involved in adrenaline and noradrenaline transport, 
and its release can be triggered by acute stress situations, we also tried to 
correlate VMAT2 expression with acute phase reactants (C-reactive protein 
and procalcitonin), in order to rule out the possible influence of fever or acute 
disease in the expression of this protein, since our control population was 
selected from a group of children under suspicion of an active infectious 
process. C-reactive protein and procalcitonin levels were not related with total 
CSF protein concentration, nor with VMAT 2 expression.  
2.4 Discussion 
We aimed to explore the possibility of detecting key dopaminergic and 
GABAergic synaptic proteins in a control population of children. To our 
knowledge, this is the first report of detection of these proteins in CSF in a 
paediatric population.  
In spite of their low abundance compared to global CSF proteome (Thouvenot 
et al., 2008), the intensity and definition of the different bands obtained with 
the present procedure (Figure 2.1) lends strong support to the applicability of 
this analysis in neurochemical research.  
The presence of transmembrane synaptic proteins in CSF can be explained in 
several ways. It has been suggested that membrane protein detection is the 
consequence of extensive protease actions that cleave the fragments from 
proteins that are embedded in membranes, and that these fragments enter 
the CSF (Egana et al., 2009) (Zougman et al., 2008). However, our study 
demonstrates that these proteins are detected at the expected molecular 
weight, indicating that there is no fragmentation, or at least, that they are 
intact in part. Harrington and co-workers (Harrington et al., 2009) identified the 
presence of CSF membranous nanostructures, thought to play a 
physiologically active role, and not merely the result of blebbing, apocrine 
secretion, or apoptosis events, or cellular debris. These structures can 
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provide an appropriate environment for transmembrane proteins, which are 
hydrophobic in nature. Their morphology is similar to that of synaptic vesicles 
and exosomes; their structure resembles that of nanotubules, cell-to-cell 
interactions that facilitate the selective transfer of membrane vesicles and 
organelles but which seem to impede the flow of small molecules (Rustom et 
al., 2004). In the first months of life, a period of intense synaptogenesis and 
neuronal circuitry formation, cell-to-cell exchange of synaptic machinery is 
thought to be carried out by small dense core vesicles (~80nm) (Sorra et al., 
2006). However, extracellular localization of these structures is not well 
documented.  
Based on our previous experience with the quantification of biogenic amines 
in a population of children without neurological disease (Ormazabal et al., 
2005) who exhibited a decrease from the first days of life until reaching adult 
age, we aimed to learn whether the same tendency was observed with the 
synaptic proteins included in the study. For DAT, D2R and GABA VT, it was 
possible to establish a statistically significant relation, particularly in the group 
of children under 6 months of age from whom most of our sample was drawn. 
Age-related changes in DAT functionally active protein have been described 
in rats (Volz et al., 2009), showing a decrease between young adolescent rat 
levels and adult levels. Interestingly, in the same report, no difference 
between VMAT 2 immunoreactivity in the two groups was found, although 
conflicting data had previously been published (Volz et al., 2006). 
Furthermore, because VMAT2 is involved in fast neurotransmission, its 
regulation could appear to be related to rapid communication needs and not 
to age. Another result that deserves discussion is the relation discovered 
between D2 and DAT expression. Numerous studies have supported the 
notion that DAT is subjected to dynamic regulation in the plasma membrane, 
and this regulation has been extensively reviewed by Eriksen and co-workers 
(Eriksen et al., 2010). There is strong evidence that D2 R causes an increase 
in dopamine uptake through an increase in DAT surface expression. 
Additionally, loss of D2R/DAT co-immunoprecipitation has been described in 
schizophrenia, suggesting a role for the loss of the interaction in the disease 
process (Bolan et al., 2007).   
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Currently, several CSF investigations in disorders of suspected 
neurometabolic origin are performed; these include examination of 
cytochemistry (cells, glucose, proteins), lactate, amino acids, biogenic amine 
metabolites, pterins and 5-methyltetrahydrofolate. However, only a few 
disorders can be detected by means of these analyses (Garcia-Cazorla, 
2010). Furthermore, the diagnosis of monogenic defects of dopaminergic 
neurotransmission is almost exclusively based on the quantitative 
determination of their metabolites in CSF (Marin-Valencia et al., 2008). 
Secondary deficiencies of dopamine are found in about 10% of patients who 
undergo a lumbar puncture in the diagnostic work-up of a suspected 
neurometabolic disorder (Garcia-Cazorla et al., 2007) (Van Der Heyden et al., 
2003). Disorders such as mitochondrial diseases (Garcia-Cazorla et al., 2008) 
and Lesch-Nyhan disease (Serrano et al., 2008) are amongst the main known 
causes of secondary deficiencies. The analysis of these and other synaptic 
proteins is expected to be useful to both increased understanding of the 
mechanisms of disturbed neurotransmission and identification of new causes 
of dopaminergic defects. Concerning primary deficiencies such as tyrosine 
hydroxylase deficiency, this approach could be useful to improve 
understanding of the variable response that patients have to L-dopa therapy 
(from normalisation to almost absent effect) (Willemsen et al., 2010), but we 
need further data to document this hypothesis. 
To conclude, we report the detection of transmembrane synaptic proteins in 
the CSF of a population of children without neurological disorders. This 
approach was made as a means of monitoring neurotransmitter genetic 
disease outcome and response to treatment, but its applications can be 
extended to the investigation of a growing group of neurological and 
psychiatric disorders related to neurotransmission. The proteins included in 
this study were chosen because of their relevance for dopaminergic and 
GABAergic transmission but there are many other proteins of interest that can 
be selected for analysis with this methodology. 
The findings reported here deserve further investigation, especially in the field 
of CSF-neuron and inter-cellular interactions, in order to better understanding 
of their physiological implications in the developing brain and their 
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pathophysiological role in disease states. Significant correlation with age was 
found with D2R, DAT and GABA VT expression, as expected from the 
previously reported decrease of biogenic amines in a paediatric population. 
Coordinated regulation of DAT by stimulation of D2 R is further reinforced by 
our results.  
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In the next chapter, I will describe the results of the study of cation chloride 
cotransporters in the cerebrospinal fluid of RTT patients. Before performing 
this study, we studied a control pediatric population, searching for changes in 
CSF during normal postnatal development. Jansen and co-workers (Jansen et 
al., 2010) demonstrated in frozen brains of normal controls that the ratio of 
NKCC1 to KCC2 expression is very high in the youngest infants, decreases 
rapidly until around 2 years of age, and then remains low into adulthood.  
We have determined KCC2 and NKCC1 expression in the CSF of a pediatric 
population without neurological disorders and this work gave us the possibility 
of having a control population for the work described in Chapter 2. Our 
findings suggest that this maturation is very variable, but in the CSF, KCC2 
shows some predominance in patients after 7 months of life. The discrepancy 
between the age of functional switch suggested by the neuropathology study 
(2 years of life) and the present findings (global switch around 7 months of 
life) could be explained by the fact that this physiological pattern develops in a 
caudal-rostral progression. The CSF levels are expected to reflect a global 
functional state of all GABAergic neurons, while the cortical tissue 
quantification of these proteins reflects the encephalic changes that occur 
later in life. The variability is also supported by our experience in the neonatal 
intensive care unit, where different newborns have different and sometimes 
paradoxical responses to pharmacological treatment with GABAAR agonists 
that can increase epileptic activity at this neurodevelopmental stage. 
The major advantage of doing this study in vivo, in children with severe 
neurologic disorders like epileptic encephalopathies of the first year of life or 
RTT, is the possibility of searching for disturbances in the normal 
developmental pattern that can underlie the pathogenesis of these disorders, 
and also the possible orientation of a rationale treatment with anti-epileptic 
agents. 
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Figure 2.4 Evolution of the relative expression of NKCC1 and KCC2, with 
age.  
Before 7 months of extra-uterine life, NKCC1 and KCC2 are both expressed without 
a clear predominance. After this period, the expression of KCC2 shows a tendency to 
be higher, contributing to a mature pattern of neuronal chloride physiology, related 
with the hyperpolarizing effect of GABAAR activation. Optic densities are expressed 
in arbitrary units.  
 
Starting from the results in this control population, we searched for differences 
in RTT patients, as described in Chapter 3. 
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Abstract 
Objective: RTT is a neurodevelopmental disorder caused mainly by mutations 
in the gene encoding MeCP 2. The relevance of MeCP2 for GABAergic 
function was previously documented in animal models. In these models, 
animals show deficits in BDNF, which is thought to contribute to the 
pathogenesis of this disease. Neuronal Cation Chloride Cotransporters play a 
key role in GABAergic neuronal maturation, and BDNF is implicated in the 
regulation of Cation Chloride Cotransporters  expression during development. 
Our aim was to analyse the expression of two relevant Cation Chloride 
Cotransporters, NKCC1 and KCC2, in the CSF of RTT patients and compare 
it with a normal control group.  
Methods: The presence of bumetanide sensitive NKCC1 and KCC2 was 
analysed in CSF samples from a control pediatric population (1 day to 14 
years of life) and from RTT patients (2 to 19 years of life), by immunoblot 
analysis.  
Results: Both proteins were detected in the CSF and their levels are higher in 
the early postnatal period. However, RTT patients showed significantly 
reduced levels of KCC2 and KCC2/NKCC1 ratio when compared to the 
control group.  
Conclusions:  Reduced KCC2/NKCC1 ratio in the CSF of RTT patients 
suggests a disturbed process of GABAergic neuronal maturation and open up 
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3.1  Introduction 
RTT is an X-linked neurodevelopmental disorder with an incidence of 1:10000 
live female births and is one of the leading causes of mental retardation and 
autistic behavior in females (Hagberg et al., 1983). Loss-of-function mutations 
in the gene encoding MeCP2 cause most cases of RTT. Individuals affected 
with RTT experience normal development up to the age of 6–18 months, at 
which time they fail to acquire new skills and enter a period of motor 
regression (Monteggia and Kavalali, 2009). Autistic features are a hallmark of 
this disorder and epilepsy is frequent (Nissenkorn et al., 2010). RTT patient 
brain does not show obvious signs of neurodegeneration, atrophy, gliosis, 
demyelination, or neuronal migration defects (Jellinger et al., 1988) (Reiss et 
al., 1993), suggesting that neurological symptoms may primarily stem from 
subtle defects of subcellular compartments such as dendrites, axons, or 
synaptic structures (Boggio et al., 2010). MeCP2 is a transcriptional regulatory 
protein, and in its absence, a large number of genes exhibit abnormal 
expression with implications in the balance between synaptic excitation and 
inhibition (Chao et al., 2010; Kron et al., 2012). MeCP2 might be particularly 
important for GABAergic function and there is evidence that the expression of 
MeCP2 is approximatelly 50% higher in GABAergic neurons when compared 
to non GABAergic neurons. Mice with conditional deletion of Mecp2 in 
GABAergic neurons initially show normal behavior but in the course of 
development start displaying forepaw stereotyped movements, compulsive 
grooming, impaired motor coordination, learning/ memory deficits, abnormal 
EEG hyperexcitability, severe respiratory dysrhythmias and premature 
lethality (Chao et al., 2010). 
GABA is the main inhibitory neurotransmitter in the adult brain. During early 
development, activation of the chloride- permeable, postsynaptic, GABAAR 
can induce depolarization and the basal intracellular chloride concentration is 
determinant for the action of GABA in the developing neurons (Blaesse et al., 
2009). Two major contributors to intracellular chloride concentration are 
NKCC1 (Na+, K+, 2Cl− cotransporter, that accumulates chloride in the cell), 
and KCC2 (K+, Cl− cotransporter, that extrudes chloride). Several lines of 
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research correlate epileptogenesis with altered function of NKCC1 and KCC2 
(Munoz et al., 2007; Woo et al., 2002). In vitro, experiments suggest that 
bumetanide, a potent NKCC1 inhibitor, can increase GABAergic inhibition, in 
combination with phenobarbital (Dzhala et al., 2005). Bumetanide has also 
been reported useful in a neonatal patient with seizures (Kahle et al., 2009) 
and in autistic children (Lemonnier et al., 2012).  
Moreover, the brain of MeCP2 deficient animal models shows deficits in 
BDNF (Wang et al., 2006), which is thought to contribute to the pathogenesis 
of RTT.  BDNF can also promote the functional maturation of GABAAR 
mediated responses by inducing upregulation of KCC2 (Aguado et al., 2003; 
Carmona et al., 2006; Plotkin et al., 1997). 
Human age related changes in GABAAR physiology remain controversial, 
although neuropathological studies have already identified postnatal 
developmental changes of NKCC1 and KCC2 cortical expression (Jansen et 
al., 2010). The detection of synaptic proteins in the CSF gives us the 
possibility to indirectly access synaptic composition and alterations, using the 
CSF of patients with disorders related to neurotransmission, with the 
advantage of performing these studies in vivo (Duarte et al., 2011). 
We hypothesize that changes in BDNF expression levels or the direct effect of 
the underlying MECP2 genetic mutation can interfere with the normal 
expression of NKCC1 and KCC2 leading to a reduction in the KCC2/NKCC1 
ratio, characteristic of the immature GABAergic system.  A comparison of 
NKCC1 and KCC2 protein levels in the CSF of patients affected with RTT and 
a control population was made in order to address this question.  
3.2 Methods 
3.2.1 Patients and controls 
Sixteen patients with RTT were recruited to this study, aged between 2 to 19 
years at the moment of CSF collection. Patients’ clinical characteristics are 
summarized in table 1.  Patients without a documented mutation fulfilled 
clinical criteria for RTT according to the last updated revision (Neul et al., 
2010). The control study was performed in 67 subjects (age range: 1 day - 14 
years; mean: 740 days; female: 27; male: 40) whose CSF samples were 
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submitted to HSJD laboratory under suspicion of viral or bacterial meningitis 
or encephalitis. Exclusion criteria were: diagnosis of viral or bacterial 
meningitis, neurologic disease, and hematic or xantocromic CSF (blood 
contamination).   
3.2.2 CSF Samples 
CSF samples were collected by lumbar puncture as previously described 
(Ormazabal et al., 2005). They were obtained after parent’s written informed 
consent and in accordance with the Helsinki Declaration of 1964, as revised in 
2000. The ethical committee of HSJD approved the study. After lumbar 
puncture, the first ten drops were used for routine 
cytochemical/microbiological studies and then CSF was immediately stored in 
4 aliquots at -80ºC until the moment of analysis. Biogenic amines metabolites 
and synaptic proteins were studied using the following 20 drops. 
3.2.3 Western Blot analysis 
NKCC1 and KCC2 expression levels were analyzed by western blot. Twenty 
µL of CSF were loaded on gel and proteins were separated on a 10% sodium 
dodecyl sulphate-polyacrylamide gel and transferred to polyvinylidene 
difluoride membrane (AmershamTM HybondTM –ECL, GE Healthcare). 
Membranes were blocked in TBST buffer (0.02M Tris-base, pH7.6, 0.8% 
NaCl, 0.1% Tween 20) with 5% dry skimmed milk for 60 min at room 
temperature. Anti-NKCC1 (1:500; Santa Cruz Biotechnology®) and anti-KCC2 
(1:500; Millipore®) antibodies were added and incubated at 4 ºC overnight. 
Membranes were washed three times with TBST buffer followed by incubation 
with appropriate anti-rabbit (1:3000, Promega®) IgG secondary antibody at 
room temperature for 1 h. The blot was then washed six times with TBST and 
signal was revealed with ECL (Pierce® ECL Western Blotting Substract, 
Thermo Scientific). Relative levels of each protein were quantified by 
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3.2.4 Statistical analysis 
Statistical analysis was performed using IBM Statistical Package for the 
Social Sciences (IBM SPSS Statistics Version 19.0, SPSS Inc: Chicago, IL). A 
significance level of .05 was used in all analyses. Outlier analysis was done 
taking into account the primary variable in the study – healthy/RTT. Outliers 
(defined as values 1.5 times lower than the 1st quartile or 1.5 times higher 
than the 3rd quartile (Maroco, 2007 #631) were found in 8 cases (1 RTT 
patient, 7 healthy controls) for KCC2/ NKCC1 ratio, 4 cases for NKCC1 (1 
RTT patient, 3 healthy controls) and in 1 case (healthy control) for KCC2. 
Outliers were excluded from the respective analyses. 
Non-parametric tests were applied when possible for age, NKCC1 and KCC2, 
since the assumption of normal distribution was not fulfilled for these 
variables.  
3.3 Results 
Total CSF protein concentration values (M = 33.27, SD = 19.04, range: 7 – 73 
g/l) were within normal limits according to different age ranges (Biou et al., 
2000). Clinical and genetic features of RTT patients are described in table 1. 
NKCC1 and KCC2 western blot analysis were performed on the CSF of 
controls and RTT patients. Cation Chloride Cotransporters were detected in 
the CSF of this population, at the expected molecular weight (Figure 3.1.A). 
Considering the reported sexually dimorphic expression of KCC2 and GABA 
function in the substantia nigra (Galanopoulou, 2008b) it was decided to 
control for gender in all reported analysis. 
Furthermore, the homogenous distribution of the demographical variable age 
was verified with Mann-Whitney Test (U). Controls (M = 746.00 days, SD = 
1075.89) were significantly (U = 932.00, p < .001) younger than RTT patients 
(M = 3444.69 days, SD = 2173.59) therefore we have controlled for this 





	   84	  
Table 3.1 Socio-demographic variable: mean values (and standard 
deviations) of age. Significant differences among the groups were assessed 
with Mann-Whitney Test (U).  
 
 










U=932.00 < .001 
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Table 3.2. Clinical and laboratory features of RTT patients included in 
the study. Age is expressed in years at CSF collection. DEL: Deletion. LP: 
Lumbar Puncture. AED: Anti epileptic drugs. VPA: Valproic Acid. CBZ: 
Carbamazepine. LEV: Levetiracetam. TPM: Topiramate 
3.3.1 KCC2 expression is decreased in the CSF of RTT patients 
As patients grew older their OD signal of KCC2 in the CSF decreased.  Partial 
correlation analysis was performed to clarify the relationship between age and 
the OD signal of the different synaptic proteins (NKCC1, KCC2) in each group 
(RTT, Controls), controlling for the effect of gender. A negative correlation 
between age and the OD signal of KCC2 (r (74) = -.292, n = 80, p < .05) has 
been clearly identified in our data, i.e. as the participants grew older their OD 
signal of KCC2 decreased, even when controlling for the effect of gender. 
Meaning that, KCC2 levels decrease in CSF throughout aging. However, 
concerning the OD signal of NKCC1 this correlation did not reach statistical 
significance (r (74) = -.207, p > .05). Interestingly, if the effect of gender was 
not taken into consideration, a strong, negative correlation between age and 
the OD signal of KCC2 (rs (80) = -.509, p < .0001) and NKCC1 (rs (78)= -.472, 
p < .0001) would have been identified in our data, i.e. as the participants grew 
older their OD signals of KCC2 and NKCC1 decrease.  
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Figure 3.1 NKCC1 and KCC2 Cotransporters in the CSF of RTT Patients 
and Controls. 
(A) Immunoblot results in RTT patients and controls. Numbers refer to the patient ID 
numbers of Table 1. Comparison of patients and age matched controls. (B) Mean 
Optic Densities of NKCC1 and KCC2 Cotransporter Proteins for RTT Patients and 
Controls suggesting discrepant cotransporter levels between Patients and Controls 
supported by the respective MANCOVA (F (1, 73) = 6.99, p<.01, ηp2 = .087). Error 
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RTT patients present a significantly lower OD signal of KCC2 than 
Healthy controls (Figure 3.1.B): To determine whether there were 
statistically significant differences in the OD signal of the different synaptic 
proteins (NKCC1, KCC2) between healthy controls and RTT patients, a 
between-subjects MANCOVA was performed, controlling for the effects of age 
and gender. This analysis revealed a statistically significant difference 
between healthy controls and RTT patients, F (1, 73) = 6.99, p < .01, ηp2 = 
.087 even when controlling for the possible confounding effects of age and 
gender. The subsequent follow-up Univariate ANCOVAs run to specify the 
characteristics of this finding revealed that RTT patients presented a 
significantly lower OD signal of KCC2 (M= 81383.80, SD= 82370.99; F (1, 76) 
= 12.28, p ˂ .001, ηp2 = .139) than healthy controls (M= 692663.52, SD= 
425753.91). Notwithstanding, NKCC1 expression does not differ significantly 
between patients (M= 307834.25, SD= 162592.59) and healthy controls, (M= 
608703.27, SD= 416157.33; F (1, 74) = 1.87, p > .05).  
3.3.2 KCC2/NKCC1 ratio is decreased in the CSF of RTT patients 
To determine whether there were significant differences in the ratio of the two 
synaptic proteins (KCC2/NKCC1) on the CSF of the healthy population and 
RTT patients a between-subjects ANCOVA was performed, controlling for the 
effect of age and gender. This analysis revealed a statistically significant 
difference between Healthy controls and RTT patients, F (1, 70) = 26.56, p < 
.001, ηp2 = .28 even when controlling for the possible confounding effect of 
age and gender (Figure 3.2.B and Figure 3.2.C). RTT patients presented a 
significantly lower KCC2/ NKCC1 ratio (M= .26, SD= .30) than Healthy 
controls (M= 1.08, SD= .56). Even if the effects of age and gender would not 
have been controlled for in the analysis the decrease in KCC2/NKCC1 ratio 
was still significant (F (1, 70) = 30.08, p = .001, ηp2 = .29).  
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Figure 3.2 Cation Chloride Cotransporters ratio. 
(A) Immunoblot analysis of NKCC1 and KCC2. (B) Scatterplot of the relationship 
between Cotrasporters ratio (KCC2/NKCC1) and age for RTT Patients and Controls. 
Lines show a LOWESS smooth (locally-weighted polynomial regression - 
nonparametric smooth) suggesting a discrepant cotransporter ratio between Patients 
and Controls supported by the respective ANCOVA (F (1, 70) = 30.08, p = .001, ηp2 = 
.29). (C) Boxplot of Cotransporters ratio (KCC2/NKCC1) for RTT Patients and 
Controls (males and females). *p = 0.001. 
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3.4 Discussion 
 In this study, we demonstrate reduced KCC2 levels and KCC2/NKCC1 ratio 
in the CSF of RTT patients. These findings suggest that altered inhibitory 
GABA function can underlie the pathophysiology of RTT and also play a role 
in the epileptogenesis of this neurodevelopmental disorder, in which epilepsy 
is present in around 70% of patients (Nissenkorn et al., 2010). Detection of 
transmembrane synaptic proteins in the CSF is a useful tool in the study of 
neurotransmission disorders, as recently reported by our group (Duarte et al., 
2011).  Despite their low abundance compared to the global CSF proteome 
(Thouvenot et al., 2008), the proteins here studied (NKCC1 and KCC2) were 
readily detected and at the expected molecular weight. Harrington and co-
workers (Harrington et al., 2009) identified the presence of CSF membranous 
nanostructures that can provide an appropriate environment for 
transmembrane proteins, which are hydrophobic in nature. Their morphology 
is similar to that of synaptic vesicles and exosomes; their structure resembles 
that of nanotubules, cell-to-cell interacting structures that facilitate the 
selective transfer of membrane vesicles and organelles but which seem to 
impede the flow of small molecules (Rustom et al., 2004). The intensity and 
resolution of the different bands obtained with the immunoblot procedure 
(Figure 3.1.A and Figure 3.2.A) strongly supports the applicability of this 
analysis in neurochemical research. To our knowledge, this is the first report 
of detection of cation chloride cotransporters in CSF. 
CSF turnover ratio and the extent of central nervous system cell death and 
synaptic pruning can influence circulating protein levels but these factors are 
likely to affect both proteins, NKCC1 and KCC2, equally. During the first 
months of postnatal life there is a period of intense synaptogenesis that 
subsequentially decreases.  This is probably the cause for the reduction of 
protein levels in CSF observed during the first year of life. In fact, regarding 
transmembrane proteins like NKCC1 and KCC2, we have observed the same 
tendency that also was detected with other synaptic proteins (Duarte et al., 
2011). The same phenomena could explain the fact that, in the CSF, both 
cation chloride cotransporters exhibit a reduction and KCC2 does not increase 
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in the CSF, as was expected from previous studies in brain tissue (Deng et 
al., 2007; Galanopoulou, 2008a). Experimental limitations in humans have 
been an obstacle in obtaining direct evidence of age-related changes in 
GABAA-R physiology (Galanopoulou, 2008a).  
In mice, loss of MeCP2 leads to reduced expression of BDNF after birth 
(Wang et al., 2006) and in humans evidence of BDNF reduction in RTT has 
also been detected (Deng et al., 2007). The effects of BDNF on 
neurotransmission in developing and mature neurons have been partly 
associated with the regulation of GABAergic transmission. Apart from its 
effects on GABAergic innervation (Danglot et al., 2006), BDNF can also 
promote the functional maturation of GABAA-R mediated responses by 
inducing upregulation of KCC2 (Aguado et al., 2003; Carmona et al., 2006). 
The imbalance between excitatory and inhibitory functions in RTT has been 
associated with reduced BDNF (Kline et al., 2010) and GABA levels, 
decreased expression of GABA receptor subunits (Medrihan et al., 2008), 
reduced expression of the enzymes glutamic acid decarboxylase 67 and 
glutamic acid decarboxylase 65 (Chao et al., 2010), reduced number of 
glutamatergic synapses (Chao et al., 2007) and reduced strength of basal 
inhibitory rhythms (Zhang et al., 2008). Moreover, exogenous BDNF has been 
shown to rescue synaptic dysfunction in Mecp-2 null mice.  However, the 
mechanism by which reduced levels of BDNF contribute to disease and also 
to the phenotypical rescue is not completely understood (Kline et al., 2010). 
Our results suggest an immature pattern of GABAergic neurotransmission in 
RTT patients, by revealing a dysregulation on the KCC2/NKCC1 ratio (the two 
major contributors to intracellular chloride concentration) and this evidence in 
humans is in accordance with the relevance of MeCP2 for GABAergic function 
described in animal models (Chao et al., 2010). An imbalance between 
excitatory and inhibitory synaptic events, in the brain of children with 
neurodevelopmental disorders that have epilepsy and autism as key features, 
is a postulated general mechanism. Moreover, KCC2/NKCC1 ratio 
dysregulation is a particularly interesting specific molecular change, already 
described for diseases like tuberous sclerosis (Talos et al., 2012).  
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3.5 Conclusions 
We describe a significant decrease of KCC2 in the cerebrospinal fluid of RTT 
patients. A major advantage of doing these in vivo studies in children with 
severe neurologic disorders like RTT, is that it allows to search for 
disturbances in the normal developmental pattern. Therefore, our findings 
might have implications for the understanding of RTT pathophysiology, 
considering that KCC2 is a neuronal specific protein with a key role for 
neuronal electrical function and structure, properties that are known to be 
altered in Mecp2 mutated neurons. Moreover, these results could bring light to 
new therapeutic approaches, particularly through the pharmacological 
manipulation of the cation chloride cotransporters. Further studies in the 
Mecp2 knockout model and other models to study the disease process are 
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Abstract 
 
RTT is the main cause of intellectual disability in females and is caused 
mainly by mutations in the X-linked MECP2 gene. In RTT, BDNF signaling is 
impaired. BDNF regulates neuronal survival, differentiation and synaptic 
plasticity such as LTP, an accepted neurophysiological paradigm for learning 
and memory. The increase of BDNF signaling in these patients’ brain would 
be a significant breakthrough, but has been hampered by the difficulty to 
administer BDNF to the central nervous system. Adenosine is a 
neuromodulator that acts mainly through A1 and A2AR. The activation of 
A2AR potentiates BDNF synaptic actions in healthy animals. Therefore, we 
explored whether the activation of A2AR facilitates BDNF action upon LTP in 
a RTT animal model. Mecp2 KO (B6.129P2 (C)-Mecp2tm1.1Bird/J) animals 
were used for neurophysiology and molecular assays.  
BDNF facilitatory actions upon LTP are absent in the RTT animal model. A 
reduction in TrkB-FL receptor levels, described for the first time in the present 
study, can contribute to this impairment.  Additionally, mRNA quantification of 
A1Rs and A2ARs, performed in human brain tissue from a RTT patient and 
compared with an aged matched control, suggests an increase in A1Rs and a 
decrease in A2ARs in RTT.  
When BDNF was combined with the selective A2ARs agonist CGS2168, 
before the LTP experiment, BDNF effect upon LTP was restored, similar to 
what was observed in hippocampal slices from WT animals with BDNF alone. 
Together our data highlight A2ARs as new possible therapeutic targets 
to overcome the BDNF-TrkB signaling impairment in RTT.  
  
	   	  Chapter 4 
 
	   96	  
4.1  Introduction 
RTT (MIM312750) is a rare neurodevelopmental disorder caused primarily by 
mutations in the X-linked gene MECP2. RTT is considered the leading cause 
of severe intellectual disability in females with a prevalence estimated at 
1/9,000 in girls under the age of 12, whereas prevalence in the general 
population is estimated at approximately 1/30,000 (source: Orphanet). 
Developmental stagnation usually becomes apparent between 6 to 18 months 
of life and head growth typically decelerates, leading to microcephaly, by the 
second or third year of life. Loss of purposeful hand skills combined with the 
development of stereotypic hand movements is a hallmark of the disease. 
With disease evolution cognitive deficit and motor disturbances like ataxia, 
apraxia and dystonia are observed together with autonomic features like 
vasomotor disturbances and abnormal breathing patterns. Epilepsy is 
common in RTT, has an age-related pattern of occurrence and younger age 
of onset is associated with greater epilepsy severity. Other signs and 
symptoms like anxiety, sleep disturbances, scoliosis, life threatening cardiac 
abnormalities (tachycardia, prolonged corrected QT interval, and sinus 
bradycardia) are frequently described (Chahrour and Zoghbi, 2007; Glaze et 
al., 2010; Hagberg, 2005; Neul et al., 2010; Nissenkorn et al., 2015; Zoghbi 
and Bear, 2012). MeCP2 is a multifunctional protein involved not only in 
transcriptional silencing but also in transcriptional activation, chromatin 
remodeling, RNA splicing and microRNA processing control, with key 
regulatory activity during neurodevelopment (Cheng et al., 2014; Johnson et 
al., 2012). In accordance with the wide spectrum of clinical and particularly 
neurological features, MeCP2 is widely expressed in the CNS and not limited 
to specific cell types, indicating that the pathogenesis of RTT is caused by 
multiple impairments of the CNS development and mature function (Guy et 
al., 2007; Robinson et al., 2012). RTT is mainly caused by MeCP2 deficiency, 
but duplications of MECP2-containing loci are also detrimental to neural 
development and proper brain functions (Schmid et al., 2012). These 
observations underpin the relevance of a fine regulation of MeCP2 
expression, since the levels of MeCP2 protein are critical for the development 
of the central nervous system. Although no specific treatments for RTT are 
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currently available, several studies have demonstrated that the Mecp2-related 
condition in mice is, at least, partially reversible, as phenotypic rescue is 
possible (Guy et al., 2007; Pitcher et al., 2015; Robinson et al., 2012). These 
studies suggest that therapeutic strategies aiming to restore MeCP2 
dependent functions and circuits, even in symptomatic patients, might be 
beneficial. However, since the slightest perturbation in MeCP2 levels is 
deleterious for brain functioning, MeCP2-encoding gene therapy does not 
seem to be a valid approach in the near future. Thus, great advances in the 
RTT research field will be made if useful therapeutic approaches are 
developed, targeting MeCP2-associated dysfunctions. 
MeCP2 functions are still being unraveled, despite of extensive research in 
the field. The recent consensual view is that it acts as a fine-tuning regulator 
of gene transcription. Along with the transcriptional control, MeCP2 interferes 
with various posttranscriptional regulatory mechanisms (Cheng et al., 2014). 
One of the most prominent genes under the jurisdiction of MeCP2 is the 
BDNF gene (Chen et al., 2003). BDNF is a neurotrophin that acts through a 
dual receptor system, to modulate diverse and sometimes opposing biological 
actions, that consists of a specific high affinity receptor, the full lenght tyrosine 
kinase receptor B (TrkB-FL), and a common low affinity receptor, p75 
neurotrophin receptor (Encinas et al., 1999; Tsai, 2015). 
Through TrkB-FL receptor activation, BDNF regulates neuronal survival, 
differentiation and synaptic plasticity (Huang and Reichardt, 2003) such as 
LTP, the neurophysiological basis for learning and memory (Bliss and 
Collingridge, 1993). Reduced BDNF signaling through TrkB-FL leads to 
impaired spatial memory (Kemppainen et al., 2012; Minichiello, 2009) while 
overexpression of TrkB-FL enhances memory (Kemppainen et al., 2012; 
Koponen et al., 2004). The TrkB gene (NTRK2) also encodes for truncated 
isoforms (Klein et al., 1990), which may act as negative modulators of TrkB-
FL signaling (Dorsey et al., 2006; Eide et al., 1996) and decreases in the ratio 
between FL and truncated (Tc) receptors have been detected in several 
neurological disorders (Jeronimo-Santos et al., 2014). In symptomatic mice 
models of RTT, which recapitulate the most prominent symptoms presented 
by RTT patients, BDNF levels are decreased in the whole brain lysate (Chang 
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et al., 2006), suggesting that MeCP2 acts as an activator of BDNF 
expression. However, the regulation of BDNF expression is highly complex 
and this complexity is necessary for appropriate response to different 
neuronal functional states and region specific demands (Li and Pozzo-Miller, 
2014).  
Inspired in the rational that impairment of BDNF signaling could be 
strongly involved in the symptoms presented by RTT patients, work has been 
developed in order to study the impact of potentiating BDNF effects in animal 
models. Experiments designed to increase BDNF signaling mediated by TrkB-
FL phosphorylation had positive results regarding breathing function and 
locomotor activity (Johnson et al., 2012; Ogier et al., 2007; Schmid et al., 
2012) and the overexpression of BDNF demonstrated to extend the lifespan 
and reverse some electrophysiological deficits observed in these animals 
(Chang et al., 2006). However, until now there is no commercially available 
pharmacological treatment directed towards boosting BDNF effects. This 
might be explained by the high complexity of BDNF signaling deregulation in 
RTT, that it is not yet fully understood. Additionally, BDNF short bioavailability  
and low blood–brain barrier penetration have also been a constraint. 
Therefore, in order to overcome this limitation, other strategies should be 
considered, such as the use of other molecules able to boost BDNF actions. It 
is now currently accepted that most of BDNF actions are dependent on the 
activation of a particular type of adenosine receptors, the A2ARs (Sebastiao 
et al., 2011).  
Adenosine is an ubiquitous homeostatic substance present in all cells 
including neurons and glia (see (Ribeiro et al., 2003)). This neuromodulator is 
neither stored nor released as a classical neurotransmitter since it does not 
accumulate in synaptic vesicles, but is instead released from the cytoplasm 
into extracellular space through a nucleoside transporter (see e.g. (Ribeiro et 
al., 2003)). Adenosine receptors have been intensively studied, and to the 
present date, four different receptors have been cloned and designated as A1, 
A2A, A2B and A3 receptors. Modulation of adenosine receptors, mostly A1R 
and A2AR is potentially a useful strategy in the treatment of multiple 
pathological states in the nervous system, such as sleep disorders, epilepsy 
and neurodegenerative diseases (Sebastiao and Ribeiro, 2009b).  Actually, 
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clinical trials using drugs that modulate adenosine receptors were already 
developed (Chen et al., 2007).   
In spite of the previous knowledge about: i) the crosstalk between BDNF and 
adenosine receptors, ii) the advantages of potentiating BDNF actions in RTT, 
and iii) the deregulation of adenosinergic system in several pathological 
conditions occurring with epilepsy, no research has been developed so far, 
considering adenosine receptors as possible therapeutic targets in RTT. 
Accordingly, in the present work, we used the Mecp2 knockout (KO) 
(B6.129P2 (C)-Mecp2tm1.1Bird/J) RTT mice model, to study strategies to 
potentiate BDNF effects through pharmacological modulation of adenosine 
receptors.    In order to better characterize adenosine receptors expression in 
RTT, we also quantified their mRNA expression in tissue dissected from a 
RTT human brain, compared with an age-matched control. 
4.2 Materials and Methods: 
4.2.1  Animals 
The molecular characterization of BDNF and TrkB receptors was done in 
hippocampi taken from 1, 3, and 6 week old wild type (Huber et al.) and 
Mecp2 Knockout (KO) (B6.129P2 (C)-Mecp2tm1.1Bird/J) animals. These 
animals exhibit an initial period free of symptoms and, at around 3 to 8 weeks 
of life, develop a stiff, uncoordinated gait and reduced spontaneous 
movement. Most animals subsequently developed hindlimb clasping  and 
irregular breathing. Variable progression of symptoms lead ultimately to rapid 
weight loss and death at approximately 54 days. (Guy et al., 2001) Several 
studies have shown that this model mimics a panoply of human RTT 
symptoms, including repetitive movements, microcephaly, abnormal 
breathing, seizures, cognitive and motor impairment (Katz et al., 2012). 
Electrophysiological recordings were performed in hippocampi and cortex 
from 6 week old animals (WT and KO). All the animals were handled 
according to the Portuguese law on Animal Care and European Union 
guidelines (86/609/EEC). Animals were housed in the local Animal House on 
a 12hours light/dark cycle and were provided food and water ad libitum. Care 
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was taken so to reduce the number of used animals to the absolutely 
necessary.  The genotype of the mice was determined by polymerase chain 
reaction (Guy et al., 2007). 
4.2.2 Human Brain Tissue Samples 
The brain tissue of a 11 year-old girl affected with RTT (MECP2 mutation -
R255X) who died after a severe pneumonia, was dissected in different 
anatomic regions and were immediately frozen at -80ºC. Parent informed 
consent and ethical approval from HSJD were obtained. Control tissue was 
kindly provided by the biobank of HSJD. 
4.2.3 Western Blot Analysis 
Protein extracts for western blot analysis were prepared from snap-frozen 
hippocampi or cortex. Sodium dodecyl sulfate (SDS)-polyacrylamide gel 
electrophoresis (Zeng et al.) was used to evaluate the levels of BDNF and 
TrkB receptors. Brain tissue was disrupted in sucrose-Tris solution with a 
Teflon pestle and the protein content in the supernatants was determined 
using a commercial Bradford assay (Sigma, MO, United States of America). 
Total proteins (70 µg) were separated on 10% SDS-polyacrylamide 
electrophoresis gels and blotted onto a polyvinylidene fluoride membrane 
according to the standard procedures. The blots were probed overnight at 4ºC 
either with the polyclonal rabbit anti-BDNF or monoclonal mouse anti-TrkB in 
3% BSA (Bovine Serum Albumin). After washing (3 x 5 min in TBST [10 mM 
Tris, 150 mM NaCl, 0,05% Tween 20 in H2O]), blots were then incubated with 
secondary antibodies conjugated with horseradish peroxidase and bands 
were visualized with a commercial enhanced chemiluminescence detection 
method (ECL) kit (PerkinElmer Life Sciences, MA, United States of America). 
Values were normalized to the β-actin or α-Tubulin or GAPDH loading control 
and the relative intensities were normalized to WT (set as 1). Densitometry of 
the bands was performed using the Image J processing software (NIH, MD, 
United States of America). 
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4.2.4  Ex vivo electrophysiological recordings  
The hippocampus was dissected free within ice-cold aCSF solution composed 
of: NaCl 124 mM; KCl 3 mM; NaH2PO4 1.25 mM; NaHCO3 26 mM; MgSO4 1 
mM; CaCl2 2 mM; and glucose 10 mM, previously gassed with 95% O2 and 
5% CO2, pH 7.4. Slices (400 µm thick) were cut perpendicularly to the long 
axis of hippocampus with a McIlwain tissue chopper and allowed to recover 
functionally and energetically for 1 h in a resting chamber, filled with same 
solution, at room temperature. Slices were transferred to a recording chamber 
for submerged slices and continuously superfused at 3 ml/min with gassed 
bathing solution at 32ºC; drugs were added to this superfusion solution in an 
open circuit. Recordings were obtained with an Axoclamp 2B amplifier and 
digitized (Axon Instruments, Foster City, CA). Individual responses were 
monitored, and averages of six consecutive responses continuously stored on 
a personal computer with the LTP software (Anderson and Collingridge, 
2001). 
Basal synaptic transmission: Field excitatory post-synaptic potentials 
(fEPSPs) were recorded through an extracellular microelectrode (4M NaCl, 2–
6 MΩ resistance) placed in stratum radiatum of CA1 area. Stimulation 
(rectangular 0.1 ms pulses, once every 15 s) was delivered through a 
concentric electrode placed on the Schaffer collateral–commissural fibers, in 
stratum radiatum near CA3–CA1 border. The intensity of stimulus (80–200 
µA) was initially adjusted to obtain a large fEPSP slope with a minimum 
population spike contamination. Alteration in synaptic transmission induced by 
drugs was evaluated as the % change in the average slope of the fEPSP in 
relation to the average slope of the fEPSP measured during the 10 min that 
preceded the addition of drugs as described previously (Diogenes et al., 
2004). 
LTP induction and quantification: fEPSPs (Figure 4.1.A2) were recorded 
through extracellular microelectrode (4M NaCl, 2–6MΩ resistance) placed in 
stratum radiatum of CA1 area as represented in Figure 4.1.A1 In LTP 
experiments, stimulation (rectangular 0.1 ms pulses, once every 10 s) was 
delivered alternatively to two independent pathways through bipolar 
concentric electrodes placed on Shaffer collateral/commissural fibers in 
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stratum radiatum (Figure 4.1.A1). LTP was induced by θ-burst protocol 
consisting of three trains of 100 Hz, three stimuli, separated by 200 ms as 
previously described (Diogenes et al., 2011) and shown in Figure 4.1.A3.  
The intensity of the stimulus was maintained during the induction protocol. 
LTP was quantified as the % change in the average slope of the fEPSP taken 
from 46 to 60 min after LTP induction in relation to the average slope of the 
fEPSP measured during the 14 min that preceded the induction of LTP. In 
each individual experiment, the same LTP-inducing paradigm was delivered 
to each pathway. At 1 h after LTP induction in one of the pathways, BDNF (20 
ng/ml) was added to the superfusion solution and LTP was induced in the 
second pathway, no less than 20 min after BDNF perfusion and only after 
stability of fEPSP slope values was observed for at least 10 min. The effect of 
BDNF upon LTP was evaluated by comparing the magnitude of LTP in the 
first pathway in the absence of BDNF (control pathway), with the magnitude of 
LTP in the second pathway in the presence of BDNF (test pathway); each 
pathway was used as control or test on alternate days. To test the 
modification of the effect of BDNF upon LTP, the modulatory drugs were 
added to superfusion bath at least 20 min before induction of LTP in the first 
pathway and remained in bath up to the end of the experiment. BDNF was 
added, as usual, 60 min after the induction of LTP in the first pathway. Thus, 
modulatory drugs were present during both LTP-inducing periods, whereas 
BDNF was only present during the second induction of LTP. This protocol 
allows the comparison between the effects of BDNF upon LTP under different 
experimental conditions, keeping the magnitude of LTP under the same drug 
condition, without BDNF in the same slice as an internal control. When testing 
the effect of a drug upon LTP (rather than the modulation of the BDNF effect 
on LTP), the drug was added to bath 20 min before induction of LTP in the 
second pathway and the magnitude of the resulting LTP was compared with 
that previously obtained (first pathway) in the absence of the drug (see, 
(Diogenes et al., 2011)). In control experiments performed with hippocampal 
slices taken from any age group, we confirmed that when the θ-burst 
paradigm was sequentially applied to each of the two pathways in the 
absence of any drug, the synaptic potentiation obtained in the first pathway 
was similar to that achieved in the second pathway.  
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Input–output curve: Input–output (I/O) curves in slices from the two genotypes 
were performed to ensure that modifications in LTP magnitude were not due 
to changes in basal synaptic transmission. After obtaining a stable baseline 
for at least 15 min, the stimulus delivered to the slice was decreased until 
disappearance of the fEPSPs. The stimuli delivered to the slice were 
successively increased by steps of 20 µA. For each stimulation condition, data 
from three consecutive averaged fEPSP (each averaged fEPSP is the 
computerized mean of six individual fEPSP) were stored. The range of all 
inputs delivered to the slice was typically from 60 µA to supra-maximum 
stimulation amplitude of 340 µA. The input–output curve was plotted as the 
relationship of fEPSP slope vs stimulus intensity, which provides a measure of 
synaptic efficiency as previously described (Diogenes et al., 2012). 
 
Figure 4.1 Extracellular recordings in 
hippocampal slices 
Schematic representation of a hippocampal 
transverse slice preparation showing the recording 
configuration used to obtain extracellular responses 
in the CA1 dendritic layer (stratum radiatum) 
evoked by stimulation of two (A1) separate sets of 
the Schaffer pathway (S1 and S2). (A2) Example of 
a representative trace obtained after stimulation 
composed by the stimulus artifact (1), followed by 
the pre-synaptic volley (2) and the field excitatory 
post-synaptic potentials (fEPSP) (3). A schematic 
representation of the stimulation paradigms used in 
plasticity experiments is represented in (A3). Adapted from Diógenes et al., 2011 
(Diogenes et al., 2011). 
4.2.5 RNA extraction and cDNA synthesis 
Total RNA was extracted from brain cortex using RNeasy Lipid Tissue Mini Kit 
(Qiagen) from cortex tissue, according to the manufacturer’s instructions. 
RNA concentration and purity were evaluated by spectrometry on the basis of 
optical density (OD) measurements at 260 and 280 nm.  
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cDNA synthesis was performed in a 20 µl reaction mixture. A 4.3 µg total RNA 
was mixed with 1 µl random primer hexamer (Amersham) and 1 µl each of 
dATP, dTTP, dCTP, dGTP (each 10 mM) and incubated for 5 min at 65ºC. 
After cooling for 2 min at 4ºC, the solution was mixed with 4 µl of 25 mM 
MgCl2, 2 µl of 10X RT Buffer, 2 µl of 0.1M DTT, 0.5 µl SuperScript III Reverse 
Transcriptase (200 U; Invitrogen Life Technologies). The reaction was 
performed for 50 min at 42ºC and terminated by 15 min incubation at 70ºC. 
Parallel reactions for each RNA sample were run in the absence of 
SuperScript III to assess the degree of any genomic DNA contamination. 
Completed RT reactions were stored at −20 ◦C until use. 
 
Quantative PCR 
 qPCR for mRNA was done using Power SYBR® Green PCR Master 
Mix (Life Technologies), the pre amplified cDNA was used as the template for 
the real-time PCR run Rotor Gene 6000 (Corbett Life Science), according to 
the manufacturer´s recommendations. Negative Control PCR samples were 
run with no template. Fold-changes were calculated using Cq method and 
normalized to the expression of GAPDH with Rotor-Gene Series Software 1.7 













Table 4.1. Primers used for qPCR. 
Gene	   Primers	  (5’-­‐-­‐>3’)	  




A1R F: 5’- GCCACAGACCTACTTCCACA-3’ 
R: 5’- CCTTCTCGAACTCGCACTTG-3’ 
A2AR F: 5’- AACCTGCAGAACGTCAC-3’ 
R:5’- GTCACCAAGCCATTGTACCG-3’ 
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Data was normalized according to the following formula: Cq = Cq (target 
gene) – Cq (reference gene). 
4.2.6 Drugs 
BDNF was generously provided by Regeneron Pharmaceuticals, 2-[p-(2-
carboxyethyl)phenethylamino]-50-N-ethylcarboxamido adenosine (CGS-
21680) was from Sigma; Aliquots of the stock solutions were kept frozen at -
20ºC until use. 
4.2.7 Antibodies 
Anti-TrkB antibody was from BD Biosciences, anti-β-actin antibody, anti-
BDNF and anti-α-Tubulin were obtained from Abcam, anti-GAPDH was 
purchased from Life Technologies and secondary antibodies were from 
Biorad Laboratories.  
4.2.8 Data Analysis 
The data are expressed as mean ± SEM of the n number of independent 
experiments. The significance of differences between the means of 2 
conditions was evaluated by Student’s t-test. Values of P<0.05 were 
considered to represent statistically significant differences.  
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4.3  Results 
4.3.1 BDNF and TrkB-FL receptor are severely decreased in 
symptomatic MeCp2 KO animals 
Evidence supports MeCP2 actions as a repressor and also as an activator of 
gene expression (Chahrour and Zoghbi, 2007). Given that the BDNF gene is 
under MeCP2 regulation (Chen et al., 2003) attention has been directed to 
BDNF alterations on RTT.  
Bdnf expression levels are low in the rodent brain during prenatal 
development, and rise dramatically during the postnatal period, which 
coincides with the pattern of Mecp2 expression (Li and Pozzo-Miller, 2014).  It 
was already described that Bdnf expression is impaired in RTT mice model 
exhibiting neuropathological and behavioral phenotypes (Chang et al., 2006). 
Less attention has been directed to TrkB receptors, crucial players in BDNF 
mediated neuroprotection (Huang and Reichardt, 2003). Accordingly, together 
with the evaluation of BDNF levels, TrkB receptors levels were also evaluated 
in both presymptomatic and symptomatic stages.  
During the presymptomatic stage, hippocampi from 1 and 3 week old animals 
were studied. In the symptomatic period samples from 6-8 week old animals 
were evaluated. Interestingly, we observed a decrease of BDNF levels by 
approximately 20 % in the hippocampi taken from presymptomatic 3 week old 
KO animals when compared with the age matched WT animals (p<0.05, n=4, 
Figure 4.2.B1,2). Our preliminary data from 1 week old animals (n=2, Figure 
4.2.A1,2), suggest increased levels of BDNF in this period of life.  
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Figure 4.2 BDNF and TrkB receptor are decreased in symptomatic 
MECP2 KO animals 
In A2, B2 and C2 are shown the averaged of BDNF density evaluated by western 
blot analysis in hippocampal homogenates prepared from hippocampi taken from WT 
(black bars) and KO (white bars) in different stages: presymptomatic stage, 1 week of 
age (A2) and 3 weeks of age (B2) and symptomatic stage, 6 weeks of age (C2). A1, 
B1 and C1 show representative western blots for each age of the animals using an 
antibody which recognizes BDNF (~15 KDa). Α-Tubulin (~50 KDa) was used as 
loading control. In D2, E2 and F2 are shown the averaged OD of TrkB-FL receptors  
evaluated by western blot analysis in hippocampal homogenates prepared from 
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hippocampi taken from WT (black bars) and KO (white bars) in different stages: 
presymptomatic stage, 1 week of age (D2) and 3 weeks of age (E2) and symptomatic 
stage, 6 weeks of age (F2). In D3, E3 and F3 are shown the averaged of TrkB-TC 
receptors density evaluated by western blot analysis in hippocampal homogenates 
prepared from hippocampi taken from WT (black bars) and KO (white bars) in 
different stages: presymptomatic stage, 1 week of age (D3) and 3 weeks of age (E3) 
and symptomatic stage, 6 weeks of age (F3). D1, E1 and F1 show representative 
western blots for each age of the animals using an antibody that recognizes TrkB-FL 
receptors (~145 KDa) and TrkB-Tc receptors (~95 KDa).  GAPDH (~35 KDa) or β-
Actin (~42 KDa) were used as loading controls. All values are mean ± standard error 
of mean. *P<0.05 (Student’s t-test). The hippocampal homogenates used in the 
analysis were taken from the same animals used in electrophysiological experiments. 
The values obtained for WT samples were considered 1. 
 
 
As expected, in the symptomatic KO animals (Chang et al., 2006) the 
hippocampal levels of BDNF are decreased by approximately 30% (p<0.05, 
n=5, Figure 4.2.C1,2).  Regarding TrkB receptor levels, there is a significant 
reduction on the full length (FL) protein by approximately 46% (p<0.05, n=8-
10, Figure 4.2.F1,2) in symptomatic 6-8 week old KO animals comparing to 
the age matched controls. The data obtained in two hippocampal samples 
from 1 week old animals, suggest the presence of decreased levels of TrkB-
FL receptors in this period of life (n=2, Figure 4.2.D1,2). No significant 
changes were detected on the protein levels of TrkB truncated forms 
throughout ages studied (Figure 4.2.D1,3; E1,3; F1,3). 
4.3.2 BDNF loses the facilitatory effect upon LTP in Mecp2 KO animals  
BDNF has a well-documented ability to increase LTP, an accepted 
neurophysiological paradigm for learning and memory, on hippocampal CA1 
area through TrkB-FL receptors activation (Figurov et al., 1996; Korte et al., 
1996). In order to evaluate the functional impact of the molecular changes 
detected in symptomatic KO animals, the effect of exogenous BDNF upon 
LTP was evaluated. Therefore, as described in the methods section, 
electrophysiological recordings were performed using hippocampal slices 
taken from 6-8 week old WT and KO animals (symptomatic stage). As 
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expected (Diogenes et al., 2011; Fontinha et al., 2008), the θ-burst stimulus 
applied to hippocampal slices, taken from WT animals, in the presence of 
BDNF (20 ng/mL) induced a robust LTP (LTPWT-BDNF: 46.9 ± 5.6% increase in 
fEPSP slope, n=4, Figure 4.2.A), which was significantly higher (P<0.05) than 
the obtained in the absence of the neurotrophin (LTPWT-CTR: 24.1 ± 6.1% 
increase in fEPSP slope; n = 4, Figure 4.2.A1,2). The θ-burst stimulation 
induced a small LTP, in the absence of BDNF (control pathway), but 
statistically significant when compared to the baseline (P<0.05, n=4). On the 
contrary, in hippocampal slices taken from KO animals the same θ-burst 
protocol did not induced a significant increase on the slope of fEPSP 
compared to the baseline. Moreover, BDNF (20 ng/ml) did not further 
increased LTP magnitude (LTPKO-CTR: 10.1 ± 11.9% and LTPKO-BDNF: 14.5 ± 
7.0%, n=5, Figure 4.2.B) in hippocampal slices taken from KO animals.  
To evaluate whether the changes observed in LTP magnitude could be 
due to changes in baseline synaptic efficiency, I/O curves were performed 
and are shown in Figure 4.3. Hippocampal slices taken from KO animals 
displayed higher Emax values when compared with WT animals (EmaxWT= 
0.9901 ± 0.04626, n= 4; EmaxKO= 1.781 ± 0.2129, n=4, p<0.05, F test;). 
Therefore suggesting, that the absence of a robust LTP in KO animals is not 
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Figure 4.3 BDNF loses the facilitatory effect upon LTP in MECP2 KO 
animals  
Panels A1 and B1 show averaged time courses changes in field excitatory post-
synaptic potential (fEPSP) slope induced by the θ-burst stimulation in the  absence 
(white symbols) or in the presence (black symbols) of BDNF (20 ng/ml) in 
hippocampal slices taken from wild type animals (A) or from Mecp2 KO animals (B). 
BDNF (20 ng/ml) was applied 60 min after the induction of LTP in the first pathway 
(white symbols) and at least 20 min before induction of LTP in the second pathway 
(black symbols). The ordinates represent normalized fEPSP slopes, where 0% 
corresponds to the averaged slopes recorded for 14 min before θ-burst stimulation 
and the abscissa represents the time of every recording. Panels (A2 and B2) depict 
the magnitude of LTP (change in the fEPSP slope at 46–60 min) induced by θ-burst 
stimulation in relation to pre-θ-burst values (0%) in the absence of (white bars), or in 
the presence of BDNF (black bars) alone in hippocampal slices from WT animals 
(A2) or KO animals (B2). In A3 and B3 are shown traces obtained in representative 
experiments in A1 and B1, respectively; Panel C shows the input/output (O/I) curves 
corresponding to responses generated by various stimulation intensities (60–340 µA) 
in WT slices (filled circles) and KO slices (filled triangles).   
All values are mean ± standard error of mean. *P<0.05 (paired Student’s t-test) as 
compared with absence of BDNF in the same experiments; # p<0.05 (paired 
student’s t-test) as compared with baseline in the same experiments. n.s. not 
significant;  
Part of the I/O curve experiments were performed by Cátia Palminha and are 
included in her Master thesis. 
4.3.3 The activation of A2AR restores LTP magnitude and the effect of 
BDNF upon LTP 
A considerable number of data have been published demonstrating that there 
is a cross talk between BDNF and a particular type of adenosine receptors the 
A2ARs (Sebastiao et al., 2011). Accordingly, many BDNF effects are 
dependent and or facilitated by activation of A2ARs. This cross talk is present 
even when there is a strong reduction on TrkB-FL receptor levels, as in aging 
(Diogenes et al., 2007), where the activation of A2ARs is able to promote 
synaptic actions of BDNF (Diogenes et al., 2007). Therefore, the activation of 
A2ARs has been seen as a way to potentiate synaptic effects of BDNF. 
Indeed, in the presence of the selective A2ARs agonist, CGS 21680 (10 nM) 
	   	  Chapter 4 
 
	   112	  
(Jarvis et al., 1989) added 60 minutes after the LTP induction in the first 
pathway and at least 20 minutes before BDNF (20 ng/ml) superfusion, the 
neurotrophin significantly increased LTP magnitude (LTPKO-CTR: 9.1 ± 
10.0% and LTPKO-CGS+BDNF: 43.9 ± 4.3%, n=6, p<0.05; Figure 
4.4.B1,2,3). Alone CGS 21680 did not affect LTP magnitude when compared 
to the LTP induced in the first pathway (control-CTR) (Figure 4.4.A1,2,3). 
Interestingly, the θ-burst stimulation in the presence of CGS 21680 induced 
an increase on fEPSP slope (P<0.05, Figure 4.4.A2) as compared with 
baseline.  
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Figure 4.4 Activation of A2ARs restores the effect of BDNF upon LTP 
Panel A1 shows averaged time courses changes in field excitatory post-synaptic 
potential (fEPSP) slope induced by the θ-burst stimulation in the  absence (open 
triangles) or in the presence (filled triangles) of CGS21680 (10nM) and BDNF 
(20ng/ml) in hippocampal slices taken from MECP2 knockout (KO) animals. BDNF 
was applied at least 20 min after CGS21680 (10nM) applications which was applied 
60 min after the induction of LTP in the first pathway (open triangles). Panel A2 
shows averaged time courses changes in fEPSP slope induced by the θ-burst 
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stimulation in the  absence (open triangles) or in the presence (filled triangles) of the 
selective A2A agonist, CGS21680 (10nM) in hippocampal slices taken from Mecp2 
KO animals. CGS21680 (10nM) was applied 60 min after the induction of LTP in the 
first pathway (open triangles) and at least 20 min before induction of LTP in the 
second pathway (filled triangles). In A1 and A2 the ordinates represent normalized 
fEPSP slopes, where 0% corresponds to the averaged slopes recorded for 14 min 
before θ-burst stimulation and the abscissa represents the time of every recording. 
Panels (B1 and B2) depict the magnitude of LTP (change in the fEPSP slope at 46–
60 min) induced by θ-burst stimulation in relation to pre-θ-burst values (0%) in the 
absence of any drug (open bars), in the presence of BDNF + CGS21680 (B1) (filled 
bars) or in the presence of CGS 21680 (B2) in hippocampal slices from KO animals. 
In B3 traces from representative experiments are shown.   All values are mean ± 
standard error of mean. *P<0.05 (paired Student’s t-test) as compared with absence 
of BDNF in the same experiments; # p<0.05 (paired student’s t-test) as compared 
with baseline in the same experiments. n.s.- not significant;  
4.3.4 A1R and A2AR expression is reduced in one human brain sample  
Given the results obtained regarding BDNF, TrkB-FL levels and also 
unpublished results from Maria Jose Diogenes lab that suggested increased 
A1R  and decreased A2AR expression changes in the animal RTT model, we 
performed mRNA quantification experiments in brain tissue from an 11 years 
old girl with RTT and compared the results with an age matched control 
mRNA sample extracted from the same cortical region. Adenosine A2AR 
mRNA level is reduced (Figure 4.5.A) (0.44 when control value is considered 
1). Adenosine A1R mRNA level is increased (Figure 4.5.A) (4 fold increase, 
when control value is considered 1). Fold changes between mRNA 
quantification of TrkB-FL (1.4), TrkB-TC (1.1) and BDNF (1.2) were not 
remarkable (Figure 4.5.B). 
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Figure 4.5 mRNA quantification studies of adenosine A2AR, A1R, TrkB-
FL and TrkB-TC in RTT human cortical tissue. 
A. Adenosine A2AR mRNA level in the RTT patient cortical tissue was reduced (44 
% of control). Adenosine A1R mRNA level was increased (4 fold increase, black 
bars), when compared with an age matched control (white bars). B. Differences 
between mRNA levels of TrkB- FL (1.4), TrkB-TC (1.1) and BDNF (1.2) of control 
(white bars) and patient (black bar) were irrelevant. 
4.4  Discussion  
In the present work, in addition to the previously documented decreased 
levels of endogenous hippocampal BDNF in Mecp2 KO symptomatic animals, 
a severe decrease on the TrkB-FL receptors levels was found. The detailed 
evaluation of BDNF and TrkB receptor levels throughout postnatal 
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development shows increased levels of BDNF during the first week of life, 
coupled with a down regulation of TrkB-FL receptors. In symptomatic stages, 
both BDNF levels and TrkB-FL receptors are decreased in the hippocampus. 
Hippocampal BDNF signaling has been pointed as crucial for memory 
formation. Therefore, these changes can be involved in the intectual 
disabilities described in RTT. 
 
Figure 4.6 In MECP2 KO animals the deregulation of endogenous 
adenosine tone can aggravate the impairments on BDNF signaling. 
Hippocampal extracellular tone of adenosine, exerts upstream control over 2 major 
adenosine-dependent pathways: (1) A2AR-dependent promotion of BDNF-signaling, 
and (2) A1R-dependent inhibition of synaptic transmission. In WT animals (left 
panel), normal levels of adenosine facilitate BDNF actions by TrkB-FL receptors 
activation upon synaptic plasticity through the activation of A2A and inhibit synaptic 
transmission through A1R. In Mecp2 KO animals (right panel), decreased levels of 
BDNF and TrkB-FL receptors were observed and also a possible decrease on 
adenosine levels, which in turn could induce an upregulation on A1R. The reduced 
activation of adenosine receptors (dashed arrows) in particular A2AR, that appears to 
be downregulated, implies an aggravation on the BDNF signaling impairment. These 
findings reinforce BDNF signaling pathways (orange asterisks) as possible 
pharmacological targets but importantly add adenosine and its receptors as new 
promising pharmacological targets (orange asterisks). 
Increased BDNF levels detected during the early post natal life could 
contribute to a possible downregulation of TrkB-FL receptors (Sommerfeld et 
al., 2000). However, a direct effect of Mecp2 in TrkB-FL receptor levels should 
also be considered. RTT is a dynamic disorder with evolving clinical stages 
(Hagberg, 2002) that reflect the effect of MeCP2 impairment upon the 
developing brain, normal brain function and also secondary adaptative 
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changes to the original defect. The follow up of molecular and functional 
changes throughout development seems like a valuable approach to 
understand how neurodevelopmental disorders progress and also to delineate 
earlier therapeutic strategies that can prevent adaptative responses, which 
further aggravate the disease phenotype. 
The increase on BDNF levels in RTT patients has been pointed as a 
promising therapeutic strategy. In that way, multiple strategies have been 
developed in order to increase BDNF actions (Li and Pozzo-Miller, 2014) on 
animal models. Notwithstanding, less attention has been devoted to BDNF 
receptors. In the present work, for the first time, we demonstrated that there is 
a strong decrease on TrkB-FL receptors in Mecp2 KO animals without any 
significant changes in the truncated forms. Both decreases in TrkB-FL 
receptors and BDNF levels have been detected in several neurologic 
disorders associated with cognitive deficits and are also now reported in this 
thesis in the RTT animal model.  
BDNF is a neurotrophin that promotes neuronal survival, differentiation, 
and synaptic plasticity such as LTP through activation of TrkB-FL. 
Accordingly, LTP is deeply impaired in BDNF homozygous and heterozygous 
mutant mice and can be rescued by exogenous BDNF (Korte et al., 1996; 
Patterson et al., 1996). Moreover, the effect of exogenous BDNF upon 
hippocampal LTP is dependent on a proper adenosinergic tonus via activation 
of A2ARs (Diogenes et al., 2011; Fontinha et al., 2008). Therefore, whenever 
the endogenous activation of A2ARs is compromised, BDNF loses the ability 
to potentiate LTP (Diogenes et al., 2011; Fontinha et al., 2008). Here we 
describe that the effect of BDNF upon LTP induced by θ-burst stimulation is 
completely abolished in hippocampal slices taken from Mecp2 KO animals. 
Thus, one could ask whether this could be explained by changes on 
adenosine signaling pathways.  
A2AR mRNA quantification in cortical tissue from a girl with RTT suggested a 
reduction in A2ARs levels. As previously mentioned, several important actions 
of BDNF are dependent on A2ARs activation. Since BDNF and TrkB-FL 
receptors levels and the A2ARs expression are reduced in symptomatic 
stages of the RTT model, we postulated that the activation of A2AR, together 
with the exogenous administration of BDNF, could rescue BDNF actions upon 
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LTP. The selective A2AR agonist, CGS2168 (Jarvis et al., 1989) was used to 
test this hypothesis. Indeed, we found that it could restore BDNF facilitatory 
effect upon LTP, similar to what is observed in hippocampal slices from WT 
animals. 
These findings open up a therapeutic window in RTT, through the modulation 
of adenosine signaling. Further studies are needed to consolidate our 
knowledge about adenosine dysfunction in RTT. However, in view of the 
present results, increasing adenosine tonus or acting directly at the specific 
receptors could have a potential beneficial role in this disorder. Increasing 
A1R activity would prevent pathological excitability and epilepsy susceptibility. 
On the other hand, activation of A2ARs, could bypass the impairment of TrkB-
FL signaling, restoring BDNF actions upon LTP, with potential benefic effects 
on cognition. Combining BDNF administration with increased adenosine 
availability or direct activation of A2ARs could be beneficial for cognitive 
impairment in RTT.  
In conclusion, we found that BDNF actions upon LTP are impaired in RTT 
animal model. This dysfunction could be explained by the changes in TrkB 
receptors levels, described for the first time in the present study. 
Adenosinergic system is also compromised in this RTT model, according to 
our results, in favour of a reduction of an impaired expression of adenosine 
A2ARs. Since robust evidence suggests that BDNF and TrkB receptors levels 
are impaired in RTT models, BDNF signaling modulation, through A2ARs 
activation, potentiating TrkB-FL signaling pathway, is a promising therapeutic 
approach for RTT.  
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ABSTRACT 
Standardization of culture methods for human pluripotent stem cell (PSC) 
neural differentiation can greatly contribute to the development of novel 
clinical advancements through the comprehension of neurodevelopmental 
diseases. Here, we report an approach that reproduces neural commitment 
from human iPSCs using dual-SMAD inhibition under defined conditions in a 
vitronectin-based monolayer system. By employing this method it was 
possible to obtain neurons derived from both control and RTT patients’ 
pluripotent cells. During differentiation mutated cells displayed alterations in 
the number of neuronal projections, and production of Tuj1 and MAP2-
positive neurons. Although investigation of a broader number of patients 
would be required, these observations are in accordance with previous 
studies showing impaired differentiation of these cells. Consequently, our 
experimental methodology was proved useful not only for the generation of 
neural cells, but also made possible to compare neural differentiation behavior 
of different cell lines under defined culture conditions. This study thus expects 
to contribute with an optimized approach to study the neural commitment of 
human PSCs, and to produce patient-specific neural cells that can be used to 
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5.1  Introduction 
Pluripotent stem cells (PSCs) are cells capable to differentiate and give rise to 
every tissue cell in the human body (Mitalipov and Wolf, 2009). Until recently, 
these cells could only be isolated from the inner cell mass of the blastocyst, 
being designated ESCs (Keller and Snodgrass, 1999; Thomson et al., 1998). 
However, in 2007, Shinya Yamanaka and co-workers were able to reprogram 
human somatic cells into the pluripotent stem cell state using transfection of 
four transcription factors (Oct-3/4, Sox2, KLF4 and c-Myc). These human 
iPSCs brought many expectations into the biomedical field due to their 
potential applications in disease modeling, drug and toxicity screening, 
patient-tailored therapies and engineered tissues (Takahashi et al., 2007), 
potentially preventing immunosuppression and graft rejection, and paving the 
way for the next generation of personalized medicine (Yamanaka, 2009). 
Countless protocols for in vitro expansion and differentiation of human PSCs 
have been developed since then, which typically comprise the use of 
undefined culture components (Chambers et al., 2009; Zhang et al., 2001) 
(Kennedy et al., 2007; Koivisto et al., 2004; Laflamme et al., 2007; Yang et al., 
2008). Problematically, this presents many difficulties to the translation of 
these protocols from basic research to tangible applications (Abbasalizadeh 
and Baharvand, 2013). For example, the use of products from animal origin 
renders the produced cells unsuitable for clinical applications due to the risk of 
cross-species contamination and immunogenic reactions (Martin et al., 2005; 
Oh and Choo, 2006). Furthermore, the use of undefined culture conditions 
poses barriers to the understanding of the biological processes involved in 
pluripotency and lineage specification and compromises the reproducibility of 
these culture systems. Therefore, there is an urgent need to develop methods 
and protocols that use defined culture conditions and allow reproducibility 
when generating specific cell populations from PSCs. 
In particular, neural specification can be induced by the synergistic inhibition 
of both Activin/Nodal and BMP signaling pathways with small molecules 
resulting in blockage of mesoderm, endoderm and trophoblast lineages while 
allowing neuroectodermal specification (Chambers et al., 2009; Shi et al., 
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2012b). Despite being relatively efficient and straightforward, this method 
uses substrates and medium components of animal origin and of undefined 
nature (e.g. matrigel and serum replacements). Chemically defined substrates 
based on proteins, polymers and hybrids of polymers with active biomolecules 
have been developed, exhibiting low lot-to-lot variability and presenting high 
reproducibility (Azarin and Palecek, 2010) (Jin et al., 2012; Rodin et al., 
2010). Truncated, recombinant vitronectin (VTN) conjugates, in particular, 
have been used as a support for robust expansion and differentiation of 
human PSCs under standardized and totally defined culture conditions(Chen 
et al., 2011; Jin et al., 2012; Lippmann et al., 2014; Melkoumian et al., 2010). 
Such system would greatly benefit neural commitment protocols, allowing the 
foundation of defined settings for in vitro studies of neural development and 
ensuring reliable methods for the anticipated biomedical applications. 
In this study, we have validated the use of defined culture conditions to 
achieve an efficient and reproducible neural commitment of human PSCs. A 
defined culture medium supplemented with chemical inhibitors of BMP and 
TGFβ signaling, together with vitronectin for adherent growth, was shown to 
be sufficient to generate neural precursors (NPs) expressing SOX1, PAX6, 
and NESTIN. As a proof-of-concept, we have validated the neural 
commitment protocol using different cell lines, including patient-specific RTT-
derived iPSCs. This neurological disorder is characterized by autistic-like 
behaviors and is commonly caused by mutations in the X-linked MECP2 
gene, which is vital for proper functioning of the brain and acts as one of the 
many biochemical switches for gene expression (Marchetto et al., 2010; 
Walsh and Hochedlinger, 2010). Consequently, abnormal expression of this 
gene causes atypical brain function, leading to many disease processes that 
are mostly uncharacterized (Laccone et al., 2001; Li et al., 2013). Thus, this 
study also expects to contribute with a novel methodology capable to provide 
patient-specific neural cells that could be used to gain a better understanding 
of the disease. Furthermore, the ability to recapitulate the development of the 
human nervous system in vitro will provide important insights on the 
mechanisms involved in the maturation of specific neural cell types, making 
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this approach transversal to other related areas in neurodevelopmental 
research.  
5.2 Materials and Methods 
5.2.1 Cell lines 
Two human iPSC lines obtained from healthy donors (46, XY) were used: 
WT-Évora F0000B13 and iLB-C1-30 m-r12. WT-Évora was kindly provided by 
TCLab (Évora, Portugal), and iLB-C1-30 m-r12 cells were derived at the 
University of Bonn, Germany. These cell lines were reprogrammed from 
fibroblasts through retroviral transduction of human genes OCT4, SOX2, c-
MYC and KLF4 (Takahashi et al., 2007), and were used as wild type controls 
to verify the robustness of the neural commitment method. The EMC23i cell 
line was generated at the iPSC Facility, Erasmus Medical Center, Rotterdam, 
using engineered color-coded lentiviral vectors (as described by Warlich and 
coworkers (Warlich et al., 2011)), and was derived from a patient (46, XX) 
with a MECP2 mutation (R306C). Cells were routinely evaluated for karyotype 
abnormalities by conventional cytogenetics using the services of Genomed 
SA (Lisbon, Portugal). Biological samples collected for this work were 
obtained following rigorous national and European ethical guidelines and 
informed consent from donor or patient’s legal guardian. 
5.2.2 Feeder-free culture of human iPSCs  
Human iPSCs were thawed and cultured in mTeSRTM1 medium (StemCell 
TechnologiesTM), on MatrigelTM (BD)-coated, SynthemaxTM (Corning®)-
coated, or Vitronectin (VTN-N, Gibco®)-coated plates. Medium was changed 
daily and cells were passaged every 3-4 days, using EDTA dissociation buffer 
0.5mM (Gibco®, diluted in sterile PBS) with a split-ratio of 1:4 (Chen et al., 
2011). 
5.2.3 Neural induction of human iPSCs  
When human iPSC cultures were nearly confluent, two different strategies 
were followed for neural induction, based on Chambers, et al (Chambers et 
al., 2009) and Shi, et al (Shi et al., 2012b). The first protocol was performed 
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using DMEM/serum replacement (SR)-based differentiation medium (KO-
DMEM medium (Gibco®) supplemented with 20% (v/v) KO-SR (Gibco®), 1% 
(v/v) non-essential aminoacids (Gibco®), 1 mM L-glutamine (Gibco®), 0.1 mM 
β-mercaptoethanol (Sigma®) and 1% (v/v) Penicillin/Streptomycin (PenStrep, 
Gibco®)), while the other was performed in N2B27 medium (50% (v/v) 
DMEM/F12/N2 medium (DMEM-F12 (Gibco®), supplemented with 1% (v/v) 
N2 (Gibco®), 1 mM L-glutamine, 1.6 g/L Glucose (Sigma®), 1% (v/v) 
PenStrep, and 20 µg/mL Insulin (Sigma®)) and 50% (v/v) of B27 medium 
(Neurobasal (Gibco®) supplemented with 2% (v/v) B27-supplement (Gibco®), 
1 mM glutamine and 1% (v/v) PenStrep)). In both cases, media formulation 
was supplemented with 10 µM SB-431542 (SB) and 100 nM LDN-193189 
(Wernig et al.) (both from Stemgent®), as outlined in Figure 5.2.A. 
5.2.4 Neuronal differentiation 
At day 12 of differentiation, cells were passaged with EDTA dissociation buffer 
(0.5mM) and re-plated onto laminin (Sigma®)-coated plates (split ratio of 1:3). 
When neural rosettes were observable (around day 14), N2B27 was 
supplemented with 10 ng/mL of bFGF (Peprotech®) for two to four days. At 
day 17, cells were passaged using EDTA to new laminin-coated plates (split 
ratio of 1:3) (Shi et al., 2012a). Cells were then cultured until day 28-30 in 
N2B27 medium without the addition of small molecules or any other factors. 
Finally, cells were split with accutase (Sigma®) and plated at a density of 
100,000 cells/cm2. Cells were further cultured until day 150 with medium 
replacement every other day (Figure 5.1). 
 
Figure 5.1 Schematic representation of neural commitment and 
subsequent neural differentiation of human pluripotent stem cells.  
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Neural commitment is initiated under defined culture conditions using dual SMAD 
inhibition for 12 days. At this stage cells are passed as clumps using EDTA 
dissociation to laminin-coated plates. At around day 14 bFGF is added to facilitate 
proliferation of neural rosettes until day 17. Subsequent replating onto laminin is 
done using EDTA dissociation, and further differentiation occurs in the absence of 
growth factors or chemical inhibitors. A final single-cell passaging step is done at day 
28-30 and cells are allowed to differentiate until day 150 with periodic medium 
change and laminin supplementation. 
5.2.5 Immunofluorescence staining of intracellular markers 
We performed immunofluorescence staining as previously described 
(Rodrigues et al., 2014). Briefly, cells were fixed in paraformaldehyde (PFA, 
Gibco®) 4% for 30 minutes, followed by blocking for 60 minutes at room 
temperature. Primary antibodies were then added and left at 4ºC overnight. 
Secondary antibodies (goat anti-mouse or goat anti-rabbit IgG, Alexa Fluor® 
–488 or –546, 1:500 (v/v) dilution, Molecular Probes®) were prepared and 
incubated with cells for 1 hour at room temperature. DAPI (Sigma®) was used 
to counterstain cell nuclei. Primary antibodies used were FoxG1 (1:100, 
Abcam®), GFAP (1:100, Millipore), Ki-67 (1:100, BD), MAP2 (1:400, 
Abcam®), NANOG (1:5000, Millipore), NESTIN (1:400, R&DTM), OCT4 
(1:500, Millipore), OTX1/2 (1:100, Millipore), PAX6 (1:400, Covance®), SOX2 
(1:200, R&DTM), Tuj1 (1:5000, Covance®), VGLUT1 (1:300, Synaptic 
Systems) and ZO-1 (1:100, Novex®). 
5.2.6 Quantification of immunofluorescence images 
Quantification of OCT4 and PAX6-expressing cells was performed using Fiji® 
software (for ImageJ). A macro was developed to perform conversion of the 
original image to 8 bits, adjustment of a threshold, watershed treatment, and 
definition of parameters for particle analysis. Firstly, total cell nuclei were 
counted using DAPI images. Then, PAX6 and OCT4 positive nuclei were 
counted in the same way and the ratio between positive cells and the total 
number of cells was calculated.   
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5.2.7  Flow Cytometry Analysis 
For staining, approximately 500,000 cells were resuspended in FACS buffer 
with the diluted primary antibody, and incubated for 15 min at room 
temperature in the dark. Cells were then washed and resuspended in PBS for 
later analysis by flow cytometry (FACSCalibur, Becton Dickinson). Antibodies 
used for flow cytometry were SSEA-4-PE (1:10), and Tra-1-60-PE (1:10) 
(Stemgent®). 
5.2.8 Quantitative real-time PCR 
Total RNA was isolated from cells at different stages of neural commitment 
(day 0, 3, 6, 9 and 12) using a high pure RNA isolation kit (Roche) according 
to manufacturer’s instructions. cDNA was synthetized from RNA, starting 
amount of 1 µg, using a transcriptor first strand cDNA synthesis kit (Roche). 
Taqman® Gene Expression Assays (20X) were selected for PAX6, SOX1, 
NANOG, OCT4/POU5F1 and GAPDH (Applied Biosystems, supporting Table 
S2). All other genes (FGF5, NESTIN, β-Tubulin III) were analyzed using 
SYBR® green chemistry (primers are presented in Supporting Table 5.S1). 
PCR-reactions were run in duplicate, using the StepOneTM RT-PCR System 
(Applied BioSystems). Reactions were normalized to the housekeeping gene 
GAPDH and results analyzed with StepOne software. 
5.2.9 Electrophysiology  
Whole-cell recordings were performed at room temperature in artificial 
cerebrospinal fluid (aCSF) containing (in mM): 124 NaCl, 3 KCl, 1.25 
NaH2PO4, 26 NaHCO3, 1 MgCl2, 2 CaCl2, 10 Glucose, pH 7.4 (gassed with 
95% O2, 5% CO2). Patch pipettes (4-9 MΩ) were pulled from borosilicate glass 
electrodes (1.5 mm outer diameter, 0.86 mm inner diameter, Harvard 
Apparatus) with PC-10 Puller (Narishige Group) and filled with an intracellular 
solution containing (in mM): 125 K-gluconate, 11 KCl, 0.1 CaCl2, 2 MgCl2, 1 
EGTA, 10 HEPES, 2 MgATP, 0.3 NaGTP, 10 phosphocreatine, pH 7.3, 
adjusted with KOH (1 M), 280-290 mOsm. Cells were viewed using a Carl 
Zeiss Axioskop 2FS upright microscope equipped with a differential 
interference contrast-infrared (DIC-IR) CCD video camera (VX44, Till 
Photonics) and screen and recorded with an EPC-7 electrical amplifier (List 
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Biologic). Signals were low-pass filtered using a 3- and 10-kHz three-pole 
Bessel filter of an EPC-7 amplifier, digitized at 10 kHz using a Digidata 1322A 
board, and registered by the Clampex software version 10.2 (Molecular 
Devices). Series resistance was not compensated during voltage-clamp 
recordings, but was regularly monitored throughout each experiment with a -5 
mV, 50 ms pulse, and cells with >20% change in series resistance were 
excluded from the data. Data were not corrected for junction potentials. 
GABA-evoked postsynaptic currents (GABA-PSCs) were evoked through a 
micropipette (2-4 MΩ) containing GABA (30 µM in aCSF) coupled to a 
pressure application system (Picopump PV820, World Precision Instruments) 
and positioned close to the soma of the recorded cell. Single pulses of 100-
150 ms and 6-8 psi were applied every 2 min. Action potential firing was 
systematically evoked in current-clamp mode by injecting current pulses of -
50 to +300 pA, in 50 pA increments for 1000ms from an initial holding 
potential of −70 mV. 
5.2.10 Statistical Analysis 
Results are presented as mean ± standard error of mean (Semyanov et al.). 
Comparisons between experimental results were determined by Mann-
Whitney test for independent samples. Unless stated otherwise, three 
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5.3  Results 
5.3.1 Human iPSCs efficiently commit to the neuroectoderm lineage 
without the need for serum replacement-based medium 
The dual-SMAD inhibition protocol is a procedure for the rapid commitment of 
confluent human PSCs into early PSC-derived neural precursors 
(NPs)(Chambers et al., 2009; Rodrigues et al., 2014; Shi et al., 2012a) 
(Figure 5.2.A). Cells are first plated as cell colonies in conditions that support 
pluripotency, and allowed to reach confluence (Figure 5.2.B-I and -II). Culture 
conditions are then changed to include chemical inhibitors of BMP and 
Activin/Nodal signaling pathways, causing the emergence of a neuroepithelial 
cell sheet (Figure 5.2.B-III).  This swift induction is due to the blocking of 
SMAD signaling transduction by SB and LDN small molecules (Boergermann 
et al., 2010; Inman et al., 2002). When combined, these inhibitors repress 
mesoendodermal fates, directing the differentiation towards neuroectoderm 
(Smith et al., 2008). 
In this work we first compared different strategies to achieve human NPs 
based on two different methods (Chambers et al., 2009; Shi et al., 2012a) 
(Figure 5.2.A). In both cases human PSCs were first plated in matrigel-coated 
plates as clumps using a non-enzymatic passaging procedure (Beers et al., 
2012). This yielded compact colonies of cells (Fgure 5.2.B-I) that stained 
positively for pluripotency markers OCT4 and SOX2 (Figure 5.2.C and Figure 
5.2.D, respectively). At this stage, a high percentage (> 95%) of cells were 
positive for these markers (Figure 5.2.E). Cells were then allowed to reach 
confluence (Figure 5.2.B-II), at which point the two neural induction strategies 
were tested. 
The first consisted in the use of serum replacement (SR)-based medium for 
the first 4 days of commitment supplemented with both SB and LDN. From 
day 5 to 11, N2 supplementation was gradually added to the medium, while 
LDN-mediated inhibition of BMP was maintained (Chambers et al., 2009). In 
the second protocol, neural commitment was induced in N2B27 medium 
supplemented with SB and LDN for 12 days (Shi et al., 2012a). In both cases 
a neuroephitelial sheet of cells was obtained, but some qualitative differences 
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in the efficiency of the neural commitment process were immediately 
visualized using immunofluorescence (Figure 5.2.F and Figure 5.2.G).  
 
Figure 5.2 Neural commitment of human PSCs.  
(A) Neural induction was initiated when cells reached confluence and two strategies 
were tested in parallel. The first strategy involved the use of serum replacement-
based medium (KO-DMEM/SR) for the first four days and a gradual increase in N2 
medium thereafter. In the second case, N2B27 defined medium was used for 12 
days. Small molecule inhibitors of SMAD signaling (SB and LDN) were used as 
described in the scheme. (B) Human PSCs were cultured in adherent conditions (I) 
until confluence (II). A neuroepithelial sheet of cells could be observed after neural 
induction (III). (C) and (D) PSC colonies stained for pluripotency markers OCT4 and 
SOX2 (scale bars: 100µm). (E) At the start of neural commitment, high percentages 
(> 95%) of cells positive for OCT4 and SOX2 could be measured. (F) After 12 days 
of differentiation, immunofluorescence staining revealed that OCT4-positive cells 
were still present in serum replacement (KOSR) conditions (scale bars: 100µm). (G) 
PAX6 and NESTIN immunostaining for differentiated cells in N2B27 or KOSR-based 
medium (scale bars: 50µm). (H) Quantification of OCT4- and PAX6-positive cells for 
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value < 0.05. Results presented in this figure were obtained using iLB-C1-30 m-r12 
PSCs and matrigel coating.  
 
While in the case of SR-based medium OCT4-positive cells still persisted in 
culture 12 days after neural induction with chemical inhibitors, for N2B27-
based induction these cells were virtually absent (Figure 5.2.F). Additionally, 
the distribution of PAX6- and NESTIN-positive cells was more homogeneous 
in the case of N2B27 when compared with SR-based medium, which 
presented islands of PAX6-positive cells surrounded by NESTIN expressing 
cells instead of a homogeneous monolayer (Figure 5.2.G). Using image-
processing software we then quantified OCT4- and PAX6-expressing cells for 
both protocols (Figure 5.2.H). Neural commitment in N2B27 medium resulted 
in more than 80% of NPs positive for PAX6 and very low numbers of OCT4-
positive PSCs (< 2%), while in KO-SR medium, an average of 40% PAX6-
positive cells was obtained, with more than 20% of OCT4-positive cells still in 
culture (Mann-Whitney test, p-value < 0.05). 
These results highlight the importance of medium formulation in maximizing 
differentiation yield (Lippmann et al., 2014). By comparing data from both 
differentiation media it is possible to conclude that the chemically defined, 
serum-free composition of N2B27 yields a more efficient neural conversion 
into NPs. This medium was particularly optimized for neural cell culture, and 
contains insulin and retinoids, which have been shown to be crucial for the 
neuroepithelial induction of human PSCs (Shi et al., 2012b). The relatively 
high percentage of pluripotent cells and potential non-neural differentiated 
cells obtained in SR-based medium (Figure 5.3) is not desirable since these 
cells may interfere with the outcome of in vitro differentiation protocols 
(Rodrigues et al., 2014). 
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Figure 5.3 Immunofluorescence staining of human iPSC-derived cells at 
day 120 of differentiation after neural commitment for 12 days using 
matrigel and serum replacement-based medium.  
In addition to typical neural phenotypes, cells marking positive for alpha smooth 
muscle actin (SMA) and cardiac troponin T (cTNT) could be identified at this stage of 
differentiation. DAPI was used to counterstain the cell nuclei. Scale bar: 100 µm. 
5.3.2  Human PSCs generate neural precursor cells using dual SMAD 
signaling inhibition under defined culture conditions 
In addition to medium formulation, the composition of the extracellular matrix 
to which cells adhere is also a potential source of ill-defined components. This 
is the case of matrigel, whose constituents include an heterogeneous mixture 
of structural proteins of animal origin (Hughes et al., 2010). However, non-
xenogeneic, defined substrates that   support   the culture of human PSCs 
have also been proposed in the literature (Azarin and Palecek, 2010). In 
particular, vitronectin (VTN) peptide sequences have shown to support both 
expansion and differentiation of human PSCs under totally defined culture 
conditions (Chen et al., 2011; Jin et al., 2012; Lippmann et al., 2014; 
Melkoumian et al., 2010). Our next goal was to compare two different 
extracellular matrixes in supporting neural commitment from human iPSCs in 
combination with a fully defined culture medium, allowing the foundation of 
defined settings for in vitro studies of neural development. 
A side-by-side comparison was made using N2B27 medium together with 
matrigel or VTN (Figure 5.4). The dual SMAD inhibition yielded similar 
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outcomes in both cases, and cells presented typical neuroectodermal markers 
(Figure 5.4.A). These included the neuroectoderm fate determinant PAX6 
(Zhang et al., 2010), the forebrain marker FoxG1 (Chambers et al., 2009), and 
the midbrain/forebrain marker OTX1/2 (Pankratz et al., 2007), in addition to 
SOX2 and NESTIN. Cells differentiated for 12 days in both substrates showed 
up-regulation of PAX6 and SOX1 mRNA, with corresponding down-regulation 
of pluripotency transcription factors (OCT4/POU5F1 and NANOG) (Figure 
5.4.B). Additionally, real-time PCR analysis indicated that for both substrates 
expression of the pluripotency markers sharply decreased in the first three 
days of neural induction (Figure 5.4.C). After this point, both OCT4/POU5fF1 
and NANOG retain minor levels of expression when compared to day 0. Also, 
PAX6 and SOX1 expression increased rapidly from day 0, reaching maximum 
levels after day 3 in both matrigel and VTN (Figure 5.4.D). At the same time, 
when human PSCs entered differentiation, the presence of cell surface 
markers characteristic of the pluripotent state (Tra-1-60 and SSEA-4) was 
reduced, and the percentage of cells positive for these markers dropped 
progressively during the 12 days of neural commitment (Figure 5.5.A). The 
simultaneous up-regulation of FGF5 expression (Figure 5.5.B), together with 
down-regulation of pluripotency genes (Figure 5.4.C) and up-regulation of 
PAX6 and SOX1 (Figre 5.4.D), most likely resulted from the emergence of an 
initial population of NPs after neural induction (Abranches et al., 2009).  
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Figure 5.4 Efficient neural commitment of human PSCs using defined 
medium and vitronectin coating.  
(A) Immunofluorescence staining of PSC-derived NPs after 12 days of induction with 
chemical inhibitors in matrigel or VTN. Cells were stained for PAX6, NESTIN, FoxG1, 
OTX1/2 and SOX2 (scale bars: 50µm). (B) RT-PCR analysis of NPs generated in 
matrigel and VTN. After 12 days of commitment down-regulation of pluripotency 
genes (POU5F1, NANOG) was observed whereas neuroectodermal markers (PAX6, 
SOX1) were up-regulated regardless of the surface coating used. (C) and (D) 
Temporal gene expression analysis during neural commitment of human PSCs in 
matrigel and VTN. Pluripotency genes (POU5F1, NANOG) and neuroectodermal 
markers (PAX6, SOX1) were evaluated by quantitative real-time PCR at different 
time points. GAPDH expression was used as internal control. Results presented in 
this figure were obtained using the iLB-C1-30 m-r12 cell line. 
 
Taken together, these outcomes demonstrate that human iPSCs can 
effectively differentiate to NPs using the dual SMAD inhibition protocol under 
defined culture conditions composed of N2B27 and VTN as adhesion 
substrate. 
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To further confirm the generation of competent NPs after 12 days of dual 
SMAD inhibition, cells were re-plated onto laminin-coated plates as small 
clumps, and cultured in N2B27 medium without chemical inhibitors SB and 
LDN. Two to five days after re-plating, a substantial number of neural rosette-
like structures were observed (Figure 5.5.C). Rosettes were radially arranged 
like neuroepithelial cells, which were positive for PAX6, NESTIN, and SOX2, 
and already showed signs of polarization, with apical ZO1 expression. When 
neural rosettes were first visible, bFGF was added to the medium, to induce 
proliferation of progenitors, and around day 17 of differentiation cells were re-
plated onto new laminin-coated plates and cultured until day 28-30 without the 
addition of small molecules or any other factors. Substantial maturation of 
NPs within rosettes was observed (Figure 5.5.D and Figure 5.5.E). As 
expected, after peaking during the initial stage of commitment, expression of 
typical neural markers (PAX6, SOX1 and NESTIN) declined during further 
differentiation (Figure 5.5.D). This was followed by up-regulation of the 
neuronal marker β-Tubulin III. Using immunofluorescence staining we were 
able to see a proliferative (Ki67-positive) population of progenitors within 
polarized rosettes (apical expression of ZO1), and to confirm a reduction of 
the number of PAX6-positive cells. At this stage of differentiation, Tuj1-
positive neurons outgrew from neural rosettes (Figure 5.5.E). 
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Figure 5.5 Neural maturation capability of cells derived under defined 
conditions using vitronectin coating.  
(A) During neural commitment the percentage of cells positive for surface antigens 
Tra-1-60 and SSEA4 gradually decreased. Tra-1-60- and SSEA4-positive cells were 
evaluated by flow cytometry. (B) Gene expression analysis by quantitative real-time 
PCR showed an increase of the early specification marker FGF5. (C) After re-plating 
onto laminin-coated surfaces, immunostaining analysis demonstrated that cells 
formed neural rosettes. Cells within these structures were radially arranged and 
positive for PAX6, NESTIN, and SOX2. Rosettes showed signs of polarization 
marking ZO1 at the center (scale bars: 50µm). (D) Expression of typical neural 
markers (PAX6, SOX1 and NESTIN) declined after further differentiation, as 
assessed by quantitative real-time PCR. This was followed by up-regulation of the 
neuronal marker β-Tubulin III. (E) By day 28, Ki67-positive cells could be seen within 
polarized rosettes (ZO1-centered). These cells still marked positive for neural 
markers (PAX6, NESTIN), but Tuj1-positive neuronal projections started to develop 
(scale bars: 50µm). Results presented in this figure were obtained using iLB-C1-30 
m-r12 PSCs.  
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Taken together, these results demonstrate and validate the capacity to 
generate functional NPs using the dual SMAD inhibition protocol under 
defined culture conditions. Our results show efficient (> 80%) generation of 
PAX6-positive NPs, and the capacity of these cells to self-organize into neural 
rosettes upon passaging. Further differentiation into more mature cells was 
achieved within rosettes, which can be correlated with events leading to the 
neural tube formation in vivo (Chambers et al., 2009; Shi et al., 2012a). As 
previously demonstrated in similar systems (Chen et al., 2011; Jin et al., 
2012; Lippmann et al., 2014; Melkoumian et al., 2010; Pennington et al., 
2015) peptide conjugates can support robust expansion and differentiation of 
human PSCs under defined conditions, and in our case VTN supported neural 
commitment of human PSCs in conjugation with N2B27 medium 
supplemented with SMAD inhibitors. 
5.3.3 Generation of patient-specific neural precursors and further neural 
maturation  
At this stage we have established conditions that allowed the study of neural 
specification of human PSCs without interference of undetermined 
components stemming from serum replacements (Chambers et al., 2009) or 
extracellular matrix protein mixtures (Hughes et al., 2010; Shi et al., 2012a). 
This is an important feature of our system since undisclosed constituents may 
interfere with different signaling pathways, and thus affect cell fate decisions. 
Therefore, to further explore and demonstrate the usefulness of our method 
for neural specification studies, we have taken advantage of the potential of 
iPSC technology to investigate the neural commitment of patient-specific 
iPSCs, in particular RTT patient-derived cells (Dajani et al., 2013). This 
disorder is caused by mutations in the MECP2 gene of the X chromosome 
and affects 1 in 10,000-20,000 girls worldwide (Walsh and Hochedlinger, 
2010). Hallmarks of this condition include impaired motor function, seizures, 
autistic behavior (Amir et al., 1999), and changes in neuronal density and in 
brain size (Kim et al., 2011; Marchetto et al., 2010). 
Control and RTT-derived fibroblasts were reprogrammed to a 
pluripotent state as described elsewhere (Takahashi et al., 2007). The iPSC 
lines used in this work showed typical characteristics of pluripotent stem cells, 
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and could be maintained in culture for dozens of passages without signs of 
differentiation or atypical karyotype (Supporting Table 5.1, Figure 5.6). 
 
Table 5.1: Flow cytometry analysis of pluripotency markers. Human iPSC lines 
used in this work were analyzed using flow cytometry for transcription factors OCT4, 
SOX2, and NANOG, and surface antigens Tra-1-60 and SSEA4. All cell lines 
presented high percentages of cells marking positive for these markers. 
   
Cell Line OCT4 SOX2 NANOG Tra-1-60 SSEA4 






































Figure 5.6 Immunofluorescence staining of human iPSC colonies 
derived from a control/wild type individual (top panel) and a RTT 
mutated patient (bottom panel).  
Cells were plated in VTN-coated plates and expanded in pluripotency 
maintenance conditions, as described in the Material and Methods section. 
Cells were stained for the pluripotency markers OCT4, Tra-1-60, and SSEA4. 
In the case of OCT4 staining, DAPI was used to counterstain the cell nuclei. 
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For surface markers Tra-1-60 and SSEA4, bright field (BF) images are shown 
for comparison. Scale bar: 100 µm.    
These cells were then adapted to our culturing conditions using a non-
enzymatic passaging procedure and plated in VTN-coated surfaces (Chen et 
al., 2011). Both RTT and control-derived iPSCs were cultured in pluripotency 
maintenance conditions using mTESR, and stained for typical pluripotency 
markers (Figure 5.7.A and Figure 5.7.C, Figure 5.6). After reaching 
confluence, medium was changed to N2B27 and small molecule inhibitors of 
SMAD signaling (LDN and SB) were added to culture for 12 days. Both 
normal and patient-derived cells were able to differentiate and presented 
typical neuroectodermal markers such as PAX6, NESTIN, FoxG1, OTX1/2 
and SOX2 (Figure 5.7.B and Figure 5.7.D). Also, at this time point, 
pluripotency markers like OCT4 were virtually absent. 
After 12 days of dual SMAD inhibition, NPs were re-plated onto laminin-
coated plates as small clumps, and cultured in N2B27 medium without 
chemical inhibitors. At day 17, after stimulation with bFGF, both normal and 
mutant cells were able to form neural rosettes without any noticeable 
differences (Figure 5.7.E and Figure 5.7.G). Substantial maturation of NPs 
within rosettes was observed with cells expressing neural markers (NESTIN, 
PAX6, SOX2) within polarized structures (ZO1). At this stage, cells were 
again re-plated onto laminin to allow further neural differentiation. 
Proliferative, Ki67-positive cells within rosettes could still be identified in both 
cultures, and polarization could also be seen with apical localization of ZO1  
(Figure 5.7.F and Figure 5.7.H). Nevertheless, while in normal cells Tuj1-
positive neurons started to migrate outwards of rosettes, forming neuronal 
projections and connections, RTT derived-neurons were substantially less 
frequent, and neurites less complex (Figure 5.7.F and Figure 5.7.H). 
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Figure 5.7 Neural commitment and further neural differentiation of both 
normal and RTT patient specific iPSCs. 
 (A) and (C) Immunofluorescence staining of both normal or RTT patient-derived 
iPSCs showing typical expression of pluripotency marker NANOG (scale bars: 
100µm). (B) and (D) Immunofluorescence staining of neural markers (PAX6, 
NESTIN, FoxG1, OTX1/2, SOX2, scale bars: 50 µm) and of pluripotency marker 
OCT4 (scale bars: 100 µm) after twelve days of dual SMAD inhibition using a defined 
culture system. (E) and (G) After re-plating onto laminin, immunostaining analysis 
demonstrated that both normal and affected cells were capable to form neural 
rosettes. Cells within these structures were positive for PAX6, NESTIN, and SOX2. 
Rosettes showed signs of polarization, marking ZO1 at the center (scale bars: 
50µm). (F) and (H) Direct comparison of further neural maturation revealed that both 
cell types marked for neural markers (PAX6, NESTIN), and Ki67-positive cells could 
be seen within polarized rosettes (ZO1-centered). However, Tuj1-positive neuronal 
projections were more frequent and pronounced in ‘wild type’ cells (scale bars: 
50µm). Results presented in this figure were obtained using iLB-C1-30 m-r12, WT-
Évora F0000B13, and EMC23i PSCs. 
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To further assess the neuronal maturation state, cells were finally passed as 
single-cells at day 30 onto laminin-coated plates and maintained in N2B27 
medium. This procedure was expected to generate cortical projection neurons 
in about 80 days (Shi et al., 2012a). At day 75 of differentiation, we evaluated 
not only neuronal maturation, but also differentiation into glial cells, like 
astrocytes, in two non-affected ‘wild type’ human iPSCs and one RTT-derived 
mutant line (Figure 5.8.A). A substantial number of widespread neuronal 
projections was observed in both normal cell lines. Furthermore, extensive 
gliogenesis had occurred in such cultures and GFAP-positive astrocytes could 
be seen interspersed with Tuj1-positive neurons. This process was minimally 
reproduced in affected cells, showing less neurons, similarly to what had been 
visualized at day 28 of differentiation. Similar conclusions could be taken from 
MAP2 staining at day 100 (Figure 5.8.B). These observations are in 
accordance with other reports in the literature (Kim et al., 2011; Marchetto et 
al., 2010), and did not seem to result from reduced proliferation, since the 
number of DAPI stained nuclei within the microscope field of view was similar 
among samples. By day 120, control neurons developed to glutamatergic 
cortical neurons presenting the vesicular transporter VGLUT1 (Figure 5.8.C), 
which could not be observed in mutated cells.  
Finally, electrophysiological recordings performed at day 120 of differentiation, 
revealed neuronal functional properties characteristic of mature neurons. 
Values of neuronal resting membrane potential, determined immediately after 
establishing whole-cell configuration, averaged -45.0 ± 2.2 mV (n=17). Action-
potentials were then evoked in current-clamp mode by injecting depolarizing 
current pulses. Most cells tested showed firing of at least one action potential 
during current injection steps, revealing a mature neuronal state (n=10, Figure 
5.8.D). In addition, GABA-evoked postsynaptic currents were observed 
(voltage-clamp mode, Vh = -70 mV) in response to pressure application of 
GABA (30µM) directly to the soma of the cell, indicating the expression of 
functional neurotransmission receptors in these cells (n=11, Figure 5.8.E). 
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Figure 5.8 Neuronal differentiation of normal and RTT-derived neural 
progenitors.  
(A) At day 75 of differentiation neuronal maturation of ‘wild type’ cells originated 
extensive neuronal projections (Tuj1-positive) together with astrocytes (GFAP-
positive). This phenomenon was less pronounced in mutated cells (scale bars: 
50µm). (B) Further differentiation and maturation of normal neurons resulted in 
MAP2-positive mature dendrites at day 100. The frequency of such structures in 
MECP2 mutated cells was reduced when compared to control ones (scale bars: 
50µm). (C) ‘Wild type’ Tuj1 neurons at 120 days of differentiation were 
immunoreactive for glutamatergic neuronal protein VGLUT1 (scale bar: 100µm). (D) 
and (E) show electrophysiological properties of ‘wild type’ cells proving maturation 
and cortical nature of generated neurons. (D) Increased depolarizing voltage steps 
(1000ms) in whole-cell current-clamp mode show the firing of action potentials with 
strong adaptation, characteristic of a mature neuron. (E) Representative GABA 
(30µM)-evoked postsynaptic currents (GABA-PSC) from a neuron recorded in whole-
cell voltage-clamp (-70mV) showing responsiveness to GABA. Black bar 
corresponds to GABA application. Electrophysiological recordings have been 
performed by DM Rombo, co-author of the paper. 
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5.4 Discussion 
We herein identify defined culture conditions to achieve efficient and 
reproducible neural commitment of human PSCs. A defined neural 
maintenance medium supplemented with chemical inhibitors of both BMP and 
TGFβ signaling pathways, together with VTN for adherent growth, was shown 
to be sufficient to induce neuronal commitment, generating a homogeneous 
population of NPs expressing typical neural markers (Figure 5.2, Figure 5.4 
and Figure 5.5). The results obtained herein are comparable with other 
reported data in terms of neural conversion efficiency (Shi et al., 2012b), 
when using N2B27 medium, demonstrating that VTN-coating does not affect 
neural commitment negatively.  
In fact, VTN-based conjugates have been previously used for PSC derivation, 
expansion (Chen et al., 2011; Melkoumian et al., 2010) and neural 
specification studies (Lippmann et al., 2014; Yan et al., 2013), and our results 
also validate the usage of VTN as a defined substrate for neural commitment. 
Another important feature of this system is the use of retinoid rich medium, 
which have been shown to increase NPs output (Shi et al., 2012b). When 
combined with VTN adhesion motifs, the use of defined medium was thought 
to facilitate progression through neural maturation, particularly during re-
plating of NPs to laminin surfaces, by promoting survival and functionality of 
differentiated cells (Xie et al., 2000). In fact, when compared with serum 
replacement-based medium, we have been able to significantly increase the 
number of PAX6-positive NPs in N2B27 (Figure 5.2). However, other studies 
have reported minimally constituted monolayer systems that could achieve 
similar efficiencies in generating PAX6-positive neuroectoderm (Lippmann et 
al., 2014), questioning the role of retinoids in neural commitment. 
Nevertheless, monolayer neural commitment protocols still require a high 
local cell density for generation of NPs with high efficiencies (Chambers et al., 
2009). It would be interesting to engage other methods (Peerani et al., 2007; 
Ungrin et al., 2008), such as micropatterning or forced aggregation of cells, to 
evaluate the local dynamics of high-density cell-to-cell contacts in the neural 
specification of human PSCs. Still, one shortcoming of monolayer systems is 
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the fact that for later stages of neural development, NPs require laminin to 
adhere and differentiate (Heaton and Swanson, 1988). Laminins are 
extracellular matrix trimeric glycoproteins and at least a dozen of different 
isoforms have been identified in nature. Commonly used laminin is isolated 
from a murine source and represents an undisclosed mixture of several of 
these natural isoforms. To fully define neural commitment, neural maturation, 
and neuronal differentiation of human PSCs in adherent conditions, specific 
laminin isoforms should be investigated and subsequently used. The 
Tryggvason's group has been able to produce recombinant laminins and 
evaluate their specific role in several biological functions (Domogatskaya et 
al., 2012), but the exact isoforms involved in neural differentiation remain 
unknown. However, potential future therapeutic strategies for neurological 
disorders might implicate the use of progenitors (Liu et al., 2013), since 
mature cells are less capable of establishing the adequate connections 
without being continuously exposed to the combination of growth factor and 
signaling molecules that orientate synaptogenesis and neuronal wiring. 
Obtaining NPs in xeno-free conditions can be a relevant first step to establish 
a safe approach for future transplant based therapies.  
As a proof-of-concept, we have validated our neural commitment protocol 
using different cell lines, including patient-specific, RTT-derived iPSCs. 
Although investigation of a broader number of patients would be required, we 
were able to replicate some of the reported RTT defects in NPs derived in our 
defined system (Figure 5.7 and Figure 5.8). Interestingly, given the fact that 
MECP2 is located on the X-chromosome and that RTT patients present 
mosaicism (Walsh and Hochedlinger, 2010), X-chromosome 
activation/inactivation during reprogramming, expansion and differentiation 
could lead to difficulties in reproducing the pathology of the disease in vitro. 
We have not confirmed these events during reprogramming of our cells, but 
Marchetto and coworkers have previously shown the capacity to recapitulate 
X-inactivation during neural differentiation, producing mosaic neuronal 
cultures with different MECP2 expression levels (Marchetto et al., 2010). 
Isogenic human iPSC lines from RTT patients can therefore be used as in 
vitro models of the disease (Ananiev et al., 2011), and our results (Figure 5.8) 
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are in accordance with the published literature (Ananiev et al., 2011; Kim et 
al., 2011; Marchetto et al., 2010). Since several studies have reported similar 
findings, and taking into consideration the different levels of MECP2 
expression in mutated cells, the contribution of non-neural cells, like 
astrocytes, to the onset of the disease should not be excluded. In fact, this 
influence was already described, indicating that glial cells carrying MECP2 
mutations can also distress healthy neurons (Ballas et al., 2009; Maezawa et 
al., 2009). 
 
In conclusion, our defined culture system provides a way to recapitulate some 
of the temporal and regional patterning events that occur during in vivo 
cortical neurogenesis (van den Ameele et al., 2014). Also, by deconstructing 
the natural complexity of neural development into a simpler experimental 
approach, we could mimic several aspects of RTT pathology potentially 
contributing to a better understanding of cortical development and disease. 
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Supporting information 
Supporting Table 5. S1: Primers for quantitative real time PCR analysis 
using SYBR® green chemistry. 
Target 
genes 
Amplicon                  
Size (bp) 
Annealing 




(fwd) 5’-ACA ACT TTG GTA 
TCG TGG AAG G-3’ 
(rev) 5’-	  GCC ATC ACG CCA 





(fwd) 5’-CAC TGA TAG GAA 
CCC TAG AGG C-3’ 
(rev) 5’-CAG ATG GAA ACC 




(fwd) 5’-GCC CTG ACC ACT 
CCA GTT TA-3’ 
(rev) 5’-GGA GTC CTG GAT 





(fwd) 5’-CCA TCT TGC TGC 
CGA CAC-3’ 
(rev) 5’-CAA TAA GAC AGA 
GAC AGG AG-3’ 
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Supporting Table S2: Taqman® assays used for quantitative real time PCR 
analysis. 
Target 








S.2. Supporting Results 
Supporting Table S3: Flow cytometry analysis of pluripotency markers. Human 
iPSC lines used in this work were analyzed using flow cytometry for transcription 
factors OCT4, SOX2, and NANOG, and surface antigens Tra-1-60 and SSEA4. All 
cell lines presented high percentages of cells marking positive for these markers. 
   
Cell Line OCT4 SOX2 NANOG Tra-1-60 SSEA4 
iLB-C1-30 m-r12  
(wild type) 99 ± 0.2%  96 ± 1.0%  97 ± 2.1%  93 ± 1.2% 97 ± 1.8%  
WT-Évora F0000B13 
(wild type) 96 ± 1.1% 94 ± 1.5% 98 ± 0.9% 92 ± 1.5% 94 ± 2.6% 
EMC23i 
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Abstract 
	  
Objective: iPSCs are a promising tool for the study of neurological diseases. 
Disruption of GABAergic activity in RTT can be related, at least in part, with a 
failure to complete the GABA functional switch that occurs during normal 
development, from excitation in immature neurons to inhibition in mature 
neurons. This switch is mainly mediated by a developmental increase in 
KCC2 expression, a cotransporter that drives Cl- efflux outside neurons, with 
the consequent decrease in intracellular Cl- concentration and GABA-
mediated hyperpolarization in mature neurons. We documented reduced 
KCC2 levels in the cerebrospinal fluid of RTT patients and aimed to test 
GABAergic function in neurons derived from RTT patients’ IPSC cells. 
Methods: Human skin biopsies were collected in accordance with European 
and National ethical regulation and human iPSCs were generated from 
fibroblast cells upon infection with a retroviral vector expressing the four 
canonical transcription factors (Oct4, Sox2, Klf4, and Myc). iPSC lines were 
obtained from patients carrying MECP2 mutations (R306C and R255X) and 
controls. Neuronal cortical populations were derived in a monolayer culture 
system using the dual-SMAD inhibition protocol. Perforated patch recordings 
were performed in these neurons and GABA-evoked postsynaptic currents 
were measured to evaluate GABAAR equilibrium potential. Additionally, we 
performed molecular and neurophysiology experiments in a RTT mouse 
model (Mecp2tm1.1Bird/J), to search for the same disturbances.  
Results: Recordings from RTT cells exhibit a GABAAR equilibrium potential 
that is more positive than in recordings from control cells, favoring changes in 
Cl- gradient characteristic of an immature state. The level of KCC2 protein 
expression is lower in Mecp2-KO mice hippocampi when compared to control 
littermates, as addressed by western blot analysis of 6 week old hippocampi. 
Conclusion: Results form the RTT animal model, iPSC-based models and 
human cerebrospinal fluid studies suggest a GABAergic dysfunction in RTT 
that includes alterations in KCC2 expression and/or activity. 
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6.1  Introduction 
RTT (OMIM: #312750) is a severe neurodevelopmental disorder and leading 
cause of severe intellectual disability and autistic-like symptoms in females. 
Clinical features include hand stereotypes, developmental stagnation, social 
withdrawal, motor abnormalities, autonomic disturbances and seizures (Dolce 
et al., 2013). RTT is caused primarily by mutations in the widely expressed X-
linked gene MECP2 (Amir et al., 1999), which encodes a multifunctional 
protein involved not only in transcriptional silencing but also in transcriptional 
activation, chromatin remodeling, RNA splicing (Damen and Heumann, 2013) 
and other posttranscriptional regulatory mechanisms (Cheng et al., 2014). 
MeCP2 is highly expressed in the brain and MeCP2 levels are critical for CNS 
development (Shahbazian et al., 2002). The timing of MECP2 expression, in 
mouse and human, correlates with CNS maturation, with the ontogenetically 
older structures such as the spinal cord and brainstem starting expression 
before newer structures such as the hippocampus and cerebral cortex. The 
level of MeCP2 is also up-regulated during postnatal neuronal development 
(Ding, 2015). 
Several studies have shown that partial phenotypical rescue can be attained 
upon restoration of Mecp2 expression in postmitotic neurons of Mecp2-
deficient mice (Guy et al., 2007) (Robinson et al., 2012) (Lang et al., 2014), 
revealing that MeCP2 deficiency does not lead to permanent and irreversible 
alterations. However, gene therapy is not a valid approach for RTT, since the 
slightest perturbation in MeCP2 levels is deleterious for brain function (Cheng 
and Qiu, 2014). Thus, alternative treatment approaches should rely on the 
identification of downstream effectors of MeCP2, and its associated 
dysfunctions. One reported dysfunction involves a compromised synaptic 
maturation in RTT patients, associated, at least in part, to disruption of GABA 
activity during cortical development (Smrt et al., 2007). There is evidence for 
the impact of MECP2 conditional deletion in cortical excitability and 
GABAergic circuit formation, both in GABAergic neurons (Chao et al., 2010) 
and forebrain excitatory neurons (Zhang et al., 2014), indicating that MeCp2 is 
relevant for GABA metabolism and presynaptic release, and also for 
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appropriate GABAergic postsynaptic actions. 
GABA is the main inhibitory (hyperpolarizing) neurotransmitter in the adult 
brain, but has excitatory (depolarizing) action in the developing brain. The 
magnitude and direction of the ionic current through GABAARs exquisitely 
depends on its driving force, defined as the difference between the 
electrochemical equilibrium potential of Cl- anions (reversal potential, Ecl) and 
the resting membrane potential (RMP) of the neuron. If this difference is 
positive or negative, there will be a net flux of Cl- anions through the plasma 
membrane following GABAAR opening, and this will result in a change in the 
membrane potential of the neuron. In particular, the net flux of Cl- anions 
through GABAAR (i.e., toward inside or outside the cell) critically depends on 
its intracellular concentration ([Cl-]i). (Deidda et al., 2014). A shift in 
GABAergic function therefore occurs during development (Ben-Ari, 2002). 
Failure to complete this shift might result in network hyperexcitability and 
seizure activity in the early post-natal brain. [Cl-]i is mainly regulated by two 
ion transporters: NKCC1 (allows chloride to accumulate inside the cell), and 
KCC2 (the major chloride extruder in mature neurons), encoded in the gene 
SLC12A5. The higher [Cl-]i in young neurons depends on high expression of 
NKCC1 (Dzhala et al., 2005), and results in depolarizing GABAA 
transmission. As development proceeds, KCC2 becomes expressed at higher 
levels than NKCC1 (Dzhala et al., 2005; Rivera et al., 1999), and 
hyperpolarizing GABAergic transmission takes over (Ben-Ari, 2002). 
(Cancedda et al., 2007) (Sernagor et al., 2010). Balanced activity of NKCC1 
and KCC2 is therefore determinant for neuronal response to GABA.  
RTT neurons display reduced spine density, motility, impaired synaptic 
plasticity and deficits in hippocampal-dependent learning and memory, which 
could ultimately account for intellectual disability. Interestingly, genetic 
ablation of KCC2 prevents spinogenesis and excitatory synapse formation in 
immature neurons, through a mechanism independent of KCC2 transporter 
function (Li et al., 2007). 
In Chapter 2, we described a lower abundance of KCC2 in RTT patients’ 
CSF, suggesting lower cerebral KCC2 expression levels (Duarte et al., 2013). 
This observation prompted us to search for additional evidence to document a 
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specific defect in GABAergic function, with potential impact in impaired 
learning and cognition, epilepsy, and eventually also behavioral disturbances 
of RTT. 
To pursue this aim, as described in this chapter, we reprogrammed fibroblasts 
from RTT patients to generate iPSCs, an important tool for the study of 
neurological diseases. By offering an unlimited source of patient-specific 
disease-relevant neuronal and glial cells, iPSC-based disease models hold 
enormous promise for identification of disease mechanisms, discovery of 
molecular targets and development of phenotypic screens for drug discovery 
(Saporta et al., 2011). After successful reprogramming of patient’s iPSC and 
controls, a multistep protocol for cortical neuronal directed differentiation was 
optimized (see Chapter 5). This system enables functional studies of human 
cerebral cortex development, and the generation of patient-specific cortical 
networks ex vivo for disease modeling and therapeutic purposes (Shi et al., 
2012b). To further document KCC2 impaired expression in RTT, we 
performed protein expression studies in tissue from a RTT mouse model 
(Mecp2tm1.1Bird/J), in order to characterize Kcc2 expression and neuronal 
excitability during postnatal development in this model. 
6.2 Methods 
6.2.1 Human Skin Samples 
Human skin punch biopsy samples were collected using the standard 
technique. A small 3 mm skin biopsy was obtained from patients carrying two 
different MECP2 mutations (R306C and R255X) and, for control samples, a 
protocol was established with the Paediatric Surgery Department at Centro 
Hospitalar de Lisboa Norte (CHLN) to collect skin samples when minor 
surgeries were performed. Biopsy tissue was incubated in cell-culture medium 
and transported to the Instituto de Medicina Molecular (IMM) for in vitro 
expansion. HSJD and CHLN Ethic Committees approved the study and 
written informed consent was obtained from patient’s legal guardians.  
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6.2.2  Establishment of human fibroblast cultures  
Skin biopsies were washed with phosphate-buffered saline (PBS) and 
subcutaneous tissue and epidermis were excised. The dermal sample was 
placed in a new dish and cut into small squares. Fragments were transferred 
to a 6-well plate and after attachment were cultivated with complete growth 
medium that included DMEM (Life Technologies) supplemented with 20% 
FBS, 1% nonessential amino acid mixture (Life technologies), 1% 
penicillin/streptomycin (Life Technologies) and 1% sodium pyruvate (Life 
Technologies). After fibroblast expansion and migration, cells were passaged 
to a 25 cm2 using trypsin/EDTA (10%, Invitrogen).  Medium was changed 
every 3 to 4 days until the culture becomes confluent. Fibroblasts were 
harvested and ressuspended in 10% DMSO/90% complete DMEM at 1x105 
per ml for cryopreservation. 
  
6.2.3  iPSC generation and culture 
To generate human iPSCs, 1x105 human fibroblasts from lines R1 (female 
patient, R306C MECP2 mutation), R2 (female patient, R255X MECP2 
mutation) and F7 (female, age-matched control)  were seeded per well of a 6-
well plate. The next day, cells were transduced with a polycistronic lentiviral 
reprogramming vector (Warlich et al., 2011) for 16 hours in the presence of 4 
µg/ml polybrene (Millipore). Cells were further cultured in fibroblast medium 
(as in 7.2.2) at 20% O2. At day 4 post-transduction, 5x104 cells were seeded 
on irradiated Mouse Embryonic Fibroblasts (MEFs) in fibroblast medium. One 
day later, medium was changed to standard hESC medium. From day 2 to 9 
medium was supplemented with 2 mmol/l valproic acid (Calbiochem) as 
described by Warlich et al. (Warlich et al.). iPSC colonies were picked 
between day 22 to 25 and further propagated on MEFs. Human iPSC lines 
growing on conventional/standard medium were passaged weekly using 
collagenase IV (1 mg/ml, Invitrogen) on γ-irradiated MEFs. All analysis 
(pluripotency markers quantification and immunohistochemistry, embryoid 
bodies characterization, chromosome count, mycoplasma testing) for 
characterization of iPSC was performed prior to cryopreservation. 
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All human iPSCs were maintained in hESC culture medium, consisting of 
DMEM/F12 (Gibco-Invitrogen) supplemented with 20% knock-out serum 
replacement (Gibco-Invitrogen), 1% L-glutamine, 1% penicillin/streptomycin, 
1% MEM-non-essential amino acids (PAA Laboratories GmbH), 0.1mM β-
mercaptoethanol (Sigma), and 10 ng/ml bFGF (Invitrogen) filtered through a 
0.22µm filter (Corning). To generate Embryoid Bodies (EBs), iPSCs were 
differentiated in suspension culture for 1 week in EB medium, consisting of 
IMDM-glutamax, 15% foetal calf serum, 100 U ml penicillin, 100 mg ml 
streptomycin, 1% non-essential amino acids (all Invitrogen), 37.8 ml l 
monothioglycerol (Sigma) and 50 mg/ml ascorbic acid (Sigma). 
An additional iPSC line from a male carrying a different MECP2 mutation 
(Q83X) was kindly provided by Alysson Muotri (UCSD, USA). A control line, 
WT-Évora was kindly provided by TCLab (Évora, Portugal). This line was 
obtained from a male control with 3 years old. Moreover, fibroblasts from the 7 
years old control were also reprogramed at Prof. Luis Pereira de Almeida Lab, 
Centro de Neurociências de Coimbra (CNC) and characterized at Stem Cell 
Bioengineering Laboratory, Centre for Biological and Chemical Engineering, 
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Table 6.1. iPSC lines (MECP2 mutated and controls). 
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6.2.4  Feeder-free culture of human iPSCs  
iPSCs were thawed on mitotically inactivated MEFs. Cells were ressuspended 
in hESC medium, prepared as described in section 6.2.3. After initial 
expansion, iPSCs were dissociated with EDTA dissociation buffer 0.5mM 
(Gibco®, diluted in sterile PBS) and cultured in mTeSRTM1 medium (StemCell 
TechnologiesTM), on MatrigelTM (BD)-coated plates. Medium was changed 
daily and cells were passaged every 3-4 days, using with a split-ratio of 1:4 
(Chen et al., 2011). 
6.2.5 Neural induction of human iPSCs  
When human iPSC cultures were nearly confluent (Shi et al., 2012b), 
neuronal induction was started in N2B27 medium (50% (v/v) DMEM/F12/N2 
medium (DMEM-F12 (Gibco®), supplemented with 1% (v/v) N2 (Gibco®), 1 
mM L-glutamine, 1.6 g/L Glucose (Sigma®), 1% (v/v) PenStrep, and 20 
µg/mL Insulin (Sigma®)) and 50% (v/v) of B27 medium (Neurobasal (Gibco®) 
supplemented with 2% (v/v) B27-supplement (Gibco®), 1 mM glutamine and 
1% (v/v) PenStrep)). Media formulation was supplemented with 10 µM SB-
431542 (SB) and 100 nM LDN-193189 (Wernig et al.) (both from Stemgent®) 
for 12 days. 
6.2.6 Neuronal differentiation  
At day 12 of differentiation, cells were passaged with EDTA dissociation buffer 
(0.5mM) and re-plated onto laminin (Sigma®)-coated plates (split ratio of 1:3). 
Neural induction was confirmed as explained in Chapter 5. When neural 
rosettes were observable (around day 14), N2B27 was supplemented with 10 
ng/mL of bFGF (Peprotech®) for two to four days. At day 17, cells were 
passaged using EDTA to new laminin-coated plates (split ratio of 1:3) (Shi et 
al., 2012a). Cells were then cultured until day 28-30 in N2B27 medium without 
the addition of small molecules or any other factors. Finally, cells were split 
with accutase (Sigma®) and plated at as single cells at a density of 200,000 
cells/cm2. Cells were further cultured in laminin coated plates until day 120 
with N2B27 medium replacement every other day (Figure 6.6) 
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6.2.7  Electrophysiology experiments 
Electrophysiology experiments in iPSC derived neurons were performed by 
Diogo Rombo and Raquel Dias at Prof. Ana Sebastião Lab. Cells were 
recorded in culture medium, in order to reduce osmotic pressure.  
Whole-cell recordings were performed as described in 5.2.9. For perforated 
patch clamp recordings, gramicidin was diluted in the pippete solution to a 
final concentration of 25 µg/mL immediately before use. GABA (30µM)-
evoked postsynaptic currents (GABA-PSC) were measured to evaluate 
GABAA receptor equilibrium potential (EGABAA). Recordings were performed 
under voltage clamp at multiple holding potentials. Peak current amplitude 
and holding potential were ploted to yield the chloride equilibrium potential. 
Electrophysiology experiments in mice hippocampi were performed by Raquel 
Dias. Whole cell patch-clamp recordings were obtained from CA1 pyramidal 
cells. The resting membrane potential was measured immediately on 
establishing whole cell configuration. For each neuron, the threshold for action 
potential generation was determined as the difference between the resting 
membrane potential and the membrane potential at which phase plot slope 
reached 10mV/ms (Felix-Oliveira et al., 2014). 
6.2.8 Animals 
The expression studies of KCC2 was done in hippocampi taken from 6 week 
old wild type and Mecp2 Knockout (KO) (B6.129P2 (C)-Mecp2tm1.1Bird/J) 
animals. Animals were handled according to the Portuguese law on Animal 
Care and European Union guidelines (86/609/EEC). Care was taken so to 
reduce the number of used animals to the absolutely necessary.  The 
genotype of the mice was determined by polymerase chain reaction (Guy et 
al., 2007) using supplier instructions. 
6.2.9 Western blot analysis 
Protein extracts for western blot analysis were prepared from snap-frozen 
hippocampi or human cell lysates. Sodium dodecyl sulfate (SDS)-
polyacrylamide gel electrophoresis (Zeng et al.) was used to evaluate the 
levels of KCC2. Brain tissue was disrupted in sucrose-Tris solution with a 
Teflon pestle and the protein content in the supernatants was determined 
	   	  Chapter 6 
 
	   159	  
using a commercial Bradford assay (Sigma, MO, United States of America). 
Total proteins (70 µg) were separated on 10% SDS-polyacrylamide 
electrophoresis gels and blotted onto a polyvinylidene fluoride membrane 
according to the standard procedures. The blots were probed overnight at 4ºC 
either with the polyclonal rabbit anti-KCC2 (1/500) in 3% BSA (Bovine Serum 
Albumin). After washing (3 x 5 min in TBST [10 mM Tris, 150 mM NaCl, 
0,05% Tween 20 in H2O]), blots were then with secondary antibodies 
conjugated with horseradish peroxidase and bands were visualized with a 
commercial enhanced chemiluminescence detection method (ECL) kit 
(PerkinElmer Life Sciences, MA, United States of America). Values were 
normalized to the β-actin or α-Tubulin or GAPDH loading control and the 
relative intensities were normalized to WT (set as 1). Densitometry of the 
bands was performed using the Image J processing software (NIH, MD, 
United States of America). 
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6.3 Results 
6.3.1 Fibroblasts from RTT patients with different MECP2 mutations 
(R306C and R255X) and age-matched controls were reprogrammed into 
iPSC lines. 
To generate iPSC lines, fibroblasts from RTT patients and age-matched 
controls were transduced with a polycistronic lentiviral vector expressing 
OCT4, SOX2, KLF4, and MYC, and a dTomato reporter, under the control of 
a retroviral promoter (SFFV) that is rapidly silenced during the reprogramming 
process (Warlich et al., 2011) (Figure 6.1). 
	  
	  	  
Figure 6.1 Generation of human iPSC lines from fibroblasts 
A. Schematic representation of the lentiviral reprogramming cassete (Warlich et al., 
2011) used to establish F7, R1 and R2 human iPSC lines. B. Transduced cell lines 
express dTomato and red colonies are observed at around 10 days and after 22 
days, colonies are ready to pick. C. Human fibroblasts in culture. D. Human iPSC 
colony.  
 
Fibroblasts were plated on mouse embryonic fibroblasts and cultured in the 
presence of standard hESC medium. After approximately 10 days, small 
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clusters of cells appeared that started to develop hESC morphology. These 
clusters gradually lost the expression of the dTomato reporter, which indicated 
proper silencing of the lentiviral transgene, required to establish fully 




Figure 6.2 Characterization of EMC lines with immunohistochemistry 
Imunohistochemistry analysis of representative clones with pluripotency markers.  
 
For each one of the different donors, we obtained several iPSC clones. All 
these iPSC clones showed morphology resembling hESCs and expression of 
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key endogenous pluripotency factors, including NANOG and REX1, KLF4, 
cMYC, OCT3/4, SOX2, GDF3, FGF4, ESG1, at different passages after 
establishment (Figure 6.2 and Figure 6.3). 
 
	  
Figure 6.3 Characterization of EMC lines with qRT-PCR analysis 
qRT-PCR analysis of pluripotency factors in EMC25I/WT-R/F7  line. Expression of 
the same factors in hESC line H9 (Amit et al., 2000) served as a control and was set 
at 100%.  Clones with higher NANOG expression and reduced c-myc expression are  
pointed with arrows.  
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EB differentiation was also performed and qPCR analysis indicated that most 
human iPSC lines showed expression of endodermal (FLK1, AFP), 
mesodermal (GATA2), and ectodermal (PAX6) marker genes (Figure 6.4). 
 
 
Figure 6.4 Characterization of embryoid bodies derived from EMC lines. 
Differentiation markers mRNA quantification at day 8: PAX-6 (ectoderm), FLK1 and 
GATA2 (mesoderm) and AFP (endoderm). 
 
In order to select iPSC clones to differentiate into neurons, several factors 
were considered: i) expression of pluripotency factors- clones with higher 
NANOG expression and lower c-MYC expression were selected. ii) karyotype: 
clones with aberrant number of chromosomes were excluded.  
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Figure 6.5 Characterization of COIMBRA/F7line 
A. Flow cytometry analysis of pluripotency markers. COIMBRA/F7clones were 
analyzed using flow cytometry for transcription factors OCT4, SOX2, and NANOG, 
and surface antigens Tra-1-60 and SSEA4. All cell lines presented high percentage 
of cells expressing these markers. B. Karyotype photo. Experiments performed by 
Claudia Gaspar and Tiago Fernandes.  
 
Regarding chromosome count, all iPSC clones were tested. Clones with a 
correct number of chromosomes were clone 2 and 3 of EMC23i/R1 (R1), 
clone 3 of EMC24i/R2 (R2) and clone 1, 5 and 7 of EMC25i/WT-R/F7 (F7).  
Clones initially selected for neuronal differentiation were R1 – clone 2, R2 - 
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clone 3 and F7/Coimbra clone P. 
6.3.2 Functional neurons derived from RTT and wild type lines using a 
protocol for directed differentiation into cortical neurons. 
In order to model a neurodevelopmental disorder with cognitive impairment 
and epilepsy like RTT, with clinical features associated with cortical 
dysfunction, a human neuronal differentiation protocol designed to direct 
neuronal differentiation to cortical neurons (Shi et al., 2012a; Shi et al., 2012b) 
was optimized with wild-type iPSCs, as described in chapter 5. This system 
was designed to obtain neurons from different cortical layers with functional 
synapses, after a period of prolonged neuronal maturation that resembles the 
process of human cortex development in utero. Moreover, since we aimed to 
study RTT and, more precisely, effects of MeCP2 impairment that are thought 
to be dependent of BDNF deregulation, this protocol was convenient because 
it does not require the addiction of exogenous BDNF. A schematic figure of 
the protocol is shown in Figure 6.6, and representative examples are shown in 
Figure 6.6 and 6.7, for different stages of differentiation. 
  
Figure 6.6 Schematic representation of neural commitment and 
subsequent neural differentiation of human pluripotent stem cells.  
	   	  Chapter 6 
 
	   166	  
Neural commitment is initiated under defined culture conditions using dual SMAD 
inhibition for 12 days. At this stage cells are passed as clumps using EDTA 
dissociation to laminin-coated plates. At day 14, bFGF is added to facilitate 
proliferation of neural rosettes until day 17. Subsequent re-plating onto laminin is 
done using EDTA dissociation, and further differentiation occurs in the absence of 
growth factors or chemical inhibitors. A final single-cell passaging step is done at day 
28-30, and cells are allowed to differentiate until day 120 with periodic medium 
change and laminin supplementation. a. iPSCs colony; b. confluent iPSCs colonies, 
ready to start neural induction; c. Foxg1+ neural precursors; d. rosettes appear after 
re-plating. e. polarized rosettes (day 25); f. Tuj 1 neurons. Adapted from Fernandes 
TG, Duarte ST, et al. Neural commitment of human pluripotent stem cells under 
defined conditions recapitulates neural development and generates patient-specific 
neural cells. Biotechnol J. 2015 Jun 30 (Fernandes et al., 2015) 
 
iPSCs from lines F7, R1, R2, Rett Male and WT Évora were thawed and 
expanded. Several vials of different clones of the EMC F7 line were thawed, 
but we were not successful in expanding these cells. For this reason, we used 
COIMBRA/F7 as wild-type iPSCs, reprogramed at Prof. Luis Pereira de 
Almeida Lab with the same reprograming technique. 
After 12 days of neuronal commitment, combining retinoids and dual SMAD 
inhibition, a downregulation of pluripotency markers like OCT4, NANOG and 
POU5F1 was observed, and an upregulation of neuroectodermal markers 
(PAX 6 and SOX 1) was also detected (Figure 5.4). Imunostaining confirmed 
that these cells do not express OCT4 but express SOX4, FOXG1, PAX 6 and 
OTX1/2 (Figure 5.4). Thus, neuronal progenitors were successfully derived 
from iPSC lines. 
Rosettes were observable two to five days after the first passage at day 12 
(Figure 6.6.D), and at day 18 imunostaining confirmed that rosettes were 
radially arranged like neuroepithelial cells, being positive for PAX6, NESTIN 
(Figure 6.7.B), and SOX2 expression, and showing already signs of 
polarization, with apical ZO1 expression (Figure 6.7.C, D). When neural 
rosettes were first visible, bFGF was added to the medium, to induce 
proliferation of progenitors, and around day 17 of differentiation cells were re-
plated onto new laminin-coated plates and cultured until day 28-30 without the 
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addition of small molecules or any other factors. Substantial maturation of 
NPs within rosettes was observed.  
 
 
Figure 6.7 Neuronal differentiation steps  
iPSCs were thawed and expanded and pluripotency markers expression like SOX2 
were reanalyzed with immunohistochemistry (A). At day 12 of neural induction, 
rosettes were observed. At day 18 immunohistochemistry revealed rosettes positive 
for NESTIN, PAX6, SOX2 and apical ZO1 expression (B, C, D). At day 77 of 
neuronal differentiation, homogeneous of NESTIN positive neuronal precursors were 
observed (E) and also positive cells for TUJ1 and GFAP, identifying neurons and 
glial cells, respectively (F). These cells remained in culture for synaptic maturation 
until day 120-130 (G). Whole cell patch clamp experiments were performed early, at 
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day 49, showing spontaneous activity that indicated the presence of synapses. Firing 
pattern was immature at this stage (H1).  After 120 days in culture, 
electrophysiological recordings revealed mature neurons (H2). Patch Clamp 
experiments were performed by Raquel Dias.  
	  
The presence of glial cells was detected around day 75 of diferentiation, and 
confirmed with imunostaining for GFAP (Figure 6.7.F). The presence of 
synapses was confirmed with imunostaining for VGLUT and SNAP25 (Figure 
6.8.A). Finally and as mentioned in chapter 5, cells at dat 120 of differentiation 
displayed excitability parameters compatible with a mature neuronal state, as 
assessed by the resting membrane potential, the action potential firing pattern 
and response to GABA (see also Figure 6.7.H2 and Figure 6.8.B1-B2).  
6.3.3 RTT neurons exhibit a GABAAR equilibrium potential characteristic 
of an immature state. 
After obtaining mature neurons from iPSC lines derived from patients with 
RTT mutations and aged matched controls, functional studies were performed 
to characterize GABAAR equilibrium potential in these neurons. Perforated 
whole-cell patch-clamp is a variant of the patch-clamp technique used to 
measure the sum activity of ion channels in the plasma membrane of a single 
cell (Linley, 2013). Its defining feature is that electrical access to the cell is 
obtained through inclusion of a pore-forming antibiotic in the patch pipette 
which perforates the sealed patch of membrane in contact with the patch 
pipette. The antibiotic pores allow equilibration of small monovalent ions 
between the patch pipette and the cytosol whilst maintaining endogenous 
levels of divalent ions such as Ca(2+) and signalling molecules such as 
cAMP. Therefore, the perforated patch-clamp technique is ideal for studying 
ion dynamics and this technique was selected to study GABAAR chloride 
dynamics in patient derived neurons. GABA (30µM)-evoked postsynaptic 
currents (GABA-PSC) were measured to evaluate GABAA receptor 
equilibrium potential (EGABAA). Recordings were performed under voltage 
clamp at multiple holding potentials. Peak current amplitude and holding 
potential were ploted to yield the chloride equilibrium potential.  
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As shown in Figure 6.8.B3a and B3b, preliminary data indicates that RTT 
patient derived neurons exhibit a GABAAR equilibrium potential that is more 
positive than in control cells, suggesting changes in chloride gradient 
characteristic of an immature state. 
 
	  
Figure 6.8 GABAAR equilibrium potential in RTT patients’ derived 
neurons is suggestive of an immature state. 
A. Immunofluorescence analysis of iPS-derived neuronal cells using the dual-SMAD 
inhibition protocol. Cortical deep layer neurons (CTIP2), Glial cells (GFAP), 
differentiated neurons (Tuj1) glutamatergic neurons (Vglut) and synapses (SNAP25). 
B. Derived neurons are functional. B1 Changes in membrane potential and AP were 
evoked under current clamp mode by injection current pulses from an initial holding 
potential of −70 mV. B2 Representative GABA (30µM)-evoked postsynaptic currents 
(GABA-PSC) from a neuron recorded in whole-cell voltage-clamp (-70mV) showing 
responsiveness to GABA. B3 Changes in chloride equilibrium potential (Ecl) in RTT 
cells characteristic of an immature state. Gramicidin-perforated patch recordings 
were performed and GABA (30µM)-evoked postsynaptic currents (GABA-PSC) were 
measured. B3a Two representative experiments showing the peak amplitude of 
GABA-PSC (pA) as a function of voltage (mV). Lines represent linear regression 
curves fitting the data. B3b Interpolated ECl from linear regression curves. 
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All values are mean ± standard error of mean. *P<0.05 (paired Student’s t-test). WT 
is represented in black and MECP2 mutated in red. Note: Action potential threshold 
generation was measured as the beginning of the upward rise of the AP when dV/dT 
exceeded 10 mV/ms. Neurons studied in these experiments were derived from Rett 
Male iPSC line. Patch Clamp experiments were performed by Diogo Rombo. Traces 
in B1 and B2 are the same as those depicted in Figure 5.8 and are herein repeated 
for the sake of clarity.  
6.3.4 KCC2 expression is reduced in Mecp2-KO mice hippocampi, and 
intrinsic neuronal excitability is increased in CA1 pyramidal neurons 
Taking advantage of the possibility of performing molecular and 
neurophysiological studies in the RTT animal model brain, we decided to 
investigate KCC2 levels in the hippocampi of symptomatic (6-8 weeks old) 
male mice, using imunoblot analysis. A significant reduced level of KCC2 
expression was found (0,5457 ± 0,1227, n=7; p= 0.0115) (Student’s t test) 
(Figure 6.9).  
	  
Figure 6.9 KCC2 hippocampal protein level expression in the MECP2 KO 
mouse model 
KCC2 density evaluated by western blot analysis in hippocampal homogenates 
prepared from hippocampi taken from WT (red bar) and KO (black bar).  Value is 
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mean ± standard error of mean. *P<0.05 (Student’s t-test). The values obtained for 
WT samples were considered 1.  
 
Moreover, to address changes in intrinsic excitability whole cell patch clamp 
recordings under current clamp mode were performed in neurons from 
hippocampi of control and Mecp2 KO mice. A significant difference was found 
regarding the resting membrane potentilal (RPM) of neurons from controls 
and Mecp2 KO mice (Figure 6.10) and also regarding action potential (AP) 
firing threshold (difference between the RMP of each neuron and the 
membrane potential at which they first fired an AP), thus showing an 




Figure 6.10 Increased intrinsic neuronal excitability from CA1 
Hippocampal 
Changes in membrane potential and action potentials (AP) were evoked 
under current clamp mode by injection current pulses from an initial holding 
potential of −70 mV. The difference between the resting membrane potential 
(RMP) of each neuron and the threshold potential (Vt) at which they first fired 
an AP (ΔVm) was significantly different between conditions. Wild type (WT) 
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6.4  Discussion 
Mutations in MECP2 cause RTT, an X-linked neurodevelopmental disorder 
associated with synaptic dysfunction, intellectual disability, and autism 
symptoms (Chahrour and Zoghbi, 2007). MeCP2 controls the transcription of 
several genes relevant for CNS development and function, with BDNF being 
one of the genes most consistently reported as being under MeCP2 
transcriptional control (Chen et al., 2003). RTT is a synaptic disorder with 
changes in synaptic structure and morphology with documented decreased 
dendritic arborization and synaptic immaturity (Kaufmann et al., 2000) and 
also functional disturbances of synaptic development and plasticity (Boggio et 
al., 2010) (Weng et al., 2011). In this chapter, we have explored the 
hypothesis that KCC2 expression is deregulated in RTT.  
KCC2 is exclusively expressed in neurons and Kcc2 genetically modified 
models have revealed KCC2 determinant functions for neuronal, and 
particularly synaptic functions (Blaesse et al., 2009). Genetic inactivation of 
KCC2 expression is lethal at birth (Hubner et al., 2001), while genetic 
inactivation of only the KCC2b isoform leads to spontaneous seizures and 
death, 2–3 weeks postnatally (Woo et al., 2002) (Uvarov et al., 2009). 
However, KCC2 exhibits several transport-independent properties at 
excitatory synapses: (1) it binds scaffolding proteins within dendritic spines to 
promote spine development (Li et al., 2007) (2) it affects dendritic spine 
morphology (Fiumelli et al., 2013); (Kelleher and Bear) (Kelleher and Bear) it 
influences the lateral membrane diffusion of AMPA receptors (Gauvain et al., 
2011); and (4) it forms complexes with kainate receptors (Mahadevan et al., 
2014). Moreover, the relevance for both inhibitory and excitatory synapses 
places KCC2 as a potential candidate to contribute to the balance between 
excitatory and inhibitory synapse formation. 
An initial clinical observation of KCC2 reduced levels in the CSF of RTT 
patients prompted us to search for functional neuronal changes in RTT 
patients’ derived neurons that could translate this molecular change. In the 
present study, we have derived iPSCs from patients with two different MECP2 
mutations: R306C (missense) and R255X (nonsense), and from an age 
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matched female control.  
The results described in this Chapter suggest that neurons derived from RTT 
iPSCs have an immature response to GABA.  This functional finding is in 
accordance with the reduced levels of KCC2 detected in the CSF, and also 
with the significant reduced KCC2 protein expression in Mecp2 mice 
hippocampus, also described for the first time in this Chapter. This finding is 
relevant for:  
 
I. Understanding RTT pathophysiology: the alteration in GABA reversal 
potential in RTT iPSC derived neurons indicates that these have higher Cl- 
intracelular concentration, which likely reflects a lower activity of KCC2 
and contributes to higher excitability. Previous reports described that 
specific inactivation of Mecp2 in mouse GABAergic neurons leads to a 
presynaptic reduction in GABA release, causing similar neurological 
phenotypes to those shown by Mecp2 null mice (Chao et al., 2010). Our 
results address mainly post-synaptic effects of GABA dysfunction and our 
finding of an abnormal response to GABA in RTT-derived neurons adds 
another perspective on the complexity of GABAergic dysfunction in RTT. 
Moreover, it allows us to focus on a particular mechanism involved in the 
post-synaptic response to GABA - KCC2 downregulation, which has been 
previously associated with epilepsy (Dzhala et al., 2005) and autism (Tyzio 
et al., 2014). In fact, KCC2 downregulation is a common characteristic to 
other  neurodevelopmental disorders like Tuberous sclerosis (Talos et al., 
2012) and Fragile X syndrome (He et al., 2014), all exhibiting epilepsy and 
autistic traits as key clinical features, and abnormal synaptic plasticity as a 
key underlying neurobiology dysfunction. KCC2 dysfunction, with impact in 
Cl- transport or in ion transport independent properties, is becoming a new 
common link between these disorders. Targeting a common node in the 
complex mechanisms underlying such disorders would allow us to 
interfere with a series of related neurodevelopmental disorders at once. 
The fact that results from different models, the murine RTT model and 
human iPSC derived neurons, are convergent in this particular mechanism 
is relevant for the robustness of this finding. 
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II.  The search of potential pharmacological strategies for RTT and related 
disorders. The balance between KCC2 and NKCC1 expression is 
determinant for GABAergic actions upon GABAAR activation. The 
unbalance of cation chloride cotransporters can be pharmacologically 
addressed through NKCC1 inhibitors like the FDA-approved drug 
bumetanide (Deidda et al., 2015), or through direct and indirect strategies 
to enhance KCC2-mediated neuronal chloride extrusion (Silayeva et al., 
2015) (Puskarjov et al., 2014). A possible way to manipulate cation 
chloride cotransporters activity is by targeting their upstream regulatory 
molecules. For example, N-terminal threonine phosphorylation of NKCC1, 
required for the activity of this transporter, is catalyzed by the WNK/SPAK 
(with no lysine/Ste20-related proline alanine-rich kinase) kinase cascade. 
This is in contrast to the situation with KCC2, where activation of WNK 
kinases appears to have a suppressing effect on KCC2-mediated K-Cl 
cotransport (de Los Heros et al., 2014). Specific manipulation of such 
kinase pathways with apparently opposing effects on KCC2 versus 
NKCC1 may configure a novel pharmacotherapeutic strategy (Kahle et al., 
2013). The fast membrane recycling of KCC2 (Lee et al., 2007) could be 
exploited by generating KCC2-activating drugs that would act to modulate 
KCC2 membrane insertion and functionality. On this line, a recent high-
throughput screening identified the compound CLP257 and its carbamate 
prodrug derivative CLP290 as KCC2-activating molecules (Gagnon et al., 
2013).   
III.  Optimization of a system to test pharmacological approaches in human 
neurons. After identifying this particular GABAergic dysfunction, the effect 
of pharmacological  approaches can be tested easily in iPSC derived 
neurons, with the advantage of performing this test in human neurons with 
identified pathogenic mutations.  
 
In mammals, X chromosome inactivation (XCI) is a process in which one 
of the two X chromosomes is silenced. Human iPSCs can change their X 
inactivation state during reprograming (Bruck and Benvenisty, 2011). This 
process could hamper the interpretation of our results, since the mutated 
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allele can be silenced if the correspondent X chromosome is randomly 
inactivated after reprograming. RTT iPSCs derived from female patients 
give origin to a mixed population of neurons, some expressing the mutated 
MECP2 and others the non-mutated one (Marchetto et al., 2010). This 
mixed population reproduces what happens in the brain, but when 
experiments are performed at the single cell level, an increased number of 
cells would have to be studied. In order to overcome this difficulty, we 
have used iPSCs derived from a male RTT patient (kindly provided by 
Prof. Alyson Moutry), and all the reported neurophysiology experiments in 
this chapter were done on neurons derived from this iPSC line.  
6.5 Conclusions 
	  
Hippocampal KCC2 protein content is reduced in a symptomatic RTT mice 
model (Mecp2-mutant), when compared to wild-type animals. Furthermore, 
electrophysiological recordings show reduction of membrane resting potential 
and threshold potential in Mecp2-mutant hippocampal slices. In cortical 
neurons generated from RTT patient-derived iPSCs, we observed a shift in 
the equilibrium potential for chloride towards more depolarized values, as 
usually observed in more immature neurons when compared to normal 
IPSCs-derived neurons.  RTT is a disorder characterized by synaptic 
immaturity and altered network excitability. Considering the relevant role of 
KCC2 for GABAergic physiologic actions in the mature brain, and also for a 
proper synaptic structure and function, deregulation of this cation chloride 
cotransporter expression can have a significant contribution for RTT 
pathophysiology. Searching for strategies to mitigate this dysfunction can 
bring advances in treatment strategies for RTT and for several other 
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The experiments and results described in this thesis reflect different 
approaches to study synaptic dysfunction in early encephalopathies, in 
particular in Rett Syndrome. In this chapter, I will summarize the main findings 
of my work and outline the main conclusions that can be reached. 
 
1. The CSF studies reported in this thesis can reflect disturbances of CNS 
physiology in disease and are thus useful for the diagnosis of several 
child neurology disorders. The advantages of this approach include the 
possibility of obtaining results in vivo, specific for each patient, 
contributing to a “personalized medicine” strategy. Moreover, these 
studies can contribute to biomarker research, which can improve 
directly the diagnosis and also bring cues for the development of more 
refined research studies in disease models.  
Our aim was to explore the possibility of detecting synaptic proteins in 
the CSF, to characterize a group of child neurology disorders, from a 
“synaptic perspective”. We were able to conclude that synaptic proteins 
can be detected in the CSF and are more abundant during the first 
months of life, a period of intense synaptogenesis, pruning and circuit 
remodelling. This finding is relevant for the study of early 
encephalopathies, offering the possibility of using synaptic proteins as 
biomarkers of disease states to obtain information about their 
pathophysiology. However, in spite of providing a global perspective of 
what is going on in the child CNS, this type of proteomic study raises 
the question of the origin of these proteins, i.e, which neuronal 
populations are responsible for their production and shedding into the 
CSF. Also, it is not yet clear how the presence of synaptic proteins in 
the CSF might be related to specific neuronal dysfunctions. Since it is a 
study that can be performed in vivo, and due to the difficulties of 
obtaining human tissue samples to study, this is a relevant approach to 
study child neurology disorders.  
Besides the original publication (Duarte et al., 2011), this work 
contributed to further research in RTT, described in Chaper 3 (Duarte 
et al., 2013), and in other child neurology disorders (Ortez et al., 2015). 
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2. GABAergic system is highly relevant during development, contributing 
for synaptogenesis, wiring and neuronal circuit formation, allowing the 
neurons to fire together and consequently wire together. Modulation of 
GABAergic transmission is achieved in diverse ways, ranging from 
regulation of GABAAR expression/activity and GABA metabolism to 
regulation of intracellular chloride concentration. GABAergic system 
impairment is associated with several neurological and psychiatric 
disorders and neurodevelopmental disorders like RTT are increasingly 
being noted as examples of diseases where this impairment is 
determinant. We focused on intracellular chloride concentration 
regulation in different models of RTT. We described a reduction in 
KCC2 levels in RTT patient’s cerebrospinal fluid (Chapter 3), (Duarte et 
al., 2013) and our studies demonstrate that hippocampal KCC2 protein 
content is drastically reduced in symptomatic RTT mice model (Mecp2-
mutant) comparing to wild type animals (Chapter 6). Furthermore, 
electrophysiological recordings show reduction of membrane resting 
potential and threshold potential in Mecp2-mutant hippocampal slices. 
Synaptic transmission evaluated by Input/Output curves reveals an 
increased excitatory synaptic transmission. To further characterize 
GABAAR chloride dinamics, we obtained neurons from RTT patients’ 
iPSCs. Remarkably, in cortical neurons generated from RTT patient-
derived IPSCs, we observed a shift in the equilibrium potential for 
chloride towards more depolarized values, as usually observed in more 
immature neurons when compared to normal iPSCs-derived neurons. 
All together, these findings point to the same disturbed mechanism, 
deregulation of cation chloride cotransporters expression, and 
particularly KCC2 downregulation, as underlying various 
neurodevelopmental disorders that have as common features epilepsy, 
autistic traits and cognitive impairment, as originally hipothesyzed.  
Cation Chloride Cotransporters have very relevant roles for neuronal 
structure and function (reviewed in (Blaesse et al., 2009). One of the 
main tasks of Cation Chloride Cotransporters is to maintain a constant 
[Cl–]i in the face of channel-mediated fluxes that tend to dissipate the 
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transmembrane electrochemical Cl– gradient, i.e., the driving force of 
GABAAR-mediated Cl– currents. KCC2 has also a relevant role in 
spine formation, a role that is independent of its ion transport actions 
(Li et al., 2007). Therefore, KCC2 downregulation can contribute to an 
abnormal inhibitory action of GABA and also to an abnormal 
glutamatergic synaptic communication. Pharmacological targeting of 
this dysfunction can have impact in epilepsy, autistic traits and 
eventually also in the intellectual impairment described in RTT. The 
human in vitro neuronal differentiation model that we have developed 
can be an interesting tool to test these pharmacological approaches 
and also to understand how KCC2 downregulation interferes with 
synaptogenesis. In addition, it can help in testing whether a modulation 
of this process can influence synaptic structure and function. 
 
3. MeCP2 is a multifunctional protein that acts as a transcriptional 
repressor and also as a transcriptional activator. Several additional 
regulatory roles, including at the posttranscriptional level, have been 
described for this protein. A more recent view is that MeCP2 acts as a 
fine-tune regulator of gene transcription, during neuronal development 
and also during normal neuronal function. One of best studied 
transcriptional targets of MeCP2 is the BDNF gene. We studied BDNF 
expression on the animal model during development, and also the 
expression of the relevant TrkB receptors. Interestingly, we have 
preliminary data that points to higher levels of BDNF during the first 
week of life, and TrkB-FL receptors levels are reduced during the same 
period. It is possible that the initially higher levels of BDNF can 
contribute to the TrkB-FL downregulation that we observed in 
symptomatic mice. When exogenous BDNF was added to cultured 
brain slices and LTP was induced, the facilitatory effect of BDNF, 
observed in WT animals, was lost in symptomatic mice. This lack of 
effect can be related, at least in part, with the reduced TrkB receptor 
levels.  
Based on previous work from Professor Ana Sebastião Lab, which 
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provided evidence for a positive modulation of adenosine upon BDNF-
TrkB signaling (through A2ARs), we tested if activation of A2AR would 
be a strategy to recover BDNF-TrkB effects. We found that, when the 
selective A2AR agonist CGS2168 was applied in combination with 
BDNF, the BDNF effect upon LTP was restored, similar to what was 
observed in hippocampal slices from WT animals with BDNF alone. 
Together, our data highlight A2ARs as a new possible therapeutic 
target for boosting BDNF effects in RTT. Results from molecular 
studies described in the thesis, and unpublished data from the 
Professor Ana Sebastião Lab, point to a reduction of A2ARs 
expression and increased expression of A1Rs, and also decreased 
adenosine levels in symptomatic RTT mouse model. Pharmacological 
targeting of A2ARs, with an excitatory effect, could increase excitability 
and reduce seizure threshold in RTT patients. However, an additional 
rational therapeutical approach would be the use of strategies to 
increase adenosine levels, in order to act on both A1Rs, with inhibitory 
effects, useful to control epilepsy, and also on A2ARs, with facilitatory 
effects on BDNF actions. 
 
4. During the optimization of the neuronal differentiation protocol, we 
have shown that neural commitment from human iPSCs using dual-
SMAD inhibition can be performed under defined conditions in a 
vitronectin-based monolayer system. These progenitors were further 
diferentiatiated to functional neurons. Obtaining neuronal progenitors in 
xeno-free conditions can be a relevant first step to establish a safe 
approach for future transplant based therapies. Compared with mature 
neurons, neuronal progenitors transplanted to a lesioned region of the 
CNS have the potential to differentiate in situ, with local environmental 
cues like neurotrophins and signaling molecules that can facilitate their 
integration. On the other hand, neuronal progenitors can be genetically 
modified to produce neurotrophic factors or other molecules that can 
stimulate the regeneration of the original neuronal population. 
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Intellectual disability, autistic traits, and epilepsy are important features of a 
group of neurodevelopmental disorders that collectively affect a significant 
percentage of the world population (Braat and Kooy, 2015a). 
GABAARmodulation is increasingly being pointed as a new pharmacological 
strategy for different neurodevelopmental disorders like fragile X (Braat and 
Kooy, 2015b), Down Syndrome (Deidda et al., 2015), Neurofibromatosis type 
1 (Violante et al., 2013), Tourette Syndrome , Schizophrenia, and monogenic 
epilepsy or ASD (reviewed in (Ramamoorthi, 2011 #656) and (Deidda et al., 
2014)). Finding a common molecular pathway for heterogeneous disorders 
with clinical similarities can be relevant for future therapeutic strategies that 
target these symptoms. 
In the present thesis work, we started from a clinical observation and set up to 
perform functional studies in human neurons that could better characterize 
GABAARs dysfunction in RTT. After establishing the possibility of detecting 
synaptic proteins in the CSF, an abnormally reduced KCC2 level in the CSF 
of RTT patients was found. Inspired by these results, we searched for the 
same mechanism in the RTT animal model, and documented the predicted 
hyper excitability, along with a reduced expression of KCC2 in the 
hippocampus of these animals. Using perforated patch clamp, we also have 
preliminary results that point to an abnormal functional pattern in neurons 
derived from RTT patients’ iPSCs. These neurons display changes in 
GABAAR chloride equilibrium potential characteristic of an immature state.  
This work paves the way for further experimental approaches and brings 
additional questions that can be addressed in the future. I discuss below 
several of these approaches and questions: 
 
1. Delineating strategies to characterize chloride dinamics in neurons 
derived from RTT patients’ iPSCs. The ultimate aim will be to address 
whether the depolarizing/hyperpolarizing shift does occur in RTT-derived 
neurons, and if chloride homeostasis is altered. To achieve this aim, an 
interesting approach will involve genetic manipulation of iPSCs to express a 
“chloride sensor”, i.e., a fluorescent optogenetic sensor (Grimley et al., 2013) 
that monitors [Cl−]i  and  therefore can report on this  synaptic action of GABA 
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on GABAAR. A first-generation Cl− sensor, Clomeleon, has been used to 
monitor such dynamic changes in [Cl−]i in cultured neurons (Kuner and 
Augustine, 2000) and in brain tissue (Berglund et al., 2006). Clomeleon is a 
sensor that has been optimized for optimal time resolution, and consists of a 
fusion of the yellow fluorescent protein (YFP), which contains a serendipitous 
Cl− binding site adjacent to its chromophore, and the chloride-insensitive cyan 
fluorescent protein (CFP) (Grimley et al., 2013). Halide binding to YFP 
quenches fluorescence emission, altering fluorescence resonance energy 
transfer (FRET) between the CFP donor and the YFP acceptor (Kuner and 
Augustine, 2000). The use of FRET enables ratiometric determination of [Cl−]i, 
which is unaffected by variations in fluorescence emission intensity 
associated with differences in indicator concentration, optical path length, or 
excitation intensity (Miyawaki, 2005). Alterations in chloride homeostasis can 
thus be tested by chloride sensor live imaging, and can be further confirmed 
by measuring EGABA using gramicidin perforated-patch recordings of 
currents evoked by GABA, improving the quantification of GABAAR chloride 
gradients. In parallel, chloride homeostasis can be addressed in the mouse 
model by measuring EGABA in Mecp2-deficient hippocampal slices at 
different developmental stages.  
The aim will be to have a clearly defined developmental window for the 
GABAergic switch in normal controls and in RTT models. With this information 
and the functional tools in practice, we hope to better define the timings and 
molecular characteristics of this process. In addition, we should also be able 
to test how different pharmacological strategies con contribute to a 
normalization of this pathological process. 
 
2-Another relevant step to understand the downstream effect of MeCP2 
impairment on Cation Chloride Cotransporters deregulation would be to 
study the impact of KCC2 downregulation on spine development, 
excitatory synapses and LTP. Although KCC2 function primarily influences 
the efficacy of GABAergic signaling through chloride transport, several other 
ion transport independent properties are relevant for excitatory synapse 
formation and function. KCC2 has also been considered relevant for the 
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balance between inhibitory and excitatory synaptogenesis. I thus propose to 
explore whether RTT-derived neurons display defects in spine maturation, 
excitatory synaptic transmission plasticity, through morphological studies and 
using electrophysiology paradigms for neuronal plasticity. Different paradigms 
and different techniques can be applied for the study of plasticity at different 
levels, from extracellular field recordings and LTP paradigms at the neuronal 
population level, to glutamate uncaging at the single spine level, using two 
photon microscopy. This last technology shall allow us to study individual 
synaptic responses to glutamatergic stimulation, and the dynamics between 
neighboring spines in normal and pathological conditions.   
KCC2 can also be genetically targeted with a reporter and in this way facilitate 
the understanding of how changes in KCC2 expression or phosphorylation 
can impact on spine morphology and function. 
 
3. In order to better characterize the impact of KCC2 in neuronal function, a 
pharmacological approach to target Cation Chloride Cotransporters is 
proposed in order to determine their impact on RTT phenotype. Phenotypical 
rescue of various RTT features with this pharmacological approach will 
be addressed in both iPSC-derived neurons (intracellular chloride levels, 
spine number and morphology), and in Mecp2-deficient mouse models. 
Bumetanide is a drug that blocks the activity of NKCC1 resulting in decreased 
intracellular chloride concentration, reinforcing GABAergic inhibition. It has 
been demonstrated to improve neonatal seizures (Dzhala et al., 2008). 
CLP257 is a drug that restores impaired chloride transport in neurons by 
increasing KCC2 activity (Gagnon et al., 2013). To restore chloride 
homeostasis in RTT neurons, systemic administration of the NKCC1 
antagonist bumetanide (or analogs) and KCC2 activity enhancer CLP257 will 
be performed in both human iPSCC-derived neurons and in the mouse model. 
These strategies can be applied to neurons derived from another iPSC line, 
already available, from a patient with mutations in the KCC2 gene- SLC12A5, 
who showed severe epileptic encephalopathy (unpublished data). This 
approach might offer a promising model to pharmacologically target KCC2 
dysfunction. 
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4. There is evidence that upregulation of KCC2 expression is induced by 
BDNF (Aguado et al., 2003; Carmona et al., 2006). However, depending on 
the stage of neuronal maturation, BDNF can either up-regulate or down-
regulate KCC2 expression (Rivera et al., 2004). Also, there is some evidence 
that BDNF plays a role in the observed KCC2 upregulation after a seizure 
(Shulga et al., 2008). I therefore propose to test whether boosting BDNF 
effects through A2ARs activation could have an impact in KCC2 expression 
and function.  
IGF1, a compound undergoing clinical trials for RTT, has similar effects to 
BDNF but crosses the blood brain barrier. This compound, or  other BDNF 
mimetics, can thus be tested in our RTT and SLC12A5 mutated models to 
reestablish KCC2 actions. 
 
5. In order to characterize GABAergic signaling in vivo in different brain areas, 
brain imaging techniques can be applied to study the RTT animal model and 
also human patients with RTT. Due to the scarcity of postmortem materials, 
imaging techniques are a relevant tool to characterize brain synaptic changes 
in disease. If we can perform the same studies in human patients and in the 
animal model, potentially relevant information can be obtained about how we 
can interpret data from animal model and if it translates into similar results in 
patients. 
To study and monitor GABA levels, we can apply GABA spectroscopy. 
Magnetic resonance spectroscopy (MRS) is a powerful methodology that 
allows the direct detection of endogenous metabolites in the human body non-
invasively in vivo (Puts and Edden, 2012). J-edited PRESS-based methods, 
such as MEGA-PRESS, have been applied in a number of different brain 
regions – occipital, parietal and frontal regions (including the anterior 
cingulate). It is probably fair to say that edited methods in general, and the 
MEGA-PRESS method specifically, are currently the most widely used 
methods to quantify GABA at 3T (Puts and Edden, 2012). Using MRS to 
measure GABA levels in patients with neurofibromatosis type 1, Violante et al 
(Violante et al., 2013) demonstrated reduced GABA in the visual cortex. It is 
also possible to couple magnetic resonance GABA spectroscopy 
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measurement with functional magnetic resonance, to assess the functional 
correlates of the magnetic resonance spectroscopy signal. 
Positron Emission Tomography (PET) uses trace amounts of short-lived 
radioactive material to map functional processes in the brain. When the 
material undergoes radioactive decay a positron is emitted, which can be 
picked up by the detector. Areas of high radioactivity are associated with brain 
activity. [-11C]Flumazenil, a highly selective benzodiazepine antagonist is the 
most extensively used GABAAR ligand for PET. This technique was used to 
demonstrate a reduced binding of GABA to its receptor in patients with 
succinic semialdehyde dehydrogenase  deficiency, an autosomal recessive 
disorder of GABA metabolism clinically characterized by intellectual 
impairment, hypotonia, hyporeflexia, hallucinations, autistic behaviors, and 
seizures (Pearl et al., 2009). It was also used to study patients with epilepsy, 
Angelman Syndrome and Prader-Willi Syndrome (Sundaram et al., 2005). We 
aim to perform similar studies in RTT patients and to compare the results with 
autoradiographic labeling in the murine model. 
 
 
In conclusion, the present thesis work allowed the establishment of several 
fruitful collaborations and I shall pursue the aim of better understanding 
GABAergic system maturation in neurodevelopmental disorders. Current 
medications that systemically potentiate GABA-mediated inhibition can be 
effective at suppressing seizures, but prolonged drug treatment can have 
unwanted cognitive or neurobehavioral side effects, particularly during the 
maturation of the CNS. The challenge is to find harmless ways to modulate 




	   	  Acknowledgments 
 
	   187	  
ACKNOWLEDGMENTS 
I would like to thank Prof. Angels Garcia-Cazorla. From the first time that we met, 
when I started a Child Neurology rotation in Hospital San Joan de Déu, she has been 
a mentor and a source of inspiration to my career. We have had endless science, 
politics, literature, and also personal discussions that have been crucial for the 
development of this thesis. 
I would also like to thank Prof. Ana Sebastião and Prof. Domingos Henrique. They 
opened the doors of their groups at Instituto de Medicina Molecular and gave me the 
possibility to pursue my scientific questions, giving precious inputs to this work. 
Prof. Maria Jose Diógenes has been a source of strength and persistence, helping 
“to make it possible”. Our friendship has been one of the most precious 
achievements of the last three years, the kind of achievements that we do not add to 
our CVs but give sense to our daily work routine. She has always been available to 
help, to give a friendly word, and also to give wonderful advices that reflect her 
experience in science. 
Claudia Gaspar helped me from the beginning at Instituto de Medicina Molecular. 
She contributed with her work, ideas, experience and friendship to this PhD Thesis. I 
am extremely grateful for her help and endless contributions.  
I want to express my gratitude also to the Bioengenering team at Instituto Superior 
Técnico. Their support and friendship have been crucial. In particular, I want to thank 
Tiago Fernandes, Prof. Margarida Diogo and Prof. Joaquim Sampaio Cabral for their 
generosity and trust. 
I established a wonderful collaboration with Mehrnaz Gahzvini and Joost Gribnau, 
from the iPSC facility of Erasmus Medical School.  
I want to aknowledge all my colleagues and Professors from my PhD Programe, 
Gulbenkian Foundation Programe for Advanced Medical Education. We received an 
amazing preparation for research that opened our minds to new ideas and 
approaches to answer relevant questions in biology. I have to mention Prof. António 
Coutinho and Prof. João Ferreira for their help and inspiration. 
I also want to acknowledge Dr. Eulália Calado in particular, and all my colleagues at 
the Child Neurology Department - Hospital Dona Estefânia for their support. Dr. 
Eulalia was always a source of strength and motivation for this work.  
Patients and their families, in particular the Spanish families of Rett Syndrome 
Patients, made this work possible in several ways, from biological sample donations 
to funding through the BioRett Fund, that supported a grant for Diogo Rombo, to 
perform neurophysiology experiments. 
	   	  Acknowledgments 
 
	   188	  
I also want to thank to my colleagues in the diferent Labs were I worked during these 
years. I am specially grateful to Raquel Dias, Carlos Rodrigues, Tiago Martins 
Rodrigues and Sara Ferreira. 
Catarina Lourenço is a very motivated student and she contributed to several parts of 
this thesis. 
My friends helped me during the inevitable difficult moments and were also present 
to celebrate my achievements. 
 
 
My family, specially my husband and kids, were always with me. Their love and 




	   	  References 
 




Abbasalizadeh, S., and Baharvand, H. (2013). Technological progress and 
challenges towards cGMP manufacturing of human pluripotent stem cells 
based therapeutic products for allogeneic and autologous cell therapies. 
Biotechnology advances 31, 1600-1623. 
Abranches, E., Silva, M., Pradier, L., Schulz, H., Hummel, O., Henrique, D., 
and Bekman, E. (2009). Neural differentiation of embryonic stem cells in vitro: 
a road map to neurogenesis in the embryo. PLoS One 4, e6286. 
Abuhatzira, L., Makedonski, K., Kaufman, Y., Razin, A., and Shemer, R. 
(2007). MeCP2 deficiency in the brain decreases BDNF levels by 
REST/CoREST-mediated repression and increases TRKB production. 
Epigenetics : official journal of the DNA Methylation Society 2, 214-222. 
Aguado, F., Carmona, M.A., Pozas, E., Aguilo, A., Martinez-Guijarro, F.J., 
Alcantara, S., Borrell, V., Yuste, R., Ibanez, C.F., and Soriano, E. (2003). 
BDNF regulates spontaneous correlated activity at early developmental 
stages by increasing synaptogenesis and expression of the K+/Cl- co-
transporter KCC2. Development 130, 1267-1280. 
Alipio, Z., Liao, W., Roemer, E.J., Waner, M., Fink, L.M., Ward, D.C., and Ma, 
Y. (2010). Reversal of hyperglycemia in diabetic mouse models using 
induced-pluripotent stem (iPS)-derived pancreatic beta-like cells. Proceedings 
of the National Academy of Sciences of the United States of America 107, 
13426-13431. 
Allen, N.J., and Barres, B.A. (2009). Neuroscience: Glia - more than just brain 
glue. Nature 457, 675-677. 
Amir, R.E., Van den Veyver, I.B., Wan, M., Tran, C.Q., Francke, U., and 
Zoghbi, H.Y. (1999). Rett syndrome is caused by mutations in X-linked 
MECP2, encoding methyl-CpG-binding protein 2. Nature genetics 23, 185-188. 
	   	  References 
 
	   190	  
Amit, M., Carpenter, M.K., Inokuma, M.S., Chiu, C.P., Harris, C.P., Waknitz, 
M.A., Itskovitz-Eldor, J., and Thomson, J.A. (2000). Clonally derived human 
embryonic stem cell lines maintain pluripotency and proliferative potential for 
prolonged periods of culture. Developmental biology 227, 271-278. 
Ananiev, G., Williams, E.C., Li, H., and Chang, Q. (2011). Isogenic pairs of 
wild type and mutant induced pluripotent stem cell (iPSC) lines from Rett 
syndrome patients as in vitro disease model. PLoS One 6, e25255. 
Anderson, W.W., and Collingridge, G.L. (2001). The LTP Program: a data 
acquisition program for on-line analysis of long-term potentiation and other 
synaptic events. J Neurosci Methods 108, 71-83. 
Azarin, S.M., and Palecek, S.P. (2010). Matrix revolutions: a trinity of defined 
substrates for long-term expansion of human ESCs. Cell stem cell 7, 7-8. 
Backx, L., Ceulemans, B., Vermeesch, J.R., Devriendt, K., and Van Esch, H. 
(2009). Early myoclonic encephalopathy caused by a disruption of the 
neuregulin-1 receptor ErbB4. European journal of human genetics : EJHG 17, 
378-382. 
Ballas, N., Lioy, D.T., Grunseich, C., and Mandel, G. (2009). Non-cell 
autonomous influence of MeCP2-deficient glia on neuronal dendritic 
morphology. Nature neuroscience 12, 311-317. 
Basel-Vanagaite, L., Hershkovitz, T., Heyman, E., Raspall-Chaure, M., Kakar, 
N., Smirin-Yosef, P., Vila-Pueyo, M., Kornreich, L., Thiele, H., Bode, H., et al. 
(2013). Biallelic SZT2 mutations cause infantile encephalopathy with epilepsy 
and dysmorphic corpus callosum. American journal of human genetics 93, 
524-529. 
Bayes, A., van de Lagemaat, L.N., Collins, M.O., Croning, M.D., Whittle, I.R., 
Choudhary, J.S., and Grant, S.G. (2011). Characterization of the proteome, 
diseases and evolution of the human postsynaptic density. Nature 
neuroscience 14, 19-21. 
	   	  References 
 
	   191	  
Beers, J., Gulbranson, D.R., George, N., Siniscalchi, L.I., Jones, J., Thomson, 
J.A., and Chen, G. (2012). Passaging and colony expansion of human 
pluripotent stem cells by enzyme-free dissociation in chemically defined 
culture conditions. Nature protocols 7, 2029-2040. 
Ben-Ari, Y. (2002). Excitatory actions of gaba during development: the nature 
of the nurture. Nature reviews Neuroscience 3, 728-739. 
Ben-Ari, Y. (2014). The GABA excitatory/inhibitory developmental sequence: 
A personal journey. Neuroscience 279C, 187-219. 
Berglund, K., Schleich, W., Krieger, P., Loo, L.S., Wang, D., Cant, N.B., Feng, 
G., Augustine, G.J., and Kuner, T. (2006). Imaging synaptic inhibition in 
transgenic mice expressing the chloride indicator, Clomeleon. Brain cell 
biology 35, 207-228. 
Biou, D., Benoist, J.F., Nguyen-Thi, C., Huong, X., Morel, P., and Marchand, 
M. (2000). Cerebrospinal fluid protein concentrations in children: age-related 
values in patients without disorders of the central nervous system. Clinical 
chemistry 46, 399-403. 
Blaesse, P., Airaksinen, M.S., Rivera, C., and Kaila, K. (2009). Cation-chloride 
cotransporters and neuronal function. Neuron 61, 820-838. 
Bliss, T.V., and Collingridge, G.L. (1993). A synaptic model of memory: long-
term potentiation in the hippocampus. Nature 361, 31-39. 
Boergermann, J.H., Kopf, J., Yu, P.B., and Knaus, P. (2010). Dorsomorphin 
and LDN-193189 inhibit BMP-mediated Smad, p38 and Akt signalling in 
C2C12 cells. The international journal of biochemistry & cell biology 42, 1802-
1807. 
Boggio, E.M., Lonetti, G., Pizzorusso, T., and Giustetto, M. (2010). Synaptic 
determinants of rett syndrome. Frontiers in synaptic neuroscience 2, 28. 
Boison, D. (2009). Adenosine-based modulation of brain activity. Current 
neuropharmacology 7, 158-159. 
	   	  References 
 
	   192	  
Bolan, E.A., Kivell, B., Jaligam, V., Oz, M., Jayanthi, L.D., Han, Y., Sen, N., 
Urizar, E., Gomes, I., Devi, L.A., et al. (2007). D2 receptors regulate 
dopamine transporter function via an extracellular signal-regulated kinases 1 
and 2-dependent and phosphoinositide 3 kinase-independent mechanism. 
Molecular pharmacology 71, 1222-1232. 
Braat, S., and Kooy, R.F. (2015a). The GABA Receptor as a Therapeutic 
Target for Neurodevelopmental Disorders. Neuron 86, 1119-1130. 
Braat, S., and Kooy, R.F. (2015b). Insights into GABAAergic system deficits in 
fragile X syndrome lead to clinical trials. Neuropharmacology 88, 48-54. 
Brooks-Kayal, A.R. (2005). Rearranging receptors. Epilepsia 46 Suppl 7, 29-
38. 
Bruck, T., and Benvenisty, N. (2011). Meta-analysis of the heterogeneity of X 
chromosome inactivation in human pluripotent stem cells. Stem cell research 
6, 187-193. 
Cancedda, L., Fiumelli, H., Chen, K., and Poo, M.M. (2007). Excitatory GABA 
action is essential for morphological maturation of cortical neurons in vivo. 
The Journal of neuroscience : the official journal of the Society for 
Neuroscience 27, 5224-5235. 
Cao, C., Rioult-Pedotti, M.S., Migani, P., Yu, C.J., Tiwari, R., Parang, K., 
Spaller, M.R., Goebel, D.J., and Marshall, J. (2013). Impairment of TrkB-PSD-
95 signaling in Angelman syndrome. PLoS biology 11, e1001478. 
Carmona, M.A., Pozas, E., Martinez, A., Espinosa-Parrilla, J.F., Soriano, E., 
and Aguado, F. (2006). Age-dependent spontaneous hyperexcitability and 
impairment of GABAergic function in the hippocampus of mice lacking trkB. 
Cerebral cortex 16, 47-63. 
Cartier, E.A., Parra, L.A., Baust, T.B., Quiroz, M., Salazar, G., Faundez, V., 
Egana, L., and Torres, G.E. (2010). A biochemical and functional protein 
complex involving dopamine synthesis and transport into synaptic vesicles. J 
Biol Chem 285, 1957-1966. 
	   	  References 
 
	   193	  
Carvill, G.L., Weckhuysen, S., McMahon, J.M., Hartmann, C., Moller, R.S., 
Hjalgrim, H., Cook, J., Geraghty, E., O'Roak, B.J., Petrou, S., et al. (2014). 
GABRA1 and STXBP1: novel genetic causes of Dravet syndrome. Neurology 
82, 1245-1253. 
Casillas-Espinosa, P.M., Powell, K.L., and O'Brien, T.J. (2012). Regulators of 
synaptic transmission: roles in the pathogenesis and treatment of epilepsy. 
Epilepsia 53 Suppl 9, 41-58. 
Cea-Del Rio, C.A., and Huntsman, M.M. (2014). The contribution of inhibitory 
interneurons to circuit dysfunction in Fragile X Syndrome. Frontiers in cellular 
neuroscience 8, 245. 
Chahrour, M., and Zoghbi, H.Y. (2007). The story of Rett syndrome: from 
clinic to neurobiology. Neuron 56, 422-437. 
Chambers, S.M., Fasano, C.A., Papapetrou, E.P., Tomishima, M., Sadelain, 
M., and Studer, L. (2009). Highly efficient neural conversion of human ES and 
iPS cells by dual inhibition of SMAD signaling. Nature biotechnology 27, 275-
280. 
Chamma, I., Heubl, M., Chevy, Q., Renner, M., Moutkine, I., Eugene, E., 
Poncer, J.C., and Levi, S. (2013). Activity-dependent regulation of the K/Cl 
transporter KCC2 membrane diffusion, clustering, and function in 
hippocampal neurons. The Journal of neuroscience : the official journal of the 
Society for Neuroscience 33, 15488-15503. 
Chang, C.W., Lai, Y.S., Pawlik, K.M., Liu, K., Sun, C.W., Li, C., Schoeb, T.R., 
and Townes, T.M. (2009). Polycistronic lentiviral vector for "hit and run" 
reprogramming of adult skin fibroblasts to induced pluripotent stem cells. 
Stem cells 27, 1042-1049. 
Chang, Q., Khare, G., Dani, V., Nelson, S., and Jaenisch, R. (2006). The 
disease progression of Mecp2 mutant mice is affected by the level of BDNF 
expression. Neuron 49, 341-348. 
	   	  References 
 
	   194	  
Chao, H.T., Chen, H., Samaco, R.C., Xue, M., Chahrour, M., Yoo, J., Neul, 
J.L., Gong, S., Lu, H.C., Heintz, N., et al. (2010). Dysfunction in GABA 
signalling mediates autism-like stereotypies and Rett syndrome phenotypes. 
Nature 468, 263-269. 
Chao, H.T., Zoghbi, H.Y., and Rosenmund, C. (2007). MeCP2 controls 
excitatory synaptic strength by regulating glutamatergic synapse number. 
Neuron 56, 58-65. 
Chapleau, C.A., Larimore, J.L., Theibert, A., and Pozzo-Miller, L. (2009). 
Modulation of dendritic spine development and plasticity by BDNF and 
vesicular trafficking: fundamental roles in neurodevelopmental disorders 
associated with mental retardation and autism. Journal of 
neurodevelopmental disorders 1, 185-196. 
Chattopadhyaya, B. (2011). Molecular mechanisms underlying activity-
dependent GABAergic synapse development and plasticity and its 
implications for neurodevelopmental disorders. Neural plasticity 2011, 734231. 
Chen, G., Gulbranson, D.R., Hou, Z., Bolin, J.M., Ruotti, V., Probasco, M.D., 
Smuga-Otto, K., Howden, S.E., Diol, N.R., Propson, N.E., et al. (2011). 
Chemically defined conditions for human iPSC derivation and culture. Nature 
methods 8, 424-429. 
Chen, J.F., Sonsalla, P.K., Pedata, F., Melani, A., Domenici, M.R., Popoli, P., 
Geiger, J., Lopes, L.V., and de Mendonca, A. (2007). Adenosine A2A 
receptors and brain injury: broad spectrum of neuroprotection, multifaceted 
actions and "fine tuning" modulation. Progress in neurobiology 83, 310-331. 
Chen, L., Chen, K., Lavery, L.A., Baker, S.A., Shaw, C.A., Li, W., and Zoghbi, 
H.Y. (2015). MeCP2 binds to non-CG methylated DNA as neurons mature, 
influencing transcription and the timing of onset for Rett syndrome. 
Proceedings of the National Academy of Sciences of the United States of 
America 112, 5509-5514. 
	   	  References 
 
	   195	  
Chen, W.G., Chang, Q., Lin, Y., Meissner, A., West, A.E., Griffith, E.C., 
Jaenisch, R., and Greenberg, M.E. (2003). Derepression of BDNF 
transcription involves calcium-dependent phosphorylation of MeCP2. Science 
302, 885-889. 
Cheng, T.L., and Qiu, Z. (2014). MeCP2: multifaceted roles in gene regulation 
and neural development. Neuroscience bulletin 30, 601-609. 
Cheng, T.L., Wang, Z., Liao, Q., Zhu, Y., Zhou, W.H., Xu, W., and Qiu, Z. 
(2014). MeCP2 suppresses nuclear microRNA processing and dendritic 
growth by regulating the DGCR8/Drosha complex. Developmental cell 28, 
547-560. 
Cohen, S., Gabel, H.W., Hemberg, M., Hutchinson, A.N., Sadacca, L.A., Ebert, 
D.H., Harmin, D.A., Greenberg, R.S., Verdine, V.K., Zhou, Z., et al. (2011). 
Genome-wide activity-dependent MeCP2 phosphorylation regulates nervous 
system development and function. Neuron 72, 72-85. 
Cohen, S., and Greenberg, M.E. (2010). A bird's-eye view of MeCP2 binding. 
Molecular cell 37, 451-452. 
Corradini, I., Verderio, C., Sala, M., Wilson, M.C., and Matteoli, M. (2009). 
SNAP-25 in neuropsychiatric disorders. Annals of the New York Academy of 
Sciences 1152, 93-99. 
Craddock, N., and Owen, M.J. (2010). Data and clinical utility should be the 
drivers of changes to psychiatric classification. The British journal of 
psychiatry : the journal of mental science 197, 158; author reply 158-159. 
Crevecoeur, J., Kaminski, R.M., Rogister, B., Foerch, P., Vandenplas, C., 
Neveux, M., Mazzuferi, M., Kroonen, J., Poulet, C., Martin, D., et al. (2014). 
Expression pattern of synaptic vesicle protein 2 (SV2) isoforms in patients 
with temporal lobe epilepsy and hippocampal sclerosis. Neuropathology and 
applied neurobiology 40, 191-204. 
	   	  References 
 
	   196	  
Dajani, R., Koo, S.E., Sullivan, G.J., and Park, I.H. (2013). Investigation of 
Rett syndrome using pluripotent stem cells. Journal of cellular biochemistry 
114, 2446-2453. 
Damen, D., and Heumann, R. (2013). MeCP2 phosphorylation in the brain: 
from transcription to behavior. Biological chemistry 394, 1595-1605. 
Danglot, L., Triller, A., and Marty, S. (2006). The development of hippocampal 
interneurons in rodents. Hippocampus 16, 1032-1060. 
Dani, V.S., Chang, Q., Maffei, A., Turrigiano, G.G., Jaenisch, R., and Nelson, 
S.B. (2005). Reduced cortical activity due to a shift in the balance between 
excitation and inhibition in a mouse model of Rett syndrome. Proceedings of 
the National Academy of Sciences of the United States of America 102, 
12560-12565. 
Darabi, R., Pan, W., Bosnakovski, D., Baik, J., Kyba, M., and Perlingeiro, R.C. 
(2011). Functional myogenic engraftment from mouse iPS cells. Stem cell 
reviews 7, 948-957. 
de Los Heros, P., Alessi, D.R., Gourlay, R., Campbell, D.G., Deak, M., 
Macartney, T.J., Kahle, K.T., and Zhang, J. (2014). The WNK-regulated 
SPAK/OSR1 kinases directly phosphorylate and inhibit the K+-Cl- co-
transporters. The Biochemical journal 458, 559-573. 
De Mei, C., Ramos, M., Iitaka, C., and Borrelli, E. (2009). Getting specialized: 
presynaptic and postsynaptic dopamine D2 receptors. Current opinion in 
pharmacology 9, 53-58. 
Deidda, G., Bozarth, I.F., and Cancedda, L. (2014). Modulation of GABAergic 
transmission in development and neurodevelopmental disorders: investigating 
physiology and pathology to gain therapeutic perspectives. Frontiers in 
cellular neuroscience 8, 119. 
Deidda, G., Parrini, M., Naskar, S., Bozarth, I.F., Contestabile, A., and 
Cancedda, L. (2015). Reversing excitatory GABAAR signaling restores 
	   	  References 
 
	   197	  
synaptic plasticity and memory in a mouse model of Down syndrome. Nature 
medicine 21, 318-326. 
Deng, V., Matagne, V., Banine, F., Frerking, M., Ohliger, P., Budden, S., 
Pevsner, J., Dissen, G.A., Sherman, L.S., and Ojeda, S.R. (2007). FXYD1 is 
an MeCP2 target gene overexpressed in the brains of Rett syndrome patients 
and Mecp2-null mice. Human molecular genetics 16, 640-650. 
Di Giorgio, F.P., Carrasco, M.A., Siao, M.C., Maniatis, T., and Eggan, K. 
(2007). Non-cell autonomous effect of glia on motor neurons in an embryonic 
stem cell-based ALS model. Nature neuroscience 10, 608-614. 
Ding, B. (2015). Gene expression in maturing neurons: regulatory 
mechanisms and related neurodevelopmental disorders. Sheng li xue bao : 
[Acta physiologica Sinica] 67, 113-133. 
Diogenes, M.J., Assaife-Lopes, N., Pinto-Duarte, A., Ribeiro, J.A., and 
Sebastiao, A.M. (2007). Influence of age on BDNF modulation of hippocampal 
synaptic transmission: interplay with adenosine A2A receptors. Hippocampus 
17, 577-585. 
Diogenes, M.J., Costenla, A.R., Lopes, L.V., Jeronimo-Santos, A., Sousa, 
V.C., Fontinha, B.M., Ribeiro, J.A., and Sebastiao, A.M. (2011). Enhancement 
of LTP in aged rats is dependent on endogenous BDNF. 
Neuropsychopharmacology 36, 1823-1836. 
Diogenes, M.J., Dias, R.B., Rombo, D.M., Vicente Miranda, H., Maiolino, F., 
Guerreiro, P., Nasstrom, T., Franquelim, H.G., Oliveira, L.M., Castanho, M.A., 
et al. (2012). Extracellular alpha-synuclein oligomers modulate synaptic 
transmission and impair LTP via NMDA-receptor activation. The Journal of 
neuroscience : the official journal of the Society for Neuroscience 32, 11750-
11762. 
Diogenes, M.J., Fernandes, C.C., Sebastiao, A.M., and Ribeiro, J.A. (2004). 
Activation of adenosine A2A receptor facilitates brain-derived neurotrophic 
factor modulation of synaptic transmission in hippocampal slices. The Journal 
	   	  References 
 
	   198	  
of neuroscience : the official journal of the Society for Neuroscience 24, 2905-
2913. 
Dolce, A., Ben-Zeev, B., Naidu, S., and Kossoff, E.H. (2013). Rett syndrome 
and epilepsy: an update for child neurologists. Pediatric neurology 48, 337-
345. 
Domogatskaya, A., Rodin, S., and Tryggvason, K. (2012). Functional diversity 
of laminins. Annual review of cell and developmental biology 28, 523-553. 
Dorsey, S.G., Renn, C.L., Carim-Todd, L., Barrick, C.A., Bambrick, L., 
Krueger, B.K., Ward, C.W., and Tessarollo, L. (2006). In vivo restoration of 
physiological levels of truncated TrkB.T1 receptor rescues neuronal cell death 
in a trisomic mouse model. Neuron 51, 21-28. 
Duarte, S.T., Armstrong, J., Roche, A., Ortez, C., Perez, A., O'Callaghan Mdel, 
M., Pereira, A., Sanmarti, F., Ormazabal, A., Artuch, R., et al. (2013). 
Abnormal expression of cerebrospinal fluid cation chloride cotransporters in 
patients with Rett syndrome. PLoS One 8, e68851. 
Duarte, S.T., Ortez, C., Perez, A., Artuch, R., and Garcia-Cazorla, A. (2011). 
Analysis of synaptic proteins in the cerebrospinal fluid as a new tool in the 
study of inborn errors of neurotransmission. Journal of inherited metabolic 
disease 34, 523-528. 
Dulac, O. (2001). Epileptic encephalopathy. Epilepsia 42 Suppl 3, 23-26. 
Dzhala, V.I., Brumback, A.C., and Staley, K.J. (2008). Bumetanide enhances 
phenobarbital efficacy in a neonatal seizure model. Annals of neurology 63, 
222-235. 
Dzhala, V.I., Talos, D.M., Sdrulla, D.A., Brumback, A.C., Mathews, G.C., 
Benke, T.A., Delpire, E., Jensen, F.E., and Staley, K.J. (2005). NKCC1 
transporter facilitates seizures in the developing brain. Nature medicine 11, 
1205-1213. 
	   	  References 
 
	   199	  
Egana, L.A., Cuevas, R.A., Baust, T.B., Parra, L.A., Leak, R.K., Hochendoner, 
S., Pena, K., Quiroz, M., Hong, W.C., Dorostkar, M.M., et al. (2009). Physical 
and functional interaction between the dopamine transporter and the synaptic 
vesicle protein synaptogyrin-3. The Journal of neuroscience : the official 
journal of the Society for Neuroscience 29, 4592-4604. 
Ehninger, D., Li, W., Fox, K., Stryker, M.P., and Silva, A.J. (2008). Reversing 
neurodevelopmental disorders in adults. Neuron 60, 950-960. 
Eide, F.F., Vining, E.R., Eide, B.L., Zang, K., Wang, X.Y., and Reichardt, L.F. 
(1996). Naturally occurring truncated trkB receptors have dominant inhibitory 
effects on brain-derived neurotrophic factor signaling. The Journal of 
neuroscience : the official journal of the Society for Neuroscience 16, 3123-
3129. 
El-Khoury, R., Panayotis, N., Matagne, V., Ghata, A., Villard, L., and Roux, 
J.C. (2014). GABA and glutamate pathways are spatially and developmentally 
affected in the brain of Mecp2-deficient mice. PLoS One 9, e92169. 
Emsley, J.G., Mitchell, B.D., Magavi, S.S., Arlotta, P., and Macklis, J.D. 
(2004). The repair of complex neuronal circuitry by transplanted and 
endogenous precursors. NeuroRx : the journal of the American Society for 
Experimental NeuroTherapeutics 1, 452-471. 
Encinas, M., Iglesias, M., Llecha, N., and Comella, J.X. (1999). Extracellular-
regulated kinases and phosphatidylinositol 3-kinase are involved in brain-
derived neurotrophic factor-mediated survival and neuritogenesis of the 
neuroblastoma cell line SH-SY5Y. J Neurochem 73, 1409-1421. 
Endele, S., Rosenberger, G., Geider, K., Popp, B., Tamer, C., Stefanova, I., 
Milh, M., Kortum, F., Fritsch, A., Pientka, F.K., et al. (2010). Mutations in 
GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause 
variable neurodevelopmental phenotypes. Nature genetics 42, 1021-1026. 
	   	  References 
 
	   200	  
Eriksen, J., Jorgensen, T.N., and Gether, U. (2010). Regulation of dopamine 
transporter function by protein-protein interactions: new discoveries and 
methodological challenges. J Neurochem 113, 27-41. 
Ethell, I.M., and Pasquale, E.B. (2005). Molecular mechanisms of dendritic 
spine development and remodeling. Progress in neurobiology 75, 161-205. 
Fang, M., Shen, L., Yin, H., Pan, Y.M., Wang, L., Chen, D., Xi, Z.Q., Xiao, Z., 
Wang, X.F., and Zhou, S.N. (2011). Downregulation of gephyrin in temporal 
lobe epilepsy neurons in humans and a rat model. Synapse 65, 1006-1014. 
Felix-Oliveira, A., Dias, R.B., Colino-Oliveira, M., Rombo, D.M., and Sebastiao, 
A.M. (2014). Homeostatic plasticity induced by brief activity deprivation 
enhances long-term potentiation in the mature rat hippocampus. Journal of 
neurophysiology 112, 3012-3022. 
Fernandes, T.G., Duarte, S.T., Ghazvini, M., Gaspar, C., Santos, D.C., 
Porteira, A.R., Rodrigues, G.M., Haupt, S., Rombo, D.M., Armstrong, J., et al. 
(2015). Neural commitment of human pluripotent stem cells under defined 
conditions recapitulates neural development and generates patient-specific 
neural cells. Biotechnology journal. 
Figurov, A., Pozzo-Miller, L.D., Olafsson, P., Wang, T., and Lu, B. (1996). 
Regulation of synaptic responses to high-frequency stimulation and LTP by 
neurotrophins in the hippocampus. Nature 381, 706-709. 
Finlay, B.L., and Darlington, R.B. (1995). Linked regularities in the 
development and evolution of mammalian brains. Science 268, 1578-1584. 
Fischer, M., Kaech, S., Knutti, D., and Matus, A. (1998). Rapid actin-based 
plasticity in dendritic spines. Neuron 20, 847-854. 
Fiumelli, H., Briner, A., Puskarjov, M., Blaesse, P., Belem, B.J., Dayer, A.G., 
Kaila, K., Martin, J.L., and Vutskits, L. (2013). An ion transport-independent 
role for the cation-chloride cotransporter KCC2 in dendritic spinogenesis in 
vivo. Cerebral cortex 23, 378-388. 
	   	  References 
 
	   201	  
Florio, M., and Huttner, W.B. (2014). Neural progenitors, neurogenesis and 
the evolution of the neocortex. Development 141, 2182-2194. 
Fontinha, B.M., Diogenes, M.J., Ribeiro, J.A., and Sebastiao, A.M. (2008). 
Enhancement of long-term potentiation by brain-derived neurotrophic factor 
requires adenosine A2A receptor activation by endogenous adenosine. 
Neuropharmacology 54, 924-933. 
Freund, T.F., and Katona, I. (2007). Perisomatic inhibition. Neuron 56, 33-42. 
Fritschy, J.M., Harvey, R.J., and Schwarz, G. (2008). Gephyrin: where do we 
stand, where do we go? Trends in neurosciences 31, 257-264. 
Gagnon, M., Bergeron, M.J., Lavertu, G., Castonguay, A., Tripathy, S., Bonin, 
R.P., Perez-Sanchez, J., Boudreau, D., Wang, B., Dumas, L., et al. (2013). 
Chloride extrusion enhancers as novel therapeutics for neurological diseases. 
Nature medicine 19, 1524-1528. 
Galanopoulou, A.S. (2008a). GABA(A) receptors in normal development and 
seizures: friends or foes? Current neuropharmacology 6, 1-20. 
Galanopoulou, A.S. (2008b). Sexually dimorphic expression of KCC2 and 
GABA function. Epilepsy research 80, 99-113. 
Garcia-Cazorla, A., Cortes-Saladelafont, E., and Duarte, S. (2015). [Neuronal 
communication and synaptic metabolism in childhood epilepsy]. Revista de 
neurologia 60, 219-228. 
Garcia-Cazorla, A., Duarte, S., Serrano, M., Nascimento, A., Ormazabal, A., 
Carrilho, I., Briones, P., Montoya, J., Garesse, R., Sala-Castellvi, P., et al. 
(2008). Mitochondrial diseases mimicking neurotransmitter defects. 
Mitochondrion 8, 273-278. 
Garcia-Cazorla, A., and Duarte, S.T. (2014). Parkinsonism and inborn errors 
of metabolism. Journal of inherited metabolic disease 37, 627-642. 
Garcia-Cazorla, A., Serrano, M., Perez-Duenas, B., Gonzalez, V., Ormazabal, 
A., Pineda, M., Fernandez-Alvarez, E., Campistol, J.M., and Artuch, R.M. 
	   	  References 
 
	   202	  
(2007). Secondary abnormalities of neurotransmitters in infants with 
neurological disorders. Developmental medicine and child neurology 49, 740-
744. 
Garcia-Cazorla, A.W., NI. Hoffman GF (2010). Inherited Metabolic Diseases: 
A Clinical Approach. In  (Berlin Heidelberg Springer-Verlag ), pp. 127-159. 
Gauvain, G., Chamma, I., Chevy, Q., Cabezas, C., Irinopoulou, T., Bodrug, N., 
Carnaud, M., Levi, S., and Poncer, J.C. (2011). The neuronal K-Cl 
cotransporter KCC2 influences postsynaptic AMPA receptor content and 
lateral diffusion in dendritic spines. Proceedings of the National Academy of 
Sciences of the United States of America 108, 15474-15479. 
Glaze, D.G., Percy, A.K., Skinner, S., Motil, K.J., Neul, J.L., Barrish, J.O., 
Lane, J.B., Geerts, S.P., Annese, F., Graham, J., et al. (2010). Epilepsy and 
the natural history of Rett syndrome. Neurology 74, 909-912. 
Glickstein, S.B., and Schmauss, C. (2001). Dopamine receptor functions: 
lessons from knockout mice [corrected]. Pharmacology & therapeutics 91, 63-
83. 
Gowing, G., and Svendsen, C.N. (2011). Stem cell transplantation for motor 
neuron disease: current approaches and future perspectives. 
Neurotherapeutics : the journal of the American Society for Experimental 
NeuroTherapeutics 8, 591-606. 
Gozlan, H., and Ben-Ari, Y. (2003). Interneurons are the source and the 
targets of the first synapses formed in the rat developing hippocampal circuit. 
Cerebral cortex 13, 684-692. 
Grabrucker, A.M. (2014). A role for synaptic zinc in ProSAP/Shank PSD 
scaffold malformation in autism spectrum disorders. Developmental 
neurobiology 74, 136-146. 
Grimley, J.S., Li, L., Wang, W., Wen, L., Beese, L.S., Hellinga, H.W., and 
Augustine, G.J. (2013). Visualization of synaptic inhibition with an optogenetic 
sensor developed by cell-free protein engineering automation. The Journal of 
	   	  References 
 
	   203	  
neuroscience : the official journal of the Society for Neuroscience 33, 16297-
16309. 
Guy, J., Gan, J., Selfridge, J., Cobb, S., and Bird, A. (2007). Reversal of 
neurological defects in a mouse model of Rett syndrome. Science 315, 1143-
1147. 
Guy, J., Hendrich, B., Holmes, M., Martin, J.E., and Bird, A. (2001). A mouse 
Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. 
Nature genetics 27, 322-326. 
Hacein-Bey-Abina, S., von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., 
McIntyre, E., Radford, I., Villeval, J.L., Fraser, C.C., Cavazzana-Calvo, M., et 
al. (2003). A serious adverse event after successful gene therapy for X-linked 
severe combined immunodeficiency. The New England journal of medicine 
348, 255-256. 
Hagberg, B. (2002). Clinical manifestations and stages of Rett syndrome. 
Mental retardation and developmental disabilities research reviews 8, 61-65. 
Hagberg, B. (2005). Rett syndrome: long-term clinical follow-up experiences 
over four decades. J Child Neurol 20, 722-727. 
Hagberg, B., Aicardi, J., Dias, K., and Ramos, O. (1983). A progressive 
syndrome of autism, dementia, ataxia, and loss of purposeful hand use in 
girls: Rett's syndrome: report of 35 cases. Annals of neurology 14, 471-479. 
Hamdan, F.F., Gauthier, J., Dobrzeniecka, S., Lortie, A., Mottron, L., Vanasse, 
M., D'Anjou, G., Lacaille, J.C., Rouleau, G.A., and Michaud, J.L. (2011). 
Intellectual disability without epilepsy associated with STXBP1 disruption. 
European journal of human genetics : EJHG 19, 607-609. 
Han, S.S., Williams, L.A., and Eggan, K.C. (2011). Constructing and 
deconstructing stem cell models of neurological disease. Neuron 70, 626-644. 
Hanna, J., Wernig, M., Markoulaki, S., Sun, C.W., Meissner, A., Cassady, J.P., 
Beard, C., Brambrink, T., Wu, L.C., Townes, T.M., et al. (2007). Treatment of 
	   	  References 
 
	   204	  
sickle cell anemia mouse model with iPS cells generated from autologous skin. 
Science 318, 1920-1923. 
Harms, K.J., and Dunaevsky, A. (2007). Dendritic spine plasticity: looking 
beyond development. Brain Res 1184, 65-71. 
Harrington, M.G., Fonteh, A.N., Oborina, E., Liao, P., Cowan, R.P., McComb, 
G., Chavez, J.N., Rush, J., Biringer, R.G., and Huhmer, A.F. (2009). The 
morphology and biochemistry of nanostructures provide evidence for 
synthesis and signaling functions in human cerebrospinal fluid. Cerebrospinal 
fluid research 6, 10. 
He, Q., Nomura, T., Xu, J., and Contractor, A. (2014). The developmental 
switch in GABA polarity is delayed in fragile X mice. The Journal of 
neuroscience : the official journal of the Society for Neuroscience 34, 446-450. 
Heaton, M.B., and Swanson, D.J. (1988). The influence of laminin on the 
initial differentiation of cultured neural tube neurons. J Neurosci Res 19, 212-
218. 
Hill, R.S., and Walsh, C.A. (2005). Molecular insights into human brain 
evolution. Nature 437, 64-67. 
Hong, S.G., Winkler, T., Wu, C., Guo, V., Pittaluga, S., Nicolae, A., Donahue, 
R.E., Metzger, M.E., Price, S.D., Uchida, N., et al. (2014). Path to the clinic: 
assessment of iPSC-based cell therapies in vivo in a nonhuman primate 
model. Cell reports 7, 1298-1309. 
Hu, H., Gan, J., and Jonas, P. (2014). Interneurons. Fast-spiking, 
parvalbumin(+) GABAergic interneurons: from cellular design to microcircuit 
function. Science 345, 1255263. 
Huang, E.J., and Reichardt, L.F. (2003). Trk receptors: roles in neuronal 
signal transduction. Annu Rev Biochem 72, 609-642. 
	   	  References 
 
	   205	  
Huber, K.M., Sawtell, N.B., and Bear, M.F. (1998). Brain-derived neurotrophic 
factor alters the synaptic modification threshold in visual cortex. 
Neuropharmacology 37, 571-579. 
Hubner, C.A., Stein, V., Hermans-Borgmeyer, I., Meyer, T., Ballanyi, K., and 
Jentsch, T.J. (2001). Disruption of KCC2 reveals an essential role of K-Cl 
cotransport already in early synaptic inhibition. Neuron 30, 515-524. 
Hughes, C.S., Postovit, L.M., and Lajoie, G.A. (2010). Matrigel: a complex 
protein mixture required for optimal growth of cell culture. Proteomics 10, 
1886-1890. 
Hyman, S.E. (2014). How far can mice carry autism research? Cell 158, 13-14. 
Inman, G.J., Nicolas, F.J., Callahan, J.F., Harling, J.D., Gaster, L.M., Reith, 
A.D., Laping, N.J., and Hill, C.S. (2002). SB-431542 is a potent and specific 
inhibitor of transforming growth factor-beta superfamily type I activin receptor-
like kinase (ALK) receptors ALK4, ALK5, and ALK7. Molecular pharmacology 
62, 65-74. 
Ioannidis, J.P. (2012). Extrapolating from animals to humans. Science 
translational medicine 4, 151ps115. 
Ito, D., Okano, H., and Suzuki, N. (2012). Accelerating progress in induced 
pluripotent stem cell research for neurological diseases. Annals of neurology 
72, 167-174. 
Jansen, L.A., Peugh, L.D., Roden, W.H., and Ojemann, J.G. (2010). Impaired 
maturation of cortical GABA(A) receptor expression in pediatric epilepsy. 
Epilepsia 51, 1456-1467. 
Jarvis, M.F., Schulz, R., Hutchison, A.J., Do, U.H., Sills, M.A., and Williams, M. 
(1989). [3H]CGS 21680, a selective A2 adenosine receptor agonist directly 
labels A2 receptors in rat brain. J Pharmacol Exp Ther 251, 888-893. 
Jellinger, K., Armstrong, D., Zoghbi, H.Y., and Percy, A.K. (1988). 
Neuropathology of Rett syndrome. Acta neuropathologica 76, 142-158. 
	   	  References 
 
	   206	  
Jeronimo-Santos, A., Vaz, S.H., Parreira, S., Rapaz-Lerias, S., Caetano, A.P., 
Buee-Scherrer, V., Castren, E., Valente, C.A., Blum, D., Sebastiao, A.M., et al. 
(2014). Dysregulation of TrkB Receptors and BDNF Function by Amyloid-beta 
Peptide is Mediated by Calpain. Cerebral cortex. 
Jin, S., Yao, H., Weber, J.L., Melkoumian, Z.K., and Ye, K. (2012). A synthetic, 
xeno-free peptide surface for expansion and directed differentiation of human 
induced pluripotent stem cells. PLoS One 7, e50880. 
Johnson, M.A., Weick, J.P., Pearce, R.A., and Zhang, S.C. (2007). Functional 
neural development from human embryonic stem cells: accelerated synaptic 
activity via astrocyte coculture. The Journal of neuroscience : the official 
journal of the Society for Neuroscience 27, 3069-3077. 
Johnson, R.A., Lam, M., Punzo, A.M., Li, H., Lin, B.R., Ye, K., Mitchell, G.S., 
and Chang, Q. (2012). 7,8-dihydroxyflavone exhibits therapeutic efficacy in a 
mouse model of Rett syndrome. J Appl Physiol (1985) 112, 704-710. 
Jones, P.L., Veenstra, G.J., Wade, P.A., Vermaak, D., Kass, S.U., 
Landsberger, N., Strouboulis, J., and Wolffe, A.P. (1998). Methylated DNA 
and MeCP2 recruit histone deacetylase to repress transcription. Nature 
genetics 19, 187-191. 
Julu, P.O., Kerr, A.M., Apartopoulos, F., Al-Rawas, S., Engerstrom, I.W., 
Engerstrom, L., Jamal, G.A., and Hansen, S. (2001). Characterisation of 
breathing and associated central autonomic dysfunction in the Rett disorder. 
Archives of disease in childhood 85, 29-37. 
Kahle, K.T., Barnett, S.M., Sassower, K.C., and Staley, K.J. (2009). 
Decreased seizure activity in a human neonate treated with bumetanide, an 
inhibitor of the Na(+)-K(+)-2Cl(-) cotransporter NKCC1. Journal of child 
neurology 24, 572-576. 
Kahle, K.T., Deeb, T.Z., Puskarjov, M., Silayeva, L., Liang, B., Kaila, K., and 
Moss, S.J. (2013). Modulation of neuronal activity by phosphorylation of the 
K-Cl cotransporter KCC2. Trends in neurosciences 36, 726-737. 
	   	  References 
 
	   207	  
Kaila, K. (1994). Ionic basis of GABAA receptor channel function in the 
nervous system. Progress in neurobiology 42, 489-537. 
Kaila, K., Price, T.J., Payne, J.A., Puskarjov, M., and Voipio, J. (2014a). 
Cation-chloride cotransporters in neuronal development, plasticity and 
disease. Nature reviews Neuroscience 15, 637-654. 
Kaila, K., Ruusuvuori, E., Seja, P., Voipio, J., and Puskarjov, M. (2014b). 
GABA actions and ionic plasticity in epilepsy. Current opinion in neurobiology 
26, 34-41. 
Kaji, K., Norrby, K., Paca, A., Mileikovsky, M., Mohseni, P., and Woltjen, K. 
(2009). Virus-free induction of pluripotency and subsequent excision of 
reprogramming factors. Nature 458, 771-775. 
Kato, M., Koyama, N., Ohta, M., Miura, K., and Hayasaka, K. (2010). 
Frameshift mutations of the ARX gene in familial Ohtahara syndrome. 
Epilepsia 51, 1679-1684. 
Katz, B. (1969). The release of Neural Transmitter Substances (Springfield, Ill., 
Thomas). 
Katz, D.M., Berger-Sweeney, J.E., Eubanks, J.H., Justice, M.J., Neul, J.L., 
Pozzo-Miller, L., Blue, M.E., Christian, D., Crawley, J.N., Giustetto, M., et al. 
(2012). Preclinical research in Rett syndrome: setting the foundation for 
translational success. Disease models & mechanisms 5, 733-745. 
Kauer, J.A., and Malenka, R.C. (2007). Synaptic plasticity and addiction. 
Nature reviews Neuroscience 8, 844-858. 
Kaufmann, W.E., MacDonald, S.M., and Altamura, C.R. (2000). Dendritic 
cytoskeletal protein expression in mental retardation: an 
immunohistochemical study of the neocortex in Rett syndrome. Cerebral 
cortex 10, 992-1004. 
Kelleher, R.J., 3rd, and Bear, M.F. (2008). The autistic neuron: troubled 
translation? Cell 135, 401-406. 
	   	  References 
 
	   208	  
Keller, G., and Snodgrass, H.R. (1999). Human embryonic stem cells: the 
future is now. Nature medicine 5, 151-152. 
Kemppainen, S., Rantamaki, T., Jeronimo-Santos, A., Lavasseur, G., Autio, 
H., Karpova, N., Karkkainen, E., Staven, S., Vicente Miranda, H., Outeiro, T.F., 
et al. (2012). Impaired TrkB receptor signaling contributes to memory 
impairment in APP/PS1 mice. Neurobiol Aging 33, 1122 e1123-1139. 
Kennedy, M., D'Souza, S.L., Lynch-Kattman, M., Schwantz, S., and Keller, G. 
(2007). Development of the hemangioblast defines the onset of 
hematopoiesis in human ES cell differentiation cultures. Blood 109, 2679-
2687. 
Kim, E., and Sheng, M. (2004). PDZ domain proteins of synapses. Nature 
reviews Neuroscience 5, 771-781. 
Kim, K.Y., Hysolli, E., and Park, I.H. (2011). Neuronal maturation defect in 
induced pluripotent stem cells from patients with Rett syndrome. Proceedings 
of the National Academy of Sciences of the United States of America 108, 
14169-14174. 
Klausberger, T., and Somogyi, P. (2008). Neuronal diversity and temporal 
dynamics: the unity of hippocampal circuit operations. Science 321, 53-57. 
Klein, R., Conway, D., Parada, L.F., and Barbacid, M. (1990). The trkB 
tyrosine protein kinase gene codes for a second neurogenic receptor that 
lacks the catalytic kinase domain. Cell 61, 647-656. 
Kline, D.D., Ogier, M., Kunze, D.L., and Katz, D.M. (2010). Exogenous brain-
derived neurotrophic factor rescues synaptic dysfunction in Mecp2-null mice. 
The Journal of neuroscience : the official journal of the Society for 
Neuroscience 30, 5303-5310. 
Klitgaard, H., and Verdru, P. (2007). Levetiracetam: the first SV2A ligand for 
the treatment of epilepsy. Expert opinion on drug discovery 2, 1537-1545. 
	   	  References 
 
	   209	  
Koivisto, H., Hyvarinen, M., Stromberg, A.M., Inzunza, J., Matilainen, E., 
Mikkola, M., Hovatta, O., and Teerijoki, H. (2004). Cultures of human 
embryonic stem cells: serum replacement medium or serum-containing media 
and the effect of basic fibroblast growth factor. Reproductive biomedicine 
online 9, 330-337. 
Koponen, E., Voikar, V., Riekki, R., Saarelainen, T., Rauramaa, T., Rauvala, 
H., Taira, T., and Castren, E. (2004). Transgenic mice overexpressing the full-
length neurotrophin receptor trkB exhibit increased activation of the trkB-
PLCgamma pathway, reduced anxiety, and facilitated learning. Mol Cell 
Neurosci 26, 166-181. 
Korte, M., Griesbeck, O., Gravel, C., Carroll, P., Staiger, V., Thoenen, H., and 
Bonhoeffer, T. (1996). Virus-mediated gene transfer into hippocampal CA1 
region restores long-term potentiation in brain-derived neurotrophic factor 
mutant mice. Proceedings of the National Academy of Sciences of the United 
States of America 93, 12547-12552. 
Kramer, A.S., Harvey, A.R., Plant, G.W., and Hodgetts, S.I. (2013). 
Systematic review of induced pluripotent stem cell technology as a potential 
clinical therapy for spinal cord injury. Cell transplantation 22, 571-617. 
Kron, M., Howell, C.J., Adams, I.T., Ransbottom, M., Christian, D., Ogier, M., 
and Katz, D.M. (2012). Brain activity mapping in Mecp2 mutant mice reveals 
functional deficits in forebrain circuits, including key nodes in the default mode 
network, that are reversed with ketamine treatment. The Journal of 
neuroscience : the official journal of the Society for Neuroscience 32, 13860-
13872. 
Kulkarni, V.A., and Firestein, B.L. (2012). The dendritic tree and brain 
disorders. Molecular and cellular neurosciences 50, 10-20. 
Kuner, T., and Augustine, G.J. (2000). A genetically encoded ratiometric 
indicator for chloride: capturing chloride transients in cultured hippocampal 
neurons. Neuron 27, 447-459. 
	   	  References 
 
	   210	  
Kurian, M.A., Meyer, E., Vassallo, G., Morgan, N.V., Prakash, N., Pasha, S., 
Hai, N.A., Shuib, S., Rahman, F., Wassmer, E., et al. (2010). Phospholipase 
C beta 1 deficiency is associated with early-onset epileptic encephalopathy. 
Brain : a journal of neurology 133, 2964-2970. 
Laccone, F., Huppke, P., Hanefeld, F., and Meins, M. (2001). Mutation 
spectrum in patients with Rett syndrome in the German population: Evidence 
of hot spot regions. Human mutation 17, 183-190. 
Laflamme, M.A., Chen, K.Y., Naumova, A.V., Muskheli, V., Fugate, J.A., 
Dupras, S.K., Reinecke, H., Xu, C., Hassanipour, M., Police, S., et al. (2007). 
Cardiomyocytes derived from human embryonic stem cells in pro-survival 
factors enhance function of infarcted rat hearts. Nature biotechnology 25, 
1015-1024. 
Lang, M., Wither, R.G., Colic, S., Wu, C., Monnier, P.P., Bardakjian, B.L., 
Zhang, L., and Eubanks, J.H. (2014). Rescue of behavioral and EEG deficits 
in male and female Mecp2-deficient mice by delayed Mecp2 gene reactivation. 
Human molecular genetics 23, 303-318. 
Lee, H.H., Walker, J.A., Williams, J.R., Goodier, R.J., Payne, J.A., and Moss, 
S.J. (2007). Direct protein kinase C-dependent phosphorylation regulates the 
cell surface stability and activity of the potassium chloride cotransporter KCC2. 
J Biol Chem 282, 29777-29784. 
Lee-Kubli, C.A., and Lu, P. (2015). Induced pluripotent stem cell-derived 
neural stem cell therapies for spinal cord injury. Neural regeneration research 
10, 10-16. 
Lemonnier, E., Degrez, C., Phelep, M., Tyzio, R., Josse, F., Grandgeorge, M., 
Hadjikhani, N., and Ben-Ari, Y. (2012). A randomised controlled trial of 
bumetanide in the treatment of autism in children. Translational psychiatry 2, 
e202. 
Levinson, J.N., and El-Husseini, A. (2005). Building excitatory and inhibitory 
synapses: balancing neuroligin partnerships. Neuron 48, 171-174. 
	   	  References 
 
	   211	  
Lewis, J.D., Meehan, R.R., Henzel, W.J., Maurer-Fogy, I., Jeppesen, P., Klein, 
F., and Bird, A. (1992). Purification, sequence, and cellular localization of a 
novel chromosomal protein that binds to methylated DNA. Cell 69, 905-914. 
Li, H., Khirug, S., Cai, C., Ludwig, A., Blaesse, P., Kolikova, J., Afzalov, R., 
Coleman, S.K., Lauri, S., Airaksinen, M.S., et al. (2007). KCC2 interacts with 
the dendritic cytoskeleton to promote spine development. Neuron 56, 1019-
1033. 
Li, T., Ren, G., Lusardi, T., Wilz, A., Lan, J.Q., Iwasato, T., Itohara, S., Simon, 
R.P., and Boison, D. (2008). Adenosine kinase is a target for the prediction 
and prevention of epileptogenesis in mice. The Journal of clinical investigation 
118, 571-582. 
Li, W., and Pozzo-Miller, L. (2014). BDNF deregulation in Rett syndrome. 
Neuropharmacology 76 Pt C, 737-746. 
Li, Y., Wang, H., Muffat, J., Cheng, A.W., Orlando, D.A., Loven, J., Kwok, 
S.M., Feldman, D.A., Bateup, H.S., Gao, Q., et al. (2013). Global 
transcriptional and translational repression in human-embryonic-stem-cell-
derived Rett syndrome neurons. Cell stem cell 13, 446-458. 
Linley, J.E. (2013). Perforated whole-cell patch-clamp recording. Methods in 
molecular biology 998, 149-157. 
Lionel, A.C., Vaags, A.K., Sato, D., Gazzellone, M.J., Mitchell, E.B., Chen, 
H.Y., Costain, G., Walker, S., Egger, G., Thiruvahindrapuram, B., et al. (2013). 
Rare exonic deletions implicate the synaptic organizer Gephyrin (GPHN) in 
risk for autism, schizophrenia and seizures. Human molecular genetics 22, 
2055-2066. 
Lioy, D.T., Garg, S.K., Monaghan, C.E., Raber, J., Foust, K.D., Kaspar, B.K., 
Hirrlinger, P.G., Kirchhoff, F., Bissonnette, J.M., Ballas, N., et al. (2011). A 
role for glia in the progression of Rett's syndrome. Nature 475, 497-500. 
	   	  References 
 
	   212	  
Lippmann, E.S., Estevez-Silva, M.C., and Ashton, R.S. (2014). Defined 
human pluripotent stem cell culture enables highly efficient neuroepithelium 
derivation without small molecule inhibitors. Stem cells 32, 1032-1042. 
Liu, S.P., Fu, R.H., Huang, S.J., Huang, Y.C., Chen, S.Y., Chang, C.H., Liu, 
C.H., Tsai, C.H., Shyu, W.C., and Lin, S.Z. (2013). Stem cell applications in 
regenerative medicine for neurological disorders. Cell transplantation 22, 631-
637. 
Ludwig, A., Uvarov, P., Soni, S., Thomas-Crusells, J., Airaksinen, M.S., and 
Rivera, C. (2011). Early growth response 4 mediates BDNF induction of 
potassium chloride cotransporter 2 transcription. The Journal of 
neuroscience : the official journal of the Society for Neuroscience 31, 644-649. 
Luscher, B., and Keller, C.A. (2004). Regulation of GABAA receptor trafficking, 
channel activity, and functional plasticity of inhibitory synapses. Pharmacology 
& therapeutics 102, 195-221. 
Lynch, M.A. (2004). Long-term potentiation and memory. Physiological 
reviews 84, 87-136. 
Maezawa, I., Swanberg, S., Harvey, D., LaSalle, J.M., and Jin, L.W. (2009). 
Rett syndrome astrocytes are abnormal and spread MeCP2 deficiency 
through gap junctions. The Journal of neuroscience : the official journal of the 
Society for Neuroscience 29, 5051-5061. 
Mahadevan, V., Pressey, J.C., Acton, B.A., Uvarov, P., Huang, M.Y., Chevrier, 
J., Puchalski, A., Li, C.M., Ivakine, E.A., Airaksinen, M.S., et al. (2014). 
Kainate receptors coexist in a functional complex with KCC2 and regulate 
chloride homeostasis in hippocampal neurons. Cell reports 7, 1762-1770. 
Marchetto, M.C., Carromeu, C., Acab, A., Yu, D., Yeo, G.W., Mu, Y., Chen, G., 
Gage, F.H., and Muotri, A.R. (2010). A model for neural development and 
treatment of Rett syndrome using human induced pluripotent stem cells. Cell 
143, 527-539. 
	   	  References 
 
	   213	  
Marin-Valencia, I., Serrano, M., Ormazabal, A., Perez-Duenas, B., Garcia-
Cazorla, A., Campistol, J., and Artuch, R. (2008). Biochemical diagnosis of 
dopaminergic disturbances in paediatric patients: analysis of cerebrospinal 
fluid homovanillic acid and other biogenic amines. Clinical biochemistry 41, 
1306-1315. 
Marshall, C.R., Young, E.J., Pani, A.M., Freckmann, M.L., Lacassie, Y., 
Howald, C., Fitzgerald, K.K., Peippo, M., Morris, C.A., Shane, K., et al. (2008). 
Infantile spasms is associated with deletion of the MAGI2 gene on 
chromosome 7q11.23-q21.11. American journal of human genetics 83, 106-
111. 
Martin, M.J., Muotri, A., Gage, F., and Varki, A. (2005). Human embryonic 
stem cells express an immunogenic nonhuman sialic acid. Nature medicine 
11, 228-232. 
Matagne, A., Margineanu, D.G., Kenda, B., Michel, P., and Klitgaard, H. 
(2008). Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 
34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. Br J 
Pharmacol 154, 1662-1671. 
Medrihan, L., Tantalaki, E., Aramuni, G., Sargsyan, V., Dudanova, I., Missler, 
M., and Zhang, W. (2008). Early defects of GABAergic synapses in the brain 
stem of a MeCP2 mouse model of Rett syndrome. Journal of neurophysiology 
99, 112-121. 
Melkoumian, Z., Weber, J.L., Weber, D.M., Fadeev, A.G., Zhou, Y., Dolley-
Sonneville, P., Yang, J., Qiu, L., Priest, C.A., Shogbon, C., et al. (2010). 
Synthetic peptide-acrylate surfaces for long-term self-renewal and 
cardiomyocyte differentiation of human embryonic stem cells. Nature 
biotechnology 28, 606-610. 
Michels, G., and Moss, S.J. (2007). GABAA receptors: properties and 
trafficking. Critical reviews in biochemistry and molecular biology 42, 3-14. 
	   	  References 
 
	   214	  
Milh, M., Boutry-Kryza, N., Sutera-Sardo, J., Mignot, C., Auvin, S., Lacoste, C., 
Villeneuve, N., Roubertie, A., Heron, B., Carneiro, M., et al. (2013). Similar 
early characteristics but variable neurological outcome of patients with a de 
novo mutation of KCNQ2. Orphanet journal of rare diseases 8, 80. 
Minichiello, L. (2009). TrkB signalling pathways in LTP and learning. Nature 
reviews Neuroscience 10, 850-860. 
Mitalipov, S., and Wolf, D. (2009). Totipotency, pluripotency and nuclear 
reprogramming. Advances in biochemical engineering/biotechnology 114, 
185-199. 
Miyawaki, A. (2005). Innovations in the imaging of brain functions using 
fluorescent proteins. Neuron 48, 189-199. 
Mizrahi, A., Crowley, J.C., Shtoyerman, E., and Katz, L.C. (2004). High-
resolution in vivo imaging of hippocampal dendrites and spines. The Journal 
of neuroscience : the official journal of the Society for Neuroscience 24, 3147-
3151. 
Monteggia, L.M., and Kavalali, E.T. (2009). Rett syndrome and the impact of 
MeCP2 associated transcriptional mechanisms on neurotransmission. Biol 
Psychiatry 65, 204-210. 
Mount, R.H., Hastings, R.P., Reilly, S., Cass, H., and Charman, T. (2001). 
Behavioural and emotional features in Rett syndrome. Disability and 
rehabilitation 23, 129-138. 
Munoz, A., Mendez, P., DeFelipe, J., and Alvarez-Leefmans, F.J. (2007). 
Cation-chloride cotransporters and GABA-ergic innervation in the human 
epileptic hippocampus. Epilepsia 48, 663-673. 
Murer, M.G., Yan, Q., and Raisman-Vozari, R. (2001). Brain-derived 
neurotrophic factor in the control human brain, and in Alzheimer's disease and 
Parkinson's disease. Progress in neurobiology 63, 71-124. 
	   	  References 
 
	   215	  
Nakanishi, M., and Otsu, M. (2012). Development of Sendai virus vectors and 
their potential applications in gene therapy and regenerative medicine. 
Current gene therapy 12, 410-416. 
Nakazawa, K., Zsiros, V., Jiang, Z., Nakao, K., Kolata, S., Zhang, S., and 
Belforte, J.E. (2012). GABAergic interneuron origin of schizophrenia 
pathophysiology. Neuropharmacology 62, 1574-1583. 
Nan, X., Tate, P., Li, E., and Bird, A. (1996). DNA methylation specifies 
chromosomal localization of MeCP2. Molecular and cellular biology 16, 414-
421. 
Neul, J.L., Kaufmann, W.E., Glaze, D.G., Christodoulou, J., Clarke, A.J., Bahi-
Buisson, N., Leonard, H., Bailey, M.E., Schanen, N.C., Zappella, M., et al. 
(2010). Rett syndrome: revised diagnostic criteria and nomenclature. Annals 
of neurology 68, 944-950. 
Nicaise, C., Mitrecic, D., Falnikar, A., and Lepore, A.C. (2015). 
Transplantation of stem cell-derived astrocytes for the treatment of 
amyotrophic lateral sclerosis and spinal cord injury. World journal of stem 
cells 7, 380-398. 
Nimchinsky, E.A., Sabatini, B.L., and Svoboda, K. (2002). Structure and 
function of dendritic spines. Annual review of physiology 64, 313-353. 
Nissenkorn, A., Gak, E., Vecsler, M., Reznik, H., Menascu, S., and Ben Zeev, 
B. (2010). Epilepsy in Rett syndrome---the experience of a National Rett 
Center. Epilepsia 51, 1252-1258. 
Nissenkorn, A., Levy-Drummer, R.S., Bondi, O., Renieri, A., Villard, L., Mari, 
F., Mencarelli, M.A., Lo Rizzo, C., Meloni, I., Pineda, M., et al. (2015). 
Epilepsy in Rett syndrome-Lessons from the Rett networked database. 
Epilepsia 56, 569-576. 
Noutel, J., Hong, Y.K., Leu, B., Kang, E., and Chen, C. (2011). Experience-
dependent retinogeniculate synapse remodeling is abnormal in MeCP2-
deficient mice. Neuron 70, 35-42. 
	   	  References 
 
	   216	  
Ogier, M., Wang, H., Hong, E., Wang, Q., Greenberg, M.E., and Katz, D.M. 
(2007). Brain-derived neurotrophic factor expression and respiratory function 
improve after ampakine treatment in a mouse model of Rett syndrome. The 
Journal of neuroscience : the official journal of the Society for Neuroscience 
27, 10912-10917. 
Oh, S.K., and Choo, A.B. (2006). Human embryonic stem cells: technological 
challenges towards therapy. Clinical and experimental pharmacology & 
physiology 33, 489-495. 
Okita, K., Ichisaka, T., and Yamanaka, S. (2007). Generation of germline-
competent induced pluripotent stem cells. Nature 448, 313-317. 
Okita, K., Nakagawa, M., Hyenjong, H., Ichisaka, T., and Yamanaka, S. 
(2008). Generation of mouse induced pluripotent stem cells without viral 
vectors. Science 322, 949-953. 
Oliveira, G., Ataide, A., Marques, C., Miguel, T.S., Coutinho, A.M., Mota-
Vieira, L., Goncalves, E., Lopes, N.M., Rodrigues, V., Carmona da Mota, H., 
et al. (2007). Epidemiology of autism spectrum disorder in Portugal: 
prevalence, clinical characterization, and medical conditions. Developmental 
medicine and child neurology 49, 726-733. 
Ormazabal, A., Garcia-Cazorla, A., Fernandez, Y., Fernandez-Alvarez, E., 
Campistol, J., and Artuch, R. (2005). HPLC with electrochemical and 
fluorescence detection procedures for the diagnosis of inborn errors of 
biogenic amines and pterins. Journal of neuroscience methods 142, 153-158. 
Ortez, C., Duarte, S.T., Ormazabal, A., Serrano, M., Perez, A., Pons, R., 
Pineda, M., Yapici, Z., Fernandez-Alvarez, E., Domingo-Jimenez, R., et al. 
(2015). Cerebrospinal fluid synaptic proteins as useful biomarkers in tyrosine 
hydroxylase deficiency. Molecular genetics and metabolism 114, 34-40. 
Otsuka, M., Oguni, H., Liang, J.S., Ikeda, H., Imai, K., Hirasawa, K., Imai, K., 
Tachikawa, E., Shimojima, K., Osawa, M., et al. (2010). STXBP1 mutations 
	   	  References 
 
	   217	  
cause not only Ohtahara syndrome but also West syndrome--result of 
Japanese cohort study. Epilepsia 51, 2449-2452. 
Overman, J.J., and Carmichael, S.T. (2014). Plasticity in the injured brain: 
more than molecules matter. The Neuroscientist : a review journal bringing 
neurobiology, neurology and psychiatry 20, 15-28. 
Paciorkowski, A.R., Thio, L.L., and Dobyns, W.B. (2011a). Genetic and 
biologic classification of infantile spasms. Pediatric neurology 45, 355-367. 
Paciorkowski, A.R., Thio, L.L., Rosenfeld, J.A., Gajecka, M., Gurnett, C.A., 
Kulkarni, S., Chung, W.K., Marsh, E.D., Gentile, M., Reggin, J.D., et al. 
(2011b). Copy number variants and infantile spasms: evidence for 
abnormalities in ventral forebrain development and pathways of synaptic 
function. European journal of human genetics : EJHG 19, 1238-1245. 
Panja, D., and Bramham, C.R. (2014). BDNF mechanisms in late LTP 
formation: A synthesis and breakdown. Neuropharmacology 76 Pt C, 664-676. 
Pankratz, M.T., Li, X.J., Lavaute, T.M., Lyons, E.A., Chen, X., and Zhang, S.C. 
(2007). Directed neural differentiation of human embryonic stem cells via an 
obligated primitive anterior stage. Stem cells 25, 1511-1520. 
Pearl, P.L., Gibson, K.M., Quezado, Z., Dustin, I., Taylor, J., Trzcinski, S., 
Schreiber, J., Forester, K., Reeves-Tyer, P., Liew, C., et al. (2009). 
Decreased GABA-A binding on FMZ-PET in succinic semialdehyde 
dehydrogenase deficiency. Neurology 73, 423-429. 
Peerani, R., Rao, B.M., Bauwens, C., Yin, T., Wood, G.A., Nagy, A., 
Kumacheva, E., and Zandstra, P.W. (2007). Niche-mediated control of human 
embryonic stem cell self-renewal and differentiation. EMBO J 26, 4744-4755. 
Pennington, B.O., Clegg, D.O., Melkoumian, Z.K., and Hikita, S.T. (2015). 
Defined Culture of Human Embryonic Stem Cells and Xeno-Free Derivation of 
Retinal Pigmented Epithelial Cells on a Novel, Synthetic Substrate. Stem cells 
translational medicine 4, 165-177. 
	   	  References 
 
	   218	  
Petralia, R.S. (2012). Distribution of extrasynaptic NMDA receptors on 
neurons. TheScientificWorldJournal 2012, 267120. 
Petralia, R.S., Sans, N., Wang, Y.X., and Wenthold, R.J. (2005). Ontogeny of 
postsynaptic density proteins at glutamatergic synapses. Molecular and 
cellular neurosciences 29, 436-452. 
Pinard, A., Seddik, R., and Bettler, B. (2010). GABAB receptors: physiological 
functions and mechanisms of diversity. Advances in pharmacology 58, 231-
255. 
Pitcher, M.R., Herrera, J.A., Buffington, S.A., Kochukov, M.Y., Merritt, J.K., 
Fisher, A.R., Schanen, N.C., Costa-Mattioli, M., and Neul, J.L. (2015). Rett 
syndrome like phenotypes in the R255X Mecp2 mutant mouse are rescued by 
MECP2 transgene. Human molecular genetics 24, 2662-2672. 
Plotkin, M.D., Snyder, E.Y., Hebert, S.C., and Delpire, E. (1997). Expression 
of the Na-K-2Cl cotransporter is developmentally regulated in postnatal rat 
brains: a possible mechanism underlying GABA's excitatory role in immature 
brain. Journal of neurobiology 33, 781-795. 
Poudel, K.R., and Bai, J. (2014). Synaptic vesicle morphology: a case of 
protein sorting? Current opinion in cell biology 26, 28-33. 
Pouille, F., and Scanziani, M. (2001). Enforcement of temporal fidelity in 
pyramidal cells by somatic feed-forward inhibition. Science 293, 1159-1163. 
Puskarjov, M., Kahle, K.T., Ruusuvuori, E., and Kaila, K. (2014). 
Pharmacotherapeutic targeting of cation-chloride cotransporters in neonatal 
seizures. Epilepsia 55, 806-818. 
Puts, N.A., and Edden, R.A. (2012). In vivo magnetic resonance spectroscopy 
of GABA: a methodological review. Progress in nuclear magnetic resonance 
spectroscopy 60, 29-41. 
Rakic, P. (2009). Evolution of the neocortex: a perspective from 
developmental biology. Nature reviews Neuroscience 10, 724-735. 
	   	  References 
 
	   219	  
Ramocki, M.B., Peters, S.U., Tavyev, Y.J., Zhang, F., Carvalho, C.M., Schaaf, 
C.P., Richman, R., Fang, P., Glaze, D.G., Lupski, J.R., et al. (2009). Autism 
and other neuropsychiatric symptoms are prevalent in individuals with MeCP2 
duplication syndrome. Annals of neurology 66, 771-782. 
Rauen, K.A. (2013). The RASopathies. Annual review of genomics and 
human genetics 14, 355-369. 
Reiss, A.L., Faruque, F., Naidu, S., Abrams, M., Beaty, T., Bryan, R.N., and 
Moser, H. (1993). Neuroanatomy of Rett syndrome: a volumetric imaging 
study. Annals of neurology 34, 227-234. 
Rett, A. (1966). [On a unusual brain atrophy syndrome in hyperammonemia in 
childhood]. Wiener medizinische Wochenschrift 116, 723-726. 
Ribeiro, J.A., Sebastiao, A.M., and de Mendonca, A. (2003). Participation of 
adenosine receptors in neuroprotection. Drug News Perspect 16, 80-86. 
Rivera, C., Voipio, J., Payne, J.A., Ruusuvuori, E., Lahtinen, H., Lamsa, K., 
Pirvola, U., Saarma, M., and Kaila, K. (1999). The K+/Cl- co-transporter KCC2 
renders GABA hyperpolarizing during neuronal maturation. Nature 397, 251-
255. 
Rivera, C., Voipio, J., Thomas-Crusells, J., Li, H., Emri, Z., Sipila, S., Payne, 
J.A., Minichiello, L., Saarma, M., and Kaila, K. (2004). Mechanism of activity-
dependent downregulation of the neuron-specific K-Cl cotransporter KCC2. J 
Neurosci 24, 4683-4691. 
Robinson, L., Guy, J., McKay, L., Brockett, E., Spike, R.C., Selfridge, J., De 
Sousa, D., Merusi, C., Riedel, G., Bird, A., et al. (2012). Morphological and 
functional reversal of phenotypes in a mouse model of Rett syndrome. Brain : 
a journal of neurology 135, 2699-2710. 
Rodin, S., Domogatskaya, A., Strom, S., Hansson, E.M., Chien, K.R., Inzunza, 
J., Hovatta, O., and Tryggvason, K. (2010). Long-term self-renewal of human 
pluripotent stem cells on human recombinant laminin-511. Nature 
biotechnology 28, 611-615. 
	   	  References 
 
	   220	  
Rodrigues, G.M., Matos, A.F., Fernandes, T.G., Rodrigues, C.A., Peitz, M., 
Haupt, S., Diogo, M.M., Brustle, O., and Cabral, J.M. (2014). Integrated 
platform for production and purification of human pluripotent stem cell-derived 
neural precursors. Stem cell reviews 10, 151-161. 
Rothlisberger, B., Hoigne, I., Huber, A.R., Brunschwiler, W., and Capone Mori, 
A. (2010). Deletion of 7q11.21-q11.23 and infantile spasms without deletion of 
MAGI2. American journal of medical genetics Part A 152A, 434-437. 
Rustom, A., Saffrich, R., Markovic, I., Walther, P., and Gerdes, H.H. (2004). 
Nanotubular highways for intercellular organelle transport. Science 303, 1007-
1010. 
Saitsu, H., Kato, M., Mizuguchi, T., Hamada, K., Osaka, H., Tohyama, J., 
Uruno, K., Kumada, S., Nishiyama, K., Nishimura, A., et al. (2008). De novo 
mutations in the gene encoding STXBP1 (MUNC18-1) cause early infantile 
epileptic encephalopathy. Nature genetics 40, 782-788. 
Saitsu, H., Kato, M., Okada, I., Orii, K.E., Higuchi, T., Hoshino, H., Kubota, M., 
Arai, H., Tagawa, T., Kimura, S., et al. (2010). STXBP1 mutations in early 
infantile epileptic encephalopathy with suppression-burst pattern. Epilepsia 51, 
2397-2405. 
Saitsu, H., Osaka, H., Sugiyama, S., Kurosawa, K., Mizuguchi, T., Nishiyama, 
K., Nishimura, A., Tsurusaki, Y., Doi, H., Miyake, N., et al. (2012). Early 
infantile epileptic encephalopathy associated with the disrupted gene 
encoding Slit-Robo Rho GTPase activating protein 2 (SRGAP2). American 
journal of medical genetics Part A 158A, 199-205. 
Saporta, M.A., Grskovic, M., and Dimos, J.T. (2011). Induced pluripotent stem 
cells in the study of neurological diseases. Stem cell research & therapy 2, 37. 
Schmid, D.A., Yang, T., Ogier, M., Adams, I., Mirakhur, Y., Wang, Q., Massa, 
S.M., Longo, F.M., and Katz, D.M. (2012). A TrkB small molecule partial 
agonist rescues TrkB phosphorylation deficits and improves respiratory 
	   	  References 
 
	   221	  
function in a mouse model of Rett syndrome. The Journal of neuroscience : 
the official journal of the Society for Neuroscience 32, 1803-1810. 
Schott, J.W., Galla, M., Godinho, T., Baum, C., and Schambach, A. (2011). 
Viral and non-viral approaches for transient delivery of mRNA and proteins. 
Current gene therapy 11, 382-398. 
Sebastiao, A.M., Assaife-Lopes, N., Diogenes, M.J., Vaz, S.H., and Ribeiro, 
J.A. (2011). Modulation of brain-derived neurotrophic factor (BDNF) actions in 
the nervous system by adenosine A(2A) receptors and the role of lipid rafts. 
Biochim Biophys Acta 1808, 1340-1349. 
Sebastiao, A.M., and Ribeiro, J.A. (2009a). Adenosine receptors and the 
central nervous system. Handbook of experimental pharmacology, 471-534. 
Sebastiao, A.M., and Ribeiro, J.A. (2009b). Tuning and fine-tuning of 
synapses with adenosine. Curr Neuropharmacol 7, 180-194. 
Semyanov, A., Walker, M.C., Kullmann, D.M., and Silver, R.A. (2004). 
Tonically active GABA A receptors: modulating gain and maintaining the tone. 
Trends in neurosciences 27, 262-269. 
Seok, J., Warren, H.S., Cuenca, A.G., Mindrinos, M.N., Baker, H.V., Xu, W., 
Richards, D.R., McDonald-Smith, G.P., Gao, H., Hennessy, L., et al. (2013). 
Genomic responses in mouse models poorly mimic human inflammatory 
diseases. Proceedings of the National Academy of Sciences of the United 
States of America 110, 3507-3512. 
Sernagor, E., Chabrol, F., Bony, G., and Cancedda, L. (2010). GABAergic 
control of neurite outgrowth and remodeling during development and adult 
neurogenesis: general rules and differences in diverse systems. Frontiers in 
cellular neuroscience 4, 11. 
Serrano, M., Perez-Duenas, B., Ormazabal, A., Artuch, R., Campistol, J., 
Torres, R.J., and Garcia-Cazorla, A. (2008). Levodopa therapy in a Lesch-
Nyhan disease patient: pathological, biochemical, neuroimaging, and 
	   	  References 
 
	   222	  
therapeutic remarks. Movement disorders : official journal of the Movement 
Disorder Society 23, 1297-1300. 
Shahbazian, M.D., Antalffy, B., Armstrong, D.L., and Zoghbi, H.Y. (2002). 
Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific 
differences and correlate with neuronal maturation. Human molecular 
genetics 11, 115-124. 
Sheng, M., and Kim, E. (2011). The postsynaptic organization of synapses. 
Cold Spring Harbor perspectives in biology 3. 
Shi, Y., Kirwan, P., and Livesey, F.J. (2012a). Directed differentiation of 
human pluripotent stem cells to cerebral cortex neurons and neural networks. 
Nature protocols 7, 1836-1846. 
Shi, Y., Kirwan, P., Smith, J., Robinson, H.P., and Livesey, F.J. (2012b). 
Human cerebral cortex development from pluripotent stem cells to functional 
excitatory synapses. Nature neuroscience 15, 477-486, S471. 
Shulga, A., Thomas-Crusells, J., Sigl, T., Blaesse, A., Mestres, P., Meyer, M., 
Yan, Q., Kaila, K., Saarma, M., Rivera, C., et al. (2008). Posttraumatic 
GABA(A)-mediated [Ca2+]i increase is essential for the induction of brain-
derived neurotrophic factor-dependent survival of mature central neurons. J 
Neurosci 28, 6996-7005. 
Silayeva, L., Deeb, T.Z., Hines, R.M., Kelley, M.R., Munoz, M.B., Lee, H.H., 
Brandon, N.J., Dunlop, J., Maguire, J., Davies, P.A., et al. (2015). KCC2 
activity is critical in limiting the onset and severity of status epilepticus. 
Proceedings of the National Academy of Sciences of the United States of 
America 112, 3523-3528. 
Singh, B., Henneberger, C., Betances, D., Arevalo, M.A., Rodriguez-Tebar, A., 
Meier, J.C., and Grantyn, R. (2006). Altered balance of 
glutamatergic/GABAergic synaptic input and associated changes in dendrite 
morphology after BDNF expression in BDNF-deficient hippocampal neurons. 
	   	  References 
 
	   223	  
The Journal of neuroscience : the official journal of the Society for 
Neuroscience 26, 7189-7200. 
Skene, P.J., Illingworth, R.S., Webb, S., Kerr, A.R., James, K.D., Turner, D.J., 
Andrews, R., and Bird, A.P. (2010). Neuronal MeCP2 is expressed at near 
histone-octamer levels and globally alters the chromatin state. Molecular cell 
37, 457-468. 
Smith, J.R., Vallier, L., Lupo, G., Alexander, M., Harris, W.A., and Pedersen, 
R.A. (2008). Inhibition of Activin/Nodal signaling promotes specification of 
human embryonic stem cells into neuroectoderm. Developmental biology 313, 
107-117. 
Smrt, R.D., Eaves-Egenes, J., Barkho, B.Z., Santistevan, N.J., Zhao, C., 
Aimone, J.B., Gage, F.H., and Zhao, X. (2007). Mecp2 deficiency leads to 
delayed maturation and altered gene expression in hippocampal neurons. 
Neurobiol Dis 27, 77-89. 
Sommerfeld, M.T., Schweigreiter, R., Barde, Y.A., and Hoppe, E. (2000). 
Down-regulation of the neurotrophin receptor TrkB following ligand binding. 
Evidence for an involvement of the proteasome and differential regulation of 
TrkA and TrkB. J Biol Chem 275, 8982-8990. 
Somogyi, P., and Klausberger, T. (2005). Defined types of cortical 
interneurone structure space and spike timing in the hippocampus. The 
Journal of physiology 562, 9-26. 
Soorya, L., Kolevzon, A., Zweifach, J., Lim, T., Dobry, Y., Schwartz, L., Frank, 
Y., Wang, A.T., Cai, G., Parkhomenko, E., et al. (2013). Prospective 
investigation of autism and genotype-phenotype correlations in 22q13 deletion 
syndrome and SHANK3 deficiency. Molecular autism 4, 18. 
Sorra, K.E., Mishra, A., Kirov, S.A., and Harris, K.M. (2006). Dense core 
vesicles resemble active-zone transport vesicles and are diminished following 
synaptogenesis in mature hippocampal slices. Neuroscience 141, 2097-2106. 
	   	  References 
 
	   224	  
Stein, V., Hermans-Borgmeyer, I., Jentsch, T.J., and Hubner, C.A. (2004). 
Expression of the KCl cotransporter KCC2 parallels neuronal maturation and 
the emergence of low intracellular chloride. The Journal of comparative 
neurology 468, 57-64. 
Sudhof, T.C. (2004). The synaptic vesicle cycle. Annu Rev Neurosci 27, 509-
547. 
Sudhof, T.C. (2008). Neuroligins and neurexins link synaptic function to 
cognitive disease. Nature 455, 903-911. 
Sudhof, T.C., and Malenka, R.C. (2008). Understanding synapses: past, 
present, and future. Neuron 60, 469-476. 
Sudhof, T.C., and Rizo, J. (2011). Synaptic vesicle exocytosis. Cold Spring 
Harbor perspectives in biology 3. 
Sundaram, S.K., Chugani, H.T., and Chugani, D.C. (2005). Positron emission 
tomography methods with potential for increased understanding of mental 
retardation and developmental disabilities. Mental retardation and 
developmental disabilities research reviews 11, 325-330. 
Swadlow, H.A. (2003). Fast-spike interneurons and feedforward inhibition in 
awake sensory neocortex. Cerebral cortex 13, 25-32. 
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., 
and Yamanaka, S. (2007). Induction of pluripotent stem cells from adult 
human fibroblasts by defined factors. Cell 131, 861-872. 
Takamori, S., Holt, M., Stenius, K., Lemke, E.A., Gronborg, M., Riedel, D., 
Urlaub, H., Schenck, S., Brugger, B., Ringler, P., et al. (2006). Molecular 
anatomy of a trafficking organelle. Cell 127, 831-846. 
Talos, D.M., Sun, H., Kosaras, B., Joseph, A., Folkerth, R.D., Poduri, A., 
Madsen, J.R., Black, P.M., and Jensen, F.E. (2012). Altered inhibition in 
tuberous sclerosis and type IIb cortical dysplasia. Annals of neurology 71, 
539-551. 
	   	  References 
 
	   225	  
Tao, J., Hu, K., Chang, Q., Wu, H., Sherman, N.E., Martinowich, K., Klose, 
R.J., Schanen, C., Jaenisch, R., Wang, W., et al. (2009). Phosphorylation of 
MeCP2 at Serine 80 regulates its chromatin association and neurological 
function. Proceedings of the National Academy of Sciences of the United 
States of America 106, 4882-4887. 
Thomsen, G.M., Gowing, G., Svendsen, S., and Svendsen, C.N. (2014). The 
past, present and future of stem cell clinical trials for ALS. Exp Neurol 262 Pt 
B, 127-137. 
Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A., Swiergiel, J.J., 
Marshall, V.S., and Jones, J.M. (1998). Embryonic stem cell lines derived 
from human blastocysts. Science 282, 1145-1147. 
Thouvenot, E., Urbach, S., Dantec, C., Poncet, J., Seveno, M., Demettre, E., 
Jouin, P., Touchon, J., Bockaert, J., and Marin, P. (2008). Enhanced detection 
of CNS cell secretome in plasma protein-depleted cerebrospinal fluid. Journal 
of proteome research 7, 4409-4421. 
Tomassy, G.S., Morello, N., Calcagno, E., and Giustetto, M. (2014). 
Developmental abnormalities of cortical interneurons precede symptoms 
onset in a mouse model of Rett syndrome. J Neurochem 131, 115-127. 
Tsai, S.J. (2015). Is riluzole a potential therapy for Rett syndrome? Medical 
hypotheses. 
Tsuji, O., Miura, K., Okada, Y., Fujiyoshi, K., Mukaino, M., Nagoshi, N., 
Kitamura, K., Kumagai, G., Nishino, M., Tomisato, S., et al. (2010). 
Therapeutic potential of appropriately evaluated safe-induced pluripotent stem 
cells for spinal cord injury. Proceedings of the National Academy of Sciences 
of the United States of America 107, 12704-12709. 
Tyzio, R., Nardou, R., Ferrari, D.C., Tsintsadze, T., Shahrokhi, A., Eftekhari, 
S., Khalilov, I., Tsintsadze, V., Brouchoud, C., Chazal, G., et al. (2014). 
Oxytocin-mediated GABA inhibition during delivery attenuates autism 
pathogenesis in rodent offspring. Science 343, 675-679. 
	   	  References 
 
	   226	  
Ungrin, M.D., Joshi, C., Nica, A., Bauwens, C., and Zandstra, P.W. (2008). 
Reproducible, ultra high-throughput formation of multicellular organization 
from single cell suspension-derived human embryonic stem cell aggregates. 
PLoS One 3, e1565. 
Uvarov, P., Ludwig, A., Markkanen, M., Soni, S., Hubner, C.A., Rivera, C., 
and Airaksinen, M.S. (2009). Coexpression and heteromerization of two 
neuronal K-Cl cotransporter isoforms in neonatal brain. J Biol Chem 284, 
13696-13704. 
van den Ameele, J., Tiberi, L., Vanderhaeghen, P., and Espuny-Camacho, I. 
(2014). Thinking out of the dish: what to learn about cortical development 
using pluripotent stem cells. Trends in neurosciences 37, 334-342. 
Van Der Heyden, J.C., Rotteveel, J.J., and Wevers, R.A. (2003). Decreased 
homovanillic acid concentrations in cerebrospinal fluid in children without a 
known defect in dopamine metabolism. European journal of paediatric 
neurology : EJPN : official journal of the European Paediatric Neurology 
Society 7, 31-37. 
Violante, I.R., Ribeiro, M.J., Edden, R.A., Guimaraes, P., Bernardino, I., 
Rebola, J., Cunha, G., Silva, E., and Castelo-Branco, M. (2013). GABA deficit 
in the visual cortex of patients with neurofibromatosis type 1: genotype-
phenotype correlations and functional impact. Brain : a journal of neurology 
136, 918-925. 
Volz, T.J., Farnsworth, S.J., Rowley, S.D., Hanson, G.R., and Fleckenstein, 
A.E. (2009). Age-dependent differences in dopamine transporter and 
vesicular monoamine transporter-2 function and their implications for 
methamphetamine neurotoxicity. Synapse 63, 147-151. 
Volz, T.J., Hanson, G.R., and Fleckenstein, A.E. (2006). Kinetic analysis of 
developmental changes in vesicular monoamine transporter-2 function. 
Synapse 60, 474-477. 
	   	  References 
 
	   227	  
Waites, C.L., and Garner, C.C. (2011). Presynaptic function in health and 
disease. Trends in neurosciences 34, 326-337. 
Walsh, R.M., and Hochedlinger, K. (2010). Modeling Rett syndrome with stem 
cells. Cell 143, 499-500. 
Wang, H., Chan, S.A., Ogier, M., Hellard, D., Wang, Q., Smith, C., and Katz, 
D.M. (2006). Dysregulation of brain-derived neurotrophic factor expression 
and neurosecretory function in Mecp2 null mice. The Journal of 
neuroscience : the official journal of the Society for Neuroscience 26, 10911-
10915. 
Warlich, E., Kuehle, J., Cantz, T., Brugman, M.H., Maetzig, T., Galla, M., 
Filipczyk, A.A., Halle, S., Klump, H., Scholer, H.R., et al. (2011). Lentiviral 
vector design and imaging approaches to visualize the early stages of cellular 
reprogramming. Molecular therapy : the journal of the American Society of 
Gene Therapy 19, 782-789. 
Weng, S.M., Bailey, M.E., and Cobb, S.R. (2011). Rett syndrome: from bed to 
bench. Pediatrics and neonatology 52, 309-316. 
Wernig, M., Zhao, J.P., Pruszak, J., Hedlund, E., Fu, D., Soldner, F., Broccoli, 
V., Constantine-Paton, M., Isacson, O., and Jaenisch, R. (2008). Neurons 
derived from reprogrammed fibroblasts functionally integrate into the fetal 
brain and improve symptoms of rats with Parkinson's disease. Proceedings of 
the National Academy of Sciences of the United States of America 105, 5856-
5861. 
Willemsen, M.A., Verbeek, M.M., Kamsteeg, E.J., de Rijk-van Andel, J.F., 
Aeby, A., Blau, N., Burlina, A., Donati, M.A., Geurtz, B., Grattan-Smith, P.J., 
et al. (2010). Tyrosine hydroxylase deficiency: a treatable disorder of brain 
catecholamine biosynthesis. Brain : a journal of neurology 133, 1810-1822. 
Witzmann, F.A., Arnold, R.J., Bai, F., Hrncirova, P., Kimpel, M.W., Mechref, 
Y.S., McBride, W.J., Novotny, M.V., Pedrick, N.M., Ringham, H.N., et al. 
	   	  References 
 
	   228	  
(2005). A proteomic survey of rat cerebral cortical synaptosomes. Proteomics 
5, 2177-2201. 
Woo, N.S., Lu, J., England, R., McClellan, R., Dufour, S., Mount, D.B., Deutch, 
A.Y., Lovinger, D.M., and Delpire, E. (2002). Hyperexcitability and epilepsy 
associated with disruption of the mouse neuronal-specific K-Cl cotransporter 
gene. Hippocampus 12, 258-268. 
Xie, C., Markesbery, W.R., and Lovell, M.A. (2000). Survival of hippocampal 
and cortical neurons in a mixture of MEM+ and B27-supplemented 
neurobasal medium. Free radical biology & medicine 28, 665-672. 
Xu, D., Alipio, Z., Fink, L.M., Adcock, D.M., Yang, J., Ward, D.C., and Ma, Y. 
(2009). Phenotypic correction of murine hemophilia A using an iPS cell-based 
therapy. Proceedings of the National Academy of Sciences of the United 
States of America 106, 808-813. 
Xu, X., Miller, E.C., and Pozzo-Miller, L. (2014). Dendritic spine dysgenesis in 
Rett syndrome. Frontiers in neuroanatomy 8, 97. 
Xue, Y., Ouyang, K., Huang, J., Zhou, Y., Ouyang, H., Li, H., Wang, G., Wu, 
Q., Wei, C., Bi, Y., et al. (2013). Direct conversion of fibroblasts to neurons by 
reprogramming PTB-regulated microRNA circuits. Cell 152, 82-96. 
Yamanaka, S. (2009). A fresh look at iPS cells. Cell 137, 13-17. 
Yan, Y., Shin, S., Jha, B.S., Liu, Q., Sheng, J., Li, F., Zhan, M., Davis, J., 
Bharti, K., Zeng, X., et al. (2013). Efficient and rapid derivation of primitive 
neural stem cells and generation of brain subtype neurons from human 
pluripotent stem cells. Stem cells translational medicine 2, 862-870. 
Yang, L., Soonpaa, M.H., Adler, E.D., Roepke, T.K., Kattman, S.J., Kennedy, 
M., Henckaerts, E., Bonham, K., Abbott, G.W., Linden, R.M., et al. (2008). 
Human cardiovascular progenitor cells develop from a KDR+ embryonic-
stem-cell-derived population. Nature 453, 524-528. 
	   	  References 
 
	   229	  
Yilmaz, M., Edgunlu, T.G., Yilmaz, N., Cetin, E.S., Celik, S.K., Emir, G.K., and 
Sozen, A. (2014). Genetic variants of synaptic vesicle and presynaptic plasma 
membrane proteins in idiopathic generalized epilepsy. Journal of receptor and 
signal transduction research 34, 38-43. 
Yip, J., Soghomonian, J.J., and Blatt, G.J. (2008). Increased GAD67 mRNA 
expression in cerebellar interneurons in autism: implications for Purkinje cell 
dysfunction. J Neurosci Res 86, 525-530. 
Yoshii, A., and Constantine-Paton, M. (2010). Postsynaptic BDNF-TrkB 
signaling in synapse maturation, plasticity, and disease. Developmental 
neurobiology 70, 304-322. 
Yu, J., Hu, K., Smuga-Otto, K., Tian, S., Stewart, R., Slukvin, II, and Thomson, 
J.A. (2009). Human induced pluripotent stem cells free of vector and 
transgene sequences. Science 324, 797-801. 
Yuste, R., and Bonhoeffer, T. (2001). Morphological changes in dendritic 
spines associated with long-term synaptic plasticity. Annu Rev Neurosci 24, 
1071-1089. 
Zeng, H., Shen, E.H., Hohmann, J.G., Oh, S.W., Bernard, A., Royall, J.J., 
Glattfelder, K.J., Sunkin, S.M., Morris, J.A., Guillozet-Bongaarts, A.L., et al. 
(2012). Large-scale cellular-resolution gene profiling in human neocortex 
reveals species-specific molecular signatures. Cell 149, 483-496. 
Zhang, L., He, J., Jugloff, D.G., and Eubanks, J.H. (2008). The MeCP2-null 
mouse hippocampus displays altered basal inhibitory rhythms and is prone to 
hyperexcitability. Hippocampus 18, 294-309. 
Zhang, S.C., Wernig, M., Duncan, I.D., Brustle, O., and Thomson, J.A. (2001). 
In vitro differentiation of transplantable neural precursors from human 
embryonic stem cells. Nature biotechnology 19, 1129-1133. 
Zhang, W., Peterson, M., Beyer, B., Frankel, W.N., and Zhang, Z.W. (2014). 
Loss of MeCP2 from forebrain excitatory neurons leads to cortical 
	   	  References 
 
	   230	  
hyperexcitation and seizures. The Journal of neuroscience : the official journal 
of the Society for Neuroscience 34, 2754-2763. 
Zhang, X., Huang, C.T., Chen, J., Pankratz, M.T., Xi, J., Li, J., Yang, Y., 
Lavaute, T.M., Li, X.J., Ayala, M., et al. (2010). Pax6 is a human 
neuroectoderm cell fate determinant. Cell stem cell 7, 90-100. 
Zhou, F.W., and Roper, S.N. (2010). Densities of glutamatergic and 
GABAergic presynaptic terminals are altered in experimental cortical 
dysplasia. Epilepsia 51, 1468-1476. 
Zhou, H., Wu, S., Joo, J.Y., Zhu, S., Han, D.W., Lin, T., Trauger, S., Bien, G., 
Yao, S., Zhu, Y., et al. (2009). Generation of induced pluripotent stem cells 
using recombinant proteins. Cell stem cell 4, 381-384. 
Zhou, Z., Hong, E.J., Cohen, S., Zhao, W.N., Ho, H.Y., Schmidt, L., Chen, 
W.G., Lin, Y., Savner, E., Griffith, E.C., et al. (2006). Brain-specific 
phosphorylation of MeCP2 regulates activity-dependent Bdnf transcription, 
dendritic growth, and spine maturation. Neuron 52, 255-269. 
Zhu, L., Lovinger, D., and Delpire, E. (2005). Cortical neurons lacking KCC2 
expression show impaired regulation of intracellular chloride. Journal of 
neurophysiology 93, 1557-1568. 
Zimmerman, A.W., and Connors, S.L. (2014). Neuroscience. Could autism be 
treated prenatally? Science 343, 620-621. 
Zoghbi, H.Y., and Bear, M.F. (2012). Synaptic dysfunction in 
neurodevelopmental disorders associated with autism and intellectual 
disabilities. Cold Spring Harb Perspect Biol 4. 
Zougman, A., Pilch, B., Podtelejnikov, A., Kiehntopf, M., Schnabel, C., Kumar, 
C., and Mann, M. (2008). Integrated analysis of the cerebrospinal fluid 
peptidome and proteome. Journal of proteome research 7, 386-399. 
Zuccato, C., and Cattaneo, E. (2009). Brain-derived neurotrophic factor in 
neurodegenerative diseases. Nature reviews Neurology 5, 311-322.  
ORIGINAL ARTICLE
Analysis of synaptic proteins in the cerebrospinal fluid
as a new tool in the study of inborn errors
of neurotransmission
Sofia T. Duarte & Carlos Ortez & Ana Pérez &
Rafael Artuch & Angels García-Cazorla
Received: 26 September 2010 /Revised: 22 November 2010 /Accepted: 25 November 2010 /Published online: 13 January 2011
# SSIEM and Springer 2010
Abstract In a few rare diseases, specialised studies in
cerebrospinal fluid (CSF) are required to identify the
underlying metabolic disorder. We aimed to explore the
possibility of detecting key synaptic proteins in the CSF, in
particular dopaminergic and gabaergic, as new procedures
that could be useful for both pathophysiological and
diagnostic purposes in investigation of inherited disorders
of neurotransmission. Dopamine receptor type 2 (D2R),
dopamine transporter (DAT) and vesicular monoamine
transporter type 2 (VMAT2) were analysed in CSF samples
from 30 healthy controls (11 days to 17 years) by western
blot analysis. Because VMAT2 was the only protein with
intracellular localisation, and in order to compare results,
GABA vesicular transporter, which is another intracellular
protein, was also studied. Spearman’s correlation and
Student’s t tests were applied to compare optical density
signals between different proteins. All these synaptic
proteins could be easily detected and quantified in the
CSF. DAT, D2R and GABA VT expression decrease with
age, particularly in the first months of life, reflecting the
expected intense synaptic activity and neuronal circuitry
formation. A statistically significant relationship was found
between D2R and DAT expression, reinforcing the previous
evidence of DAT regulation by D2R. To our knowledge, there
are no previous studies on human CSF reporting a reliable
analysis of these proteins. These kinds of studies could help
elucidate new causes of disturbed dopaminergic and gabaergic
transmission as well as understanding different responses to
L-dopa in inherited disorders affecting dopamine metabolism.
Moreover, this approach to synaptic activity in vivo can be
extended to different groups of proteins and diseases.
Introduction
Specialised investigations in cerebrospinal fluid can be
crucial to identify some inborn errors of metabolism.
Defects of biogenic amines (dopamine and serotonine),
GABA and glycine make up the group of diseases that are
currently considered to be inborn errors of neurotransmitters.
In these disorders, quantification of some particular CSF
metabolites (biogenic amines, GABA or glycine) is necessary
in the diagnostic process. However, although growing
evidence suggests that genetic or pathologic alterations of
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proteins involved in synaptic transmission may underlie a
number of neurological and psychiatric disorders (Südhof and
Malenka 2008; Südhof 2008; Witzmann et al. 2005;
Corradini et al. 2009; Kauer and Malenka 2007), the study
of these proteins is not normally included in the array of
investigations carried out in disorders of this kind. In vivo
measurement of synaptic activity is difficult to carry out in
humans. CSF samples are easily accessible by standard
lumbar puncture techniques. Additionally, biochemical
changes in CSF may reflect pathological alteration of CNS
physiology, as previously demonstrated (Ormazabal et al.
2005). Accordingly, CSF receives a wide variety of molecules
released by different CNS cell populations (Thouvenot et al.
2008). Several authors, including some from our group, have
shown that there is a strong variability of CSF biogenic
amines with age in children not suffering neurologic disease
(Ormazabal et al. 2005), which suggests that the same
variability may be expected when analysing synaptic proteins
related to classical neurotransmitter function.
Synaptic transmission depends on neurotransmitter pools
stored within vesicles that undergo regulated exocytosis. In
the case of dopaminergic transmission, the vesicular
monoamine transporter-2 (VMAT2) is responsible for the
loading of dopamine (DA) and other monoamines into
synaptic vesicles (Cartier et al. 2010). The DA transporter
(DAT) carries DA across the plasmalemmal membrane
from the synaptic cleft into the cytoplasm (Volz et al. 2009).
The central actions of DA are mediated by five distinct
receptors that belong to the G-protein receptor family. They
are classified as D1-like (D1 and D5) and D2-like (D2, D3
and D4), and their interaction with dopamine translates into
activation/inhibition of specific neurons and circuitries (De
Mei et al. 2009). Those suffering D2 receptor (D2 R)
genetic mutations exhibit postural abnormalities, bradykinesia
with delayed initiation of movements, impaired coordination
and prolonged periods of immobility (Glickstein and Schmauss
2001). These symptoms are also characteristic of patients
suffering from dopaminergic neurotransmission disorders.
In spite of the critical role of these proteins in dopaminergic
transmission (Fig. 1), information about procedures for
studying them in CSF is very scarce, to our knowledge.
However, such knowledge would be useful to increase
understanding of the mechanisms of disturbed dopaminergic
transmission in primary (inherited disorders of dopamine)
and secondary deficiencies.
We aimed to analyse, in the CSF of a control
population, the synaptic proteins VMAT2, DAT and D2
R. Because VMAT2 was the only protein with intracel-
lular localisation, GABA vesicular transporter (GABA
VT), which is another intracellular protein, was also
included in the study. We evaluated the correlation of
these proteins with each other and with the age of
controls. Additionally, because total CSF protein concen-
tration is known to decrease with age, we introduced this
variable in the age correlation studies.
Methods
CSF samples
The study was performed in 30 subjects (age range:
11 days–17 years; average: 1.8 years) whose CSF samples
were submitted to Hospital San Joan de Déu laboratory for
analysis under suspicion of viral or bacterial meningitis or
encephalitis. Lumbar puncture was performed in the
emergency room, and the first ten drops were used for
routine cytochemical/microbiological studies. Inflammatory
markers (C-reactive protein and procalcitonin) were also
analysed. Exclusion criteria were diagnosis of viral or
bacterial meningitis, a chronic neurological condition, and
hematic or xanthochromic CSF (blood contamination).
Samples from patients were obtained in accordance with
the Helsinki Declaration of 1964, as revised in 2000. The
ethical committee of the Hospital Sant Joan de Déu
approved the study. After collection, samples were stored
at !80°C up to the moment of the analysis.
Western blot
Western blot analysis was performed for each protein (DAT,
D2 R, VMAT2, GABA VT). A sample of 20 !L of CSF
was loaded into the gel and proteins were separated on 10%
sodium dodecyl sulphate-polyacrylamide gels and trans-
ferred to polyvinylidene difluoride (PVDF) membranes




Fig. 1 Schematic representation of the dopaminergic synapse,
illustrating the link between VMAT2 (vesicular monoamine transporter
2), DAT (dopamine transporter ) and D2 R (D2 receptor)
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branes were incubated in TBST buffer (0.02 M Tris-base,
pH7.6, 0.8% NaCl, 0.1% Tween 20) supplemented with 5%
dried skimmed milk for 60 min to block non-specific
binding. Anti-DAT extracellular loop (1:1,000; Sigma®),
anti-D2 R (1:1,000; Millipore®), anti-VMAT 2 (1:1,000;
Santa Cruz Biotechnology®), and anti-GABA VT (1:500;
Millipore®) antibodies were added, and the preparations were
incubated at 4°C overnight. The membranes were washed three
times with TBST buffer and then incubated with appropriate
anti-rabbit (1:3,000; Promega®) or anti-mouse (1:5,000;
Promega®) IgG secondary antibodies at room temperature for
1 h. The blot was then washed six times with TBST and
prepared with ECL (Pierce® ECLWestern Blotting Substract;
Thermo Scientific) for developing. Relative levels of each
protein were quantified by measuring optical densities (OD) of
the corresponding bands with Quantity One® V 4.3.1.
software.
CSF total protein concentration, procalcitonin
and C-reactive protein determination
CSF total protein and C-Reactive Protein concentrations
were measured by standard automated procedures in an
Architect ci8200 analyser (Abbott, USA). Procalcitonin
was measured by fluorimetric detection, with Brahams-
Kryptor-Atom® analyser.
Statistical analysis
Statistical analysis was performed with the SPSS 17.0
program. Spearman’s correlation test was applied to search
for associations among the OD signals of the different
proteins and with the age of controls. Multivariate linear
regression analysis was used to adjust the results by total
CSF protein concentration. Student’s t test was applied to
compare OD signals of the different proteins according to
gender. Statistical significance was considered as p<0.05.
Results
DAT, D2R, VMAT2 and GABA vesicular transporter were
clearly detectable at different ages using conventional western
blot analysis in all the CSF samples studied (Fig. 2).
VMAT2 expression measured as OD showed a statistically
significant negative correlation with age (Table 1.). Correlation
between DAT expression and age showed a strong tendency
to significance (p value=0.05). D2R expression and GABA
vesicular transporter expression did not show statistical
association with age when all the CSF samples were included
in the statistical study. However, since our sample population
was predominantly younger than 200 days (for age distribution,
see Fig. 3), we searched for a correlation between D2R and
GABA VT expression with age in this group. A significant
negative correlation was found for D2R and GABA VT. In
order to rule out interference of the expected decrease in total
CSF protein concentration with age, we adjusted these results
by total CSF protein concentration (range, 7–77 g/l; mean,
34.7; median, 31; standard deviation, 17.2. All values were
within normal limits according to different age ranges (Biou
et al. 2000)). Except for VMAT2, the relation between age
and expression of these synaptic proteins remained statistically
significant (Table 1).
No differences were observed when we compared DAT,
D2, VMAT2 and GABA VT protein expression according
to gender.
Concerning association studies among the different proteins,
OD signal of CSF, D2R, and DAT showed a statistically
significant positive correlation (Spearman’s rho correlation test
r=0.016; p=0.443), while no correlation was found between
D2 R and VMAT, or between DAT and VMAT.
Because VMAT2 is also involved in adrenaline and
noradrenaline transport, and its release can be triggered by
acutely stressful situations, we also tried to correlate
VMAT2 expression with acute phase reactants (C-reactive
protein and procalcitonin), in order to rule out the possible
influence of fever or acute disease in the expression of this
protein, since our control population was selected from a
group of children under suspicion of an active infectious
process. C-reactive protein and procalcitonin levels were
Fig. 2 D2, DAT, VMAT and GABAVT detection in the CSF by
western blot in different control samples (a), and a representation of
them according to age ranges (b)
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not related to total CSF protein concentration, nor with
VMAT 2 expression.
Discussion
We aimed to explore the possibility of detecting key
dopaminergic and gabaergic synaptic proteins in a control
population of children. To our knowledge, this is the first
report of detection of these proteins in CSF in a paediatric
population.
In spite of their low abundance compared to global CSF
proteome (Thouvenot et al. 2008), the intensity and
definition of the different bands obtained with the present
procedure (Fig. 1) lends strong support to the applicability
of this analysis in neurochemical research.
Fig. 3 Upper left Population age distribution. Upper middle, upper right, lower left, lower middle Correlation between age and synaptic proteins.
Lower right Correlation between DAT and D2
Table 1 Statistical data of the results for the synaptic proteins studied
D2 R DAT VMAT2 GABAVT
Mean (OD measure) 580,755.5 825,805.8 654,848.24 945,490.3
Standard deviation (OD measure) 302,541.9 598,210.0 385,135.9 356,870.5
Upper Limit (OD measure) 112,6336 211,5196 50,255 1,582,609
Lower Limit (OD measure) 99,224.4 87,053.87 1,574,680 395,287.83
Spearman’s Rho correlation test
between age and OD measure
r=!0.591; p=0.01
(if age under 200 days)
r=!0.329; p=0.05 r=!0.532; p=0.002 r=!0.681; p=0.002
(if age under 200 days)r=!0.482; p=0.015
(if age under 200 days)
Coefficients of a multivariate linear
regression model adjusted by
total protein concentration
"=!6139.738; p=0.007
(if age under 200 days)
"=16.294; p=0.834 "=!28.736; p=0.358 "=!5,886.624; p=0.001
(if age under 200 days)"=!8,119.042; p=0.016
(if age under 200 days)
Optic densities are expressed in arbitrary units
D2R D2 receptor, DAT dopamine transporter, VMAT2 vesicular monoamine transporter 2, GABA VT GABA vesicular transporter, OD optic
density
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The presence of transmembrane synaptic proteins in
CSF can be explained in several ways. It has been
suggested that membrane protein detection is the consequence
of extensive protease actions that cleave the fragments from
proteins that are embedded in membranes, and that these
fragments enter the CSF (Egaña et al. 2009; Zougman et al
2008). However, our study demonstrates that these proteins
are detected at the expected molecular weight, indicating
that there is no fragmentation, or at least that they are
intact in part. Harrington et al. (2009) identified the
presence of CSF membranous nanostructures, thought to
play a physiologically active role, and not merely the
result of blebbing, apocrine secretion, or apoptosis events,
or cellular debris. These structures can provide an
appropriate environment for transmembrane proteins
which are hydrophobic in nature. Their morphology is
similar to that of synaptic vesicles and exosomes; their
structure resembles that of nanotubules, cell-to-cell inter-
actions that facilitate the selective transfer of membrane
vesicles and organelles but which seem to impede the flow
of small molecules (Rustom et al. 2004). In the first
months of life, a period of intense synaptogenesis and
neuronal circuitry formation, cell-to-cell exchange of
synaptic machinery is thought to be carried out by small
dense core vesicles ("80 nm) (Sorra et al. 2006).
However, extracellular localisation of these structures is not
well documented.
Based on our previous experience with the quantification
of biogenic amines in a population of children without
neurological disease (Ormazabal et al. 2005) who exhibited
a decrease from the first days of life until reaching adult
age, we aimed to learn whether the same tendency was
observed with the synaptic proteins included in the study.
For DAT, D2R and GABAVT, it was possible to establish
a statistically significant relationship, particularly in the
group of children under 6 months of age from whom
most of our sample was drawn. Age-related changes in
DAT functionally active protein have been described in
rats (Volz et al. 2009), showing a decrease between young
adolescent rat levels and adult levels. Interestingly, in the
same report, no difference between VMAT 2 immunore-
activity in the two groups was found, although conflicting
data had previously been published (Volz et al. 2006).
Furthermore, because VMAT2 is involved in fast neuro-
transmission, its regulation could appear to be related to
rapid communication needs and not to age. Another result
that deserves discussion is the relationship discovered
between D2 and DAT expression. Numerous studies have
supported the notion that DAT is subjected to dynamic
regulation in the plasma membrane, and this regulation has
been extensively reviewed by Eriksen et al. (2010). There is
strong evidence that D2 R causes an increase in dopamine
uptake through an increase in DAT surface expression.
Additionally, loss of D2R/DAT co-immunoprecipitation has
been described in schizophrenia, suggesting a role for the
loss of the interaction in the disease process (Bolan et al.
2007).
Currently, investigations are underway of CSF in relation
to disorders of suspected neurometaolic origin; these
include examination of cytochemistry (cells, glucose,
proteins), lactate, amino acids, biogenic amine metabolites,
pterins and 5-methyltetrahydrofolate. However, only a few
disorders can be detected by means of these analyses
(García-Cazorla et al. 2010). Furthermore, the diagnosis of
monogenic defects of dopaminergic neurotransmission is
almost exclusively based on the quantitative determination
of their metabolites in CSF (Marín-Valencia et al. 2008).
Secondary deficiencies of dopamine are found in about
10% of patients who undergo a lumbar puncture in the
diagnostic work-up of a suspected neurometabolic disorder
(García-Cazorla et al. 2007; Van Der Heyden et al. 2003).
Disorders such as mitochondrial diseases (García-Cazorla
et al. 2008) and Lesch-Nyhan disease (Serrano et al. 2008)
are amongst the main known causes of secondary deficiencies.
The analysis of these and other synaptic proteins is expected
to be useful to both increased understanding of the mecha-
nisms of disturbed neurotransmission and identification of
new causes of dopaminergic defects. Concerning primary
deficiencies such as tyrosine hydroxylase deficiency, this
approach could be useful to improving the understanding
of the variable response that patients have to L-dopa
therapy (from normalisation to almost absent effect)
(Willemsen et al. 2010), but we need further data to
document this hypothesis.
To conclude, we report the detection of transmembrane
synaptic proteins in the CSF of a population of children
without neurological disorders. This approach was made as
a means of monitoring neurotransmitter genetic disease
outcome and response to treatment, but its applications can
be extended to the investigation of a growing group of
neurological and psychiatric disorders related to neuro-
transmission. The proteins included in this study were
chosen because of their relevance for dopaminergic and
gabaergic transmission, but there are many other proteins of
interest that can be selected for analysis with this
methodology.
The findings reported here deserve further investigation,
especially in the field of CSF-neuron and inter-cellular
interactions, in order to better understanding of their
physiological implications in the developing brain and
their pathophysiological role in disease states. Significant
correlation with age was found with D2R, DAT and
GABA VT expression, as expected from the previously
reported decrease of biogenic amines in a paediatric
population. Coordinated regulation of DAT by stimulation of
D2 R is further reinforced by our results.
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Abstract
Objective: Rett Syndrome is a progressive neurodevelopmental disorder caused mainly by mutations in the gene encoding
methyl-CpG-binding protein 2. The relevance of MeCP2 for GABAergic function was previously documented in animal
models. In these models, animals show deficits in brain-derived neurotrophic factor, which is thought to contribute to the
pathogenesis of this disease. Neuronal Cation Chloride Cotransporters (CCCs) play a key role in GABAergic neuronal
maturation, and brain-derived neurotrophic factor is implicated in the regulation of CCCs expression during development.
Our aim was to analyse the expression of two relevant CCCs, NKCC1 and KCC2, in the cerebrospinal fluid of Rett syndrome
patients and compare it with a normal control group.
Methods: The presence of bumetanide sensitive NKCC1 and KCC2 was analysed in cerebrospinal fluid samples from a
control pediatric population (1 day to 14 years of life) and from Rett syndrome patients (2 to 19 years of life), by immunoblot
analysis.
Results: Both proteins were detected in the cerebrospinal fluid and their levels are higher in the early postnatal period.
However, Rett syndrome patients showed significantly reduced levels of KCC2 and KCC2/NKCC1 ratio when compared to
the control group.
Conclusions: Reduced KCC2/NKCC1 ratio in the cerebrospinal fluid of Rett Syndrome patients suggests a disturbed process
of GABAergic neuronal maturation and open up a new therapeutic perspective.
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Introduction
Rett syndrome (RTT) is an X-linked neurodevelopmental
disorder with an incidence of 1:10000 live female births and is
one of the leading causes of mental retardation and autistic
behavior in females [1]. Loss-of-function mutations in the gene
encoding methyl-CpG binding protein 2 (MeCP2) cause most
cases of RTT. Individuals affected with RTT experience normal
development up to the age of 6–18 months, at which time they fail
to acquire new skills and enter a period of motor regression [2].
Autistic features are a hallmark of this disorder and epilepsy is
frequent [3]. RTT patient brain does not show obvious signs of
neurodegeneration, atrophy, gliosis, demyelination, or neuronal
migration defects [4,5], suggesting that neurological symptoms
may primarily stem from subtle defects of subcellular compart-
ments such as dendrites, axons, or synaptic structures [6]. MeCP2
is a transcriptional regulatory protein, and in its absence, a large
number of genes exhibit abnormal expression with implications in
the balance between synaptic excitation and inhibition [7,8].
MeCP2 might be particularly important to GABAergic function
and there is evidence that the expression of MeCP2 is
approximatelly 50% higher in GABAergic neurons when com-
pared to non GABAergic neurons. Mice with conditional deletion
of Mecp2 in GABAergic neurons initially show normal behavior
but in the course of development start displaying forepaw
stereotyped movements, compulsive grooming, impaired motor
coordination, learning/memory deficits, abnormal EEG hyperex-
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citability, severe respiratory dysrhythmias and premature lethality
[8].
c-aminobutyric acid (GABA) is the main inhibitory neurotrans-
mitter in the adult brain. During early development, activation of
the chloride- permeable, postsynaptic, GABAA receptors (GA-
BAA-R) can induce depolarization and the basal intracellular
chloride concentration is determinant for the action of GABA in
the developing neurons [9]. Two major contributors to intracel-
lular chloride concentration are NKCC1 (Na+, K+, 2Cl2
cotransporter, that accumulates chloride in the cell), and KCC2
(K+, Cl2 cotransporter, that extrudes chloride). Several lines of
research correlate epileptogenesis with altered function of NKCC1
and KCC2 [10,11]. In vitro, experiments suggest that bumetanide,
a potent NKCC1 inhibitor, can increase GABAergic inhibition, in
combination with phenobarbital [12]. Bumetanide has also been
reported useful in a neonatal patient with seizures [13] and in
autistic children [14].
Moreover, the brain of MeCP2 deficient animal models shows
deficits in brain-derived neurotrophic factor [15] (BDNF), which is
thought to contribute to the pathogenesis of RTT. BDNF can also
promote the functional maturation of GABAA-R mediated
responses by inducing upregulation of KCC2 [16,17,18].
Human age related changes in GABAA-R physiology remain
controversial, although neuropathological studies have already
identified postnatal developmental changes of NKCC1 and KCC2
cortical expression [18]. The detection of synaptic proteins in the
cerebrospinal fluid (CSF) gives us the possibility to indirectly access
synaptic composition and alterations, using the CSF of patients
with disorders related to neurotransmission, with the advantage of
performing these studies in vivo [19].
We hypothesize that changes in BDNF expression levels or the
direct effect of the underlying genetic mutation can interfere with
the normal expression of NKCC1 and KCC2 leading to a
reduction in the KCC2/NKCC1 ratio, characteristic of the
immature GABAergic system. A comparison of NKCC1 and
KCC2 protein levels in the CSF of patients affected with RTT and
a control population was made in order to address this question.
Patients and Methods
Patients and Controls
Sixteen patients with RTT were recruited to this study, aged
between 2 to 19 years at the moment of CSF collection. Patients’
clinical characteristics are summarized in table 1. Patients without
a documented mutation fulfilled clinical criteria for RTT
according to the last updated revision [20]. The control study
was performed in 67 subjects (age range: 1 day - 14 years; mean:
740 days; female: 27; male: 40) whose CSF samples were
submitted to Hospital San Joan de Deu (HSJD) laboratory under
suspicion of viral or bacterial meningitis or encephalitis. Exclusion
criteria were: diagnosis of viral or bacterial meningitis, neurologic
disease, and hematic or xantocromic CSF (blood contamination).
CSF Samples
CSF samples were collected by lumbar puncture as previously
described [21]. They were obtained after parent’s written
informed consent and in accordance with the Helsinki Declaration
of 1964, as revised in 2000. The ethical committee of HSJD
approved the study. After lumbar puncture, the first ten drops
were used for routine cytochemical/microbiological studies and
then CSF was immediately stored in 4 aliquots at 280uC until the
moment of analysis. Biogenic amines metabolites and synaptic
proteins were studied using the following 20 drops.
NKCC1 and KCC2 expression levels were analyzed by western
blot. Twenty mL of CSF were loaded on gel and proteins were
separated on a 10% sodium dodecyl sulphate-polyacrylamide gel
and transferred to polyvinylidene difluoride membrane (Amer-
shamTM HybondTM –ECL, GE Healthcare). Membranes were
blocked in TBST buffer (0.02 M Tris-base, pH7.6, 0.8% NaCl,
0.1% Tween 20) with 5% dry skimmed milk for 60 min at room
temperature. Anti-NKCC1 (1:500; Santa Cruz BiotechnologyH)
and anti-KCC2 (1:500; MilliporeH) antibodies were added and
incubated at 4 uC overnight. Membranes were washed three times
with TBST buffer followed by incubation with appropriate anti-
rabbit (1:3000, PromegaH) IgG secondary antibody at room
temperature for 1 h. The blot was then washed six times with
TBST and signal was revealed with ECL (PierceH ECL Western
Blotting Substract, Thermo Scientific). Relative levels of each
protein were quantified by measuring optical densities (OD) of the
corresponding bands with Quantity OneH V 4.3.1.software.
Statistical Analysis
Statistical analysis was performed using IBM Statistical Package
for the Social Sciences (IBM SPSS Statistics Version 19.0, SPSS
Inc: Chicago, IL). A significance level of.05 was used in all
analyses. Outlier analysis was done taking into account the
primary variable in the study – healthy/RTT. Outliers (defined as
values 1.5 times lower than the 1st quartile or 1.5 times higher
than the 3rd quartile) [22] were found in 8 cases (1 Rett patient, 7
healthy controls) for KCC2/NKCC1 ratio, 4 cases for NKCC1
(1 Rett patient, 3 healthy controls) and in 1 case (healthy control)
for KCC2. Outliers were excluded from the respective analyses.
Non-parametric tests were applied when possible for age,
NKCC1 and KCC2, since the assumption of normal distribution
was not fulfilled for these variables.
Results
Total CSF protein concentration values (M= 33.27, SD=19.04,
range: 7–73 g/l) were within normal limits according to different
age ranges [23]. Clinical and genetic features of RTT patients are
described in table 1. NKCC1 and KCC2 western blot analysis
were performed on the CSF of controls and RTT patients. CCCs
were detected in the CSF of this population, at the expected
molecular weight (Figure 1A). Considering the reported sexually
dimorphic expression of KCC2 and GABA function in the
substantia nigra [24] it was decided to control for gender in all
reported analysis.
Furthermore, the homogenous distribution of the demograph-
ical variable age was verified with Mann-Whitney Test (U).
Controls (M= 746.00 days, SD=1075.89) were significantly
(U=932.00, p,.001) younger than RTT patients
(M=3444.69 days, SD=2173.59) therefore we have controlled
for this variable in all reported analysis (table S1).
KCC2 Expression is Decreased in the CSF of Rett
Syndrome Patients
As patients grew older their OD signal of KCC2 in the CSF
decreased. Partial correlation analysis was performed to clarify the
relationship between age and the OD signal of the different
synaptic proteins (NKCC1, KCC2) in each group (RTT,
Controls), controlling for the effect of gender. A negative
correlation between age and the OD signal of KCC2 (r
(74) =2.292, n= 80, p,.05) has been clearly identified in our
data, i.e. as the participants grew older their OD signal of KCC2
decreased, even when controlling for the effect of gender. Meaning
that, KCC2 levels decrease in CSF throughout aging. However,
Cation Chloride Cotransporters in Rett Syndrome
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concerning the OD signal of NKCC1 this correlation did not
reach statistical significance (r (74) =2.207, p..05). Interestingly,
if the effect of gender was not taken into consideration, a strong,
negative correlation between age and the OD signal of KCC2 (rs
(80) =2.509, p,.0001) and NKCC1 (rs (78) = 2.472, p,.0001)
would have been identified in our data, i.e. as the participants
grew older their OD signals of KCC2 and NKCC1 decrease.
Rett Patients Present a Significantly Lower OD Signal of
KCC2 than Healthy Controls (Figure 1B)
To determine whether there were statistically significant
differences in the OD signal of the different synaptic proteins
(NKCC1, KCC2) between healthy controls and RTT patients, a
between-subjects MANCOVA was performed, controlling for the
effects of age and gender. This analysis revealed a statistically
significant difference between healthy controls and RTT patients,
F (1, 73) = 6.99, p,.01, gp
2= .087 even when controlling for the
possible confounding effects of age and gender. The subsequent
follow-up Univariate ANCOVAs run to specify the characteristics
of this finding revealed that RTT patients presented a significantly
lower OD signal of KCC2 (M=81383.80, SD=82370.99; F (1,
76) = 12.28, p,.001, gp
2= .139) than healthy controls
(M=692663.52, SD=425753.91). Notwithstanding, NKCC1 ex-
pression does not differ significantly between patients
(M=307834.25, SD=162592.59) and healthy controls,
(M=608703.27, SD=416157.33; F (1, 74) = 1.87, p..05).
KCC2/NKCC1 Ratio is Decreased in the CSF of Rett
Syndrome Patients
To determine whether there were significant differences in the
ratio of the two synaptic proteins (KCC2/NKCC1) on the CSF of
the healthy population and RTT patients a between-subjects
Table 1. Clinical and laboratory features of Rett Syndrome patients included in the study.
Age (Years
at CSF
collection) Genetic screening Epilepsy
Medication (when LP
was performed) Respiratory anomalies
KCC2/NKCC1 (optical
densities)
1 2 MECP2 screened, no
alteration found
No NO AED No 36795/310023
2 2 P.Y141X Refractory Epilepsy
Generalized seizures
NO AED No 0/242968
3 2 P.R270X Refractory epilepsy No AED Severe syperventilation bursts
and apneas
0/323889
4 4 P302H, 905C.T Generalized seizures from 2
years of life
No AED Hyperventilation bursts 167071/228307
5 5 P.R306C Epileptic status Generalized
seizures from 4 years of life
VPA Hyperventilation bursts and
apneas
0/169395
6 6 MECP2, CDKL5
screened, no
alteration found
Generalized seizures since 8
years of life
CBZ Hyperventilation bursts 177102/257110





No AED No 28646/296735
8 8 P.R255X Generalized seizures from
2 years of life
VPA Hyperventilation bursts and
apneas
15584/342592
9 9 MECP2, CDKL5
screened, no
alteration found
Refractory epilepsy VPA TPM Severe Hyperventilation and
apneas
0/54010
10 10 P.R306C Absences and partial seizures
from 8 years
CBZ Hyperventilation bursts 155391/621440
11 11 DEL EX.1–2 Generalized seizures from 8
years
No AED Hyperventilation 91959/527745
12 16 MECP2, CDKL5
screened, no
alteration found
Generalized seizures from 11
years of life









seizures from 14 years of life
VPA CBZ Hyperventilation bursts 164531/259927
14 16 P.R294X Generalized Seizures from 6
years of life
CBZ LEV Hyperventilation bursts 219795/281395
15 18 MECP2, CDKL5
screened, no
alteration found
Partial seizures CBZ Hyperventilation 7000/535292
16 19 P.R294X Partial, secondarily
generalized and absences
CBZ Hyperventilation bursts and
apneas
604155/28867
DEL: Deletion. LP: Lumbar Puncture. AED: Anti epileptic drugs. VPA: Valproic Acid. CBZ: Carbamazepine. LEV: Levetiracetam. TPM: Topiramate.
doi:10.1371/journal.pone.0068851.t001
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ANCOVA was performed, controlling for the effect of age and
gender. This analysis revealed a statistically significant difference
between Healthy controls and RTT patients, F (1, 70) = 26.56,
p,.001, gp
2= .28 even when controlling for the possible
confounding effect of age and gender (figure 2B and 2C). RTT
patients presented a significantly lower KCC2/NKCC1 ratio
(M= .26, SD= .30) than Healthy controls (M=1.08, SD= .56).
Even if the effects of age and gender would not have been
controlled for in the analysis the decrease in KCC2/NKCC1 ratio
was still significant (F (1, 70) = 30.08, p= .001, gp
2= .29).
Discussion
In this study, we demonstrate reduced KCC2 levels and
KCC2/NKCC1 ratio in the CSF of RTT patients. These findings
suggest that altered inhibitory GABA function can underlie the
pathophysiology of RTT and also play a role in the epileptogenesis
of this neurodevelopmental disorder, in which epilepsy is present
in around 70% of patients [3]. Detection of transmembrane
synaptic proteins in the CSF is a useful tool in the study of
neurotransmission disorders, as recently reported by our group
[19]. Despite their low abundance compared to the global CSF
Figure 1. NKCC1 and KCC2 Cotransporters in the CSF of Rett Syndrome (RTT) Patients and Controls. (A) Immunoblot results in RTT
patients and controls. Numbers refer to the patient ID numbers of Table 1. Comparison of patients and age matched controls. (B) Mean Optic
Densities of NKCC1 and KCC2 Cotransporter Proteins for Rett Patients and Controls suggesting discrepant cotransporter levels between Patients and
Controls supported by the respective MANCOVA (F (1, 73) = 6.99, p,.01, gp
2= .087). Error bars represent 95% Confidence Interval. *p,.01.
doi:10.1371/journal.pone.0068851.g001
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proteome [25], the proteins here studied (NKCC1 and KCC2)
were readily detected and at the expected molecular weight.
Harrington and co-workers [26] identified the presence of CSF
membranous nanostructures that can provide an appropriate
environment for transmembrane proteins, which are hydrophobic
in nature. Their morphology is similar to that of synaptic vesicles
and exosomes; their structure resembles that of nanotubules, cell-
to-cell interacting structures that facilitate the selective transfer of
membrane vesicles and organelles but which seem to impede the
flow of small molecules [27]. The intensity and resolution of the
different bands obtained with the immunoblot procedure
(Figures 1A and 2A) strongly supports the applicability of this
analysis in neurochemical research. To our knowledge, this is the
first report of detection of cation chloride cotransporters in CSF.
CSF turnover ratio and the extent of central nervous system cell
death and synaptic pruning can influence circulating protein levels
but these factors are likely to affect both proteins, NKCC1 and
KCC2, equally. During the first months of postnatal life there is a
period of intense synaptogenesis that subsequentially decreases.
This is probably the cause for the reduction of protein levels in
CSF observed during the first year of life. In fact, regarding
transmembrane proteins like NKCC1 and KCC2, we have
observed the same tendency that also was detected with other
synaptic proteins [19]. The same phenomena could explain the
fact that, in the CSF, both cation chloride cotransporters exhibit a
reduction and KCC2 does not increase in the CSF, as was
expected from previous studies in brain tissue [28,29]. Experi-
mental limitations in humans have been an obstacle in obtaining
direct evidence of age-related changes in GABAA-R physiology
[28].
In mice, loss of MeCP2 leads to reduced expression of BDNF
after birth [15] and in humans evidence of BDNF reduction in
RTT has also been detected [29]. The effects of BDNF on
neurotransmission in developing and mature neurons have been
partly associated with the regulation of GABAergic transmission.
Apart from its effects on GABAergic innervation [30], BDNF can
also promote the functional maturation of GABAA-R mediated
responses by inducing upregulation of KCC2 [16,17]. The
imbalance between excitatory and inhibitory functions in RTT
has been associated with reduced BDNF [31] and GABA levels,
decreased expression of GABA receptor subunits [32], reduced
expression of the enzymes glutamic acid decarboxylase 67 and
glutamic acid decarboxylase 65 [8], reduced number of glutama-
tergic synapses [33] and reduced strength of basal inhibitory
rhythms [34]. Moreover, exogenous BDNF has been shown to
rescue synaptic dysfunction in Mecp-2 null mice. However, the
mechanism by which reduced levels of BDNF contribute to disease
and also to the phenotypical rescue is not completely understood
[31].
Our results suggest an immature pattern of GABAergic
neurotransmission in RTT patients, by revealing a dysregulation
on the KCC2/NKCC1 ratio (the two major contributors to
intracellular chloride concentration) and this evidence in humans
is in accordance with the relevance of MeCP2 for GABAergic
function described in animal models [8]. An imbalance between
excitatory and inhibitory synaptic events, in the brain of children
with neurodevelopmental disorders that have epilepsy and autism
as key features, is a postulated general mechanism. Moreover,
KCC2/NKCC1 ratio dysregulation is a particularly interesting
specific molecular change, already described for diseases like
tuberous sclerosis [35].
Conclusions
We describe a significant decrease of KCC2 in the cerebrospi-
nal fluid of Rett patients. A major advantage of doing these in vivo
studies in children with severe neurologic disorders like RTT, is
that it allows to search for disturbances in the normal develop-
mental pattern. Therefore, our findings might have implications
for the understanding of RTT pathophysiology, considering that
KCC2 is a neuronal specific protein with a key role for neuronal
electrical function and structure, properties that are known to be
altered in Mecp2 mutated neurons. Moreover, these results could
bring light to new therapeutic approaches, particularly through the
pharmacological manipulation of the cation chloride cotranspor-
ters. Further studies in the MECP2 knockout model and other
models to study the disease process are needed to explore these
possibilities.
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1  Introduction
Pluripotent stem cells (PSCs) are cells capable to differen-
tiate and give rise to every tissue cell in the human body
[1]. Until recently, these cells could only be isolated from
the inner cell mass of the blastocyst, being designated
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embryonic stem cells (ESCs) [2, 3]. However, in 2007,
Shinya Yamanaka and co-workers were able to reprogram
human somatic cells into the pluripotent stem cell state
using transfection of four transcription factors (OCT4,
SOX2, KLF4, c-MYC). These human induced pluripotent
stem cells (iPSCs) brought many expectations into the
biomedical field due to their potential applications in dis-
ease modeling, drug and toxicity screening, patient-tai-
lored therapies and engineered tissues [4], potentially pre-
venting immunosuppression and graft rejection, and
paving the way for the next generation of personalized
medicine [5, 6].
Countless protocols for in vitro expansion and differ-
entiation of human PSCs have been developed since then,
which typically comprise the use of undefined culture
components [7–12]. Problematically, this presents many
difficulties to the translation of these protocols from basic
research to tangible applications [13]. For example, the
use of products from animal origin renders the produced
cells unsuitable for clinical applications due to the risk of
cross-species contamination and immunogenic reactions
[14, 15]. Furthermore, the use of undefined culture condi-
tions poses barriers to the understanding of the biological
processes involved in pluripotency and lineage specifica-
tion and compromises the reproducibility of these culture
systems. Therefore, there is an urgent need to develop
methods and protocols that use defined culture condi-
tions and allow reproducibility when generating specific
cell populations from PSCs.
In particular, neural specification can be induced by
the synergistic inhibition of both Activin/Nodal and BMP
signaling pathways with small molecules resulting in
blockage of mesoderm, endoderm and trophoblast lineag-
es while allowing neuroectodermal specification [7, 16].
Despite being relatively efficient and straightforward, this
method uses substrates and medium components of ani-
mal origin and of undefined nature (e.g. matrigel and
serum replacements). Chemically defined substrates
based on proteins, polymers and hybrids of polymers with
active biomolecules have been developed, exhibiting low
lot-to-lot variability and presenting high reproducibility
[17–19]. Truncated, recombinant vitronectin (VTN) conju-
gates, in particular, have been used as a support for robust
expansion and differentiation of human PSCs under stan-
dardized and totally defined culture conditions [19–22].
Such system would greatly benefit neural commitment
protocols, allowing the foundation of defined settings for
in vitro studies of neural development and ensuring reli-
able methods for the anticipated biomedical applications.
In this study, we have validated the use of defined cul-
ture conditions to achieve an efficient and reproducible
neural commitment of human PSCs. A defined culture
medium supplemented with chemical inhibitors of BMP
and TGF! signaling, together with vitronectin for adher-
ent growth, was shown to be sufficient to generate neural
precursors (NPs) expressing SOX1, PAX6, and NESTIN.
As a proof-of-concept, we have validated the neural com-
mitment protocol using different cell lines, including
patient-specific Rett syndrome-derived iPSCs. This neu-
rological disorder is characterized by autistic-like behav-
iors and is commonly caused by mutations in the X-linked
methyl CpG binding protein 2 (MECP2) gene, which is
vital for proper functioning of the brain and acts as one of
the many biochemical switches for gene expression [23,
24]. Consequently, abnormal expression of this gene caus-
es atypical brain function, leading to many disease
processes that are mostly uncharacterized [25, 26]. Thus,
this study also expects to contribute with a novel method-
ology capable to provide patient-specific neural cells that
could be used to gain a better understanding of the dis-
ease. Furthermore, the ability to recapitulate the develop-
ment of the human nervous system in vitro will provide
important insights on the mechanisms involved in the
maturation of specific neural cell types, making this
approach transversal to other related areas in neurodevel-
opmental research. 
2  Materials and methods
2.1  Cell lines
Two human iPSC lines obtained from healthy donors 
(46, XY) were used: WT-Évora F0000B13 and iLB-C1-30
m-r12. WT-Évora was kindly provided by TCLab (Évora,
Portugal), and iLB-C1-30 m-r12 cells were derived at the
University of Bonn, Germany. These cell lines were repro-
grammed from fibroblasts through retroviral transduction
of human genes OCT4, SOX2, c-MYC and KLF4 [4], and
were used as wild type controls to verify the robustness
of the neural commitment method. The EMC23i cell line
was generated at the iPSC Facility, Erasmus Medical
Center, Rotterdam, using engineered color-coded lentivi-
ral vectors (as described by Warlich and coworkers [27]),
and was derived from a patient (46, XX) with a MECP2
mutation (R306C). Cells were routinely evaluated for
karyotype abnormalities by conventional cytogenetics
using the services of Genomed SA (Lisbon, Portugal).
Biological samples collected for this work were obtained
following rigorous national and European ethical guide-
lines and informed consent from donor or patient’s legal
guardian.
2.2  Feeder-free culture of human iPSCs
Human iPSCs were thawed and cultured in mTeSRTM1
medium (StemCell TechnologiesTM), on MatrigelTM (BD)-
coated, SynthemaxTM (Corning®)-coated, or Vitronectin
(VTN-N, Gibco®)-coated plates. Medium was changed
daily and cells were passaged every three to four days,
using EDTA dissociation buffer 0.5!mM (Gibco®, diluted
in sterile PBS) with a split-ratio of 1:4 [21].
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2.3  Neural induction of human iPSCs
When human iPSC cultures were nearly confluent, two
different strategies were followed for neural induction,
based on Chambers et al [7] and Shi et al [28]. The first pro-
tocol was performed using DMEM/serum replacement
(SR)-based differentiation medium (KO-DMEM medium
(Gibco®) supplemented with 20% v/v KO-SR (Gibco®), 1%
v/v non-essential aminoacids (Gibco®), 1!mM L-gluta-
mine (Gibco®), 0.1!mM !-mercaptoethanol (Sigma®) and
1% v/v Penicillin/Streptomycin [PenStrep, Gibco®]), while
the other was performed in N2B27 medium (50% v/v
DMEM/F12/N2 medium (DMEM-F12 (Gibco®), supple-
mented with 1% v/v N2 (Gibco®), 1!mM L-glutamine,
1.6!g/L Glucose (Sigma®), 1% v/v PenStrep, and 20!µg/mL
Insulin [Sigma®]) and 50% v/v of B27 medium (Neurobasal
(Gibco®) supplemented with 2% v/v B27-supplement
(Gibco®), 1!mM glutamine and 1% v/v [PenStrep]). In both
cases, media formulation was supplemented with 10!µM
SB-431542 (SB) and 100!nM LDN-193189 (LDN) (both from
Stemgent®), as outlined in Fig.!1A.
2.4  Neuronal differentiation
At day 12 of differentiation, cells were passaged with
EDTA dissociation buffer (0.5!mM) and re-plated onto
laminin (Sigma®)-coated plates (split ratio of 1:3) [28].
When neural rosettes were observable (around day 14),
N2B27 was supplemented with 10!ng/mL of bFGF (Pepro-
tech®) for two to four days. At day 17, cells were passaged
using EDTA to new laminin-coated plates (split ratio of
1:3). Cells were then cultured until day 28–30 in N2B27
medium without the addition of small molecules or any
other factors. Finally, cells were split with accutase (Sig-
ma®) and plated at a density of 100!000 cells/cm2. Cells
were further cultured until day 150 with medium replace-
ment every other day (Supporting information, Fig.!S1).
2.5  Immunofluorescence staining 
of intracellular markers
We performed immunofluorescence staining as previous-
ly described [29]. Briefly, cells were fixed in paraformalde-
hyde (PFA, Gibco®) 4% for 30!min, followed by blocking for
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Figure 1. Neural commitment of human PSCs. (A) Neural induction was initiated when cells reached confluence and two strategies were tested in parallel.
The first strategy involved the use of serum replacement-based medium (KO-DMEM/SR) for the first four days and a gradual increase in N2 medium
thereafter. In the second case, N2B27 defined medium was used for 12 days. Small molecule inhibitors of SMAD signaling (SB and LDN) were used as
described in the scheme. (B) Human PSCs were cultured in adherent conditions (i) until confluence (ii). A neuroepithelial sheet of cells could be observed
after neural induction (iii). (C) and (D) PSC colonies stained for pluripotency markers OCT4 and SOX2 (scale bars: 100 µm). (E) Quantification of
immunofluorescence images for pluripotency markers OCT4 and SOX2 at the start of neural commitment. (F) Immunofluorescence staining for pluripo-
tency marker OCT4 after 12 days of differentiation in N2B27 medium and in serum replacement (KO-SR) conditions (scale bars: 100 µm). (G) PAX6 and
NESTIN immunostaining for differentiated cells in N2B27 or KOSR-based medium (scale bars: 50 µm). (H) Quantification of OCT4- and PAX6-positive
cells for the two medium compositions (KOSR or N2B27) used for neural commitment. *p-value<0.05. Results are presented in this figure as mean ± SEM
of three independent experiments, and were obtained using iLB-C1-30 m-r12 PSCs and matrigel coating. 
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60!minutes at room temperature. Primary antibodies were
then added and left at 4°C overnight. Secondary antibod-
ies (goat anti-mouse or goat anti-rabbit IgG, Alexa Fluor®
–488 or –546, 1:500 v/v dilution, Molecular Probes®) were
prepared and incubated with cells for 1!h at room tem-
perature. DAPI (Sigma®) was used to counterstain cell
nuclei. Primary antibodies used were FoxG1 (1:100,
Abcam®), GFAP (1:100, Millipore), Ki-67 (1:100, BD),
MAP2 (1:400, Abcam®), NANOG (1:5000, Millipore),
NESTIN (1:400, R&DTM), OCT4 (1:500, Millipore), OTX1/2
(1:100, Millipore), PAX6 (1:400, Covance®), SOX2 (1:200,
R&DTM), Tuj1 (1:5000, Covance®), VGLUT1 (1:300, Synap-
tic Systems) and ZO-1 (1:100, Novex®).
2.6  Quantification of immunofluorescence images
Quantification of OCT4, SOX2 and PAX6-expressing cells
was performed using Fiji® software (for ImageJ). A macro
was developed to perform conversion of the original
image to eight bits, adjustment of a threshold, watershed
treatment, and definition of parameters for particle analy-
sis. Firstly, total cell nuclei were counted using DAPI
images. Then, PAX6, SOX2 and OCT4 positive nuclei
were counted in the same way and the ratio between pos-
itive cells and the total number of cells was calculated. 
2.7  Flow cytometry analysis
For staining, approximately 500 000 cells were resus-
pended in FACS buffer with the diluted primary antibody,
and incubated for 15!min at room temperature in the dark.
Cells were then washed and resuspended in PBS for later
analysis by flow cytometry (FACSCalibur, Becton Dickin-
son). Antibodies used for flow cytometry were SSEA-4-PE
(1:10), and Tra-1-60-PE (1:10) (Stemgent®).
2.8  Quantitative real-time PCR
Total RNA was isolated from cells at different stages of
neural commitment (day 0, 3, 6, 9 and 12) using a high
pure RNA isolation kit (Roche) according to manufactur-
er’s instructions. cDNA was synthetized from RNA, start-
ing amount of 1!µg, using a transcriptor first strand cDNA
synthesis kit (Roche). Taqman® Gene Expression Assays
(20X) were selected for PAX6, SOX1, NANOG,
OCT4/POU5F1 and GAPDH (Applied Biosystems, Sup-
porting information, Table S2). All other genes (FGF5,
NESTIN, !-Tubulin III) were analyzed using SYBR® green
chemistry (primers are presented in Supporting informa-
tion, Table S1). PCR-reactions were run in duplicate,
using the StepOneTM RT-PCR System (Applied BioSys-
tems). Reactions were normalized to the housekeeping
gene GAPDH and results analyzed with StepOne soft-
ware.
2.9  Electrophysiology 
Whole-cell recordings were performed at room tempera-
ture in artificial cerebrospinal fluid (aCSF) containing 
(in mM): 124 NaCl, 3 KCl, 1.25 NaH2PO4, 26 NaHCO3, 
1 MgCl2, 2 CaCl2, 10 Glucose, pH 7.4 (gassed with 95% O2,
5% CO2). Patch pipettes (4–9! MO) were pulled from
borosilicate glass electrodes (1.5! mm outer diameter,
0.86!mm inner diameter, Harvard Apparatus) with PC-10
Puller (Narishige Group) and filled with an intracellular
solution containing (in mM): 125 K-gluconate, 11 KCl, 
0.1 CaCl2, 2 MgCl2, 1 EGTA, 10 HEPES, 2 MgATP, 
0.3 NaGTP, 10 phosphocreatine, pH 7.3, adjusted with
KOH (1!M), 280–290!mOsm. Cells were viewed using a
Carl Zeiss Axioskop 2FS upright microscope equipped
with a differential interference contrast-infrared (DIC-IR)
CCD video camera (VX44, Till Photonics) and screen and
recorded with an EPC-7 electrical amplifier (List Biologic).
Signals were low-pass filtered using a 3- and 10-kHz
three-pole Bessel filter of an EPC-7 amplifier, digitized at
10!kHz using a Digidata 1322A board, and registered by
the Clampex software version 10.2 (Molecular Devices).
Series resistance was not compensated during voltage-
clamp recordings, but was regularly monitored through-
out each experiment with a -5!mV, 50!ms pulse, and cells
with >20% change in series resistance were excluded
from the data. Data were not corrected for junction poten-
tials. GABA-evoked postsynaptic currents (GABA-PSCs)
were evoked through a micropipette (2–4!MO) containing
GABA (30!µM in aCSF) coupled to a pressure application
system (Picopump PV820, World Precision Instruments)
and positioned close to the soma of the recorded cell. Sin-
gle pulses of 100–150!ms and 6–8!psi were applied every
2!min. Action potential firing was systematically evoked
in current-clamp mode by injecting current pulses of –50
to +300!pA, in 50!pA increments for 1000!ms from an ini-
tial holding potential of -70!mV.
2.10  Statistical analysis
Results are presented as mean ± standard error of mean
(SEM). Comparisons between experimental results were
determined by Mann-Whitney test for independent sam-
ples. Unless stated otherwise, three replicates (n =!3) were
performed and a p-value less than 0.05 was considered
significant.
Additional methods and practical information can be
found in the Supporting information section of the paper.
www.biotechnology-journal.com www.biotecvisions.com
Biotechnology
Journal Biotechnol. J. 2015, 10
© 2015 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim 5
3  Results
3.1  Human PSCs efficiently commit to the
neuroectoderm lineage without the need 
for serum replacement-based medium
The dual-SMAD inhibition protocol is a procedure for the
rapid commitment of confluent human PSCs into early
PSC-derived neural precursors (NPs) [7, 16, 28, 29]
(Fig.!1A). Cells are first plated as cell colonies in condi-
tions that support pluripotency, and allowed to reach con-
fluence (Fig.! 1Bi and ii). Culture conditions are then
changed to include chemical inhibitors of BMP and
Activin/Nodal signaling pathways, causing the emer-
gence of a neuroepithelial cell sheet (Fig.!1Biii). This swift
induction is due to the blocking of SMAD signaling trans-
duction by SB and LDN small molecules [30, 31]. When
combined, these inhibitors repress mesoendodermal
fates, directing the differentiation towards neuroecto-
derm [32].
In this work we first compared different strategies to
achieve human NPs based on two different methods [7,
16] (Fig.!1A). In both cases human PSCs were first plated
in matrigel-coated plates as clumps using a non-enzy-
matic passaging procedure [33]. This yielded compact
colonies of cells (Fig.! 1Bi) that stained positively for
pluripotency markers OCT4 and SOX2 (Fig.!1C and 1D,
respectively). At this stage, a high percentage (>95%) of
cells were positive for these markers (Fig.!1E). Cells were
then allowed to reach confluence (Fig.! 1Bii), at which
point the two neural induction strategies were tested.
The first consisted in the use of serum replacement
(SR)-based medium for the first four days of commitment
supplemented with both SB and LDN. From day 5 to 11,
N2 supplementation was gradually added to the medium,
while LDN-mediated inhibition of BMP was maintained
[7]. In the second protocol, neural commitment was
induced in N2B27 medium supplemented with SB and
LDN for 12 days [28]. In both cases a neuroephitelial sheet
of cells was obtained, but some qualitative differences in
the efficiency of the neural commitment process were
immediately visualized using immunofluorescence
(Fig.!1F and 1G). While in the case of SR-based medium
OCT4-positive cells still persisted in culture 12 days after
neural induction with chemical inhibitors, for N2B27-
based induction these cells were virtually absent (Fig.!1F).
Additionally, the distribution of PAX6- and NESTIN-posi-
tive cells was more homogeneous in the case of N2B27
when compared with SR-based medium, which present-
ed islands of PAX6-positive cells surrounded by NESTIN
expressing cells instead of a homogeneous monolayer
(Fig.! 1G). Using image-processing software we then
quantified OCT4- and PAX6-expressing cells for both pro-
tocols (Fig.!1H). Neural commitment in N2B27 medium
resulted in more than 80% of NPs positive for PAX6 and
very low numbers of OCT4-positive PSCs (<2%), while in
KO-SR medium, an average of 40% PAX6-positive cells
was obtained, with more than 20% of OCT4-positive cells
still in culture (Mann-Whitney test, p-value <0.05).
These results highlight the importance of medium for-
mulation in maximizing differentiation yield [22]. By com-
paring data from both differentiation media it is possible
to conclude that the chemically defined, serum-free com-
position of N2B27 yields a more efficient neural conver-
sion into NPs. This medium was particularly optimized for
neural cell culture, and contains insulin and retinoids,
which have been shown to be crucial for the neuroep-
ithelial induction of human PSCs [16]. The relatively high
percentage of pluripotent cells and potential non-neural
differentiated cells obtained in SR-based medium (Sup-
porting information, Fig.!S2) is not desirable since these
cells may interfere with the outcome of in vitro differenti-
ation protocols [29].
3.2  Human PSCs generate neural precursor cells
using dual SMAD signaling inhibition under
defined culture conditions
In addition to medium formulation, the composition of the
extracellular matrix to which cells adhere is also a poten-
tial source of ill-defined components. This is the case of
matrigel, whose constituents include an heterogeneous
mixture of structural proteins of animal origin [34]. How-
ever, non-xenogeneic, defined substrates that support the
culture of human PSCs have also been proposed in the lit-
erature [17]. In particular, vitronectin (VTN) peptide
sequences have shown to support both expansion and
differentiation of human PSCs under totally defined cul-
ture conditions [19–22]. Our next goal was to compare two
different extracellular matrixes in supporting neural com-
mitment from human iPSCs in combination with a fully
defined culture medium, allowing the foundation of
defined settings for in vitro studies of neural development.
A side-by-side comparison was made using N2B27
medium together with matrigel or VTN (Fig.!2). The dual
SMAD inhibition yielded similar outcomes in both cases,
and cells presented typical neuroectodermal markers
(Fig.!2A). These included the neuroectoderm fate deter-
minant PAX6 [35], the forebrain marker FoxG1 [7], and the
midbrain/forebrain marker OTX1/2 [36], in addition to
SOX2 and NESTIN. Cells differentiated for 12 days in both
substrates showed up-regulation of PAX6 and SOX1
mRNA, with corresponding down-regulation of pluripo-
tency transcription factors (OCT4/POU5F1 and NANOG)
(Fig.!2B). Additionally, real-time PCR analysis indicated
that for both substrates expression of the pluripotency
markers sharply decreased in the first three days of  neural
induction (Fig.!2C). After this point, both OCT4/POU5fF1
and NANOG retain minor levels of expression when com-
pared to day 0. Also, PAX6 and SOX1 expression
increased rapidly from day 0, reaching maximum levels
after day 3 in both matrigel and VTN (Fig.!2D). At the
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same time, when human PSCs entered differentiation, the
presence of cell surface markers characteristic of the
pluripotent state (Tra-1-60 and SSEA-4) was reduced, and
the percentage of cells positive for these markers dropped
progressively during the 12 days of neural commitment
(Fig.! 3A). The simultaneous up-regulation of FGF5
expression (Fig.! 3B), together with down-regulation of
pluripotency genes (Fig.!2C) and up-regulation of PAX6
and SOX1 (Fig.!2D), most likely resulted from the emer-
gence of an initial population of NPs after neural induction
[37]. Taken together, these outcomes demonstrate that
human iPSCs can effectively differentiate to NPs using
the dual SMAD inhibition protocol under defined culture
conditions composed of N2B27 and VTN as adhesion sub-
strate.
To further confirm the generation of competent NPs
after 12 days of dual SMAD inhibition, cells were re-plat-
ed onto laminin-coated plates as small clumps, and cul-
tured in N2B27 medium without chemical inhibitors SB
and LDN. Two to five days after re-plating, a substantial
number of neural rosette-like structures were observed
(Fig.! 3C). Rosettes were radially arranged like neuro -
epithelial cells, which were positive for PAX6, NESTIN,
and SOX2, and already showed signs of polarization, with
apical ZO1 expression. When neural rosettes were first
visible, bFGF was added to the medium, to induce prolif-
eration of progenitors, and around day 17 of differentiation
cells were re-plated onto new laminin-coated plates and
cultured until day 28–30 without addition of small mole-
cules or any other factors. Substantial maturation of NPs
within rosettes was observed (Fig.!3D and 3E). As expect-
ed, after peaking during the initial stage of commitment,
expression of typical neural markers (PAX6, SOX1 and
NESTIN) declined during further differentiation (Fig.!3D).
This was followed by up-regulation of the neuronal mark-
er !-Tubulin III. Using immunofluorescence staining we
were able to see a proliferative (Ki67-positive) population
of progenitors within polarized rosettes (apical expression
of ZO1), and to confirm a reduction of the number of
PAX6-positive cells. At this stage of differentiation, Tuj1-
positive neurons outgrew from neural rosettes (Fig.!3E).
Taken together, these results demonstrate and vali-
date the capacity to generate functional NPs using the
dual SMAD inhibition protocol under defined culture con-
ditions. Our results show efficient (>80%) generation of
PAX6-positive NPs, and the capacity of these cells to self-
organize into neural rosettes upon passaging. Further dif-
ferentiation into more mature cells was achieved within
rosettes, which can be correlated with events leading to
the neural tube formation in vivo [7, 16]. As previously
demonstrated in similar systems [19–22, 38], peptide con-
jugates can support robust expansion and differentiation
of human PSCs under defined conditions, and in our case
VTN supported neural commitment of human PSCs in
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Figure 2. Efficient neural commitment
of human PSCs using defined medium
and vitronectin coating. (A) Immunoflu-
orescence staining of PSC-derived NPs
after 12 days of induction with chemical
inhibitors in matrigel or VTN. Cells were
stained for PAX6, NESTIN, FoxG1,
OTX1/2 and SOX2 (scale bars: 50 µm).
(B) RT-PCR analysis of NPs generated in
matrigel and VTN. Pluripotency genes
(POU5F1, NANOG) and neuroectoder-
mal markers (PAX6, SOX1) are shown
for comparison. (C) and (D) Temporal
gene expression analysis during neural
commitment of human PSCs in matrigel
and VTN. Pluripotency genes (POU5F1,
NANOG) and neuroectodermal markers
(PAX6, SOX1) were evaluated by quanti-
tative real-time PCR at different time
points. GAPDH expression was used as
internal control. Results are presented in
this figure as mean ± SEM of three inde-
pendent experiments and were obtained
using the iLB-C1-30 m-r12 cell line.
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3.3  Generation of patient-specific neural precursors
and further neural maturation 
At this stage we have established conditions that allowed
the study of neural specification of human PSCs without
interference of undetermined components resulting from
serum replacements [7] or extracellular matrix protein
mixtures [28, 34]. This is an important feature of our sys-
tem since undisclosed constituents may interfere with
different signaling pathways, and thus affect cell fate
decisions. Therefore, to further explore and demonstrate
the usefulness of our method for neural specification stud-
ies, we have taken advantage of the potential of iPSC
technology to investigate the neural commitment of
patient-specific iPSCs, in particular Rett syndrome (RTT)
patient-derived cells [39]. This disorder is caused by
mutations in the MECP2 gene of the X chromosome and
affects 1 in 10!000–20!000 girls worldwide [23]. Hallmarks
of this condition include impaired motor function,
seizures, autistic behavior [40], and changes in neuronal
density and in brain size [24, 41].
Control and RTT-derived fibroblasts were repro-
grammed to a pluripotent state as described elsewhere
[4]. The iPSC lines used in this work showed typical char-
acteristics of pluripotent stem cells, and could be main-
tained in culture for dozens of passages without signs of
differentiation or atypical karyotype (Supporting informa-
tion, Table S3 and Fig.!S3). These cells were then adapted
to our culturing conditions using a non-enzymatic pas-
saging procedure and plated to VTN-coated surfaces [21].
Both RTT and control-derived iPSCs were cultured in
pluripotency maintenance conditions using mTESR, and
stained for typical pluripotency markers (Fig.!4A and 4C,
and Supporting information, Fig.!S3). After reaching con-
fluence, medium was changed to N2B27 and small mole-
cule inhibitors of SMAD signaling (LDN and SB) were
added to culture for 12 days. Both normal and patient-
derived cells were able to differentiate and presented typ-
ical neuroectodermal markers such as PAX6, NESTIN,
FoxG1, OTX1/2 and SOX2 (Fig.!4B and 4D). Also, at this
time point, pluripotency markers like OCT4 were virtual-
ly absent.
After 12 days of dual SMAD inhibition, NPs were re-
plated onto laminin-coated plates as small clumps, and
cultured in N2B27 medium without chemical inhibitors.
At day 17, after stimulation with bFGF, both normal and
mutant cells were able to form neural rosettes without any
noticeable differences (Fig.!4E and 4G). Substantial mat-
www.biotecvisions.comwww.biotechnology-journal.com
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Figure 3. Neural maturation capability of cells derived under defined conditions using vitronectin coating. (A) Tra-1-60- and SSEA4-positive cells were eval-
uated by flow cytometry during neural commitment. (B) Gene expression analysis by quantitative real-time PCR of the early specification marker FGF5. 
(C) After re-plating onto laminin-coated surfaces, immunostaining analysis was performed on cells at day 17 of differentiation. PAX6, NESTIN, and SOX2
markers were used to identify neural rosettes, and ZO1 was used to show polarization within rosettes (scale bars: 50 µm). (D) Expression of typical neural
markers (PAX6, SOX1 and NESTIN) and of neuronal marker !-Tubulin III, as assessed by quantitative real-time PCR at different stages of neural differentia-
tion. (E) At day 28 of differentiation, Ki67 and ZO1 immunostaining were used to identify polarized rosettes (ZO1-centered). At this stage cells were also
marked for neural markers (PAX6, NESTIN), and Tuj1-positive neuronal projections (scale bars: 50 µm). Results are presented in this figure as mean 
± SEM of three independent experiments and were obtained using iLB-C1-30 m-r12 PSCs. 
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uration of NPs within rosettes was observed with cells
expressing neural markers (NESTIN, PAX6, SOX2) within
polarized structures (ZO1). At this stage, cells were again
re-plated onto laminin to allow further neural differentia-
tion. Proliferative, Ki67-positive cells within rosettes
could still be identified in both cultures, and polarization
could also be seen with apical localization of ZO1 (Fig.!4F
and 4H). Nevertheless, while in normal cells Tuj1-positive
neurons started to migrate outwards of rosettes, forming
neuronal projections and connections, RTT derived-neu-
rons were substantially less frequent, and neurites less
complex (Fig.!4F and 4H).
To further assess the neuronal maturation state, cells
were finally passed as single-cells at day 30 onto laminin-
coated plates and maintained in N2B27 medium. This
procedure was expected to generate cortical projection
neurons in about 80 days [28]. At day 75 of differentiation,
we evaluated not only neuronal maturation, but also dif-
ferentiation into glial cells, like astrocytes, in two non-
affected ‘wild type’ human iPSCs and one Rett syndrome-
derived mutant line (Fig.! 5A). A substantial number of
widespread neuronal projections was observed in both
normal cell lines. Furthermore, extensive gliogenesis had
occurred in such cultures and GFAP-positive astrocytes
could be seen interspersed with Tuj1-positive neurons.
This process was minimally reproduced in affected cells,
showing less neurons, similarly to what had been visual-
ized at day 28 of differentiation. Similar conclusions could
be taken from MAP2 staining at day 100 (Fig.!5B). These
observations are in accordance with other reports in the
literature [24, 41], and did not seem to result from reduced
proliferation, since the number of DAPI stained nuclei
within the microscope field of view was similar among
samples. By day 120, control neurons developed to gluta-
matergic neurons presenting the vesicular transporter
VGLUT1 (Fig.!5C), which could not be observed in mutat-
ed cells. 
Finally, electrophysiological recordings performed at
day 120 of differentiation, revealed neuronal functional
properties characteristic of mature neurons. Values of
neuronal resting membrane potential, determined imme-
diately after establishing whole-cell configuration, aver-
aged –45.0 ± 2.2!mV (n!=!17). Action-potentials were then
evoked in current-clamp mode by injecting depolarizing
current pulses. Most cells tested showed firing of at least
one action potential during current injection steps, reveal-
ing a mature neuronal state (n =!10, Fig.!5D). In addition,
GABA-evoked postsynaptic currents were observed (volt-
www.biotechnology-journal.com www.biotecvisions.com
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Figure 4. Neural commitment and further neural differentiation of both normal and Rett syndrome patient specific human iPSCs. (A) and (C) Immunofluo-
rescence staining of pluripotency marker NANOG for both normal and Rett syndrome patient-derived iPSCs (scale bars: 100 µm). (B) and (D) Immunoflu-
orescence staining of neural markers (PAX6, NESTIN, FoxG1, OTX1/2, SOX2, scale bars: 50 µm) and of pluripotency marker OCT4 (scale bars: 100 µm)
after twelve days of dual SMAD inhibition using a defined culture system. (E) and (G) After re-plating onto laminin, immunostaining analysis was per-
formed to demonstrate potential of both normal and affected cells to form neural rosettes. Cells were stained for PAX6, NESTIN, SOX2 and ZO1 (scale
bars: 50 µm). (F) and (H) Direct comparison of both cell types during further neural maturation. Cells were marked for neural markers (PAX6, NESTIN),
Ki67, ZO1, and Tuj1-positive neuronal projections (scale bars: 50 µm). Results presented in this figure were obtained using iLB-C1-30 m-r12, WT-Évora
F0000B13, and EMC23i PSCs.
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age-clamp mode, Vh!=!-70!mV) in response to pressure
application of GABA (30!µM) directly to the soma of the
cell, indicating the expression of functional neurotrans-
mitter receptors in these cells (n!=!11, Fig.!5E).
4  Discussion
We herein identify defined culture conditions to achieve
efficient and reproducible neural commitment of human
PSCs. A defined neural maintenance medium supple-
mented with chemical inhibitors of both BMP and TGF!
signaling pathways, together with VTN for adherent
growth, was shown to be sufficient to induce neuronal
commitment, generating a homogeneous population of
NPs expressing typical neural markers (Fig.!1, 2 and 3).
The results obtained herein are comparable with other
reported data in terms of neural conversion efficiency [16],
when using N2B27 medium, demonstrating that VTN-
coating does not affect neural commitment negatively. 
In fact, VTN-based conjugates have been previously
used for PSC derivation, expansion [20, 21] and neural
specification studies [22, 42], and our results also validate
the usage of VTN as a defined substrate for neural com-
mitment. Another important feature of this system is the
use of retinoid rich medium, which have been shown to
increase NPs output [16]. When combined with VTN
adhesion motifs, the use of defined medium was thought
to facilitate progression through neural maturation, par-
ticularly during re-plating of NPs to laminin surfaces, by
promoting survival and functionality of differentiated cells
[43]. In fact, when compared with serum replacement-
based medium, we have been able to significantly
increase the number of PAX6-positive NPs in N2B27
(Fig.!1). However, other studies have reported minimally
constituted monolayer systems that could achieve similar
efficiencies in generating PAX6-positive neuroectoderm
[22], questioning the role of retinoids in neural commit-
ment. Nevertheless, monolayer neural commitment pro-
tocols still require a high local cell density for generation
of NPs with high efficiencies [7]. It would be interesting to
engage other methods [44, 45], such as micropatterning
or forced aggregation of cells, to evaluate the local dynam-
ics of high-density cell-to-cell contacts in the neural spec-
ification of human PSCs. Still, one shortcoming of mono-
layer systems is the fact that for later stages of neural
development, NPs require laminin to adhere and differen-
tiate [46]. Laminins are extracellular matrix trimeric gly-
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Figure 5. Neuronal differentiation of normal and Rett syndrome-derived neural progenitors. (A) Immunostaining analysis was performed at day 75 of dif-
ferentiation to evaluate neuronal maturation (Tuj1-positive) and astrocyte differentiation (GFAP-positive) in both normal and mutated cells (scale bars:
50 µm). (B) After further differentiation and maturation of neurons, immunostaining was performed to identify MAP2-positive mature dendrites at day 100.
The frequency of such structures in MECP2 mutated cells was compared to the control cells (scale bars: 50 µm). (C) Immunostaining for glutamatergic
neuronal protein VGLUT1 of ‘wild type’ Tuj1 neurons at 120 days of differentiation (scale bar: 100 µm). (D) and (E) show electrophysiological properties of
‘wild type’ cells after 120 days of differentiation. (D) Increased depolarizing voltage steps (1000 ms) in whole-cell current-clamp mode. A representative fir-
ing of action potential characteristic of mature neurons is shown. (E) Representative GABA (30 µM)-evoked postsynaptic currents (GABA-PSC) from a neu-
ron recorded in whole-cell voltage-clamp (–70 mV). Black bar corresponds to GABA application.
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coproteins and at least a dozen of different isoforms have
been identified in nature. Commonly used laminin is iso-
lated from a murine source and represents an undisclosed
mixture of several of these natural isoforms. To fully define
neural commitment, neural maturation, and neuronal dif-
ferentiation of human PSCs in adherent conditions, spe-
cific laminin isoforms should be investigated and subse-
quently used. The Tryggvason’s group has been able to
produce recombinant laminins and evaluate their specif-
ic role in several biological functions [47], but the exact
isoforms involved in neural differentiation remain
unknown. However, potential future therapeutic strate-
gies for neurological disorders might implicate the use of
progenitors [48], since mature cells are less capable of
establishing the adequate connections without being
continuously exposed to the combination of growth factor
and signaling molecules that orientate synaptogenesis
and neuronal wiring. Obtaining NPs in xeno-free condi-
tions can be a relevant first step to establish a safe
approach for future transplant based therapies. 
As a proof-of-concept, we have validated our neural
commitment protocol using different cell lines, including
patient-specific, Rett syndrome-derived iPSCs. Although
investigation of a broader number of patients would be
required, we were able to replicate some of the reported
Rett syndrome defects in NPs derived in our defined sys-
tem (Fig.! 4 and 5). Interestingly, given the fact that
MECP2 is located on the X-chromosome and that Rett
syndrome patients present mosaicism [23], X-chromo-
some activation/inactivation during reprogramming,
expansion and differentiation could lead to difficulties in
reproducing the pathology of the disease in vitro. We have
not confirmed these events during reprogramming of our
cells, but Marchetto and coworkers have previously
shown the capacity to recapitulate X-inactivation during
neural differentiation, producing mosaic neuronal cul-
tures with different MECP2 expression levels [24]. Iso-
genic human iPSC lines from Rett syndrome patients can
therefore be used as in vitro models of the disease [49],
and our results (Fig.!5) are in accordance with the pub-
lished literature [24, 41, 49]. Since several studies have
reported similar findings, and taking into consideration
the different levels of MECP2 expression in mutated cells,
the contribution of non-neural cells, like astrocytes, to the
onset of the disease should not be excluded. In fact, this
influence was already described, indicating that glial cells
carrying MECP2 mutations can also distress healthy neu-
rons [50, 51].
In conclusion, our defined culture system provides a
way to recapitulate some of the temporal and regional pat-
terning events that occur during in vivo cortical neuroge-
nesis [52]. Also, by deconstructing the natural complexi-
ty of neural development into a simpler experimental
approach, we could mimic several aspects of Rett syn-
drome pathology potentially contributing to a better
understanding of cortical development and disease.
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